0001628280-22-003669.txt : 20220224 0001628280-22-003669.hdr.sgml : 20220224 20220224095758 ACCESSION NUMBER: 0001628280-22-003669 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 124 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BALCHEM CORP CENTRAL INDEX KEY: 0000009326 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] IRS NUMBER: 132578432 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13648 FILM NUMBER: 22667172 BUSINESS ADDRESS: STREET 1: 52 SUNRISE PARK ROAD CITY: NEW HAMPTON STATE: NY ZIP: 10958 BUSINESS PHONE: (845) 326-5600 MAIL ADDRESS: STREET 1: 52 SUNRISE PARK ROAD CITY: NEW HAMPTON STATE: NY ZIP: 10958 10-K 1 bcpc-20211231.htm 10-K bcpc-20211231
2021FYfalse0000009326P3YP3Y0.66660.6666http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAssethttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAssethttp://fasb.org/us-gaap/2021-01-31#FinanceLeaseRightOfUseAssethttp://fasb.org/us-gaap/2021-01-31#FinanceLeaseRightOfUseAssethttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityCurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityNoncurrent00000093262021-01-012021-12-3100000093262021-06-30iso4217:USD00000093262022-02-10xbrli:shares00000093262021-12-3100000093262020-12-31iso4217:USDxbrli:shares00000093262020-01-012020-12-3100000093262019-01-012019-12-3100000093262018-12-310000009326us-gaap:RetainedEarningsMember2018-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000009326us-gaap:CommonStockMember2018-12-310000009326us-gaap:AdditionalPaidInCapitalMember2018-12-310000009326us-gaap:RetainedEarningsMember2019-01-012019-12-310000009326us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-3100000093262019-12-310000009326us-gaap:CommonStockMember2019-01-012019-12-310000009326us-gaap:RetainedEarningsMember2019-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000009326us-gaap:CommonStockMember2019-12-310000009326us-gaap:AdditionalPaidInCapitalMember2019-12-310000009326us-gaap:RetainedEarningsMember2020-01-012020-12-310000009326us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000009326us-gaap:CommonStockMember2020-01-012020-12-310000009326us-gaap:RetainedEarningsMember2020-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000009326us-gaap:CommonStockMember2020-12-310000009326us-gaap:AdditionalPaidInCapitalMember2020-12-310000009326us-gaap:RetainedEarningsMember2021-01-012021-12-310000009326us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000009326us-gaap:CommonStockMember2021-01-012021-12-310000009326us-gaap:RetainedEarningsMember2021-12-310000009326us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000009326us-gaap:CommonStockMember2021-12-310000009326us-gaap:AdditionalPaidInCapitalMember2021-12-310000009326srt:MinimumMemberus-gaap:BuildingMember2021-01-012021-12-310000009326us-gaap:BuildingMembersrt:MaximumMember2021-01-012021-12-310000009326srt:MinimumMemberus-gaap:EquipmentMember2021-01-012021-12-310000009326us-gaap:EquipmentMembersrt:MaximumMember2021-01-012021-12-3100000093262020-04-012020-06-300000009326bcpc:HumanNutritionAndHealthMember2021-12-310000009326bcpc:HumanNutritionAndHealthMember2020-12-310000009326bcpc:AnimalNutritionAndHealthMember2021-12-310000009326bcpc:AnimalNutritionAndHealthMember2020-12-310000009326bcpc:SpecialtyProductsMember2021-12-310000009326bcpc:SpecialtyProductsMember2020-12-310000009326bcpc:IndustrialProductsMember2021-12-310000009326bcpc:IndustrialProductsMember2020-12-310000009326srt:MinimumMemberus-gaap:CustomerListsMember2021-01-012021-12-310000009326srt:MaximumMemberus-gaap:CustomerListsMember2021-01-012021-12-310000009326srt:MinimumMemberus-gaap:TrademarksAndTradeNamesMember2021-01-012021-12-310000009326us-gaap:TrademarksAndTradeNamesMembersrt:MaximumMember2021-01-012021-12-310000009326srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310000009326srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310000009326srt:MinimumMemberbcpc:RegulatoryRegistrationCostsMember2021-01-012021-12-310000009326srt:MaximumMemberbcpc:RegulatoryRegistrationCostsMember2021-01-012021-12-310000009326srt:MinimumMemberbcpc:PatentsTradeSecretsMember2021-01-012021-12-310000009326srt:MaximumMemberbcpc:PatentsTradeSecretsMember2021-01-012021-12-310000009326srt:MinimumMemberbcpc:OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMember2021-01-012021-12-310000009326bcpc:OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMembersrt:MaximumMember2021-01-012021-12-310000009326bcpc:HumanNutritionAndHealthMember2019-01-012019-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-05-280000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2019-05-280000009326bcpc:ZumbroRiverBrandIncMember2019-12-132019-12-310000009326bcpc:ZumbroRiverBrandIncMember2019-12-130000009326bcpc:ZumbroRiverBrandIncMember2020-05-012020-05-310000009326bcpc:ZumbroRiverBrandIncMemberbcpc:HumanNutritionAndHealthMember2019-12-130000009326bcpc:ZumbroRiverBrandIncMemberus-gaap:CustomerRelationshipsMember2019-12-130000009326bcpc:ZumbroRiverBrandIncMemberus-gaap:DevelopedTechnologyRightsMember2019-12-130000009326bcpc:ZumbroRiverBrandIncMemberus-gaap:TradeNamesMember2019-12-130000009326bcpc:ZumbroRiverBrandIncMemberus-gaap:CustomerRelationshipsMember2019-12-132019-12-130000009326bcpc:ZumbroRiverBrandIncMemberus-gaap:TradeNamesMember2019-12-132019-12-130000009326bcpc:ZumbroRiverBrandIncMemberus-gaap:DevelopedTechnologyRightsMember2019-12-132019-12-130000009326bcpc:ChemogasHoldingNVAndSubsidiariesMember2019-05-27xbrli:pure0000009326bcpc:ChemogasHoldingNVAndSubsidiariesMember2019-05-272019-05-27iso4217:EUR0000009326bcpc:ChemogasHoldingNVAndSubsidiariesMemberus-gaap:CustomerRelationshipsMember2019-05-270000009326bcpc:ChemogasHoldingNVAndSubsidiariesMemberus-gaap:DevelopedTechnologyRightsMember2019-05-270000009326bcpc:ChemogasHoldingNVAndSubsidiariesMemberus-gaap:TradeNamesMember2019-05-270000009326bcpc:ChemogasHoldingNVAndSubsidiariesMemberus-gaap:CustomerRelationshipsMember2019-05-272019-05-270000009326bcpc:ChemogasHoldingNVAndSubsidiariesMemberus-gaap:TradeNamesMember2019-05-272019-05-270000009326bcpc:ChemogasHoldingNVAndSubsidiariesMemberus-gaap:DevelopedTechnologyRightsMember2019-05-272019-05-270000009326bcpc:ChemogasAndZumbroRiverBrandIncMember2021-01-012021-12-310000009326bcpc:ChemogasAndZumbroRiverBrandIncMember2020-01-012020-12-310000009326bcpc:ChemogasAndZumbroRiverBrandIncMember2019-01-012019-12-310000009326us-gaap:CostOfSalesMember2021-01-012021-12-310000009326us-gaap:CostOfSalesMember2020-01-012020-12-310000009326us-gaap:CostOfSalesMember2019-01-012019-12-310000009326us-gaap:OperatingExpenseMember2021-01-012021-12-310000009326us-gaap:OperatingExpenseMember2020-01-012020-12-310000009326us-gaap:OperatingExpenseMember2019-01-012019-12-31bcpc:plan0000009326bcpc:OmnibusIncentivePlan2017Member2021-12-310000009326bcpc:StockPlan1999Member2021-12-310000009326bcpc:OmnibusIncentivePlan2017Member2021-01-012021-12-310000009326us-gaap:EmployeeStockOptionMemberbcpc:OmnibusIncentivePlan2017Member2021-12-310000009326bcpc:OmnibusIncentivePlan2017Membersrt:DirectorMember2021-01-012021-12-310000009326us-gaap:PerformanceSharesMemberbcpc:EmployeeMember2021-01-012021-12-310000009326us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000009326us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000009326us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000009326us-gaap:PerformanceSharesMemberbcpc:EmployeeMember2020-01-012020-12-310000009326us-gaap:PerformanceSharesMemberbcpc:EmployeeMember2019-01-012019-12-310000009326srt:MinimumMemberbcpc:EmployeeMemberus-gaap:RestrictedStockMember2021-01-012021-12-310000009326srt:MaximumMemberbcpc:EmployeeMemberus-gaap:RestrictedStockMember2021-01-012021-12-310000009326srt:MinimumMembersrt:DirectorMemberus-gaap:RestrictedStockMember2021-01-012021-12-310000009326srt:MaximumMembersrt:DirectorMemberus-gaap:RestrictedStockMember2021-01-012021-12-310000009326bcpc:ExercisePriceRange1Member2021-01-012021-12-310000009326bcpc:ExercisePriceRange1Member2021-12-310000009326bcpc:ExercisePriceRange2Member2021-01-012021-12-310000009326bcpc:ExercisePriceRange2Member2021-12-310000009326bcpc:ExercisePriceRange3Member2021-01-012021-12-310000009326bcpc:ExercisePriceRange3Member2021-12-310000009326us-gaap:RestrictedStockMember2020-12-310000009326us-gaap:RestrictedStockMember2019-12-310000009326us-gaap:RestrictedStockMember2018-12-310000009326us-gaap:RestrictedStockMember2021-01-012021-12-310000009326us-gaap:RestrictedStockMember2020-01-012020-12-310000009326us-gaap:RestrictedStockMember2019-01-012019-12-310000009326us-gaap:RestrictedStockMember2021-12-310000009326us-gaap:PerformanceSharesMember2020-12-310000009326us-gaap:PerformanceSharesMember2019-12-310000009326us-gaap:PerformanceSharesMember2018-12-310000009326us-gaap:PerformanceSharesMember2021-01-012021-12-310000009326us-gaap:PerformanceSharesMember2020-01-012020-12-310000009326us-gaap:PerformanceSharesMember2019-01-012019-12-310000009326us-gaap:PerformanceSharesMember2021-12-310000009326us-gaap:LandMember2021-12-310000009326us-gaap:LandMember2020-12-310000009326us-gaap:BuildingMember2021-12-310000009326us-gaap:BuildingMember2020-12-310000009326us-gaap:EquipmentMember2021-12-310000009326us-gaap:EquipmentMember2020-12-310000009326us-gaap:ConstructionInProgressMember2021-12-310000009326us-gaap:ConstructionInProgressMember2020-12-310000009326srt:NorthAmericaMember2021-12-310000009326srt:NorthAmericaMember2020-12-310000009326srt:EuropeMember2021-12-310000009326srt:EuropeMember2020-12-310000009326us-gaap:CustomerListsMember2021-12-310000009326us-gaap:CustomerListsMember2020-12-310000009326us-gaap:TrademarksAndTradeNamesMember2021-12-310000009326us-gaap:TrademarksAndTradeNamesMember2020-12-310000009326us-gaap:DevelopedTechnologyRightsMember2021-12-310000009326us-gaap:DevelopedTechnologyRightsMember2020-12-310000009326srt:MinimumMemberus-gaap:OtherIntangibleAssetsMember2021-01-012021-12-310000009326srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember2021-01-012021-12-310000009326us-gaap:OtherIntangibleAssetsMember2021-12-310000009326us-gaap:OtherIntangibleAssetsMember2020-12-310000009326bcpc:StGabrielCCCompanyLLCMember2013-12-310000009326bcpc:StGabrielCCCompanyLLCMemberbcpc:EastmanChemicalCompanyMember2013-12-31bcpc:vote0000009326bcpc:StGabrielCCCompanyLLCMember2021-01-012021-12-310000009326bcpc:StGabrielCCCompanyLLCMember2020-01-012020-12-310000009326bcpc:StGabrielCCCompanyLLCMember2019-01-012019-12-310000009326bcpc:StGabrielCCCompanyLLCMember2021-12-310000009326bcpc:StGabrielCCCompanyLLCMember2020-12-310000009326us-gaap:SecuredDebtMember2018-06-270000009326us-gaap:RevolvingCreditFacilityMember2018-06-2700000093262018-06-270000009326us-gaap:SecuredDebtMember2018-06-272018-06-270000009326us-gaap:SecuredDebtMember2019-05-232019-05-230000009326us-gaap:SecuredDebtMember2019-12-132019-12-130000009326us-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310000009326bcpc:RevolvingCreditAgreementMember2021-12-310000009326srt:MinimumMemberbcpc:RevolvingCreditAgreementMember2021-01-012021-12-310000009326bcpc:RevolvingCreditAgreementMembersrt:MaximumMember2021-01-012021-12-310000009326bcpc:RevolvingCreditAgreementMember2021-01-012021-12-310000009326us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000009326us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000009326us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000009326us-gaap:StateAndLocalJurisdictionMember2021-12-31bcpc:segment00000093262020-01-012020-03-31bcpc:facility0000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2020-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2020-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2020-12-310000009326us-gaap:CorporateNonSegmentMember2021-12-310000009326us-gaap:CorporateNonSegmentMember2020-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2021-01-012021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2020-01-012020-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:HumanNutritionAndHealthMember2019-01-012019-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2021-01-012021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2020-01-012020-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:AnimalNutritionAndHealthMember2019-01-012019-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2021-01-012021-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2020-01-012020-12-310000009326us-gaap:OperatingSegmentsMemberbcpc:SpecialtyProductsMember2019-01-012019-12-310000009326us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000009326us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000009326us-gaap:CorporateNonSegmentMember2019-01-012019-12-310000009326us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310000009326us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310000009326us-gaap:MaterialReconcilingItemsMember2019-01-012019-12-310000009326bcpc:ProductSalesMember2021-01-012021-12-310000009326bcpc:ProductSalesMember2020-01-012020-12-310000009326bcpc:ProductSalesMember2019-01-012019-12-310000009326bcpc:CoManufacturingMember2021-01-012021-12-310000009326bcpc:CoManufacturingMember2020-01-012020-12-310000009326bcpc:CoManufacturingMember2019-01-012019-12-310000009326bcpc:BillAndHoldMember2021-01-012021-12-310000009326bcpc:BillAndHoldMember2020-01-012020-12-310000009326bcpc:BillAndHoldMember2019-01-012019-12-310000009326bcpc:ConsignmentMember2021-01-012021-12-310000009326bcpc:ConsignmentMember2020-01-012020-12-310000009326bcpc:ConsignmentMember2019-01-012019-12-310000009326us-gaap:ProductMember2021-01-012021-12-310000009326us-gaap:ProductMember2020-01-012020-12-310000009326us-gaap:ProductMember2019-01-012019-12-310000009326us-gaap:RoyaltyMember2021-01-012021-12-310000009326us-gaap:RoyaltyMember2020-01-012020-12-310000009326us-gaap:RoyaltyMember2019-01-012019-12-310000009326country:US2021-01-012021-12-310000009326country:US2020-01-012020-12-310000009326country:US2019-01-012019-12-310000009326us-gaap:NonUsMember2021-01-012021-12-310000009326us-gaap:NonUsMember2020-01-012020-12-310000009326us-gaap:NonUsMember2019-01-012019-12-31bcpc:revenue_substream0000009326us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMember2021-01-012021-12-310000009326us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMember2020-01-012020-12-310000009326us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMember2019-01-012019-12-310000009326us-gaap:NetInvestmentHedgingMember2021-01-012021-12-310000009326us-gaap:NetInvestmentHedgingMember2020-01-012020-12-310000009326us-gaap:NetInvestmentHedgingMember2019-01-012019-12-310000009326us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000009326us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000009326us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000009326us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310000009326us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-12-310000009326us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-12-310000009326us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000009326us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000009326us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-3100000093262021-01-012021-01-010000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2020-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2019-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2021-01-012021-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2020-01-012020-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2021-12-310000009326us-gaap:DefinedBenefitPostretirementHealthCoverageMember2019-01-012019-12-310000009326bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember2021-01-012021-12-310000009326bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember2020-01-012020-12-310000009326bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember2019-01-012019-12-310000009326us-gaap:PensionPlansDefinedBenefitMemberbcpc:ChemogasDefinedPensionPlanMember2020-12-310000009326us-gaap:PensionPlansDefinedBenefitMemberbcpc:ChemogasDefinedPensionPlanMember2019-12-310000009326us-gaap:PensionPlansDefinedBenefitMemberbcpc:ChemogasDefinedPensionPlanMember2021-01-012021-12-310000009326us-gaap:PensionPlansDefinedBenefitMemberbcpc:ChemogasDefinedPensionPlanMember2020-01-012020-12-310000009326us-gaap:PensionPlansDefinedBenefitMemberbcpc:ChemogasDefinedPensionPlanMember2021-12-310000009326us-gaap:PensionPlansDefinedBenefitMemberbcpc:ChemogasDefinedPensionPlanMember2019-01-012019-12-310000009326us-gaap:MoneyMarketFundsMember2021-12-310000009326us-gaap:MoneyMarketFundsMember2020-12-310000009326us-gaap:FairValueInputsLevel1Member2021-12-310000009326us-gaap:FairValueInputsLevel1Member2020-12-310000009326us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:CurrencySwapMember2021-12-310000009326us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:CurrencySwapMember2020-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2020-12-310000009326bcpc:ServicesProvidedMemberus-gaap:CorporateJointVentureMember2021-01-012021-12-310000009326bcpc:ServicesProvidedMemberus-gaap:CorporateJointVentureMember2020-01-012020-12-310000009326bcpc:ServicesProvidedMemberus-gaap:CorporateJointVentureMember2019-01-012019-12-310000009326bcpc:RawMaterialsSoldMemberus-gaap:CorporateJointVentureMember2021-01-012021-12-310000009326bcpc:RawMaterialsSoldMemberus-gaap:CorporateJointVentureMember2020-01-012020-12-310000009326bcpc:RawMaterialsSoldMemberus-gaap:CorporateJointVentureMember2019-01-012019-12-310000009326us-gaap:CorporateJointVentureMember2021-01-012021-12-310000009326us-gaap:CorporateJointVentureMember2020-01-012020-12-310000009326us-gaap:CorporateJointVentureMember2019-01-012019-12-310000009326us-gaap:CorporateJointVentureMember2021-12-310000009326us-gaap:CorporateJointVentureMember2020-12-31bcpc:tranche0000009326srt:MinimumMemberbcpc:LesseeOperatingLeaseTrancheOneMember2021-12-310000009326srt:MaximumMemberbcpc:LesseeOperatingLeaseTrancheOneMember2021-12-310000009326bcpc:LesseeOperatingLeaseTrancheOneMember2021-12-310000009326srt:MinimumMemberbcpc:LesseeOperatingLeaseTrancheTwoMember2021-12-310000009326srt:MaximumMemberbcpc:LesseeOperatingLeaseTrancheTwoMember2021-12-310000009326bcpc:LesseeOperatingLeaseTrancheTwoMember2021-12-310000009326srt:MinimumMemberbcpc:LesseeOperatingLeaseTrancheThreeMember2021-12-310000009326bcpc:LesseeOperatingLeaseTrancheThreeMembersrt:MaximumMember2021-12-310000009326bcpc:LesseeOperatingLeaseTrancheThreeMember2021-12-310000009326bcpc:LesseeOperatingLeaseTrancheFourMember2021-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberbcpc:PayFixedInterestRateMember2019-05-280000009326us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-01-012020-12-310000009326us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2019-01-012019-12-310000009326us-gaap:DesignatedAsHedgingInstrumentMemberbcpc:PayFixedInterestRateMemberus-gaap:CurrencySwapMember2019-05-280000009326us-gaap:DesignatedAsHedgingInstrumentMemberbcpc:ReceiveFixedInterestRateMemberus-gaap:CurrencySwapMember2019-05-280000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:CurrencySwapMember2021-01-012021-12-310000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:CurrencySwapMember2020-01-012020-12-310000009326us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:CurrencySwapMember2019-01-012019-12-310000009326us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-12-310000009326us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2020-12-310000009326us-gaap:InterestRateSwapMember2021-01-012021-12-310000009326us-gaap:InterestRateSwapMember2020-01-012020-12-310000009326us-gaap:InterestRateSwapMember2019-01-012019-12-3100000093262021-01-012021-03-3100000093262021-04-012021-06-3000000093262021-07-012021-09-3000000093262021-10-012021-12-3100000093262020-07-012020-09-3000000093262020-10-012020-12-310000009326us-gaap:AllowanceForCreditLossMember2018-12-310000009326us-gaap:InventoryValuationReserveMember2018-12-310000009326us-gaap:AllowanceForCreditLossMember2019-01-012019-12-310000009326us-gaap:InventoryValuationReserveMember2019-01-012019-12-310000009326us-gaap:AllowanceForCreditLossMember2019-12-310000009326us-gaap:InventoryValuationReserveMember2019-12-310000009326us-gaap:AllowanceForCreditLossMember2020-01-012020-12-310000009326us-gaap:InventoryValuationReserveMember2020-01-012020-12-310000009326us-gaap:AllowanceForCreditLossMember2020-12-310000009326us-gaap:InventoryValuationReserveMember2020-12-310000009326us-gaap:AllowanceForCreditLossMember2021-01-012021-12-310000009326us-gaap:InventoryValuationReserveMember2021-01-012021-12-310000009326us-gaap:AllowanceForCreditLossMember2021-12-310000009326us-gaap:InventoryValuationReserveMember2021-12-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-K


(Mark One)
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission file number: 1-13648
_______________________________________________________________________________________________________________
Balchem Corporation
(Exact name of Registrant as specified in its charter)
Maryland 13-2578432
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number)

52 Sunrise Park Road, New Hampton, NY 10958
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (845) 326-5600
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Stock, par value $.06-2/3 per shareBCPCNasdaq Global Market
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☑ No ☐

Indicate by check mark whether the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☑
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☑  No ☐





Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer ☑
Accelerated filer ☐
 
 
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
The aggregate market value of the common stock, par value $.06-2/3 per share (the “Common Stock”), issued and outstanding and held by non-affiliates of the Registrant, based upon the closing price for the Common Stock on the NASDAQ Global Market on June 30, 2021 was approximately $4,224,000,000. For purposes of this calculation, shares of the Registrant held by directors and officers of the Registrant and under the Registrant’s 401(k)/profit sharing plan have been excluded.
The number of shares outstanding of Common Stock was 32,187,345 as of February 10, 2022.
DOCUMENTS INCORPORATED BY REFERENCE
Selected portions of the Registrant’s proxy statement for its 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end of December 31, 2021 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated therein.

Cautionary Statement Regarding Forward-Looking Statements
This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations or beliefs concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will,” “estimates,” “project” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and factors that could cause our results to differ materially from our expectations and beliefs include, but are not limited to, those factors set forth in this Annual Report on Form 10-K under “Item 1A. - Risk Factors” below.
We cannot assure you that the expectations or beliefs reflected in these forward-looking statements will prove correct. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Annual Report on Form 10-K and all subsequent written and oral forward-looking statements made by us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained herein.


BALCHEM CORPORATION
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
Page Numbers


PART I
Item 1.        Business (All amounts in thousands, except share and per share data)
General:
Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Previously, our four reportable segments were: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products. However, effective in the first quarter of 2020, in order to align with our strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, and given the 2019 reduction in portfolio scale of Industrial Products, we have revised our reporting segment structure to three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. These reportable segments are strategic businesses that offer products and services to different markets. This realignment has been retrospectively applied. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated" and applied retroactively to 2019. There was no change to the Consolidated Financial Statements as a result of the change to the reportable segments. We expect that the new reportable segment structure will provide investors greater understanding of and alignment with our strategic focus. In order to ensure appropriate transparency and visibility into the financial performance of the Company, sufficient detail will continue to be provided relative to Other and Unallocated, including material contributions from oil and gas and other industrial market activities.
We sell our products through our own sales force, independent distributors and sales agents. Financial information concerning our business, business segments and geographic information appears in Management’s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 below and in the Notes to our Consolidated Financial Statements included under Item 8 below, which information is incorporated herein by reference.
Human Nutrition & Health
The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. When combined with its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.
Animal Nutrition & Health
The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity.
1
Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace.
Specialty Products
Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. The Company’s 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.
The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the EPA and the DOT. Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder drum and cylinder packaging approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment.
The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life.  First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.
Acquisitions
On December 13, 2019, we completed an acquisition of Zumbro River Brand, Inc. ("Zumbro"), headquartered in Albert Lea, Minnesota. We made payments of $52,403 on the acquisition date, amounting to $47,058 to the former shareholders and $5,345 to Zumbro's lenders to pay Zumbro debt. Considering the cash acquired of $686, net payments made to the former shareholders equaled $46,372. In May 2020, we received an adjustment for working capital acquired of $561. The acquisition was primarily financed through the Company's Credit Agreement (Refer to Note 8, "Revolving Loan"). Zumbro specializes in developing, marketing, and manufacturing agglomerated and extruded products for the food and beverage industry and is a market leader in high protein and specialty extruded snacks, cereals, and crisps, marketed under the brands Z-Crisps®, Whey-Os™, Whey-Vs™, and Z-Texx Complete™. Zumbro is integrated within Balchem's HNH Segment.
On May 27, 2019, we acquired 100 percent of the outstanding common shares of Chemogas Holding NV, a privately held specialty gases company headquartered in Grimbergen, Belgium ("Chemogas"). We made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay off all Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690). The acquisition was primarily financed through our Credit Agreement (Refer to Note 8, "Revolving Loan"). Chemogas, through its subsidiary companies, has been a leader in the packaging and distribution of a wide variety of specialty gases, most notably ethylene oxide, primarily in the European and Asian markets, for medical device sterilization. Through its operational and logistical excellence, Chemogas supports its customers' needs across more than 70 countries. With the acquisition, we significantly expand our geographic presence in the packaged ethylene oxide market, enabling us to offer
2
worldwide service and support to its medical device sterilization customers within the Specialty Products segment. The Chemogas sites in Europe and Asia, along with Balchem's sites in the United States form a global network of facilities.

Raw Materials

The raw materials utilized by us in the manufacture of our products are sourced from suppliers both domestically and internationally. Such raw materials include materials derived from petrochemicals, minerals, metals, agricultural commodities and other readily available commodities and are subject to price fluctuations due to market conditions. In 2021, we experienced some difficulties in procuring certain materials due to the challenging macroeconomic environment with global supply chain disruptions because of COVID-19 pandemic. However, we were able to secure most materials from our suppliers and will continue to ensure a sustainable supply chain to support our growing business operations.
Intellectual Property
We currently hold 109 patents in the United States and overseas and use certain trade-names and trademarks. We also use know-how, trade secrets, formulae, and manufacturing techniques that assist in maintaining competitive positions of certain of our products. Formulae and know-how are of particular importance in the manufacture of a number of our proprietary products. We believe that certain of our patents, in the aggregate, are advantageous to our business. However, it is believed that no single patent or related group of patents is currently so material to us that the expiration or termination of any single patent or group of patents would materially affect our business. Our U.S. patents expire between 2022 and 2036. We believe that our sales and competitive position are dependent primarily upon the quality of our products, technical sales efforts and market conditions, rather than on patent protection.
Seasonality
While in general, the businesses of our segments are not seasonal to any material extent, the plant nutrition business within Specialty Products is a seasonal business with the vast majority of sales occurring in the first half of the year, based on the planting season in the northern hemisphere.
Backlog
At December 31, 2021, we had a total backlog of $65,661 (comprised of $45,393 for the HNH segment; $14,483 for the ANH segment; $4,935 for the Specialty Products segment, and $850 for other), as compared to a total backlog of $64,811 at December 31, 2020 (comprised of $52,293 for the HNH segment; $8,620 for the ANH segment; $3,557 for the Specialty Products segment and $341 for other). It has generally been our policy and practice to maintain an inventory of finished products and/or component materials for our segments to enable us to ship products within two months after receipt of a product order. This has been more difficult in 2021 given the macroeconomic and supply chain challenges we have been experiencing, but all orders in the current backlog are expected to be filled in the 2022 fiscal year.
Competition
Our competitors include many large and small companies, some of which have greater financial, research and development, production and other resources than us. Competition in the supplement, food and beverage markets we serve are based primarily on product performance, customer support, quality, service and price. The development of new and improved products is important to our success. This competitive environment requires substantial investments in product and manufacturing process research and development. In addition, the winning and retention of customer acceptance of our food and nutrition products involve substantial expenditures for application testing, either internally or at customer/prospect sites, and sales efforts. Our competition in this market includes a variety of ingredient and nutritional supplement companies many of which are privately-held. Therefore, it is difficult to assess the size of all of our segment competitors or where we rank in comparison to such privately-held competitors.
Competition in the animal feed and industrial markets we serve are based primarily on product performance, customer support, quality, service and price. The markets for our products are subject to competitive risks because these markets are highly price competitive. Our competition in this market includes a variety of animal nutrition and health ingredient companies, along with certain industrial companies, many of which are privately-held. Therefore, we are unable to assess the size of all of our competitors or where we rank in comparison to such privately-held competitors.
In the Specialty Products segment, we face competition from alternative sterilizing technologies and products for our performance gases business. Competition in this marketplace is based primarily on service, reliability, quality, and price. Our competition in this market varies globally, many of which are regional privately-held companies. In our plant nutrition business, competition is
3
based primarily on product performance, customer support, quality, and price. The development of new and improved products is also important to our ability to compete. Our competition in this market is primarily regional privately-held companies.
Research & Development
During the years ended December 31, 2021, 2020 and 2019, we incurred research and development expenses of approximately $13,524, $10,332, and $11,377, respectively, on Company-sponsored research and development for new products, improvements to existing products, and manufacturing processes. We have historically funded our research and development programs with funds available from current operations with the intent of recovering those costs from profits derived from future sales of products resulting from, or enhanced by, the research and development effort.
We prioritize our product development activities in an effort to allocate resources to those product candidates that, we believe, have the greatest commercial potential. Factors we consider in determining the products to pursue include projected markets and needs, status of our proprietary rights, technical feasibility, expected and known product attributes, and estimated costs to bring the product to market.
Capital Projects
We continue to invest in projects across all production facilities and capital expenditures were approximately $36,142, $32,080, and $25,790 for 2021, 2020 and 2019, respectively. In 2021, we invested $20,544 on projects expected to provide favorable returns on investment, including expanded capacity in key product lines in the HNH segment. In addition, we invested $3,138 for environmental, health, safety, and security upgrades to our facilities, $2,330 in automation projects that improved quality and efficiency of our operations, and $2,222 in research and development projects. In 2020, we invested $16,856 on projects expected to provide favorable returns on investment, including expanded capacity in key product lines in the HNH segment. In addition, we invested $3,297 for environmental, health, safety, and security upgrades to our facilities as well as $3,252 in automation projects that improved safety and quality of our operations. In 2019, we invested $6,437 to expand capacity in key product lines in the HNH segment and to invest in several other large projects including a new quality and research and development lab. In addition, we invested $3,739 for environmental, health, safety, and security upgrades to our facilities. Capital expenditures are projected to range from $30,000 to $40,000 for 2022, including our continued efforts to invest in energy and water saving projects, while exploring additional renewable energy opportunities in support of the company's sustainability efforts.
Environmental / Regulatory Matters
The Federal Insecticide, Fungicide and Rodenticide Act (“FIFRA”), a health and safety statute, requires that certain products within our Specialty Products segment must be registered with the EPA because they are considered pesticides. In order to obtain a registration, an applicant typically must demonstrate, through extensive test data, that its product will not cause unreasonable adverse effects on human health or the environment. We hold EPA registrations permitting us to sell ethylene oxide as a medical device sterilant and spice fumigant, and propylene oxide as a fumigant of nuts and spices.
In April 2008, the EPA issued a RED (“Reregistration Eligibility Decision”) for ethylene oxide which permitted the continued use of ethylene oxide “to sterilize medical or laboratory equipment, pharmaceuticals, and aseptic packaging, or to reduce microbial load on musical instruments, cosmetics, whole and ground spices and other seasoning materials and artifacts, archival material or library objects”. In 2013, the EPA has initiated a new registration review of ethylene oxide, in line with and part of the registration review scheduled for a large number of other pesticides. When the Final Work Plan was issued in March 2014, the EPA anticipated that this registration review process would take approximately seven years. In December 2016, the EPA issued its Integrated Risk Information System (“IRIS”) assessment of ethylene oxide (the "IRIS Assessment"), another aspect of EPA’s safety review of ethylene oxide. In November 2020, the EPA issued a Draft Human Health Risk Assessment for Ethylene Oxide (Draft HHRA). In this Draft HHRA, the EPA presented multiple perspectives on risk extrapolation, including the IRIS Assessment. While acknowledging the necessity of maintaining the critical uses of ethylene oxide, based on the range of unit risk provided in this qualitative assessment, the EPA has stated that there should be further mitigation measures implemented which will likely require some label changes. Several mitigation measures are under consideration and the EPA anticipates issuance of a Proposed Interim Decision (PID) in 2022. We believe that EPA intends to reregister ethylene oxide for the uses stated above with the mitigation measures potentially impacting certain users, including Balchem and its customers. The product, when used as a sterilant for certain medical devices, has no known equally effective substitute. In October 2019, the U.S. Food and Drug Administration, in a public statement said, "Although medical devices can be sterilized by several methods, ethylene oxide is the most common method of sterilization of medical devices in the U.S. and is a well-established and scientifically-proven method of preventing harmful microorganisms from reproducing and causing infections." Management believes the lack of availability of this product could not be easily tolerated by various medical device manufacturers or the health care industry due to the resultant infection potential.
4
Similarly, the EPA issued a RED for propylene oxide in August 2006. At that time, the EPA “determined that products containing the active ingredient PPO [propylene oxide] are eligible for reregistration provided that…risk mitigation measures…are adopted.” Our product label was amended as required to reflect these mitigation measures and also to show that propylene oxide has been reclassified as a restricted use pesticide. In 2013, the EPA initiated a new registration review of propylene oxide, in line with and part of the registration review scheduled for a large number of other pesticides. A Final Work Plan was issued in March 2014, and EPA anticipated that this review process would take approximately seven years. In October 2020, the EPA issued both the Proposed Interim Registration Review Decision (PID) and Draft Risk Assessment (DRA) for Propylene Oxide (PPO). In July 2021, the EPA issued the Interim Registration Review Decision. Based on these documents, the use of propylene oxide to treat nuts and spices will continue to be permitted with minimal changes to the current approved level. We expect to submit those changes and the EPA to review and approve them, in the coming months.

Our facility in Verona, Missouri, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources (“MDNR”). While we must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. We are indemnified by the sellers under our May 2001 asset purchase agreement covering our acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site and one of the sellers, in turn, has the benefit of certain contractual indemnification by the prior owner that executed the above-described Superfund remedy. In September 2020, BCP Ingredients, Inc. (“BCP”), the Company subsidiary that operates the site received a General Notice Letter from the EPA regarding BCP’s potential liability for contamination at the site and, in February 2022, received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study at the site with regard to the presence of certain contaminants, including 1,4 dioxane,. We have engaged experts to study site conditions and hydrogeology in connection with preparing our response to the notices.
In connection with normal operations at our plant facilities, we are required to maintain environmental and other permits, including those relating to the ethylene oxide operations.
We believe we are in compliance in all material respects with federal, state, local and international provisions that have been enacted or adopted regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. Such compliance includes the maintenance of required permits under air pollution regulations and compliance with requirements of the Occupational Safety and Health Administration. The cost of such compliance has not had a material effect upon the results of our operations or our financial condition.
We produce products which are required to be manufactured in conformity with current Good Manufacturing Practice (“cGMP”) regulations as interpreted and enforced by the FDA, through third party contract arrangement. Modifications, enhancements or changes in contracted manufacturing facilities or procedures relating to our pharmaceutical products are, in many circumstances, subject to FDA approval, which may be subject to a lengthy application process or which we may be unable to obtain. Any contracted manufacturing facilities that manufacture our pharmaceutical products are periodically subject to inspection by the FDA and other governmental agencies, and operations at these facilities could be interrupted or halted if the results of these inspections are unsatisfactory.
Human Capital
Our employees are our most valued asset and fundamental to our success. As of December 31, 2021, we employed approximately 1,317 full-time employees worldwide, with approximately 17% covered by collective bargaining agreements. Although we are facing challenging labor markets, we believe that we have been successful in attracting skilled and experienced personnel in a competitive environment and that our human capital resources are adequate to perform all business functions. In addition, we continue to enhance technology in order to optimize productivity and performance.
Health and Safety
Protecting the workplace environment and the health and safety of our employees, contractors, visitors, and neighbors is our top priority. Our recordable injury rate, which was defined by recordable injuries per 200,000 hours worked, was 0.99 in 2021. We continually upgrade our facilities to reduce risks and establish procedures with appropriate personnel protection for the safety of our employees. Our safety program is structured around five pillars: process safety, personal safety, industrial hygiene, transportation safety and environmental safety, and focuses on driving higher ownership and engagement from employees and contractors.
In response to the COVID-19 pandemic, we effectively deployed our Crisis Management Plan and activated our Crisis Management Team (CMT), to manage the day-to-day activities and make timely decisions related to the safety of our employees,
5
customers, and the communities in which we operate. We implemented significant changes which comply with government orders and Centers for Disease Control and Prevention (CDC) guidelines. These changes include instituting travel restrictions, a mandatory work from home policy for all of our office employees, and additional safety measures for all of our manufacturing and research and development employees.
Diversity and Inclusion
We recognize that our best performance is achieved when our teams are diverse, and accordingly, diversity and inclusion are important elements of Balchem's Human Resources strategy. We strive to promote inclusion through the implementation of inclusive leadership training across the Company and are committed to increasing representation of minorities throughout the organization. In 2021, our total workforce consisted of 76% male and 24% female among all employees and 50% male and 50% female when excluding supply chain and operations functions. With the support of our Board of Directors, we continue to explore additional diversity and inclusion initiatives.
Training and Well-Being Programs
We strive to develop employee skills and knowledge, which includes training for job-specific technical knowledge, regulatory requirements, and company policies, through our internal learning and development platform. The topics of trainings include the Company's Code of Conduct, anti-harassment and discrimination, foreign corrupt practices, antitrust, cyber security, and various other compliance subjects. Our sponsored employee Continuing Learning program offers a broad base of assistance for employees, including learning and development courses. We also deployed unconscious bias and inclusive leadership training to our management team. Employees have access to healthy lifestyle discounts through our Wellness Center, as well as debt, legal, and financial counseling. Leadership programs, peak performance training and multiple online services and courses enable our employees to choose their own learning paths and work towards achieving their goals for education, finances, and overall well-being.
Performance Review, Compensation and Benefits
Our annual performance review process is an important, objective-based dialogue to foster continuous growth and development by providing an opportunity to establish goals and deliver feedback relative to each employee's performance. Balchem's annual review process is closely aligned with a formal succession planning and talent review process designed to identify and develop the next generation of leaders.
We are dedicated to providing full-time employees with a competitive compensation package that includes medical, dental, vision, and prescription benefits in addition to a 401(k) matching program. Balchem also provides financial support for health and wellness programs such as online financial wellness content, sponsored weight loss programs and subsidized gym memberships. We also provide generous time off and leave benefits, which are important to help ensure employees can enjoy a healthy balance between work and family time.
For the year ended December 31, 2021, our turnover rate was 13% for salaried employees with an average length of service of over 10 years. We are continuing to improve employee retention with effective employment engagement efforts, a productive performance review process, and competitive compensation.
Available Information
Our headquarters is located at 52 Sunrise Park Road, New Hampton, NY 10958. Our telephone number is (845) 326-5600 and our Internet website address is www.balchem.com. We make available through our website, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to such reports, as soon as reasonably practicable after they have been electronically filed with the Securities and Exchange Commission (the "SEC"). Such reports are available via a link from the Investor Relations page on our website to a list of our reports on the SEC’s EDGAR website. The address of the SEC's website is www.sec.gov.
Item 1A.    Risk Factors
Our business is subject to a high degree of risk and uncertainty, including the following risks and uncertainties, which could adversely affect our business, financial condition, results of operation, cash flows and the trading price of our Common Stock:
Risks related to COVID-19 Pandemic
Our business, results of operations, financial condition, cash flows and stock price can be adversely affected by pandemics, epidemics or other public health emergencies, such as COVID-19.
6
Our business, results of operations, financial condition, cash flows and stock price can be adversely affected by pandemics, epidemics or other public health emergencies, such as COVID-19. The COVID-19 pandemic has resulted in governments around the world implementing certain measures to help control the spread of the virus, including quarantines, "shelter in place" and "stay at home" orders, travel restrictions, business curtailments, school closures, and other measures.
Our businesses have been deemed "essential" under the orders issued by federal, state and local governments. Although we have continued to operate our facilities to date consistent with federal guidelines and state and local orders, COVID-19 or similar viruses and any preventive or protective actions taken by governmental authorities may have a material adverse effect on our operations, supply chain, customers, and transportation networks, including business shutdowns or disruptions. The extent to which viruses such as COVID-19 and their variants may adversely impact our business depends on future developments, which are highly uncertain and unpredictable, depending upon the severity and duration of any virus outbreak and the effectiveness of actions taken globally to contain or mitigate the effects thereof. Any resulting financial impact cannot be estimated reasonably at this time, but may materially adversely affect our business, results of operations, financial condition and cash flows. Additionally, concerns over the economic impact of COVID-19 and its variants have caused extreme volatility in financial and other capital markets which may adversely impact our stock price and may affect our ability to access capital markets. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described within this report. We have also experienced reductions in the demand for certain of our products due to reductions in elective and non-essential surgical procedures. We implemented mitigation strategies as needed to protect the long-term sustainability of our company and will continue to respond as appropriate.
Business and Financial Risks
Global economic conditions may adversely affect our business, operating results and financial condition.
Unfavorable changes in economic conditions, including inflation, recession, changes in tariffs and trade relations amongst international trading partners, or other changes in economic conditions, may adversely impact the markets in which we operate. These conditions may make it extremely difficult for our customers, our vendors and us to accurately forecast and plan future business activities, and they could cause U.S. and foreign businesses to slow spending on our products which would reduce our revenues and profitability. Furthermore, during challenging economic times our customers may face issues gaining timely access to sufficient credit, which could result in an impairment of their ability to make timely payments to us. If that were to occur, we may be required to increase our allowance for doubtful accounts and cash flow would be negatively impacted. We cannot predict the timing, depth or duration of any economic slowdown or subsequent economic recovery, worldwide, or in the markets in which we operate. Also, at any point in time we have funds in our cash accounts that are with third party financial institutions. These balances in the U.S., Italy, Belgium, Malaysia, Australia, Philippines, and Singapore could exceed the Federal Deposit Insurance Corporation (“FDIC”), Fondo Interbancario di Tutela dei Depositi (“FITD”), Financial Services and Markets Authority ("FSMA"), Perbadanan Insurans Deposit Malaysia ("PIDM"), Australian Prudential Regulation Authority ("APRA"), Philippine Deposit Insurance Corporation ("PDIC"), and Singapore Deposit Insurance Corporation ("SDIC") insurance limits, respectively. While we monitor the cash balances in our accounts, these balances could be impacted if the underlying financial institutions fail or could be subject to other adverse conditions in the financial markets. Additionally, our future results of operations could be adversely affected by changes in the effective tax rate as a result of a change in the mix of earnings in jurisdictions with differing statutory tax rates, changes in tax laws, regulations and judicial rulings or changes in the interpretation thereof.
Raw material shortages or price increases could adversely affect our business and financial results.
The principal raw materials that we use in the manufacture of our products can be subject to price fluctuations due to market conditions and factors beyond our control, including the COVID-19 pandemic and inflationary pressures, both of which have impacted our business over the past two years, accelerated as 2021 progressed and are likely to continue for some time. Such raw materials include materials derived from petrochemicals, minerals, metals, agricultural commodities and other commodities. While the selling prices of our products tend to increase or decrease over time with the cost of raw materials, these changes may not occur simultaneously or to the same degree. At times, including during periods of rapidly increasing raw material prices, we may be unable to pass increases in raw material costs through to our customers due to certain contractual obligations. Such increases in the price of raw materials, if not offset by product price increases, or substitute raw materials, would have an adverse impact on our profitability. We believe we have reliable sources of supply for our raw materials under normal market conditions. We cannot, however, predict the likelihood or impact of any future raw material shortages. Any shortages or unforeseen price increases could have a material adverse impact on our results of operations.
Our international operations subject us to currency translation risk and currency transaction risk which could cause our results to fluctuate from period to period.
7
The financial condition and results of operations of our foreign subsidiaries are reported in Euros, Canadian Dollars, Malaysian Ringgits, Singapore Dollars, Australian Dollars, and Philippine Pesos and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Exchange rates between these currencies in recent years have fluctuated and may do so in the future. Furthermore, we incur currency transaction risk whenever we enter into either a purchase or a sales transaction using a currency different than the functional currency. Given the volatility of exchange rates, we may not be able to effectively manage our currency transactions and/or translation risks. Volatility in currency exchange rates could impact our business and financial results.

On May 28, 2019, we entered into a cross-currency swap to manage foreign exchange risk related to our investment in Chemogas. Although we utilize risk management tools, such as derivative instruments, to mitigate market fluctuations in foreign currencies, any changes in strategy in regard to risk management tools can also affect revenue, expenses and results of operations and there can be no assurance that such measures will result in cost savings or that all market fluctuation exposure will be eliminated.
Our debt instruments impose operating and financial restrictions which could have an adverse impact on our business and results of operations.
Our incurrence of indebtedness could have negative consequences to us, including limiting our ability to borrow additional monies for our working capital, capital expenditures, acquisitions, debt service requirements or other general corporate purposes; limiting our flexibility in planning for, or reacting to, changes in our operations, our business or the industries in which we compete; our leverage may place us at a competitive disadvantage by limiting our ability to invest in the business or in further research and development; making us more vulnerable to downturns in our business or the economy; and there would be a material adverse effect on our business and financial condition if we were unable to service our indebtedness or obtain additional financing, as needed.
Our ability to make payments on our indebtedness depends on our ability to generate cash in the future. If we do not generate sufficient cash flow to meet our debt service and working capital requirements, we may need to seek additional financing or sell assets. This may make it more difficult for us to obtain financing on terms that are acceptable to us, or at all. Without any such financing, we could be forced to sell assets to make up for any shortfall in our payment obligations under unfavorable circumstances.
Interest payable in accordance with our five-year senior secured revolving credit agreement (the "Credit Agreement") is based on a fluctuating rate. In light of potential fluctuations, we are exposed to risk resulting from adverse changes in interest rates.

On May 28, 2019, we entered into an interest rate swap to protect us against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of our outstanding debt. We use LIBOR ("the London interbank offered rate") as a reference rate in the derivative agreements. LIBOR is the basic rate of interest used in lending between banks on the London interbank market and is widely used as a reference for setting the interest rate on loans globally. On July 27, 2017, the United Kingdom’s Financial Conduct Authority (FCA), which regulates LIBOR, initially announced that it intends to phase out LIBOR by the end of 2021. FCA recently has formally announced that it has commitments from panel banks to continue to contribute to LIBOR through June 30, 2023 for USD 1-month, 3-month, and 6-month. From July 1, 2023 to June 30, 2033, LIBOR for these instruments will continue publication on a "synthetic" basis with status of "loss of representativeness", i.e. ending their reliance on panel bank submissions and calculated based on a methodology to primarily assist with a very small subset of existing contracts where it is difficult to move to the new reference rate (so called "tough legacy" contract). In preparation for the phase out of LIBOR, we may need to renegotiate our financial obligations and derivative instruments that utilize LIBOR. However, these efforts may not be successful in mitigating the legal and financial risk from changing the reference rate in our legacy agreements. Furthermore, the discontinuation of LIBOR may adversely impact our ability to manage and hedge exposures to fluctuations in interest rates using derivative instruments.
We may not be able to successfully consummate and manage acquisition, joint venture and divestiture activities which could have an impact on our results.
From time to time, we may acquire other businesses, enter into joint ventures and, based on an evaluation of our business portfolio, divest existing businesses. These acquisitions, joint ventures and divestitures may present financial, managerial and operational challenges, including diversion of management attention from existing businesses, difficulty with integrating or separating personnel and financial and other systems, increased expenses, assumption of unknown liabilities and indemnities, and potential disputes with the buyers or sellers. In addition, we may be required to incur asset impairment charges (including charges related to tangible assets, goodwill and other intangible assets) in connection with acquired businesses which may reduce our profitability. If we are unable to consummate such transactions, or successfully integrate and grow acquisitions and achieve contemplated revenue synergies and cost savings, our financial results could be adversely affected. Additionally, joint ventures
8
inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks.
Changes in our relationships with our vendors, changes in tax or trade policy, interruptions in our operations or supply chain or increased commodity or supply chain costs could adversely affect our results of operations.
We are dependent on our vendors, including common carriers, to supply merchandise to our distribution centers, stores, and guests. As we continue to add capabilities to quickly move the appropriate amount of inventory at optimal operational costs through our entire supply chain, operating our fulfillment network becomes more complex and challenging. If our fulfillment network does not operate properly, if a vendor fails to deliver on its commitments, or if common carriers have difficulty providing capacity to meet demands for their services like they experienced at times during the last two years, we could experience merchandise out-of-stocks, delivery delays or increased delivery costs, which could lead to lost sales and decreased guest confidence, and adversely affect our results of operations.
A large portion of our merchandise is sourced, directly or indirectly, from outside the U.S. Any major changes in tax or trade policy, such as the imposition of additional tariffs or duties on imported products, between the U.S. and countries from which we source merchandise could require us to take certain actions, including for example raising prices on products we sell and seeking alternative sources of supply from vendors in other countries with whom we have less familiarity, which could adversely affect our reputation, sales, and our results of operations.
Political or financial instability, currency fluctuations, the outbreak of pandemics or other illnesses (such as the COVID-19 pandemic), labor unrest, transport capacity and costs, port security, weather conditions, natural disasters, or other events that could alter or suspend our operations, slow or disrupt port activities, or affect foreign trade are beyond our control and could materially disrupt our supply of merchandise, increase our costs, and/or adversely affect our results of operations. There have been periodic labor disputes impacting the U.S. ports that have caused us to make alternative arrangements to continue the flow of inventory, and if these types of disputes recur, worsen, or occur in other countries through which we source products, it may have a material impact on our costs or inventory supply. Changes in the costs of procuring commodities used in our merchandise or the costs related to our supply chain, could adversely affect our results of operations.
Adverse publicity or consumer concern regarding the safety or quality of food products containing our products, or health concerns, whether with our products, products in the same general class as our products or for food products containing our products, may result in the loss of sales. Also, consumer preferences for products containing our products may change.
We are dependent upon consumers’ perception of the safety, quality and possible dietary benefits of products containing our food ingredient products. As a result, substantial negative publicity concerning our products or other foods and beverages in which our products are used could lead to a loss of consumer confidence in those products, removal of those products from retailers’ shelves and reduced sales and prices of our products. Product quality issues, actual or perceived, or allegations of product contamination, even when false or unfounded, could hurt the image of our products or of brands of products containing our products, and cause consumers to choose other products. Further, any product recall, whether our own or by a third party, whether due to real or unfounded allegations, could impact demand on food products containing our products or even our products.  Any of these events could have a material adverse effect on our business, results of operations and financial condition.  Consumer preferences, as well as trends, within the food industries change often and our failure to anticipate, identify or react to changes in these preferences and trends could, among other things, lead to reduced demand and price reductions, and could have an adverse effect on our business, results of operations and financial condition. While we continue to diversify our product offerings, developing new products entails risks and we cannot be certain that demand for our products and products containing our products will continue at current levels or increase in the future.
Operational Risks
Our financial success depends in part on the reliability and sufficiency of our manufacturing facilities.
Our revenues depend on the effective operation of our manufacturing, packaging, and processing facilities. The operation of our facilities involves risks, including the breakdown, failure, or substandard performance of equipment, power outages, the improper installation or operation of equipment, explosions, fires, natural disasters, failure to achieve or maintain safety or quality standards, work stoppages, supply or logistical outages, and the need to comply with environmental and other directives of governmental agencies. The occurrence of material operational problems, including, but not limited to, the above events, could adversely affect our profitability during the period of such operational difficulties.
We face risks associated with our sales to customers and manufacturing operations outside the United States.
9
For the year ended December 31, 2021, approximately 27% of our net sales consisted of sales outside the United States. In addition, we conduct a portion of our manufacturing outside the United States. The majority of our foreign sales occur through our foreign subsidiaries and the remainder of our foreign sales result from exports to foreign distributors, resellers and customers. Our foreign sales and operations are subject to a number of risks, including: longer accounts receivable collection periods; the impact of recessions and other economic conditions in economies outside the United States; export duties and quotas; changes in tariffs and trade relations including but not limited to those associated with the North American Free Trade Agreement and the exit of the United Kingdom from the European Union; unexpected changes in regulatory requirements; certification requirements; environmental regulations; reduced protection for intellectual property rights in some countries; potentially adverse tax consequences; political and economic instability; and preference for locally produced products. These factors could have a material adverse impact on our ability to increase or maintain our international sales.
We may, from time to time, experience problems in our labor relations.
In North America, approximately 91 employees, or 8% of our North American workforce, as of December 31, 2021, are represented by a union under a single collective bargaining agreement, which was re-negotiated and is effective as of July 12, 2020. It will expire in 2025. In Europe, approximately 107 employees at our Marano, Ticino, Italy facility are covered by a national collective bargaining agreement, which expires in 2022. Approximately 25 employees at our Bertinoro, Italy facility are also covered by a national collective bargaining agreement, which expired in 2019 and is currently under negotiation. We believe that our present labor relations with all our union employees are satisfactory, however, our failure to renew these agreements on reasonable terms could result in labor disruptions and increased labor costs, which could adversely affect our financial performance. Similarly, if our relations with the union portion of our workforce do not remain positive, such employees could initiate a strike, work stoppage or slowdown in the future. In the event of such an action, we may not be able to adequately meet the needs of our customers using our remaining workforce and our operations and financial condition could be adversely affected. Additionally, other portions of our workforce could become subject to union campaigns.
Technology failures or cyber security breaches could have an adverse effect on the Company’s operations.
We rely on information technology systems to process, transmit, store, and protect electronic information. For example, a significant portion of the communications between our personnel, customers, and suppliers depend on information technology. Our information technology systems may be vulnerable to a variety of interruptions due to events beyond our control including, but not limited to, natural disasters, terrorist attacks, telecommunications failures, computer viruses, hackers, and other security issues. We have technology and information security processes and disaster recovery plans in place to mitigate our risk to these vulnerabilities; however, these measures may not be adequate to ensure that our operations will not be disrupted, should such an event occur. The Company has not experienced any significant information security breaches and as a result, has not incurred any expenses with respect thereto, either with respect to penalties and settlement or otherwise. We have a robust cyber security employee education program and train our employees on email and password security, recognizing phishing and related topics on a regular basis.
Legal Risks
Our business exposes us to potential product liability claims and recalls, which could adversely impact our financial condition and performance.
Our development, manufacture and sales of food ingredient, pharmaceutical and nutritional supplement products involve an inherent risk of exposure to product liability claims, product recalls, product seizures and related adverse publicity. A product liability judgment against us could also result in substantial and unexpected expenditures, affect consumer confidence in our products, and divert management’s attention from other responsibilities. Although we maintain product liability insurance coverage in amounts we believe are customary within the industry, there can be no assurance that this level of coverage is adequate or that we will be able to continue to maintain our existing insurance or obtain comparable insurance at a reasonable cost, if at all. A product recall or a partially or completely uninsured judgment against us could have a material adverse effect on results of operations and financial condition.
Regulatory and Compliance Risks
The loss of governmental permits and approvals would materially harm some of our businesses.
Pursuant to applicable environmental and safety laws and regulations, we are required to obtain and maintain certain governmental permits and approvals, including EPA registrations under FIFRA for two of our products. We maintain EPA FIFRA registrations for ethylene oxide as a medical device sterilant and spice fumigant and for propylene oxide as a fumigant of nuts and spices. The registrations for both products are in the final stages of a FIFRA registration review process begun in 2013. Recent
10
draft documents indicate that the EPA intends to continue the registrations for both ethylene oxide and propylene oxide with certain additional mitigation measures. The EPA may re-examine the registrations in the future in accordance with the provisions of FIFRA. Any future failure of the EPA to allow reregistration of ethylene oxide or propylene oxide would have a material adverse effect on our business and financial results.
Commercial supply of pharmaceutical products that we may develop, subject to cGMP manufacturing regulations, will be performed by third-party cGMP manufacturers. Modifications, enhancements or changes in third-party manufacturing facilities or procedures of our pharmaceutical products are, in many circumstances, subject to FDA approval, which may be subject to a lengthy application process or which we may be unable to obtain. Any third-party cGMP manufacturers that we may use are periodically subject to inspection by the FDA and other governmental agencies, and operations at these facilities could be interrupted or halted if the results of these inspections are unsatisfactory. Failure to comply with the FDA or other governmental regulations can result in fines, unanticipated compliance expenditures, recall or seizure of products, total or partial suspension of production, enforcement actions, injunctions and criminal prosecution, which could have a material adverse effect on our business and financial results.
Permits and approvals may be subject to revocation, modification or denial under certain circumstances. Our operations or activities (including the status of compliance by the prior owner of the Verona, Missouri facility under Superfund remediation) could result in administrative or private actions, revocation of required permits or licenses, or fines, penalties or damages, which could have an adverse effect on us. In addition, we cannot predict the extent to which any legislation or regulation may affect the market for our products or our cost of doing business.
Concerns about ethylene oxide emissions have resulted in certain state actions against certain of our customers that are currently impacting these customers’ ability to use the ethylene oxide process to sterilize medical devices, which may, in turn, affect sales to these customers.
Certain of the Company’s customers who use ethylene oxide in the USA for the sterilization of medical devices have received ongoing state and local scrutiny for environmental concerns at their facilities. This scrutiny is associated with the IRIS Assessment described in the “Environmental / Regulatory Matters” Section above, which deemed exposure to ethylene oxide as unsafe at levels far below those found in the environment. The EPA began using the IRIS Assessment in 2020 to regulate change to existing permissible emissions’ limits at certain non-sterilization ethylene oxide users and producers, and is expected to finalize rules during 2022 that will regulate sterilization users. Additionally, some state and local regulators have drawn their own conclusions from the IRIS Assessment, which has resulted in certain state actions against our customers that are currently impacting, or have impacted at some point, these customers’ ability to use the ethylene oxide process to sterilize medical devices. Because of these actions, one customer facility has been shut down permanently, another was shut down for a period of months and has since restarted, and other customers have taken or are expected to take voluntary downtime to install new abatement equipment. The installation of the new abatement equipment is being done ahead of what is expected to be changes in the EPA regulations. The Company remains confident that the sterilization industry will be able to install abatement equipment to satisfy the new forthcoming EPA requirements. The Company is working with various stakeholders to ensure the EPA considers all available assessments to appropriately quantify ethylene oxide's risks. While the Company believes that EPA will, as it has in the past, ultimately regulate to lower emissions levels based on a combined consideration of the various assessments available and that industry will then adopt practices and procedures to ensure compliance with these new regulations, there is no assurance that this will be the case.
General Risks
Increased competition could hurt our business and financial results.
We face competition in our markets from a number of large and small companies, some of which have greater financial, research and development, production and other resources than we do. Our competitive position is based principally on performance, quality, customer support, service, breadth of product line, manufacturing or packaging technology and the selling prices of our products. Our competitors may improve the design and performance of their products and introduce new products with competitive price and performance characteristics. We expect to do the same to maintain our current competitive position and market share.

Item 1B.    Unresolved Staff Comments
None.
11
Item 2.        Properties
Our corporate headquarters is located in New Hampton, New York. Our operations are conducted at our owned and leased facilities throughout the U.S. and other foreign countries. These facilities house manufacturing and warehousing operations, as well as administrative offices. We have total 32 locations across the world and some of these locations serve multiple segments.
The following is a summary of our principal properties:

SegmentLocationAdministrativeManufacturingWarehousing
Corporate4 U.S. cities4--
HNH14 U.S. cities and 3 foreign countries2123
ANH5 U.S. cities and 4 foreign countries18-
Specialty Products5 U.S. cities and 7 foreign countries291
Other1 U.S. city and 1 foreign country-2-

We believe that our production facilities and related machinery and equipment are well maintained, suitable for their purpose, and adequate to support our businesses.

Item 3.        Legal Proceedings
We are involved in legal proceedings through the normal course of business. Management believes that any unfavorable outcome related to these proceedings will not have a material effect on our financial position, results of operations or liquidity.

Item 4.        Mine Safety Disclosures
None.

PART II
Item 5.        Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
The Common Stock is listed on the Nasdaq Global Market under the symbol “BCPC.”
On February 10, 2022 the closing price for the Common Stock on the Nasdaq Global Market was $138.07.
Record Holders
As of February 10, 2022, the approximate number of holders of record of Common Stock was 64. Such number does not include stockholders who hold their stock in street name.

12

Performance Graph
The graph below sets forth the cumulative total stockholder return on the Common Stock (referred to in the table as “BCPC”) for the five years ended December 31, 2021, the overall stock market return during such period for shares comprising the Russell 2000® Index (which we believe includes companies with market capitalization similar to that of us), and the overall stock market return during such period for shares comprising the Dow Jones U.S. Specialty Chemicals Index, in each case assuming a comparable initial investment of $100 on December 31, 2016 and the subsequent reinvestment of dividends. The Russell 2000® Index measures the performance of the shares of the 2000 smallest companies included in the Russell 3000® Index. In light of our industry segments, we do not believe that published industry-specific indices are necessarily representative of stocks comparable to us. Nevertheless, we consider the Dow Jones U.S. Specialty Chemicals Index to be potentially useful as a peer group index with respect to us. The performance of the Common Stock shown on the graph below is historical only and not necessarily indicative of future performance.
bcpc-20211231_g1.jpg

13
Issuer Purchase of Equity Securities
The following table summarizes the share repurchase activity for the year ended December 31, 2021:

 
Total Number of Shares
Purchased (1)
Average Price Paid Per Share
Total Number of Shares
Purchased as
Part of Publicly Announced
Programs(1)
Approximate Dollar Value of Shares that May Yet Be
Purchased Under the
Plans or Programs
January 1-31, 2021— $— — $123,071,229 
February 1-28, 202113,475 $118.41 13,475 $139,860,344 
March 1-31, 2021— $— — $139,860,344 
     First Quarter13,475 13,475 
April 1-30, 202116,838 $119.89 16,838 $139,592,155 
May 1-31, 202151,623 $129.34 51,623 $143,914,129 
June 1-30, 20214,188 $129.99 4,188 $144,099,802 
     Second Quarter 72,649 72,649 
July 1-31, 202145,129 $129.67 45,129 $137,892,532 
August 1-31, 202115,099 $129.62 15,099 $135,874,343 
September 1-30, 2021847 $138.98 847 $145,574,840 
     Third Quarter61,075 61,075 
October 1-31, 20212,926 $150.28 2,926 $156,973,021 
November 1-30, 202120,147 $160.29 20,147 $164,200,063 
December 1-31, 202179,576 $160.95 79,576 $152,061,457 
     Fourth Quarter102,649  102,649  
Total249,848 249,848 
(1) Our Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,818,244 shares have been purchased. There is no expiration for this program.

Item 6.        [Reserved]


Item 7.        Management’s Discussion and Analysis of Financial Condition and Results of Operations
(All amounts in thousands, except share and per share data)
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Consolidated Financial Statements and the related notes included in this report. Refer to Part II, Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (filed with the SEC on February 19, 2021) for additional discussion of our financial condition and results of operations for the year ended December 31, 2019, as well as our financial condition and results of operations for the year ended December 31, 2020 compared to the year ended December 31, 2019. Those statements in the following discussion that are not historical in nature should be considered to be forward-looking statements that are inherently uncertain. See “Cautionary Statement Regarding Forward-Looking Statements.”

Overview
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition & Health, Animal Nutrition &
14
Table of Contents
Health, and Specialty Products, as more fully described in Note 11 of the consolidated financial statements. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Balchem is committed to solving today's challenges to shape a healthier tomorrow by operating responsibly and providing innovative solutions for the health and nutritional needs of the world. Sustainability is at the heart of our company's vision to make the world a healthier place, and we proudly support the Ten Principles of the United Nations Global Compact on human rights, labor, environment and anti-corruption. In January 2022, Balchem was named one of America’s Most Responsible Companies by Newsweek magazine for the second consecutive year. This list, compiled by Newsweek in partnership with Statista Inc., recognizes the most responsible companies in the U.S. across a variety of industries, and is based on publicly available environmental, social and governance (ESG) data. Our Sustainability Framework focuses on the most critical ESG topics relevant to our business and stakeholders. We are very proud of our ESG accomplishments to date and are pleased with the recognition by Newsweek. Balchem will continue to foster these fundamental principles broadly along our entire value chain, develop new ideas and technologies that help us work smarter, and help build a world that is a better place to live.
COVID-19 Response
The COVID-19 response effort has been a primary focus for us since early last year. Our focus has been on employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate.
As a result of our broad based risk mitigation efforts of the direct impacts of the Covid-19 pandemic, our manufacturing sites have been operating at near normal conditions, our research and development teams have continued to innovate in our laboratories, and all of our other employees have been effectively carrying on their responsibilities and functions remotely or in a reduced density hybrid setting.
We are increasingly focused on managing the extraordinary supply chain disruptions that are challenging the markets we operate within that are, at least in part, related to the pandemic and/or the global recovery from the pandemic. We are experiencing severe input cost inflation, raw material shortages, logistics disruptions, and labor availability issues. These indirect pandemic related challenges accelerated as 2021 progressed and are likely to continue for some time.

Segment Results
We sell products for all three segments through our own sales force, independent distributors, and sales agents.
The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three years ended December 31, 2021, 2020 and 2019 (in thousands):

15
Table of Contents
Business Segment Net Sales
202120202019
Human Nutrition & Health$442,733 $400,330 $347,433 
Animal Nutrition & Health226,776 192,191 177,557 
Specialty Products117,020 103,566 92,257 
Other and Unallocated (1)
12,494 7,557 26,458 
Total$799,023 $703,644 $643,705 
Business Segment Earnings From Operations
202120202019
Human Nutrition & Health$76,031 $61,397 $48,429 
Animal Nutrition & Health26,179 29,979 25,868 
Specialty Products30,020 26,801 28,513 
Other and Unallocated (1)
(4,728)(7,030)(257)
Total$127,502 $111,147 $102,553 
(1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,264, $2,410 and $3,436 for years ended December 31, 2021, 2020 and 2019, respectively, and (ii) Unallocated amortization expense of $2,510, $1,606, and $551 for years ended December 31, 2021, 2020, and 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.
Acquisitions

On December 13, 2019, the Company completed an acquisition of Zumbro. The Company made payments of $52,403 on the acquisition date, amounting to $47,058 to the former shareholders and $5,345 to Zumbro's lenders to pay Zumbro debt. Considering the cash acquired of $686, net payments made to the former shareholders were $46,372. In May 2020, we received an adjustment for working capital acquired of $561. Zumbro is integrated within the HNH Segment.

On May 27, 2019, we acquired Chemogas. We made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay off all Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690). Chemogas is integrated within the Specialty Products Segment.

RESULTS OF OPERATIONS
(All amounts in thousands, except share and per share data)
Fiscal Year 2021 compared to Fiscal Year 2020
Net Earnings
(in thousands)20212020Increase
(Decrease)		% Change
Net sales$799,023 $703,644 $95,379 13.6 %
Gross margin243,174 223,897 19,277 8.6 %
Operating expenses115,672 112,750 2,922 2.6 %
Earnings from operations127,502 111,147 16,355 14.7 %
Other expenses2,269 4,730 (2,461)(52.0)%
Income tax expense29,129 21,794 7,335 33.7 %
Net earnings$96,104 $84,623 $11,481 13.6 %
16
Table of Contents
Net Sales
Increase
(Decrease)
(in thousands)20212020% Change
Human Nutrition & Health$442,733 $400,330 $42,403 10.6 %
Animal Nutrition & Health226,776 192,191 34,585 18.0 %
Specialty Products117,020 103,566 13,454 13.0 %
Other12,494 7,557 4,937 65.3 %
Total$799,023 $703,644 $95,379 13.6 %

•The increase in net sales within the Human Nutrition & Health segment for 2021 as compared to 2020 was primarily attributed to sales growth within food, beverage, and nutrition markets. Total sales for this segment grew 10.6%, with average selling prices contributing 9.3%, volume and mix contributing 1.2%, and the change in foreign currency exchange rates contributing 0.1%.
•The increase in net sales within the ANH segment for 2021 compared to 2020 was primarily the result of higher sales in both monogastric and ruminant animal markets. Total sales for this segment grew 18.0%, with average selling prices contributing 10.6%, volume and mix contributing 6.3%, and the change in foreign currency exchange rates contributing 1.2%.
•The increase in Specialty Products segment sales for 2021 compared to 2020 was primarily due to year over year sales growth in both the medical device sterilization market and plant nutrition business. Total sales for this segment increased 13.0%, with average selling prices contributing 8.6%, volume and mix contributing 3.4%, and the change in foreign currency exchange rates contributing 1.1%.
•Sales relating to Other increased from the prior year due to higher demand.
•Sales may fluctuate in future periods based on macroeconomic conditions, competitive dynamics, changes in customer preferences, and our ability to successfully introduce new products to the market.
Gross Margin
(in thousands)20212020Increase
(Decrease)		% Change
Gross margin$243,174 $223,897 $19,277 8.6 %
% of net sales30.4 %31.8 %
Gross margin dollars increased in 2021 compared to 2020 due to the aforementioned higher sales of $95,379, partially offset by an increase in cost of goods sold of $76,102. The 15.9% increase in cost of goods sold was primarily driven by the significant inflation of manufacturing input costs, primarily related to raw materials. Price increases lagged this inflation, leading to a 140 basis point decrease in gross margin as a percentage of sales.
Operating Expenses
(in thousands)20212020Increase
(Decrease)		% Change
Operating expenses$115,672 $112,750 $2,922 2.6 %
% of net sales14.5 %16.0 %
The increase in operating expenses was primarily due to certain higher compensation-related costs of $8,748, partially offset by a decrease in consulting costs and outside services of $3,000, a decrease in amortization and depreciation expenses of $1,392, and the timing of an insurance recovery amounting to $1,051.
17
Table of Contents
Earnings From Operations
(in thousands)20212020Increase
(Decrease)		% Change
Human Nutrition & Health$76,031 $61,397 $14,634 23.8 %
Animal Nutrition & Health26,179 29,979 (3,800)(12.7)%
Specialty Products30,020 26,801 3,219 12.0 %
Other and unallocated(4,728)(7,030)2,302 32.7 %
Earnings from operations$127,502 $111,147 $16,355 14.7 %
% of net sales (operating margin)16.0 %15.8 %

•Earnings from operations for the Human Nutrition & Health segment increased primarily due to the aforementioned higher sales and a 60 basis point increase in gross margin.
•Animal Nutrition & Health segment earnings from operations decreased primarily due to a 430 basis point decrease in gross margin as a percentage of sales, driven by a significant increase in certain manufacturing input costs, primarily related to raw materials, partially offset by the aforementioned higher sales. Additionally, total operating expenses for this segment increased by $3,240, primarily due to higher compensation-related costs of $3,031.
•The increase in earnings from operations for the Specialty Products segment was primarily due to the aforementioned higher sales, partially offset by a 240 basis point decrease in gross margin as a percentage of sales, driven by a significant increase in certain manufacturing input costs, primarily related to raw materials.
•The increase in Other and unallocated was primarily driven by a decrease in transaction and integration costs of $1,562 and the prior year being negatively impacted by a goodwill impairment charge related to business formerly included in the Industrial Products segment of $1,228, partially offset by an increase in costs related to a company-wide ERP implementation of $1,300.

Other Expenses (Income)
(in thousands)20212020Increase
(Decrease)		% Change
Interest expense, net$2,456 $4,439 $(1,983)(44.7)%
Other, net(187)291 (478)(164.3)%
$2,269 $4,730 $(2,461)(52.0)%

Interest expense for 2021 and 2020 was primarily related to outstanding borrowings under our credit facility. The decrease was due to a reduction in borrowings during 2021.
Income Tax Expense
(in thousands)20212020Increase
(Decrease)		% Change
Income tax expense (benefit)$29,129 $21,794 $7,335 33.7 %
Effective tax rate23.3 %20.5 %

Our effective tax rate for 2021 and 2020 was 23.3% and 20.5%, respectively. The increase was primarily due to a reduction in certain tax credits, lower tax benefits from stock-based compensation, and higher enacted state tax rates.
18
Table of Contents
LIQUIDITY AND CAPITAL RESOURCES
(All amounts in thousands, except share and per share data)
Contractual Obligations
Our short-term purchase obligations primarily include contractual arrangements in the form of purchase orders with suppliers. As of December 31, 2021, such purchase obligations were $123,828. For debt obligations, see Note 8, Revolving Loan, and for operating and finance lease obligations, see Note 16 Commitments and Contingencies.
The contractual obligations exclude a $5,881 liability for uncertain tax positions, including the related interest and penalties, recorded in accordance with ASC 740-10, as we are unable to reasonably estimate the timing of settlement, if any.

We know of no current or pending demands on, or commitments for, our liquid assets that will materially affect our liquidity.

We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so.

Cash

Cash and cash equivalents increased to $103,239 at December 31, 2021 from $84,571 at December 31, 2020.  At December 31, 2021, we had $52,071 of cash and cash equivalents held by our foreign subsidiaries.  We presently intend to permanently reinvest these funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund U.S. operations or obligations. However, if these funds are needed for U.S. operations, we could be required to pay additional withholding taxes to repatriate these funds. Working capital was $178,430 at December 31, 2021 as compared to $172,460 at December 31, 2020, an increase of $5,970. Working capital reflects the payment of the 2020 declared dividend in 2021 of $18,723, net payments on the revolving debt of $55,000, capital expenditures and intangible assets acquired of $37,449, and common stock repurchases of $35,239.
(in thousands)20212020Increase
(Decrease)		% Change
Cash flows provided by operating activities$160,514 $150,494 $10,020 6.7 %
Cash flows used in investing activities(35,300)(34,591)(709)(2.0)%
Cash flows used in financing activities(102,178)(101,164)(1,014)(1.0)%
Operating Activities
The increase in cash flows from operating activities was primarily due to increased earnings and improved changes in assets and liabilities.
Investing Activities
We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $37,449 and $33,828 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, capital expenditures are projected to range from $30,000 to $40,000 for 2022. As mentioned above, we expect that our operations will continue to generate sufficient cash flow to fund the commitments for capital expenditures. These capital expenditures are part of our continuous efforts to support our growing businesses.
Financing Activities
We borrowed $5,000 against the revolving loan and made total debt payments of $60,000 during 2021, resulting in $391,431 available under the Credit Agreement as of December 31, 2021.
We have an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,818,244 shares have been purchased. We repurchase shares from employees in connection with settlement of transactions under our equity incentive plans. We also intend to acquire shares from time to time at
19
Table of Contents
prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors.

Proceeds from stock options exercised were $6,943 and $14,155 for the years ended December 31, 2021 and 2020, respectively. Dividend payments were $18,723 and $16,705 during 2021 and 2020, respectively.
Other Matters Impacting Liquidity
We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 15 – Employee Benefit Plans. The liability recorded in other long-term liabilities on the consolidated balance sheets as of December 31, 2021 and December 31, 2020 was $1,293 and $1,374, respectively, and the plans are not funded.  Historical cash payments made under these plans have typically been less than $200 per year. We do not anticipate any changes to the payments made in the current year for the plans.

On June 1, 2018, we established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees.  Assets of the plan are held in a rabbi trust, which are included in non-current assets on our balance sheet. They are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company.  The deferred compensation liability as of December 31, 2021 and December 31, 2020 was $6,270 and $3,581, respectively, and is included in other long-term obligations on our balance sheet.

Chemogas has an unfunded defined benefit plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on our balance sheet as of December 31, 2021 and December 31, 2020 was $684 and $950, respectively, and was included in other long-term obligations.

Related Party Transactions

We were engaged in related party transactions with St. Gabriel CC Company, LLC for the years ended December 31, 2021 and December 31, 2020. Refer to Note 18, "Related Party Transactions".

Critical Accounting Estimates

Critical accounting estimates are those estimates made in accordance with generally accepted accounting principles that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Our management is required to make these critical accounting estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.

Our “critical accounting estimates” are those that require application of management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and that may change in subsequent periods. Management considers the following to be critical accounting estimates.

Goodwill and Intangible Assets

The valuation methods and assumptions used in assessing the impairment of goodwill and identified intangibles, as well as determining the useful life of an intangible asset involve a significant level of estimation uncertainty. Refer to the Goodwill and Acquired Intangible Assets section in Note 1, "Business Description and Summary of Significant Accounting Policies," for details related to the valuation and impairment process of both goodwill and intangible assets. Changes in market conditions, laws and regulations, and key assumptions made in future quantitative assessments, including expected cash flows, competitive factors and discount rates, could result in the recognition of an impairment charge, and in turn could have a material impact on our financial condition or results of operations in subsequent periods.

Significant Accounting Policies and Recent Accounting Pronouncements

See Note 1 in Notes to Consolidated Financial Statements regarding significant accounting policies and recent accounting pronouncements.

20
Table of Contents
Item 7A.     Quantitative and Qualitative Disclosures About Market Risk

Our cash and cash equivalents are held primarily in certificates of deposit and money market investment funds. In the second quarter of 2019, we entered into an interest rate swap and cross-currency swap for hedging purposes. Refer to details noted below (see Note 20). Additionally, as of December 31, 2021, our borrowings were under a revolving loan bearing interest at a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon our consolidated net leverage ratio, as defined in the Credit Agreement. A 100 basis point increase or decrease in interest rates, applied to our borrowings at December 31, 2021, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately $1,086. We are exposed to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of raw material pricing arising in our business activities. We manage these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change.

Interest Rate Risk

We have exposure to market risk for changes in interest rates, including the interest rate relating to our credit agreement dated June 27, 2018. In the second quarter of 2019, we began to manage our interest rate exposure through the use of derivative instruments. All of our derivative instruments are utilized for risk management purposes, and are not used for trading or speculative purposes. We have hedged a portion of our floating interest rate exposure using an interest rate swap (see Note 20, "Derivative Instruments and Hedging Activities"). As of December 31, 2021, the notional amount of our outstanding interest rate swap was $108,569.

Foreign Currency Exchange Risk

The financial condition and results of operations of our foreign subsidiaries are reported in Euros, Canadian Dollars, Malaysian Ringgits, Singapore Dollars, Australian Dollars, and Philippine Pesos and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Therefore, we are exposed to foreign currency exchange risk related to these currencies. Specifically, we are exposed to changes in exchange rates between the U.S. dollar and Euro. In the second quarter of 2019, we entered into a cross-currency swap, with a notional amount of $108,569, which we designated as a hedge of our net investment in Chemogas (see Note 20, "Derivative Instruments and Hedging Activities").
21
Table of Contents
Item 8.        Financial Statements and Supplementary Data

22
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Balchem Corporation
Opinions on the Financial Statements and Internal Control Over Financial Reporting
We have audited the accompanying consolidated balance sheets of Balchem Corporation and subsidiaries (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of earnings, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and schedule listed at Item 8 (collectively, the financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

Basis for Opinions
The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control Over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
23
Table of Contents
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

Valuation of Reporting Units for Goodwill Impairment Testing
As described in Note 1 and 6 to the financial statements, the Company’s goodwill balance was $524 million as of December 31, 2021. The Company performed an annual goodwill impairment test as of October 1, 2021 using a quantitative evaluation for each of its reporting units. The Company determines the fair value of its reporting units using the income approach, based on a discounted cash flow valuation model. To test for goodwill impairment, the Company compares the fair value of each reporting unit to its carrying value. When determining the fair value of each reporting unit, management makes significant estimates and assumptions related to a number of factors. The Company considers the impact of factors that are specific to each of the reporting units such as industry and economic changes as well as projected revenue and expense growth rates based upon annual budgets and longer-range strategic plans, which are highly sensitive to changes in domestic and foreign economic conditions, and the selection of appropriate discount rates.

Given the significant estimates and assumptions management makes to determine the fair value of the reporting units and the sensitivity of the operations to changes in U.S. and foreign economic conditions, we identified management’s assumptions related to the revenue and expense growth rates, the discount rates, and the terminal value calculation utilized in the valuation of the reporting units utilized in the Company’s goodwill impairment tests as a critical audit matter. Auditing the reasonableness of management’s estimates and assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.

Our audit procedures related to revenue and expense growth rates, discount rates, and the terminal value calculation utilized in the valuation of the Company’s reporting units included the following, among others:

•We obtained an understanding of the relevant controls related to the valuation of the Company’s reporting units and tested such controls for design and operating effectiveness, including management review controls related to revenue and expense growth rates and the selection of appropriate discount rates.
•We evaluated the reasonableness of management’s forecasted revenue and expense growth rates by comparing actual results to management’s historical forecasts.
•Due to the uncertain U.S and foreign economic growth, we evaluated the reasonableness of management’s forecasts of revenue and expense growth rates by comparing the forecasts to (1) the historical results, (2) internal communications to management and the Board of Directors, and (3) external communications made by management to analysts and investors.
•We evaluated changes in the regulatory environment using industry reports containing analysis of the Company’s markets and assessed whether these changes were reflected in management’s forecasts of revenue and expense growth rates.
•With the assistance of our fair value specialists, we evaluated the reasonableness of the discount rates and tested the relevance and reliability of source information underlying the determination of the discount rates, tested the mathematical accuracy of the calculation, and developed a range of independent estimates and compared those to the discount rates selected by management.
•With the assistance of our fair value specialists, we evaluated the reasonableness and tested the mathematical accuracy of the terminal value calculation.

/s/ RSM US LLP

We have served as the Company's auditor since 2004.
New York, New York
February 24, 2022

24
Table of Contents
BALCHEM CORPORATION
Consolidated Balance Sheets
December 31, 2021 and 2020
(Dollars in thousands, except share and per share data)
20212020
Current assets:
Cash and cash equivalents$103,239 $84,571 
Accounts receivable, net of allowance for doubtful accounts of $928 and $2,092 at December 31, 2021 and 2020, respectively
117,408 98,214 
Inventories, net91,058 70,620 
Prepaid expenses6,116 6,598 
Prepaid income taxes— 3,447 
Other current assets4,411 3,438 
Total current assets322,232 266,888 
Property, plant and equipment, net237,517 228,096 
Goodwill523,949 529,463 
Intangible assets with finite lives, net94,665 121,660 
Right of use assets - operating leases6,929 5,838 
Right of use assets - finance lease2,359 2,572 
Other assets11,674 11,326 
Total assets$1,199,325 $1,165,843 
Liabilities and Stockholders’ Equity
Current liabilities:
Trade accounts payable$56,243 $23,742 
Accrued expenses43,411 29,655 
Accrued compensation and other benefits19,567 19,753 
Dividends payable20,886 18,941 
Income tax payable1,334 — 
Operating lease liabilities - current2,194 2,178 
Finance lease liabilities - current167 159 
Total current liabilities143,802 94,428 
Revolving loan108,569 163,569 
Deferred income taxes46,455 51,359 
Operating lease liabilities - non-current4,811 3,607 
Finance lease liabilities - non-current2,303 2,472 
Derivative liabilities2,658 11,658 
Other long-term obligations13,712 10,517 
Total liabilities322,310 337,610 
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding
— — 
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,287,150 shares issued and outstanding at December 31, 2021 and 32,372,621 shares issued and outstanding at December 31, 2020, respectively
2,154 2,160 
Additional paid-in capital147,716 165,160 
Retained earnings732,138 656,740 
Accumulated other comprehensive (loss)/income(4,993)4,173 
Total stockholders’ equity877,015 828,233 
Total liabilities and stockholders’ equity$1,199,325 $1,165,843 
See accompanying notes to consolidated financial statements.
25
Table of Contents
BALCHEM CORPORATION
Consolidated Statements of Earnings
Years Ended December 31, 2021, 2020 and 2019
(In thousands, except per share data)
202120202019
Net sales$799,023 $703,644 $643,705 
Cost of sales555,849 479,747 432,338 
Gross margin243,174 223,897 211,367 
Operating expenses:
Selling expenses60,413 58,630 60,932 
Research and development expenses13,524 10,332 11,377 
General and administrative expenses41,735 43,788 36,505 
115,672 112,750 108,814 
Earnings from operations127,502 111,147 102,553 
Other expenses:
Interest expense, net2,456 4,439 5,959 
Other, net(187)291 116 
2,269 4,730 6,075 
Earnings before income tax expense125,233 106,417 96,478 
Income tax expense29,129 21,794 16,807 
Net earnings$96,104 $84,623 $79,671 
Basic net earnings per common share$2.98 $2.63 $2.48 
Diluted net earnings per common share$2.94 $2.60 $2.45 

See accompanying notes to consolidated financial statements.
26
Table of Contents
BALCHEM CORPORATION
Consolidated Statements of Comprehensive Income
Years Ended December 31, 2021, 2020 and 2019
(In thousands)
202120202019
Net earnings$96,104 $84,623 $79,671 
Other comprehensive (loss)/ income, net of tax:
Net foreign currency translation adjustment(11,255)12,829 (891)
Unrealized gain/(loss) on cash flow hedge, net of taxes of $654, $809, and $372 at December 31, 2021, 2020, and 2019, respectively
2,053 (2,285)(1,399)
Net change in postretirement benefit plan, net of taxes of $13, $127, and $101 at December 31, 2021, 2020 and 2019, respectively
36 (807)328 
Other comprehensive (loss)/ income, net of tax(9,166)9,737 (1,962)
Comprehensive income$86,938 $94,360 $77,709 

See accompanying notes to consolidated financial statements.
27
Table of Contents
BALCHEM CORPORATION
Consolidated Statements of Stockholders’ Equity
Years Ended December 31, 2021, 2020 and 2019
(Dollars in thousands, except share and per share data)

Total
Stockholders'
Equity		Retained
Earnings		Accumulated
Other
Comprehensive
Income (Loss)		Common StockAdditional
Paid-in
Capital
SharesAmount
Balance - December 31, 2018$691,618 $528,027 $(3,602)32,256,209 $2,151 $165,042 
Net earnings79,671 79,671 — — — — 
Other comprehensive (loss)(1,962)— (1,962)— — — 
Dividends ($.52 per share)
(16,777)(16,777)— — — — 
Repurchases of common stock(21,321)— — (240,995)(16)(21,305)
Shares and options issued under stock plans12,438 — — 186,703 13 12,425 
Balance - December 31, 2019743,667 590,921 (5,564)32,201,917 2,148 156,162 
Net earnings84,623 84,623 — — — — 
Other comprehensive income9,737 — 9,737 — — — 
Dividends ($.58 per share)
(18,804)(18,804)— — — — 
Repurchases of common stock(13,463)— — (136,629)(9)(13,454)
Shares and options issued (canceled) under stock plans22,473 — — 307,333 21 22,452 
Balance - December 31, 2020828,233 656,740 4,173 32,372,621 2,160 165,160 
Net earnings96,104 96,104 — — — — 
Other comprehensive (loss)(9,166)— (9,166)— — — 
Dividends ($.64 per share)
(20,706)(20,706)— — — — 
Repurchases of common stock(35,239)— — (249,848)(17)(35,222)
Shares and options issued under stock plans17,789 — — 164,377 11 17,778 
Balance - December 31, 2021$877,015 $732,138 $(4,993)32,287,150 $2,154 $147,716 

See accompanying notes to consolidated financial statements.
28
Table of Contents
BALCHEM CORPORATION
Consolidated Statements of Cash Flows
Years Ended December 31, 2021, 2020 and 2019
(In thousands)
 202120202019
Cash flows from operating activities:   
Net earnings$96,104 $84,623 $79,671 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization48,879 51,281 45,862 
Stock compensation expense10,802 8,303 7,596 
Deferred income taxes(5,944)(4,627)(3,563)
Provision for doubtful accounts180 140 1,776 
Unrealized (gain)/loss on foreign currency transactions and deferred compensation(384)173 72 
Asset impairment charge1,675 1,915 1,140 
(Gain)/loss on disposal of assets(1,728)153 (3,134)
Changes in assets and liabilities, net of acquired balances
Accounts receivable(20,700)(3,599)11,623 
Inventories(21,023)13,923 (11,401)
Prepaid expenses and other current assets(881)(2,856)477 
Accounts payable and accrued expenses47,067 (992)1,134 
Income taxes4,787 1,859 (5,664)
Other1,680 198 (1,128)
Net cash provided by operating activities160,514 150,494 124,461 
Cash flows from investing activities:
Capital expenditures and intangible assets acquired(37,449)(33,828)(28,413)
Cash paid for acquisitions, net of cash acquired— — (141,062)
Proceeds from sale of business and assets318 87 11,523 
Proceeds from insurance1,831 — 2,727 
Purchase of convertible notes— (850)(1,000)
Net cash used in investing activities(35,300)(34,591)(156,225)
Cash flows from financing activities:
Proceeds from revolving loan5,000 10,000 168,569 
Principal payments on revolving loan(60,000)(95,000)(76,000)
Principal payments on finance lease(159)(151)— 
Principal payment on acquired debt— — (17,567)
Proceeds from stock options exercised6,943 14,155 4,839 
Dividends paid(18,723)(16,705)(15,135)
Repurchases of common stock(35,239)(13,463)(21,321)
Net cash (used in) provided by financing activities(102,178)(101,164)43,385 
Effect of exchange rate changes on cash(4,368)4,160 (217)
Increase in cash and cash equivalents18,668 18,899 11,404 
Cash and cash equivalents beginning of period84,571 65,672 54,268 
Cash and cash equivalents end of period$103,239 $84,571 $65,672 

Supplemental Cash Flow Information - see Note 13
See accompanying notes to consolidated financial statements.
29
Table of Contents
BALCHEM CORPORATION
Notes to Consolidated Financial Statements
(All amounts in thousands, except share and per share data)

NOTE 1 - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Description
Balchem Corporation (“Balchem” or the “Company”), including, unless the context otherwise requires, its wholly-owned subsidiaries, incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries.
Principles of Consolidation
The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Revenue Recognition

Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer.

In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S., Italy, Belgium, Malaysia, Australia, Philippines, and Singapore exceed the Federal Deposit Insurance Corporation (“FDIC”), Fondo Interbancario di Tutela dei Depositi (“FITD”), Financial Services and Markets Authority ("FSMA"), Perbadanan Insurans Deposit Malaysia ("PIDM"), Australian Prudential Regulation Authority ("APRA"), Philippine Deposit Insurance Corporation ("PDIC"), and Singapore Deposit Insurance Corporation ("SDIC") insurance limits, respectively.
Accounts Receivable
Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified,
30
Table of Contents
and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
Inventories
Inventories are valued at the lower of cost (first in, first out or average) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost.
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations
Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2021, 2020 and 2019, no customer accounted for more than 10% of total net sales or accounts receivable.
Post-employment Benefits
We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.
In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets

Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. A goodwill impairment test will now be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. The guidance is effective for
31
Table of Contents
annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020.

As of October 1, 2021 and 2020, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2021. However, during the second quarter of 2020, the Company recorded a goodwill impairment charge of $1,228 related to business formerly included in the Industrial Products segment. The Company may resume performing the qualitative assessment in subsequent periods.
The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
Goodwill at December 31, 2019$523,998 
Goodwill as a result of Zumbro Acquisition432 
Goodwill impairment(1,228)
Impact due to change in foreign exchange rates6,261 
Goodwill at December 31, 2020529,463 
Impact due to change in foreign exchange rates(5,514)
Goodwill at December 31, 2021$523,949 

 December 31, 2021December 31, 2020
HNH$424,044 $424,051 
ANH17,207 17,824 
Specialty Products82,654 87,539 
Other and Unallocated44 49 
Total$523,949 $529,463 
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks & trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents & trade secrets
15 - 17
Other
 2 - 18

Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an
32
Table of Contents
intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2021, there were no triggering events which required intangible asset impairment reviews.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.

We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.

Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates
Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.
In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in either derivative asset or derivative liability, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities.
Cost of Sales
Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Selling, General and Administrative Expenses
Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.
33
Table of Contents
Research and Development
Research and development costs are expensed as incurred.
Net Earnings Per Common Share
Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation
The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets
Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. For the year ended December 31, 2019, we incurred impairment charges of $1,026 in connection with a restructuring in the HNH segment.

Derivative Instruments and Hedging Activities

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes.

On May 28, 2019, the Company entered into a pay-fixed, receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement.
At the same time, the Company also entered into a cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. This derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023.

The derivative instruments are with the above single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet.

On a quarterly basis, we assess the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. As of December 31, 2021, we assessed the hedging relationships and determined them to be highly effective. As such, the net change in fair values of the interest rate swap, that qualifies as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and is subsequently reclassified
34
Table of Contents
into interest expense as interest payments are made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remained in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, "Derivative Instruments and Hedging Activities" for detailed information about our derivative financial instruments.
New Accounting Pronouncements
Recently Adopted Accounting Standards

In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted this new Standard in 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.
In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Standard Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard Update may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new Standard on January 1, 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.
In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance contained in this ASU requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company’s consolidated financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This Update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company's consolidated financial statements and disclosures.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment”, which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new Standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The Update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The
35
Table of Contents
Company adopted the new Standard and related Updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.

NOTE 2 – SIGNIFICANT ACQUISITIONS AND DIVESTITURES
Acquisitions

On December 13, 2019, the Company completed the acquisition of Zumbro. The Company made payments of $52,403 on the acquisition date, amounting to $47,058 to the former shareholders and $5,345 to Zumbro's lenders to pay Zumbro debt. Considering the cash acquired of $686, net payments made to the former shareholders were $46,372. In May 2020, the Company received an adjustment for working capital acquired of $561.

The goodwill of $18,505 arising from the acquisition consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to Human Nutrition & Health ("HNH") and $4,723 is deductible for income taxes.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$686 
Accounts receivable3,314 
Inventories4,052 
Prepaid & other current assets521 
Property, plant and equipment15,245 
Right of use assets3,181 
Customer relationships8,200 
Developed technology4,400 
Trade name2,300 
Other non-current assets10 
Accounts payable & accrued expenses(1,651)
Lease liabilities(3,181)
Debt(5,345)
Deferred income taxes(3,740)
Goodwill18,505 
Amount paid to shareholders46,497 
Zumbro debt paid on purchase date5,345 
Total amount paid on acquisition date$51,842 
The estimated valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management's estimates and assumptions that are subject to change. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized included cost and market approaches for property, plant and equipment, excess earnings method for customer relationships and the relief from royalty method for other intangible assets.
Customer relationships are amortized over a 15-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name and developed technology are amortized over 10 years and 12 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
The Company is indemnified for tax liabilities related to periods prior to the acquisition date. Indemnified tax liabilities will create an indemnification asset (receivable). An indemnification asset balance has not been established.
36
Table of Contents
On May 27, 2019, the Company acquired 100 percent of the outstanding common shares of Chemogas. The Company made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690).
The goodwill of $59,319 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Specialty Products segment and is not tax deductible for income tax purposes.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$4,412 
Accounts receivable4,176 
Inventories957 
Property, plant and equipment15,972 
Customer relationships39,158 
Developed technology2,461 
Trade name1,119 
Other assets1,491 
Accounts payable(3,261)
Bank debt(12,222)
Other liabilities(1,030)
Pension obligation (net)(594)
Deferred income taxes(12,856)
Goodwill59,319 
Amount paid to shareholders99,102 
Chemogas bank debt paid on purchase date12,222 
Total amount paid on acquisition date$111,324 
The valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized included cost and market approaches for property, plant and equipment, excess earnings method for customer relationships and the relief from royalty method for other intangible assets.
Customer relationships are amortized over a 20-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name and developed technology are amortized over 2 years and 10 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
The Company is indemnified for tax liabilities related to periods prior to the acquisition date. Indemnified tax liabilities will create an indemnification asset (receivable). An indemnification asset balance has not been established.

In connection with Chemogas and Zumbro acquisitions, the Company incurred transaction and integration costs of $26, $1,480, and $1,947 for the years ended December 31, 2021, 2020 and 2019, respectively.

Total transaction and integration costs related to recent acquisitions, including the Chemogas and Zumbro acquisitions described above, are recorded in general and administrative expenses. These costs amounted to $448, $2,011, and $2,273 for the years ended December 31, 2021, 2020 and 2019, respectively.
Divestiture
On September 6, 2019, the Company sold an insignificant portion of its business. As a result of the transaction, the Company recorded a gain on sale, which was immaterial to the consolidated financial statements and included in general and administrative
37
Table of Contents
expenses. Operating results for the portion of the business sold were insignificant relative to the Company’s consolidated financial results for year ended December 31, 2019.

NOTE 3 - STOCKHOLDERS’ EQUITY
STOCK-BASED COMPENSATION
All share-based payments, including grants of stock options, are recognized in the statements of earnings as operating expenses, based on their fair values.
The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest.
The Company’s results for the years ended December 31, 2021, 2020 and 2019 reflected the following compensation cost and such compensation cost had the following effects on net earnings:
 Increase/(Decrease) for the
Year Ended, December 31
 202120202019
Cost of sales$845 $1,115 $1,147 
Operating expenses9,957 7,188 6,449 
Net earnings(8,370)(6,332)(5,884)
On December 31, 2021, the Company had one share-based compensation plan under which awards may be granted, which is described below.
In June 2017, the Company adopted the Balchem Corporation 2017 Omnibus Incentive Plan (“2017 Plan”) for officers, employees and directors of the Company and its subsidiaries. The 2017 Plan replaced the 1999 Stock Plan and amendments and restatements thereto (collectively to be referred to as the “1999 Plan"), which expired on April 9, 2018. No further awards will be made under the 1999 Plan, and the shares that remained available for grant under the 1999 Plan will only be used to settle outstanding awards granted under the 1999 Plan and will not become available under the 2017 Plan. The 2017 Plan is administered by the Compensation Committee of the Board of Directors of the Company. The 2017 Plan provides as follows: (i) for a termination date of June 13, 2027; (ii) the authorization of 1,600,000 shares for future grants (which represents a reduction from the 6,000,000 shares authorized for grant under the 1999 Plan); (iii) for the making of grants of stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards, as well as for the making of cash performance awards; (iv) except as provided in an employment agreement as in effect on the effective date of the 2017 Plan, no automatic acceleration of outstanding awards upon the occurrence of a change in control of the Company; (v) certain annual limits on the number of shares and amount of cash that may be granted; (vii) for dividends or dividend equivalents otherwise payable on an unvested award to accrue and be paid only at such time as the vesting conditions applicable to the underlying award have been satisfied; (vii) for certain discretionary compensation recovery if the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirements under the securities laws; and (viii) for compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). No option will be exercisable for longer than ten years after the date of grant.
The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2021, the 2017 Plan had 703,707 shares available for future awards.
The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Common Stock have been granted, ranging from 70 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements.
The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents.
38
Table of Contents
The fair value of each option award issued under the Company’s stock plans is estimated on the date of grant using a Black-Scholes based option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
Year Ended December 31,
Weighted Average Assumptions:202120202019
Expected Volatility32.9 %26.9 %24.0 %
Expected Term (in years)4.93.94.0
Risk-Free Interest Rate0.5 %1.3 %2.5 %
Dividend Yield0.5 %0.5 %0.6 %
The value of the restricted shares is based on the fair value of the award at the date of grant.
Performance Share expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the Performance Share vests. The assumptions used in the fair value determination were risk free interest rates of 0.2%, 1.4%, and 2.5%; dividend yields of 0.6%, 0.5%, and 0.5%; volatilities of 33%, 24%, and 24%; and initial TSR’s of 11.7%, 10.9%, and -5.9% in each case for the years ended December 31, 2021, 2020, and 2019, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The Performance Shares will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.
Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three to four years for employee restricted stock awards, three years for employee performance share awards, and three to four years for non-employee director restricted stock awards.
A summary of stock option plan activity for 2021, 2020, and 2019 for all plans is as follows:

202120202019
# of
Shares
(000s)		Weighted Average
Exercise Price		# of
Shares
(000s)		Weighted Average
Exercise Price		# of
Shares
(000s)		Weighted Average
Exercise Price
Outstanding at beginning of year858 $80.58 951 $68.18 887 $61.59 
Granted129 119.12 174 111.75 197 85.13 
Exercised(109)63.42 (256)55.26 (112)43.67 
Forfeited(10)106.93 (11)92.94 (17)80.88 
Cancelled(1)74.57 — — (4)70.90 
Outstanding at end of year867 $88.19 858 $80.58 951 $68.18 
Exercisable at end of year538 $75.51 494 $69.04 581 $59.29 

The aggregate intrinsic value for outstanding stock options was $69,711, $29,735 and $31,814 at December 31, 2021, 2020 and 2019, respectively, with a weighted average remaining contractual term of 6.4 years at December 31, 2021. Exercisable stock options at December 31, 2021 had an aggregate intrinsic value of 50,128 with a weighted average remaining contractual term of 5.3 years.

Other information pertaining to option activity during the years ended December 31, 2021, 2020 and 2019 is as follows:

39
Table of Contents
 Years Ended December 31,
 202120202019
Weighted-average fair value of options granted$33.11 $24.36 $18.51 
Total intrinsic value of stock options exercised ($000s)$7,866 $12,698 $6,135 

Additional information related to stock options outstanding under all plans at December 31, 2021 is as follows:

  Options OutstandingOptions Exercisable
Range of Exercise
Prices		Shares
Outstanding
(000s)		Weighted
Average
Remaining
Contractual
 Term		Weighted
Average
 Exercise
Price		Number
Exercisable
(000s)		Weighted
Average
Exercise
Price
$29.06 - $57.17
26 2.1$47.26 26 $47.26 
$58.52 - $85.40
541 5.575.55 476 74.37 
$91.56 - $120.60
300 8.5114.46 36 109.84 
 867 6.4$88.19 538 $75.51 

Non-vested restricted stock activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:

202120202019
 Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 159 $90.71 138 $80.03 79 $72.75 
Granted42 123.58 46 110.53 73 85.69 
Vested(24)85.83 (21)67.60 (8)58.52 
Forfeited(11)90.49 (4)91.91 (6)84.65 
Non-vested balance at end of year 166 $99.70 159 $90.71 138 $80.03 

Non-vested performance share activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:
202120202019
 Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 71 $91.99 70 $81.26 53 $75.61 
Granted36 108.74 20 126.46 33 81.79 
Vested(24)70.64 (8)104.15 (9)65.54 
Forfeited(14)81.03 (11)82.71 (7)60.85 
Non-vested balance at end of year 69 $110.72 71 $91.99 70 $81.26 

As of December 31, 2021, 2020 and 2019, there was $13,980, $14,154 and $11,643, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2021, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.2 years. We estimate that share-based compensation expense for the year ended December 31, 2022 will be approximately $11,900.
40
Table of Contents
REPURCHASE OF COMMON STOCK
The Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,818,244 shares have been purchased. The Company’s prior presentation of reflecting treasury stock separately within stockholders’ equity has been adjusted to conform to the presentation prescribed by the State of Maryland, where the Company is incorporated. In connection therewith, $7,873 of previously acquired treasury stock has been offset against additional paid-in capital and common stock in the consolidated balance sheet as of December 31, 2020. Corresponding adjustments to balances previously reflected as treasury stock of $7,873 and $18,069 for the years ended December 31, 2020 and 2019 were made to the consolidated statements of stockholders’ equity and prior references to “Treasury shares purchased” were updated to “Repurchases of common stock”, accordingly. There was no impact to total stockholders’ equity in any of the years presented as a result of these updates. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. During 2021, 2020, and 2019, the Company purchased 249,848, 136,629, and 240,995 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $141.04, $98.54, and $88.47 per share, respectively.

NOTE 4 - INVENTORIES
Inventories, net of reserves at December 31, 2021 and 2020 consisted of the following:
 20212020
Raw materials$28,639 $24,536 
Work in progress10,563 3,050 
Finished goods51,856 43,034 
Total inventories$91,058 $70,620 
On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are reserved, if necessary. The reserve for inventory was $1,425 and $2,782 at December 31, 2021 and 2020, respectively.

NOTE 5 - PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at December 31, 2021 and 2020 are summarized as follows:
 20212020
Land$11,692 $12,215 
Building89,602 86,873 
Equipment253,995 247,884 
Construction in progress52,930 31,240 
 408,219 378,212 
Less: Accumulated depreciation170,702 150,116 
Property, plant and equipment, net$237,517 $228,096 

Geographic Area Data - Long-Lived Assets (excluding intangible assets):
 20212020
United States$197,432 $187,719 
Foreign Countries40,085 40,377 
Total$237,517 $228,096 
Depreciation expense was $23,295, $22,990 and $19,791 for the years ended December 31, 2021, 2020 and 2019, respectively.

41


NOTE 6 - INTANGIBLE ASSETS

The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The decrease in goodwill is due to foreign exchange translation adjustments.

As of December 31, 2021 and 2020, the Company had identifiable intangible assets as follows:
20212020
 Amortization
Period
(In years)		Gross
Carrying
Amount		Accumulated
Amortization		Gross
Carrying
Amount
Accumulated
Amortization
Customer relationships & lists
10-20
$240,059 $173,489 $243,557 $158,051 
Trademarks & trade names
2-17
43,116 28,985 43,208 24,974 
Developed technology
5-12
20,234 14,607 21,674 13,693 
Other
2-18
23,921 15,584 21,624 11,685 
  $327,330 $232,665 $330,063 $208,403 

Amortization of identifiable intangible assets was $25,092, $27,811 and $25,789 for 2021, 2020 and 2019, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $23,641 in 2022, $19,566 in 2023, $10,682 in 2024, $6,413 in 2025, and $5,083 in 2026. At December 31, 2021 and 2020, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2021 and 2020.

The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (the "EPA") because they are considered pesticides. Costs of such registrations are included as other in the table above.

NOTE 7 – EQUITY-METHOD INVESTMENT
In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant.  The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $557, $575, and $388 for the years ended December 31, 2021, 2020, and 2019, respectively, relating to its portion of the joint venture’s expenses in other expense. The carrying value of the joint venture at December 31, 2021 and 2020 was $4,499 and $4,971, respectively, and is recorded in other assets.

NOTE 8 – REVOLVING LOAN

On June 27, 2018, the Company and a bank syndicate entered into the Credit Agreement, which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000.  The Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”).  The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion.  The initial proceeds from the Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. On May 23, 2019, the Company drew down $108,569 to fund the Chemogas acquisition. In connection with these additional borrowings, the Company entered into an interest rate swap to protect against adverse fluctuations in interest rates (see Note 20, "Derivative Instruments and Hedging Activities"). On December 13, 2019, the Company drew down $45,000 to fund the Zumbro acquisition. As of December 31, 2021, the total balance outstanding on the
42
Credit Agreement amounted to $108,569. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. 

Amounts outstanding under the Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the Credit Agreement plus an applicable rate.  The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the Credit Agreement, and the interest rate was 1.102% at December 31, 2021.  The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the Credit Agreement and ranges from 0.15% to 0.275% (0.15% at December 31, 2021).  The unused portion of the revolving loan amounted to $391,431 at December 31, 2021.  The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.

Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the Credit Agreement.  Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $421 and $703 at December 31, 2021 and 2020, respectively, and are included in other assets on the consolidated balance sheets. Amortization expense pertaining to these costs totaled $282 for each of the years ended December 31, 2021, 2020, and 2019, and is included in interest expense in the accompanying consolidated statements of earnings.

The Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio.  At December 31, 2021, the Company was in compliance with these covenants.  Indebtedness under the Company’s loan agreements is secured by assets of the Company.

NOTE 9 - NET EARNINGS PER COMMON SHARE
The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:
Year Ended December 31,
202120202019
Net Earnings - Basic and Diluted$96,104 $84,623 $79,671 
Share (000s)
Weighted Average Common Shares - Basic32,215 32,176 32,136 
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares457 327 369 
Weighted Average Common Shares - Diluted32,672 32,503 32,505 
Net Earnings Per Share - Basic$2.98 $2.63 $2.48 
Net Earnings Per Share - Diluted$2.94 $2.60 $2.45 
The number of anti-dilutive shares were 155,294, 204,672, and 12,250 for 2021, 2020, and 2019. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.
The Company has some share-based payment awards that have non-forfeitable dividend rights. These awards are restricted shares and they participate on a one-for-one basis with holders of Common Stock. These awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share.

NOTE 10 - INCOME TAXES

The Company’s effective tax rate for 2021, 2020 and 2019 was 23.3%, 20.5%, and 17.4%, respectively. The increase from 2020 to 2021 is primarily due to a reduction in certain tax credits, lower tax benefits from stock-based compensation, and higher enacted state tax rates.

On March 27, 2020 Congress passed the Coronavirus Aid, Relief, and Economic Security Act, and on December 31, 2020 Congress passed an additional round of COVID relief legislation as part of the Bipartisan-Bicameral Omnibus COVID Relief Deal. The Company has reviewed the change in law and determined that it does not have a significant impact on the Company’s tax provision or financial statements. In addition, Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts
43
and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the SEC, and/or the Financial Accounting Standards Board ("FASB") regarding this act.

The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and the Company's specific plans for reinvestment of those subsidiary earnings. The Company projects that its foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to its legal entity structure and the complexity of U.S. and local country tax laws. If the Company decides to repatriate the undistributed foreign earnings, it will need to recognize the income tax effects in the period it changes its assertion on indefinite reinvestment.
Income tax expense consists of the following:
 202120202019
Current:   
Federal$25,019 $19,249 $17,757 
Foreign7,553 3,399 1,609 
State3,664 3,590 818 
Deferred:
Federal(3,709)(3,017)(3,707)
Foreign(3,038)167 67 
State(360)(1,594)263 
Total income tax provision$29,129 $21,794 $16,807 
The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2021, 2020, and 2019 to earnings before income tax expense due to the following:
 202120202019
Income tax at Federal statutory rate$26,299 $22,348 $20,260 
State income taxes, net of Federal income taxes2,406 2,288 (244)
Stock Options(924)(1,529)(222)
GILTI — — 2,507 
FDII(1,540)(1,400)(1,922)
Patent Box Decree (related to prior years)— — (1,948)
Foreign Tax Credits— — (1,125)
Other2,888 87 (499)
Total income tax provision$29,129 $21,794 $16,807 
44
The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 were as follows:
 20212020
Deferred tax assets:  
Inventories$495 $1,470 
Restricted stock and stock options4,082 3,862 
Lease liabilities1,807 1,641 
Currency and interest rate swap649 2,831 
Other3,657 3,308 
Total deferred tax assets10,690 13,112 
Deferred tax liabilities:
Amortization$28,133 $32,872 
Depreciation25,484 27,897 
Prepaid expenses733 915 
Right of use assets1,769 1,926 
Other1,026 731 
Total deferred tax liabilities57,145 64,341 
Valuation allowance— 130 
Net deferred tax liability$46,455 $51,359 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not the Company will not realize the benefits of these deductible differences. The amount of deferred tax asset realizable, however, could change if management’s estimate of future taxable income should change.

As of December 31, 2021, the Company has state income tax net operating loss (NOL) carryforwards of $335. The state NOL carryforwards will expire between 2025 and 2034. The Company believes that the benefit from the state NOL carryforwards will be realized, therefore a valuation allowance is not required to be established on these assets. The Company also acquired an insignificant amount of NOL carryforwards with the acquisition of Chemogas.

The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and specific plans for reinvestment of those subsidiary earnings. The Company projects that foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to the Company's legal entity structure and the complexity of U.S. and local country tax laws. If Balchem decides to repatriate the undistributed foreign earnings, the income tax effects will need to be recognized in the period the Company changes its assertion on indefinite reinvestment.
45
Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:
 202120202019
Balance at beginning of period$5,335 $4,762 $5,709 
Increases for tax positions of prior years806 267 431 
Decreases for tax positions of prior years(260)(391)(1,978)
Increases for tax positions related to current year— 697 600 
Balance at end of period$5,881 $5,335 $4,762 
All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods.
The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2021, 2020 and 2019, these amounted to approximately $262, $232 and $132, respectively. As of December 31, 2021 and 2020, accrued interest and penalties were $2,106 and $1,845, respectively.
Balchem files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2017 and management does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months.

NOTE 11 - SEGMENT INFORMATION
The Company currently reports three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Previously, the Company's four reportable segments were: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products. However, effective in the first quarter of 2020, in order to align with the Company's strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, and given the 2019 reduction in portfolio scale of Industrial Products, the Company revised its reporting segment structure to three reportable segments stated above. These reportable segments are strategic businesses that offer products and services to different markets. This realignment has been retrospectively applied. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated" and applied retroactively to 2019. There were no changes to the Consolidated Financial Statements as a result of the change to the reportable segments. The Company expects that the new reportable segment structure will provide investors greater understanding of and alignment with the Company’s strategic focus. In order to ensure appropriate transparency and visibility into the financial performance of the Company, sufficient detail will continue to be provided relative to Other and Unallocated, including material contributions from oil and gas and other industrial market activities.

Human Nutrition & Health
The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. HNH's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. When combined with its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars,
46
dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.

Animal Nutrition & Health

The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, ANH’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity.

Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a global marketplace.

Specialty Products

Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Specialty Products' 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.

The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging, which are approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment.

The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life.  First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.

47
The segment information is summarized as follows:

Business Segment Assets
 20212020
Human Nutrition & Health$727,131 $717,232 
Animal Nutrition & Health158,971 157,454 
Specialty Products184,628 190,449 
Other and Unallocated (1)
128,595 100,708 
Total$1,199,325 $1,165,843 

Business Segment Net Sales
 202120202019
Human Nutrition & Health$442,733 $400,330 $347,433 
Animal Nutrition & Health226,776 192,191 177,557 
Specialty Products117,020 103,566 92,257 
Other and Unallocated (2)
12,494 7,557 26,458 
Total$799,023 $703,644 $643,705 

Business Segment Earnings Before Income Taxes

202120202019
Human Nutrition & Health$76,031 $61,397 $48,429 
Animal Nutrition & Health26,179 29,979 25,868 
Specialty Products30,020 26,801 28,513 
Other and Unallocated (2)
(4,728)(7,030)(257)
Interest and other expense(2,269)(4,730)(6,075)
Total$125,233 $106,417 $96,478 


Depreciation/Amortization
 202120202019
Human Nutrition & Health$30,012 $32,117 $30,558 
Animal Nutrition & Health7,414 7,187 6,552 
Specialty Products8,332 9,699 7,401 
Other and Unallocated (2)
3,121 2,278 1,351 
Total$48,879 $51,281 $45,862 

Capital Expenditures
 202120202019
Human Nutrition & Health$23,714 $22,758 $18,159 
Animal Nutrition & Health8,100 6,039 3,921 
Specialty Products3,804 2,860 3,003 
Other and Unallocated (2)
524 423 707 
Total$36,142 $32,080 $25,790 


48
(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.
(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,264, $2,410 and $3,436 for years ended December 31, 2021, 2020 and 2019, respectively, and (ii) Unallocated amortization expense of $2,792, $1,888, and $833 for years ended December 31, 2021, 2020, and 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings.

NOTE 12 - REVENUE
Revenue Recognition

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to realize in exchange for those goods.

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.
 202120202019
Product Sales$762,085 $666,193 $609,741 
Co-manufacturing27,994 29,063 24,087 
Bill and Hold— 1,158 3,218 
Consignment4,439 2,939 2,299 
Product Sales Revenue794,518 699,353 639,345 
Royalty Revenue4,505 4,291 4,360 
Total Revenue$799,023 $703,644 $643,705 

The following table presents revenues disaggregated by geography, based on the billing addresses of customers:
 202120202019
United States$584,661 $516,347 $475,033 
Foreign Countries214,362 187,297 168,672 
Total$799,023 $703,644 $643,705 

Product Sales Revenues

The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of four sub-streams: product sales, co-manufacturing, bill and hold, and consignment.

Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials.  The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer.  Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided.

Royalty Revenues

Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.

Contract Liabilities

The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.

49
The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.

Practical Expedients and Exemptions

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.


NOTE 13 - SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the year for:
202120202019
Income taxes$25,355 $22,637 $21,771 
Interest$4,547 $4,666 $5,674 
Non-cash financing activities:
 202120202019
Dividends payable$20,886 $18,941 $16,855 

NOTE 14 – ACCUMULATED OTHER COMPREHENSIVE INCOME
The changes in accumulated other comprehensive income (loss) were as follows:
 Years Ended December 31,
 202120202019
Net foreign currency translation adjustment$(11,255)$12,829 $(891)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized gain/(loss) on cash flow hedge2,707 (3,094)(1,771)
Tax(654)809 372 
Net of tax2,053 (2,285)(1,399)
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service (credit)/cost and (gain)/loss arising during the period(4)(503)199 
Amortization of prior service credit/(cost)74 74 74 
Amortization of gain/(loss)(21)(50)(46)
Total before tax49 (479)227 
Tax(13)127 101 
Adjustment (1)
— (455)— 
Net of tax36 (807)328 
Total other comprehensive (loss)/income$(9,166)$9,737 $(1,962)
(1) One-time adjustment to the postretirement account.
50
Included in "Net foreign currency translation adjustment" were $4,766 of gain, $4,882 of loss, and $262 of loss, related to a net investment hedge, net of taxes of $1,527, $1,579, and $70, for the years ended December 31, 2021, 2020, and 2019, respectively. See Note 20, "Derivative Instruments and Hedging Activities."

Accumulated other comprehensive (loss)/income at December 31, 2021 consisted of the following:
 Foreign currency
translation
adjustment		Cash flow hedgePostretirement benefit planTotal
Balance December 31, 2020$7,653 $(3,684)$204 4,173 
Other comprehensive (loss)/gain(11,255)2,053 36 (9,166)
Balance December 31, 2021$(3,602)$(1,631)$240 (4,993)

NOTE 15 - EMPLOYEE BENEFIT PLANS
Defined Contribution Plans
The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. The Company provided for profit sharing contributions and matching 401(k) savings plan contributions of $1,459 and $4,142 in 2021, $1,022 and $3,751 in 2020, and $592 and $3,451 in 2019, respectively.
Postretirement Medical Plans
The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona, Missouri facility and a plan for those named as executive officers in the Company’s proxy statement. The Company uses a December 31 measurement date for its postretirement medical plans. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:
Change in benefit obligation:
 20212020
Benefit obligation at beginning of year$1,374 $1,076 
Initial adoption of new plan— — 
Service cost with interest to end of year87 68 
Interest cost23 26 
Participant contributions28 23 
Benefits paid(426)(27)
Actuarial gain207 208 
Benefit obligation at end of year$1,293 $1,374 
Change in plan assets:
 20212020
Fair value of plan assets at beginning of year$— $— 
Employer (reimbursement)/contributions398 4 
Participant contributions28 23 
Benefits paid(426)(27)
Fair value of plan assets at end of year$— $— 

51
Amounts recognized in consolidated balance sheet:
 20212020
Accumulated postretirement benefit obligation$1,293 $1,374 
Fair value of plan assets— — 
Funded status1,293 1,374 
Unrecognized prior service cost74 74 
Unrecognized net gain(50)(46)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$1,293 $1,374 
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Components of net periodic benefit cost:
 202120202019
Service cost with interest to end of year$87 $68 $63 
Interest cost23 26 39 
Amortization of prior service cost74 74 74 
Amortization of gain(24)(50)(46)
Total net periodic benefit cost$160 $118 $130 
Estimated future employer contributions and benefit payments are as follows:
Year 
2022$107 
202391 
2024113 
202591 
202676 
Years 2027-2031479 
Defined Benefit Pension Plans
The Company contributes to one multiemployer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona, Missouri facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company was to stop participating in its multiemployer plan, the Company would be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability.
The Company’s participation in this plan for the annual period ended December 31, 2021 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2021 and 2020 was affected by a 4.0% increase in the 2021 contribution rate. There have been no other significant changes that affect the comparability of 2021 and 2020 contributions. The Company does not represent more than 5% of the contributions to this pension fund.
52
Pension
Fund		EIN/Pension
Plan
Number		Pension Plan Protection Act Zone StatusFIP/RP Status
Pending/ Implemented		Contributions of Balchem CorporationSurcharge
Imposed		Expiration Date of Collective-
Bargaining
Agreement
20212020202120202019
Central States,
Southeast and
Southwest Areas
Pension Fund		36-6044243Critical & Declining as of 1/1/21Critical & Declining as of 1/1/20Implemented$816$774$677No7/12/2025

On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees.
The actuarial recorded liabilities for such unfunded defined benefit pension plan are as follows:
Change in benefit obligation:
 20212020
Benefit obligation at beginning of year$2,053 $1,738 
Service cost with interest to end of year67 104 
Interest cost14 20 
Participant contributions24 21 
Benefits paid(18)(11)
Actuarial gain(127)18 
Exchange rate changes(154)163 
Benefit obligation at end of year$1,859 $2,053 
Change in plan assets:
 20212020
Fair value of plan assets at beginning of year$1,103 895 
Actual return on plan assets76 57 
Employer (reimbursement)/contributions73 57 
Participant contributions24 21 
Benefits paid(18)(11)
Exchange rate changes(83)84 
Fair value of plan assets at end of year$1,175 $1,103 
Amounts recognized in consolidated balance sheet:
 20212020
Benefit obligation$(1,859)$(2,053)
Fair value of plan assets1,175 1,103 
Funded status(684)(950)
Unrecognized prior service costN/AN/A
Unrecognized net (gain)/lossN/AN/A
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$684 $950 
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
53
Components of net periodic benefit cost:
 202120202019
Service cost with interest to end of year$67 $104 $— 
Interest cost14 20 — 
Expected return on plan assets(34)(14)— 
Amortization of prior service cost— — — 
Amortization of net loss3 — — 
Total net periodic benefit cost$50 $110 $— 
Estimated future benefit payments are as follows:
Year 
2022$1 
2023— 
2024— 
2025— 
2026— 
Years 2027-203122 
Assumptions to determine benefit obligations:
 20212020
Discount rate1.00 %0.75 %
Assumptions to determine net cost:
 202120202019
Discount rate0.75 %1.00 %N/A
Expected return on assets3.25 %1.00 %N/A
Deferred Compensation Plan
On June 1, 2018, the Company established an unfunded, non-qualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of December 31, 2021 and 2020 was $6,270 and $3,581, respectively, and was included in other long-term obligations on the Company's balance sheet. The related rabbi trust assets were $6,267 and $3,582 as of December 31, 2021 and 2020, respectively, and were included in other non-current assets on the Company's consolidated balance sheets.

NOTE 16 - COMMITMENTS AND CONTINGENCIES
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2021 are as follows:
Year 
2022$2,900 
20232,139 
20241,891 
20251,066 
2026700 
Thereafter2,428 
Total minimum lease payments$11,124 

The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation was conducted by the
54

prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site. In September 2020, BCP Ingredients, Inc. (“BCP”), the Company subsidiary that operates the site received a General Notice Letter from the EPA regarding BCP’s potential liability for contamination at the site and, in February 2022, received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study at the site with regard to the presence of certain contaminants, including 1,4 dioxane,. The Company has engaged experts to study site conditions and hydrogeology in connection with preparing its response to the notices.

From time to time, the Company is a party to various litigation, claims and assessments.  Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.


NOTE 17 – FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2021 and 2020 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio.  The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2021 and 2020 included $933 and $817 in money market funds, respectively.
Non-current assets at December 31, 2021 and 2020 included $6,267 and $3,582, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”
The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in derivative assets or derivative liabilities, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The derivative liability related to the cross-currency swap was $500 and $6,793 at December 31, 2021 and 2020, respectively. The derivative liability related to the interest rate swap was $2,158 and $4,865 at December 31, 2021 and 2020, respectively.


NOTE 18 – RELATED PARTY TRANSACTIONS

The Company provides services on a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings.

The services the Company provided amounted to $3,637, $3,396, and $3,883, respectively, for the years ended December 31, 2021, 2020, and 2019. The raw materials purchased and subsequently sold amounted to $27,915, $13,495, and $24,786, respectively, for the years ended December 31, 2021, 2020, and 2019. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $22,043, $12,190, and $18,598, respectively for the years ended December 31, 2021, 2020, and 2019. At December 31, 2021 and 2020, the Company had receivables of $10,504 and $2,809, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold and payables of $7,552 and $2,239, respectively, for finished goods received recorded in accounts payable in 2021 and 2020. In addition, the Company had receivables in the amount of $164 and $72 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of December 31, 2021 and 2020. The
55
Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of December 31, 2021 and 2020.

NOTE 19 – LEASES

The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the ROU asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2021. In addition, the Company has historically not been exercising purchase options with equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with a new lease. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%.

In connection with the acquisition of Zumbro, the Company assumed a finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023.

Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:

Right of use assets20212020
Operating leases$6,929 $5,838 
Finance leases2,359 2,572 
Total$9,288 $8,410 


Lease liabilities - current20212020
Operating leases$2,194 $2,178 
Finance leases167 159 
Total$2,361 $2,337 

Lease liabilities - non-current20212020
Operating leases$4,811 $3,607 
Finance leases2,303 2,472 
Total$7,114 $6,079 

56
For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:

Year ended December 31
202120202019
Lease Cost
Operating lease cost$3,143 $3,105 $3,181 
Finance Lease cost
Amortization of ROU asset210 210 — 
Interest on lease liabilities129 137 — 
Total finance lease339 347 — 
Total lease cost$3,482 $3,452 $3,181 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$3,097 $2,864 $3,216 
Operating cash flows from finance leases129 137 — 
Financing cash flows from finance leases159 151 — 
$3,385 $3,152 $3,216 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$3,804 $1,042 $10,173 
ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals$— $2,782 $— 
Weighted-average remaining lease term - operating leases4.21 years4.15 years4.93 years
Weighted-average remaining lease term - finance leases11.41 years12.25 yearsn/a
Weighted-average discount rate - operating leases3.5 %4.5 %4.6 %
Weighted-average discount rate - finance leases5.1 %5.1 %n/a

Rent expense charged to operations under operating lease agreements for 2021, 2020, and 2019 aggregated approximately $3,143, $3,105, and $3,181, respectively.

NOTE 20 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with the Swap Counterparty and a cross-currency swap (net investment hedge) with the Bank Counterparty. The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk.

On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. The net interest expense related to the interest rate swap contract were $2,144 and $1,593 for the year ended December 31, 2021 and 2020. The
57
net interest income related to the interest rate swap contract was $40 for the year ended December 31, 2019. These amounts were recorded in the consolidated statements of operations under interest expense, net.
At the same time, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $2,257, $2,275, and $1,317 for the years ended December 31, 2021, 2020, and 2019, respectively, which were recorded in the consolidated statements of operations under interest expense, net.

The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheets.
As of December 31, 2021 and 2020, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:

Derivative liabilities20212020
Interest rate swap$2,158 $4,865 
Cross-currency swap500 6,793 
Derivative liabilities$2,658 $11,658 

On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.

In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.
If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting.

As of December 31, 2021, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income.

Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the year ended December 31, 2021, 2020, and 2019:

Location within Statements of Comprehensive IncomeYear ended December 31
202120202019
Cash flow hedge (interest rate swap), net of taxUnrealized gain (loss) on cash flow hedge, net$2,053 $(2,285)$(1,399)
Net investment hedge (cross-currency swap), net of taxNet foreign currency translation adjustment4,766 (4,882)(262)
$6,819 $(7,167)$(1,661)


58
NOTE 21 - QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
(In thousands, except per share data)
 20212020
 First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter		First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter
Net sales$185,656 $202,365 $197,869 $213,133 $174,436 $173,355 $175,140 $180,713 
Gross margin58,727 59,447 60,934 64,066 55,331 55,380 56,368 56,818 
Earnings before income taxes29,983 30,019 32,085 33,146 24,490 25,973 27,907 28,047 
Net earnings23,411 22,731 25,013 24,949 19,768 21,125 21,568 22,162 
Basic net earnings per common share$.73 $.71 $.78 $.78 $.62 $.66 $.67 $.69 
Diluted net earnings per common share$.72 $.70 $.77 $.76 $.61 $.65 $.66 $.68 

59
BALCHEM CORPORATION
Valuation and Qualifying Accounts
Years Ended December 31, 2021, 2020 and 2019
(In thousands)

Allowance
for Doubtful Accounts		Inventory
Reserve
Balance - December 31, 2018$610 $2,575 
Additions charged (credited) to costs and expenses1,776 7,069 
Adjustments/deductions (a)
(306)(5,363)
Balance - December 31, 20192,080 4,281 
Additions charged (credited) to costs and expenses140 5,964 
Adjustments/deductions (a)
(128)(7,463)
Balance - December 31, 20202,092 2,782 
Additions charged (credited) to costs and expenses180 7,312 
Adjustments/deductions (a)
(1,344)(8,669)
Balance - December 31, 2021$928 $1,425 
(a) Represents write-offs and other adjustments



60
Item 9.        Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.

Item 9A.    Controls and Procedures
Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2021. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; provide reasonable assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.    

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of controls effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

As of December 31, 2021, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the 2013 Internal Control-Integrated Framework (New Framework) to conduct an assessment of the effectiveness of our internal control over financial reporting. Based on this assessment, management has determined that our internal control over financial reporting was effective as of December 31, 2021.
Attestation Report of Registered Public Accounting Firm
The independent registered public accounting firm of RSM US LLP has issued an attestation report on our internal control over financial reporting, which is included herein.
Changes in Internal Control Over Financial Reporting
There has been no significant change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

61

Item 9B.    Other Information
None

62
PART III

Item 10.        Directors, Executive Officers of the Registrant, and Corporate Governance.

(a)    Directors of the Company.

The required information is to be set forth in our Proxy Statement for the 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”) under the captions “Nominees for Election as Director" and "Directors Not Standing for Election", which information is hereby incorporated herein by reference.

(b)    Executive Officers of the Company.

The required information is to be set forth in the 2022 Proxy Statement under the captions "Continuing Directors' Biographical Information" (as to Theodore L. Harris, the Company's Chief Executive Officer and President) and "Named Executive Officers" (as to the Company's other executive officers), which information is hereby incorporated herein by reference.

(c)    Code of Ethics.

The required information is to be set forth in the 2022 Proxy Statement under the caption “Codes of Business Conduct and Ethics,” which information is hereby incorporated herein by reference. Our Code of Ethics for Senior Financial Officers is available on the Corporate Governance page in the Investor Relations section of our website, www.balchem.com.

(d)    Corporate Governance.

The required information is to be set forth in the 2022 Proxy Statement under the captions “Nomination of Directors,” and “Committees of the Board of Directors,” which information is hereby incorporated herein by reference.

Item 11.        Executive Compensation.

The information required by this Item is to be set forth in the 2022 Proxy Statement under the captions “Executive Compensation,” “Compensation Committee Report,” and “Compensation Committee Interlocks and Insider Participation,” which information is hereby incorporated herein by reference.

Item 12.        Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item is to be set forth in the 2022 Proxy Statement under the caption “Security Ownership of Certain Beneficial Owners and of Management” and the caption “Equity Compensation Plan Information,” all of which information is hereby incorporated herein by reference.

Item 13.        Certain Relationships and Related Transactions and Director Independence.

The information required by this Item is to be set forth in the 2022 Proxy Statement under the caption “Related Party Transactions,” and “Director Independence,” which information is hereby incorporated herein by reference.

Item 14.        Principal Accountant Fees and Services.

The information required by this Item is to be set forth in the 2022 Proxy Statement under the caption “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm,” which information is hereby incorporated herein by reference.

63
PART IV

Item 15.     Exhibits and Financial Statement Schedules.
The following documents are filed as part of this Form 10-K:
1.Financial StatementsPage Number
 
 
 
 
 
2.Financial Statement Schedules
 
3.Exhibits
3.1
  
3.2
  
3.3
  
3.4
4.1
10.1
10.2
  
64
10.3
10.4
  
10.5
10.6
10.7
 
10.8
21
 
23.1
 
31.1
 
31.2
 
32.1
 
32.2
 
101.INSXBRL Instance Document
 
101.SCHXBRL Taxonomy Extension Schema Document
 
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
 
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
 
101.LABXBRL Taxonomy Extension Label Linkbase Document
 
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
65
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Each of the Exhibits noted by an asterisk is a management compensatory plan or arrangement.


66
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 24, 2022BALCHEM CORPORATION
 By:/s/ Theodore L. Harris
 Theodore L. Harris, President and
 Chief Executive Officer
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
/s/ Theodore L. Harris 
Theodore L. Harris, President and
Chief Executive Officer (Chairman)
Date: February 24, 2022
  
/s/ Martin Bengtsson
Martin Bengtsson, Chief Financial Officer
and Treasurer (Principal Financial Officer)
Date: February 24, 2022
/s/ William A. Backus 
William A. Backus, Chief Accounting Officer
(Principal Accounting Officer)
Date: February 24, 2022
  
/s/ David B. Fischer 
David B. Fischer, Director
Date: February 24, 2022
  
/s/ Kathleen Fish
Kathleen Fish, Director
Date: February 24, 2022
/s/ Daniel E. Knutson 
Daniel E. Knutson, Director
Date: February 24, 2022
/s/ Joyce Lee
Joyce Lee, Director
Date: February 24, 2022
  
/s/ Perry W. Premdas 
Perry W. Premdas, Director
Date: February 24, 2022
  
/s/ John Televantos 
Dr. John Televantos, Director
Date: February 24, 2022
  
/s/ Matthew Wineinger 
Matthew Wineinger, Director
Date: February 24, 2022

67
 EX-4.1 2 bcpc-20211231x10xkexhibit41.htm EX-4.1 Document

Exhibit 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

As of December 31, 2021, Balchem Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.06-2/3 per share (“common stock”). References herein to “we,” “us,” “our” and the “Company” refer to Balchem Corporation and not to any of its subsidiaries.

The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the applicable provisions of the Maryland General Corporation law (the “MGCL”), the Company’s charter (our “charter”), and its Amended and Restated Bylaws (our “bylaws”). Each of our charter and our bylaws is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part. We encourage you to read our charter, bylaws, our Corporate Governance Guidelines (which are available on our website), and the applicable provisions of the MGCL for additional information.

General

Under our charter, we may issue up to 122,000,000 shares of stock, comprised of 120,000,000 shares of common stock and 2,000,000 shares of preferred stock, par value $25.00 per share (“preferred stock”).

Our charter authorizes our board of directors (our “Board”) to issue shares of stock of the Company or securities convertible into shares of its stock. As allowed by the MGCL, our charter authorizes our Board, without stockholder approval, to issue preferred stock of the Company, in one or more series, each series to be with such preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications and terms and conditions of redemption as our Board shall determine, with the foregoing potentially having the effect of delaying, deferring or preventing a change in control of our company. We believe that the power to issue additional shares of our stock and to classify unissued shares of our preferred stock and to issue the classified shares provides us with increased flexibility in structuring possible future financings and acquisitions and in meeting other needs which might arise, but our issuance of additional shares of stock could dilute voting and other stockholder rights. See “Certain Provisions of Our Charter and Bylaws and of Maryland Law” below.

Common Stock

All of the outstanding shares of our common stock are duly authorized, fully paid and nonassessable. Our common stockholders are entitled to receive dividends when authorized by our Board and declared by us out of assets legally available for the payment of dividends. They are also: (i) entitled to share ratably in our assets legally available for distribution to our stockholders in the event of our liquidation, dissolution or winding up, after payment of, or adequate provision for, all of our known debts and liabilities, and (ii) generally are not liable for our debts or obligations. These rights may be subject to the preferential rights of any other class or series of our stock, including any preferred stock. All shares of common stock have equal dividend and liquidation rights.



Except as may otherwise be specified in the terms of a class or series of our preferred stock, each outstanding share of common stock is entitled to one vote on all matters submitted to a vote of the stockholders. There is no cumulative voting in the election of our directors. The Company’s Corporate Governance Guidelines set forth the procedures that are applicable if an incumbent director in an uncontested election receives a greater number of “withhold” votes for election than “for” votes.

Our stockholders have no exchange, sinking fund or redemption rights, and have no preemptive rights to subscribe for any future issuance of our securities. Because our stockholders do not have preemptive rights, we may issue additional shares of stock that may reduce their proportionate voting and financial interest in our company. Rights to receive dividends on our common stock may be limited by the terms of any future classified and issued shares of our preferred stock.

A Maryland corporation generally may not dissolve, amend its charter, merge, convert, consolidate, sell all or substantially all of its assets or engage in a statutory share exchange unless declared advisable by its board of directors and approved by the affirmative vote of stockholders holding at least two-thirds of the shares entitled to vote on the matter.

Transfer Agent and Registrar

The transfer agent and registrar for shares of our common stock is Broadridge Corporate Issuer Solutions, Inc.

Certain Provisions of Our Charter and Bylaws and of Maryland Law

Our Board of Directors

Our Board is divided into three classes, with the term of each class of directors expiring in a different successive year. Directors of each class are elected to serve until the third annual meeting following their election and until their successors are duly elected and qualify. We believe that the classification of our Board helps to assure the continuity and stability of our strategies and policies as determined by our Board.

Board vacancies may be filled by a majority of the remaining members of our Board even if such majority is less than a quorum. A director elected by our Board to fill a vacancy shall be elected to serve until the next annual meeting of stockholders and until his or her successor is elected and qualifies.

Under our Bylaws, directors may be removed from office by the affirmative vote of a majority of all of the votes of stockholders entitled to be cast for the election of directors and any resulting vacancy for the unexpired term of the removed director shall be filled by action of the stockholders. In addition, the MGCL provides that for so long as our Board is classified, a director may only be removed for cause.

Business Combinations

Under the MGCL, “business combinations” (as defined therein) between the Company and an “interested stockholder” or any affiliate thereof are prohibited for five years after the most recent date on which the interested stockholder became an interested stockholder. An interested stockholder is defined as:


•any person that beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock; or
•an affiliate or associate of the corporation and was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding stock of the corporation at any time within the two-year period immediately prior to the date in question.

Our Board may approve in advance the transaction by which such person otherwise would have become an interested stockholder, in which case, that person will not be an interested stockholder.

After the five-year prohibition, any business combination between us and an interested stockholder or any affiliate thereof generally must be recommended by our Board and approved by the affirmative vote of at least:

•80% of the votes entitled to be cast by holders of outstanding shares of voting stock; and
•two-thirds of the votes entitled to be cast by holders of voting stock other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or shares held by any affiliate or associate of the interested stockholder.

These super-majority vote requirements do not apply if, among other conditions, our stockholders receive a minimum price, as defined under the MGCL, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares. The statute permits various exemptions from its provisions, including, without limitation, business combinations that are exempted by our Board prior to the time that an interested stockholder becomes an interested stockholder.

Control Share Acquisitions

The MGCL provides that a holder of “control shares” of a Maryland corporation acquired in a “control share acquisition” has no voting rights with respect to such shares except to the extent approved by the affirmative vote of two-thirds of all the votes entitled to be cast on the matter, excluding “interested shares,” as defined in MGCL section 3-701(g). A “control share acquisition” means the acquisition of ownership of, or the power to direct the exercise of voting power with respect to, control shares, subject to certain exceptions. Control shares are voting shares of stock that, if aggregated with all other shares of stock owned by the acquiror or in respect of which the acquiror is entitled to exercise or direct the exercise of voting power, except solely by virtue of a revocable proxy, would entitle the acquiror to exercise voting power in electing directors within one of the ranges of voting power specified in the MGCL section 3-701(d)(i) – (iii). Control shares do not include shares the acquiror is entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation.

A person who has made or proposes to make a control share acquisition may compel our Board to call a special meeting of stockholders to consider the voting rights of the shares within 50 days of demand. This right is subject to the satisfaction of certain conditions, including an undertaking to pay the expenses of the meeting and delivering an “acquiring person statement” as described in the MGCL. If no request for a meeting is made, the Company may present the question at any stockholders’ meeting.



If voting rights are not approved at the meeting or if the acquiring person does not deliver an “acquiring person statement,” then we may redeem for “fair value” any or all of the control shares, except those for which voting rights have previously been approved. Fair value is determined, without regard to the absence of voting rights for the control shares, as of the meeting date of the non-approval of the voting rights or, if no meeting is held, as of the date of the last control share acquisition by the acquiror. If voting rights for control shares are approved at a stockholders’ meeting and the acquiror becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal rights. The fair value of the shares as determined for purposes of appraisal rights may not be less than the highest price per share paid by the acquiror in the control share acquisition.

The control share acquisition statute does not apply to shares acquired in a merger, consolidation, or statutory share exchange if we are a party to the transaction or to acquisitions approved or exempted by the charter or our bylaws.

Subtitle 8

Title 3, Subtitle 8, of the Corporations and Associations Article of the Annotated Code of Maryland (“Subtitle 8”) permits a Maryland corporation, such as the Company, with at least three directors who are not officers or employees of the corporation or affiliates of, or nominated by, a person seeking to acquire control of the corporation and a class of stock registered under the Exchange Act, to elect to be subject to any or all of the following provisions, by provision in its charter or bylaws or a resolution of its board of directors and notwithstanding any contrary provision in the charter or bylaws and without any action by stockholders:

•a classified board;
•a two-thirds vote requirement for removing a director;
•a requirement that the number of directors be fixed only by the board of directors;
•a requirement that a vacancy on the board be filled only by the remaining directors and for the remainder of the full term of the class of directors in which the vacancy occurred; or
•a majority requirement for the calling by stockholders of a special meeting of stockholders.

We have not elected to be subject to any provisions of Subtitle 8. However; through a provision in our bylaws unrelated to Subtitle 8, we have had a classified board for more than 25 years. In the future, our Board may elect, without stockholder approval, to be subject to one or more of the provisions of Subtitle 8.

Meetings of Stockholders

Under our bylaws, annual meetings of stockholders must be held each year at a date, time and place determined by our Board. Special meetings of stockholders may be called by the chair of our Board, our chief executive officer, our president and our Board. Additionally, subject to the provisions of our bylaws, a special meeting of stockholders to act on any matter that may properly be considered at a meeting of stockholders must be called by our secretary upon the written request of stockholders entitled to cast at least 25% of all of the votes entitled to be cast on the matter at such meeting. Only matters set forth in the notice of a special meeting of stockholders may be considered and acted upon at such a meeting.



Advance Notice of Director Nominations and New Business

Our bylaws provide that with respect to an annual meeting of stockholders, nominations of individuals for election to our Board and the proposal of business to be considered by stockholders may be made only:

•pursuant to our notice of the meeting (or any supplement thereto) by or at the direction of our Board;
•otherwise properly brought before the meeting by or at the direction of our Board; or
•by a stockholder of record of the Company at the time such notice of meeting is delivered, who is entitled to vote at the meeting, and who complies with the advance notice procedures of the bylaws.

With respect to special meetings of stockholders, only the business specified in our notice of the meeting may be brought before the meeting. Nominations of individuals for election to our Board at a special meeting at which directors are to be elected may only be made:

•by or at the direction of our Board; or
•provided that our Board has determined that directors will be elected at the meeting, by a stockholder of record at the time of giving notice, who is entitled to vote at the meeting and upon such election, and who complies with the advance notice provisions of the bylaws.

The purpose of requiring stockholders to give advance notice of nominations and other proposals is to afford our Board and our stockholders the opportunity to consider the qualifications of the proposed nominees or the advisability of the other proposals and, to the extent considered necessary by our Board, to inform stockholders and make recommendations regarding the nominations or other proposals.

Limitation of Liability and Indemnification of Directors and Officers

The MGCL permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (i) actual receipt of an improper benefit or profit in money, property or services or (ii) active and deliberate dishonesty that is established by a final judgment and that is material to the cause of action. Our charter contains such a provision that eliminates directors’ and officers’ liability to the maximum extent permitted by Maryland law.

Our bylaws obligate us, to the maximum extent permitted by Maryland law, to indemnify any present or former director or officer or any individual who, while a director or officer of the company and at the request of the company, serves or has served another corporation, real estate investment trust, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise as a director, officer, partner, trustee, member or manager, is made or threatened to be made a party to, or witness in, a proceeding by reason of his or her service in that capacity, and to pay or reimburse his or her reasonable expenses in advance of final disposition of a proceeding.

EX-21 3 bcpc202110k-ex21.htm EX-21 Document

Exhibit 21

LIST OF SUBSIDIARIES 
Subsidiaries of the RegistrantJurisdiction of Organization
  
BCP Ingredients, Inc.Delaware
  
Balchem BVNetherlands
  
Balchem Italia SrlItaly
Balchem Ltd.Canada
  
Aberco, Inc.Maryland
  
SensoryEffects, Inc.Delaware
  
SensoryEffects Cereal Systems, Inc.Delaware
  
Albion Laboratories, Inc.Nevada
  
Balchem NVBelgium
Balchem Sdn BhdMalaysia
Balchem Pte Ltd.Singapore
Balchem Pty Ltd.Australia
Stereo Gas Philippines Inc.Philippines
 




 EX-23.1 4 bcpc202110k-ex231.htm EX-23.1 Document

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statements (Nos. 333-219722, 333-155655, and 333-118291) on Form S-8 of Balchem Corporation and Subsidiaries of our report dated February 24, 2022, relating to the consolidated financial statements, the financial statement schedule and the effectiveness of internal control over financial reporting of Balchem Corporation and Subsidiaries, appearing in this Annual Report on Form 10-K of Balchem Corporation and Subsidiaries for the year ended December 31, 2021.

/s/ RSM US LLP 

New York, New York
February 24, 2022



 EX-31.1 5 bcpc202110k-ex311.htm EX-31.1 Document

Exhibit 31.1 
CERTIFICATIONS 
I, Theodore L. Harris, certify that:

1.I have reviewed this annual report on Form 10-K of Balchem Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 24, 2022/s/ Theodore L. Harris
 Theodore L. Harris
 President and Chief Executive Officer
 (Principal Executive Officer)
 


 EX-31.2 6 bcpc202110k-ex312.htm EX-31.2 Document

Exhibit 31.2 

CERTIFICATIONS 

I, Martin Bengtsson, certify that:

1.I have reviewed this annual report on Form 10-K of Balchem Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 24, 2022/s/ Martin Bengtsson
 Martin Bengtsson
 Chief Financial Officer and Treasurer
 (Principal Financial Officer)
 


 EX-32.1 7 bcpc202110k-ex321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Balchem Corporation (the “Company”) on Form 10-K for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Theodore L. Harris, President, and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 /s/ Theodore L. Harris
 Theodore L. Harris
 President and
 Chief Executive Officer
 (Principal Executive Officer)
 February 24, 2022

This certification accompanies the above-described Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.


 EX-32.2 8 bcpc202110k-ex322.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Balchem Corporation (the "Company") on Form 10-K for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Martin Bengtsson, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 /s/ Martin Bengtsson
 Martin Bengtsson
 Chief Financial Officer and Treasurer
 (Principal Financial Officer)
 February 24, 2022

This certification accompanies the above-described Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. 


 EX-101.SCH 9 bcpc-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0002002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 1001003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003005 - Statement - Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 1004006 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006008 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1007009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1008010 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 2108102 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2112103 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - STOCKHOLDERS' EQUITY - Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2418411 - Disclosure - STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2419412 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2420413 - Disclosure - STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2121104 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2322304 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 2124105 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2129106 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2330306 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2431418 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2132107 - Disclosure - EQUITY-METHOD INVESTMENT link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - EQUITY-METHOD INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 2134108 - Disclosure - REVOLVING LOAN link:presentationLink link:calculationLink link:definitionLink 2435420 - Disclosure - REVOLVING LOAN (Details) link:presentationLink link:calculationLink link:definitionLink 2136109 - Disclosure - NET EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2337307 - Disclosure - NET EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2438421 - Disclosure - NET EARNINGS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2139110 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2340308 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2443424 - Disclosure - INCOME TAXES - Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - INCOME TAXES - Income Tax Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 2146111 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 2347309 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2449428 - Disclosure - SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details) link:presentationLink link:calculationLink link:definitionLink 2450429 - Disclosure - SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2451430 - Disclosure - SEGMENT INFORMATION - Depreciation/Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2452431 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details) link:presentationLink link:calculationLink link:definitionLink 2153112 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 2354310 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2455432 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 2156113 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 2357311 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2458433 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 2159114 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2360312 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 2461434 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2462435 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2163115 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 2364313 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2465436 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2466437 - Disclosure - EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2467438 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2468439 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2469440 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2470441 - Disclosure - EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2471442 - Disclosure - EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details) link:presentationLink link:calculationLink link:definitionLink 2172116 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2373314 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2474443 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2175117 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2476444 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2177118 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2478445 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2179119 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2380315 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2481446 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2482447 - Disclosure - LEASES - Right-of-Use Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2483448 - Disclosure - LEASES - Schedule of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2184120 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 2385316 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2486449 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2487450 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2488451 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2189121 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 2390317 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables) link:presentationLink link:calculationLink link:definitionLink 2491452 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) link:presentationLink link:calculationLink link:definitionLink 2192122 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 2493453 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bcpc-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 bcpc-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 bcpc-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Hedging Designation [Domain] Hedging Designation [Domain] 1999 Plan Stock Plan 1999 [Member] Stock plan for officers, directors, directors emeritus and employees of and consultants of the company. Pension obligation (net) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Pension Obligations Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Pension Obligations Actuarial gain Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Net Earnings Per Common Share Earnings Per Share, Policy [Policy Text Block] Number of filing facilities Number of Filling Facilities Number of Filling Facilities State Current State and Local Tax Expense (Benefit) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Trademarks & trade names Trademarks and Trade Names [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net earnings Net earnings Net Earnings - Basic and Diluted Net Income (Loss) Attributable to Parent Income Tax Reconciliation [Abstract] Effective Income Tax Rate Reconciliation, Amount [Abstract] Right of use assets - operating leases Operating Lease - ROU Operating Lease, Right-of-Use Asset Number of votes Equity Method Investment, Number Of Votes Equity Method Investment, Number Of Votes Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Interest cost Defined Benefit Plan, Interest Cost Accrued compensation and other benefits Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Range [Domain] Statistical Measurement [Domain] Other Other Intangible Assets [Member] Derivative liabilities Derivative Liability Schedule of Other Information Pertaining to Stock Option Activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value and Grant Date Intrinsic Value [Table Text Block] Tabular disclosure of the weighted-average grant-date fair value and intrinsic value of equity options granted during the year. Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Years 5 through 9 Lessee, Operating Lease, Tranche Three [Member] Lessee, Operating Lease, Tranche Three [Member] Proceeds from sale of business and assets Proceeds from Sale of Property, Plant, and Equipment Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Other assets Other Assets, Noncurrent Investment, Name [Axis] Investment, Name [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Segments [Axis] Segments [Axis] Derivative Instruments and Hedging Activities Derivatives, Policy [Policy Text Block] Lease liabilities Deferred Tax Assets, Operating Lease Liability Deferred Tax Assets, Operating Lease Liability Dividend Yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Shares available for future awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Retirement Benefits [Abstract] Retirement Benefits [Abstract] Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Entity File Number Entity File Number Postretirement Medical Plans Postretirement Health Coverage [Member] Expected Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Income taxes Increase (Decrease) in Income Taxes Payable Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Consignment Consignment [Member] Revenues generated from consignment sales. (Gain)/loss on disposal of assets Gain (Loss) on Disposition of Assets Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Range of exercise prices, minimum (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Additions charged (credited) to costs and expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Amortization of identifiable intangible assets Amortization of Intangible Assets Useful life of intangible assets acquired Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Increases for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Related rabbi trust assets Assets Held-in-trust, Noncurrent Net change in postretirement benefit plan, net of taxes of $13, $127, and $101 at December 31, 2021, 2020 and 2019, respectively Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Chemogas Chemogas Holding NV and Subsidiaries [Member] Chemogas Holding NV and Subsidiaries Buildings Building Building [Member] Dividends payable Dividends payable Dividends Payable, Current Prepaid income taxes Prepaid Taxes Multiemployer Plans [Line Items] Multiemployer Plan [Line Items] Business Combination and Asset Acquisition [Abstract] Receivable from related party Accounts Receivable, Related Parties Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Business Acquisition [Axis] Business Acquisition [Axis] Derivative Interest Rate, Type [Axis] Derivative Interest Rate, Type [Axis] Derivative Interest Rate, Type Services Provided Services Provided [Member] Services provided to the customers. Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Relationship to Entity [Domain] Title of Individual [Domain] Equity Award [Domain] Award Type [Domain] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Exercise Price Range [Axis] Exercise Price Range [Axis] Local Phone Number Local Phone Number Assets Assets Assets [Abstract] Chemogas Defined Pension Plan Chemogas Defined Pension Plan [Member] Chemogas Defined Pension Plan Related Party Transactions [Abstract] Related Party Transactions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Amortization of gain Defined Benefit Plan, Amortization of Gain (Loss) Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Land Land [Member] Exercisable at end of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Goodwill and Acquired Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Interest and other expense Segment Reconciling Items [Member] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding Preferred Stock, Value, Issued Property, Plant and Equipment and Depreciation Property, Plant and Equipment, Policy [Policy Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Outstanding at beginning of year (in shares) Outstanding at end of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Trade name Trade Names [Member] Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Net Cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] $29.06 - $57.17 Exercise Price Range 1 [Member] Exercise price range for stock options outstanding. Payable to related party Accounts Payable, Related Parties COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Lessee, Operating Lease, Tranches [Domain] Lessee, Operating Lease, Tranches [Domain] [Domain] for Lessee, Operating Lease, Tranches [Axis] Related Party [Axis] Related Party [Axis] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Term A Loan Secured Debt [Member] Schedule of Long-Lived Assets by Geographical Area Long-lived Assets by Geographic Areas [Table Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Net change in postretirement benefit plan (see Note 15 for further information) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Cliff vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other comprehensive (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Prior service (credit)/cost and (gain)/loss arising during the period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Post-employment Benefits Postemployment Benefit Plans, Policy [Policy Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Principal payments on finance lease Principal payments on finance lease Finance Lease, Principal Payments Zumbro Zumbro River Brand, Inc. [Member] Zumbro River Brand, Inc. Unused portion of revolving loan Line of Credit Facility, Remaining Borrowing Capacity Operating expenses Operating Expense [Member] Fixed interest rate Derivative, Fixed Interest Rate Basic net earnings per common share (in dollars per share) Net earnings per share - basic (in dollars per share) Earnings Per Share, Basic Net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three REVENUE Revenue from Contract with Customer [Text Block] Non-vested balance as of beginning of year (in shares) Non-vested balance as of end of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total lease liabilities, non-current Operating and Finance Lease, Liability, Noncurrent Operating and Finance Lease, Liability, Noncurrent Allowance for Doubtful Accounts SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Disaggregation of Revenue by Source and Geography Disaggregation of Revenue [Table Text Block] 401(k) contributions Defined Contribution Plan, Cost Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] VALUATION AND QUALIFYING ACCOUNTS SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) Liability, Defined Benefit Pension Plan, Noncurrent Inventory Reserve SEC Schedule, 12-09, Reserve, Inventory [Member] Operating cash flows from operating leases Operating Lease, Payments Number of unfunded plans Defined Benefit Plan, Number of Benefit Plans Defined Benefit Plan, Number of Benefit Plans Net deferred tax liability Deferred Tax Liabilities, Net Number of shares authorized for grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Research and Development Research and Development Expense, Policy [Policy Text Block] Bill and Hold Bill And Hold [Member] Revenues generated from bill and hold in which seller of a good bills a customer for products but does not ship the product until a later date. Right of use assets Deferred Tax Liabilities, Operating Lease, Right-Of-Use Assets Deferred Tax Liabilities, Operating Lease, Right-Of-Use Assets Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Purchase of convertible notes Payments for Hedge, Investing Activities Goodwill [Roll Forward] Goodwill [Roll Forward] Entity Voluntary Filers Entity Voluntary Filers Plan Name [Axis] Plan Name [Axis] Right of use assets - finance lease Finance Lease, Right-of-Use Asset, after Accumulated Amortization Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reconciliation of Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Goodwill impairment charge Goodwill impairment Goodwill, Impairment Loss Other Other Operating Activities, Cash Flow Statement Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] State income taxes, net of Federal income taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Small Reporting Company Entity Small Business Increases for tax positions related to current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Unrealized gain/(loss) on cash flow hedge, net of taxes of $654, $809, and $372 at December 31, 2021, 2020, and 2019, respectively Net of tax Cash flow hedge (interest rate swap), net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Principal payment on acquired debt Repayments of Assumed Debt Initial adoption of new plan Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Capital expenditures and intangible assets acquired Payments to Acquire Other Productive Assets Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Additional paid-in capital Additional Paid in Capital Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Derivative liabilities Derivative Financial Instruments, Liabilities [Member] $91.56 - $120.60 Exercise Price Range 3 [Member] Exercise price range for stock options outstanding. Translated amount paid to shareholders Amount paid to shareholders Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Derivative [Line Items] Derivative [Line Items] Hedging Relationship [Domain] Hedging Relationship [Domain] Interest rate swap Interest Rate Swap [Member] Weighted Average Exercise Price of Options Exercisable (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] NET EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Operating expenses: Operating Expenses [Abstract] Ownership percentage in joint venture Equity Method Investment, Ownership Percentage Shares repurchased, average cost (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Entity Interactive Data Current Entity Interactive Data Current Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Other long-term obligations Other Long-term Debt, Noncurrent Minimum Minimum [Member] Unrealized (gain)/loss on foreign currency transactions and deferred compensation Unrealized Loss (Gain) on Foreign Currency Transactions and Deferred Compensation Unrealized Loss (Gain) on Foreign Currency Transactions and Deferred Compensation Retirement Plan Name [Axis] Retirement Plan Name [Axis] Gross margin Gross Profit 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance Sheet Location [Domain] Balance Sheet Location [Domain] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Earnings before income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Capitalized costs net of accumulated amortization Debt Issuance Costs, Net Other comprehensive (loss)/ income, net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Balance at beginning of period Balance at end of period Unrecognized Tax Benefits Total deferred tax assets Deferred Tax Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Proceeds from insurance Proceeds from Insurance Settlement, Investing Activities LEASES Lessee, Finance Leases [Text Block] Percentage of outstanding common shares acquired Business Acquisition, Percentage of Voting Interests Acquired Current liabilities: Liabilities, Current [Abstract] Total lease liabilities, current Operating and Finance Lease, Liability, Current Operating and Finance Lease, Liability, Current General and administrative expenses General and Administrative Expense SUPPLEMENTAL CASH FLOW INFORMATION Cash Flow, Supplemental Disclosures [Text Block] Cash paid for acquisitions, net of cash acquired Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Foreign currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Schedule of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Number of Options Exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable INVENTORIES Inventory Disclosure [Text Block] Specialty Products Specialty Products [Member] A reportable segment of the company that provides specialty-packaged chemicals for use in healthcare and other industries. Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Accounting Policies [Abstract] Accounting Policies [Abstract] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Weighted average remaining contractual term for outstanding stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] Number of reportable segments Number of Reportable Segments FDII Effective Income Tax Rate Reconciliation, Foreign-Derived Intangible Income Effective Income Tax Rate Reconciliation, Foreign-Derived Intangible Income Other non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Federal Current Federal Tax Expense (Benefit) Document Transition Report Document Transition Report Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,287,150 shares issued and outstanding at December 31, 2021 and 32,372,621 shares issued and outstanding at December 31, 2020, respectively Common Stock, Value, Issued Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other expenses Interest and other expense Nonoperating Income (Expense) Weighted-average period of recognition for unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-vested balance as of beginning of year (in dollars per share) Non-vested balance as of end of year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Goodwill as a result of Zumbro Acquisition Goodwill, Acquired During Period Performance Shares Performance Shares [Member] Other Other Intangible Assets Excluding Regulatory registration Costs and Patents & Trade Secrets [Member] Intangible assets classified as other excluding regulatory registration costs and patents & trade secrets. Commitments and contingencies (Note 16) Commitments and Contingencies Repurchases of common stock Treasury Stock, Value, Acquired, Par Value Method LEASES Lessee, Operating Leases [Text Block] Accumulated other comprehensive (loss)/income Accumulated Other Comprehensive Income (Loss), Net of Tax Dividends (in dollars per share) Dividends Payable, Amount Per Share Emerging Growth Company Entity Emerging Growth Company Amortization of ROU asset Finance Lease, Right-of-Use Asset, Amortization Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Exchange rate changes Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Restricted Stock Restricted Stock [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Assumptions Used in the Valuation of Option Awards Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Foreign Deferred Foreign Income Tax Expense (Benefit) Auditor Name Auditor Name Cover [Abstract] Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Goodwill [Line Items] Goodwill [Line Items] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Interest expense, net Interest Income (Expense), Net Schedule of Reconciliation of Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Number of sub-streams of revenue Number of Sub-streams of Revenue The number of sub-streams of revenue associated with revenue from contract with customers. Income Tax Authority [Axis] Income Tax Authority [Axis] Lessee, Operating Lease, Tranches [Axis] Lessee, Operating Lease, Tranches [Axis] Lessee, Operating Lease, Tranches [Axis] Work in progress Inventory, Work in Process, Net of Reserves Other receivable from related party Accounts Receivable, Related Parties, Current Eastman Chemical Company Eastman Chemical Company [Member] Refers to the entity with which the joint venture is formed. Right of use assets Business Combination, Recognized Identifiable Assets Acquires and Liabilities Assumed, Right-of-Use Assets Business Combination, Recognized Identifiable Assets Acquires and Liabilities Assumed, Right-of-Use Assets Net foreign currency translation adjustment tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Revenues from related party Revenue from Related Parties Accrued expenses Accrued Liabilities, Current Net sales Revenue from Contract with Customer, Excluding Assessed Tax Restricted stock and stock options Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Weighted Average Remaining Contractual  Term Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Finished goods Inventory, Finished Goods, Net of Reserves Dividends paid Payments of Dividends Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Stock Options Share-based Payment Arrangement, Option [Member] Installment payments required Line of Credit Facility, Periodic Payment Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Working capital acquired Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Acquired Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Acquired Shares purchased under restricted stock purchase agreements, maximum (in shares) Shares purchased under restricted stock purchase agreements, maximum The maximum number of shares purchased under restricted stock purchase agreements. Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Percentage of production offtake Percentage of Production Offtake Refers to the percentage of production offtake. Common Stock Common Stock [Member] Adjustment Other Comprehensive (Income) Loss, Defined Benefit Plan, One Time Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, One Time Adjustment, after Tax Weighted-average remaining lease term - finance leases Finance Lease, Weighted Average Remaining Lease Term SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Earnings from operations Earnings from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liabilities - current Operating leases liabilities - current Operating Lease, Liability, Current BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock compensation expense Share-based Payment Arrangement, Noncash Expense AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Years 2027-2031 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Currency and interest rate swap Deferred Tax Assets, Hedging Transactions Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Deferred compensation liability Deferred Compensation Liability, Classified, Noncurrent Income taxes Income Taxes Paid Proceeds from revolving loan Proceeds from Lines of Credit Asset impairment charge Asset Impairment Charges Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Patents & trade secrets Patents & Trade Secrets [Member] The exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, and information generally known to only a limited number of the entity's employees, such as a formula, pattern, machine, technology, and production process that may give an entity a competitive advantage. Stock Options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Other, net Other Nonoperating Income (Expense) Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Credit Agreement Revolving Credit Agreement [Member] Revolving Credit Agreement Exchange rate changes Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Capital expenditures Payments to Acquire Property, Plant, and Equipment Accumulated postretirement benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Employer (reimbursement)/contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Interest rate Line of Credit Facility, Interest Rate at Period End Maximum Maximum [Member] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves ANH Animal Nutrition & Health Animal Nutrition and Health [Member] A reportable segment of the company that provides the animal, nutrition and health markets with products derived from its micro capsulation, chelation and basic choline chloride technologies. 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value for outstanding stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Cash flows from operating and finance leases Cash Payments for Operating and Finance Leases Cash Payments for Operating and Finance Leases Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Operating loss carryforwards Operating Loss Carryforwards Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Changes in Plan Assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Aggregate intrinsic value for exercisable stock options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Prepaid & other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets EQUITY-METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Total before tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Designated as Hedging Instrument Designated as Hedging Instrument [Member] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] Repurchases of common stock Payments for Repurchase of Common Stock Percentage of operating expenses to be absorbed Percentage of Operating Expenses to be Absorbed Refers to the percentage of operating expenses to be absorbed. Estimated useful lives Property, Plant and Equipment, Useful Life Schedule of Estimated Future Employer Contributions and Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Components of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Business Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Axis] ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Operating lease liabilities - non-current Operating Lease, Liability, Noncurrent Expected return on assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Total net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Translated amount on acquisition date Total amount paid on acquisition date Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Raw Materials Sold Raw Materials Sold [Member] Raw materials sold to the customers. 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year One Regulatory registration costs Regulatory registration Costs [Member] Costs associated with the required registration, with the U.S. Environmental Protection Agency, of certain products considered pesticides under the Federal Insecticide, Fungicide and Rodenticide Act. Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Operating Segments Operating Segments [Member] Term of contract for operating leases Lessee, Operating Lease, Term of Contract Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Expiration period of options granted Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Estimated Fair Values of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Entity Filer Category Entity Filer Category GILTI Effective Income Tax Rate Reconciliation, Global Intangible Low-Tax Income And Foreign-Derived Intangible Income Effective Income Tax Rate Reconciliation, Global Intangible Low-Tax Income And Foreign-Derived Intangible Income Total deferred tax liabilities Deferred Tax Liabilities, Gross Aggregate number of shares repurchased since inception (in shares) Stock Repurchase Program, Aggregate Number of Shares Repurchased Since Inception Cumulative number of shares repurchased under the repurchase program since the inception of the program as of balance sheet date. Business Acquisition [Line Items] Business Acquisition [Line Items] Schedule of Income (Loss) on Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Risk-Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Carrying value of joint venture Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] St. Gabriel CC Company, LLC Corporate Joint Venture [Member] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] $58.52 - $85.40 Exercise Price Range 2 [Member] Exercise price range for stock options outstanding. Payments for outstanding balance Repayments of Lines of Credit Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Adjustments/deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Identifiable intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Proceeds from stock options exercised Proceeds from Stock Options Exercised Participant contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Weighted Average Exercise Price of Options Outstanding (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax expense Total income tax provision Income Tax Expense (Benefit) 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Accounts receivable, net of allowance for doubtful accounts of $928 and $2,092 at December 31, 2021 and 2020, respectively Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Inventories Deferred Tax Assets, Inventory Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Tax Identification Number Entity Tax Identification Number SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Schedule of Additional Information Relating to Stock Options Outstanding Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Number of Shares (Denominator) [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories, net Total inventories Inventory, Net Net change in postretirement benefit plan taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Shares and options issued under stock plans (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Contributions of Balchem Corporation Multiemployer Plan, Employer Contribution, Cost Stock-based Compensation Share-based Payment Arrangement [Policy Text Block] Federal Deferred Federal Income Tax Expense (Benefit) Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Cancelled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Product and Service [Axis] Product and Service [Axis] Shares and options issued (canceled) under stock plans Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Weighted-average fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Schedule of Multiemployer Plans [Table] Multiemployer Plan [Table] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Estimated share-based compensation expense for current fiscal year Estimated Share Based Compensation Expense Estimated share-based compensation expense for current fiscal year. Statement [Line Items] Statement [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Auditor Information [Abstract] Auditor Information Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Revolving loan Outstanding balance Long-term Line of Credit, Noncurrent Assets and Liabilities, Lessee [Abstract] Assets and Liabilities, Lessee [Abstract] Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Finished goods received from related party recorded in cost of goods sold Related Party Transaction, Purchases from Related Party Retirement Plan Type [Domain] Retirement Plan Type [Domain] Total finance lease Finance Lease, Cost Finance Lease, Cost Schedule of Changes in Benefit Obligation Schedule of Changes in Projected Benefit Obligations [Table Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] Finance lease liabilities - current Finance Lease, Liability, Current Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Valuation allowance Deferred Tax Assets, Valuation Allowance Auditor Location Auditor Location Losses and gains recognized in accumulated other comprehensive income (loss) Derivative, Gain (Loss) on Derivative, Net Accounts payable Accounts Payable, Related Parties, Current Other and Unallocated Corporate, Non-Segment [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Useful life of intangible assets Amortization Period Finite-Lived Intangible Asset, Useful Life Interest on lease liabilities Finance Lease, Interest Expense Co-manufacturing Co-manufacturing [Member] Revenues generated from co-manufacturing. Foreign Tax Credits Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reconciliation of the Net Earnings and Shares used in Calculating Basic and Diluted Net Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Document Annual Report Document Annual Report Other comprehensive (loss)/ income, net of tax Total other comprehensive (loss)/income Other comprehensive (loss)/gain Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Compensation Cost on Net Earnings Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Title of 12(b) Security Title of 12(b) Security Total assets Assets Assets More than 10 years Lessee, Operating Lease, Tranche Four [Member] Lessee, Operating Lease, Tranche Four [Member] Investment, Name [Domain] Investment, Name [Domain] Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Previously acquired treasury stock offset Treasury Stock, Retired, Par Value Method, Amount Non-employee Director Director [Member] Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Amount paid to former shareholders Payments to Acquire Businesses, Amount Paid to Former Shareholders The cash outflow for payment to former shareholders associated with the acquisition of a business, net of the cash acquired from the purchase. Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Earnings (Numerator) [Abstract] Net Income (Loss) Attributable to Parent [Abstract] Geographical [Domain] Geographical [Domain] Title of Individual [Axis] Title of Individual [Axis] Document Type Document Type Product and Service [Domain] Product and Service [Domain] Research and development expenses Research and Development Expense Unrecognized prior service cost Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Derivative Contract [Domain] Derivative Contract [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving loan Revolving Credit Facility [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Notional amount of derivatives Derivative Liability, Notional Amount Schedule of Lease Cost Lease, Cost [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Shares purchased under restricted stock purchase agreements, minimum (in shares) Shares purchased under restricted stock purchase agreements, minimum The minimum number of shares purchased under restricted stock purchase agreements. Geographical [Axis] Geographical [Axis] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Weighted average common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted net earnings per common share (in dollars per share) Net earnings per share - diluted (in dollars per share) Earnings Per Share, Diluted State State and Local Jurisdiction [Member] Chemogas and Zumbro Chemogas And Zumbro River Brand, Inc. [Member] Chemogas And Zumbro River Brand, Inc. Segments [Domain] Segments [Domain] Principal payments on revolving loan Repayments of Long-term Lines of Credit Summary of Pension Fund Multiemployer Plan [Table Text Block] Product Sales Revenue Product [Member] Service cost with interest to end of year Defined Benefit Plan, Service Cost Net investment hedge Net Investment Hedging [Member] Unrecognized net gain Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Hedging Relationship [Axis] Hedging Relationship [Axis] SIGNIFICANT ACQUISITIONS AND DIVESTITURES Mergers, Acquisitions and Dispositions Disclosures [Text Block] Interest Expense Interest Expense [Member] Foreign Countries Non-US [Member] Lease Cost Lease, Cost [Abstract] Amortization of prior service credit/(cost) Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent QUARTERLY FINANCIAL INFORMATION (UNAUDITED) Quarterly Financial Information [Text Block] Cost of sales Cost of Revenue Cash Paid for Income Taxes and Interest [Abstract] Cash Paid for Income Taxes and Interest [Abstract] Expected deductible amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Net of Tax [Abstract] ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals Right-of-use Asset Obtained in exchange for Finance Lease Liability, net of Right-of-Use Assets Sold Right-of-use Asset Obtained in exchange for Finance Lease Liability, net of Right-of-Use Assets Sold Schedule of Amounts Recognized in Consolidated Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Deferred income taxes Deferred Income Tax Liabilities, Net Related Party Transaction [Line Items] Related Party Transaction [Line Items] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) [Table Text Block] Loss relating to joint venture's expenses Income (Loss) from Equity Method Investments Derivative liabilities Derivative Liability, Noncurrent Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Schedule of Non-vested Restricted Stock Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] Schedule of Income Tax Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Contribution rate increase Multiemployer Plan, Contribution Rate Increase (Decrease) Impairment charges Impairment, Long-Lived Asset, Held-for-Use Depreciation and amortization Depreciation, Depletion and Amortization 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Dividends Dividends, Common Stock Proceeds from revolving loan Proceeds from Long-term Lines of Credit Net earnings Share-based Payment Arrangement, Expense, after Tax Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Accounts payable & accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Derivative [Table] Derivative [Table] Unrealized gain/(loss) on cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Repurchases of common stock (in shares) Treasury Stock, Shares, Retired Years 3 and 4 Lessee, Operating Lease, Tranche Two [Member] Lessee, Operating Lease, Tranche Two [Member] Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Number of shares authorized to be repurchased (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Quarterly Financial Information Quarterly Financial Information [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] State Deferred State and Local Income Tax Expense (Benefit) Total lease cost Lease, Cost Property, Plant and Equipment, Estimated Useful Lives Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Range of exercise prices, maximum (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Decreases for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Customer relationships Customer Relationships [Member] HNH Human Nutrition & Health Human Nutrition and Health [Member] A reportable segment of the company that provides the human, nutrition and health markets with products derived from its micro capsulation, chelation and basic choline chloride technologies. Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Total operating expenses Operating Expenses Prepaid expenses Other Prepaid Expense, Current Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Property, plant and equipment Property, Plant and Equipment, Gross Net foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Other Deferred Tax Liabilities, Other Net sales Revenues Equipment Equipment [Member] Amortization of gain/(loss) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Benefit Obligatoins Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] 2017 Plan Omnibus Incentive Plan 2017 [Member] A share-based compensation plan under which awards may be granted for officers, employees and directors of the Company and its subsidiaries. Participant contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Outstanding at beginning of year (in dollars per share) Outstanding at end of year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total right-of-use assets Operating and Finance Lease, Right-of-Use Asset Operating and Finance Lease, Right-of-Use Asset Schedule of Goodwill [Table] Schedule of Goodwill [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Stock-based compensation cost Share-based Payment Arrangement, Expense Derivative Interest Rate, Type [Domain] Derivative Interest Rate, Type [Domain] Derivative Interest Rate, Type Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Weighted average remaining contractual term for exercisable stock options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Foreign Countries Europe [Member] Entity Current Reporting Status Entity Current Reporting Status Number of multiemployer benefit pension plans Multiemployer Plan, Pension, Number Of Plans Multiemployer Plan, Pension, Number Of Plans Per Share Amount [Abstract] Earnings Per Share, Basic and Diluted [Abstract] Years 1 and 2 Lessee, Operating Lease, Tranche One [Member] Lessee, Operating Lease, Tranche One [Member] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Employee Employee [Member] An individual that is currently employed by the entity. Amortization expense pertaining to capitalized costs Amortization of Debt Issuance Costs Counterparty Name [Axis] Counterparty Name [Axis] Reserve for inventory Inventory Valuation Reserves Construction in progress Construction in Progress [Member] Cash and cash equivalents beginning of period Cash and cash equivalents end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Number of tranches Lessee, Operating Lease, Number Of Tranches Lessee, Operating Lease, Number Of Tranches United States UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Income tax payable Taxes Payable, Current Current assets: Assets, Current [Abstract] St. Gabriel CC Company, LLC St. Gabriel CC Company, LLC [Member] A joint venture formed in 2013 by the Company and Eastman Chemical Company (formerly Taminco Corporation) to design, develop, and construct an expansion of the Company's St. Gabriel aqueous choline chloride plant. Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] Identifiable intangible assets [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Intangible Assets, Estimated Useful Lives Schedule of Identifiable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Impairment of Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Number of savings plan Number of Savings Plans Number of Savings Plans Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Amortization Deferred Tax Liability, Customer list and goodwill amortization The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of customer lists and goodwill and the basis of customer lists and goodwill computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses. Schedule of Non-vested Performance Share Activity Schedule of Nonvested Performance-based Units Activity [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Revenue Recognition and Cost of Sales Revenue from Contract with Customer [Policy Text Block] Pay-Fixed Interest Rate Pay-Fixed Interest Rate [Member] Pay-Fixed Interest Rate Weighted average common shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Exercise Price Range [Domain] Selling expenses Selling Expense INCOME TAXES Income Tax Disclosure [Text Block] Related Party [Domain] Related Party [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Number of share-based compensation plans Number of Share Based Compensation Plans Number of Share Based Compensation Plans Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Product Sales Product Sales [Member] Revenues generated from product sales. STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Other and Unallocated Industrial Products [Member] A reportable segment of the company that provides certain derivatives of industrial applications predominately as a component for hydraulic fracturing of shale natural gas wells. Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Cash flow hedge Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Patent Box Decree (related to prior years) Effective Income Tax Rate Reconciliation, Patent Box Decree Effective Income Tax Rate Reconciliation, Patent Box Decree Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other expenses: Nonoperating Income (Expense) [Abstract] Auditor Firm ID Auditor Firm ID Lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Currency swap Cross-currency swap Currency Swap [Member] Discount rate Lessee, Operating Lease, Discount Rate Royalty Revenue Royalty [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Changes in assets and liabilities, net of acquired balances Increase (Decrease) in Operating Capital [Abstract] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Principles of Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Expected Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Payment made on acquisition date Payments to Acquire Businesses, Gross Transaction and integration related costs Business Combination, Transaction and Integration Related Costs This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs could include legal, accounting and other professional fees. This element also includes costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs and systems integration and conversion costs. Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Unrealized gain/(loss) on cash flow hedge taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Money Market Funds Money Market Funds [Member] Impact due to change in foreign exchange rates Goodwill, Foreign Currency Translation Gain (Loss) Trade accounts payable Accounts Payable, Trade, Current Award participation per share of common stock Participating Awards, Common Stock Participation Participating Awards, Common Stock Participation Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Debt paid on purchase date Business Combination, Cost of Acquired Entity Debt Paid Cost of debt of acquired entity paid by the acquirer in a business combination. Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Receive-Fixed Interest Rate Receive-Fixed Interest Rate [Member] Receive-Fixed Interest Rate Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Central States, Southeast and Southwest Areas Pension Fund Central States, Southeast and Southwest Areas Pension Fund [Member] A multiemployer defined benefit plan, in which the Company participates under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona facility. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Long-lived assets, excluding intangible assets Long-Lived Assets Statement [Table] Statement [Table] Other current assets Other Assets, Current Customer relationships and lists Customer Lists [Member] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Weighted Average Assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Unrecognized compensation cost related to non-vested shares Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Range [Axis] Statistical Measurement [Axis] Accounts Receivable Accounts Receivable [Policy Text Block] Income tax at Federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount United States North America [Member] Derivative liabilities Derivative Liability [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Finance lease liabilities - non-current Finance Lease, Liability, Noncurrent Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Bank Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Bank Debt Intangible assets with finite lives, net Finite-Lived Intangible Assets, Net Goodwill Goodwill, beginning of period Goodwill, end of period Goodwill Net interest income (expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Shares Outstanding (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Cost of sales Cost of Sales [Member] Inventories Inventory, Policy [Policy Text Block] Foreign Current Foreign Tax Expense (Benefit) Summary of Goodwill Schedule of Goodwill [Table Text Block] Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Pension Plan Pension Plan [Member] Schedule of Fair Value of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Finance Leases - ROU Finance Lease, Right-of-Use Asset, before Accumulated Amortization Developed technology Developed Technology Rights [Member] ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net Of Right-Of Use Assets Sold Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net Of Right-Of Use Assets Sold Operating lease cost Operating Lease, Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Postretirement benefit plan Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Initial total shareholder return percentage Initial TSR The initial percentage of total shareholder return. Profit Sharing contributions Profit Sharing Plan Cost Recognized The amount of the cost recognized during the period for profit sharing plans. Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] REVOLVING LOAN Long-term Debt [Text Block] Deferred income taxes Deferred Income Tax Expense (Benefit) Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares) Treasury Stock Shares Acquired And Reissued Number of shares that have been repurchased and reissued during the period. EX-101.PRE 13 bcpc-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 bcpc-20211231_g1.jpg begin 644 bcpc-20211231_g1.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Feb. 10, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-13648    
Entity Registrant Name Balchem Corporation    
Entity Incorporation, State or Country Code MD    
Entity Tax Identification Number 13-2578432    
Entity Address, Address Line One 52 Sunrise Park Road    
Entity Address, City or Town New Hampton    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10958    
City Area Code 845    
Local Phone Number 326-5600    
Title of 12(b) Security Common Stock, par value $.06-2/3 per share    
Trading Symbol BCPC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Small Reporting Company false    
Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 4,224
Entity Common Stock, Shares Outstanding   32,187,345  
Documents Incorporated by Reference Selected portions of the Registrant’s proxy statement for its 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end of December 31, 2021 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated therein.    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Central Index Key 0000009326    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Audit Information
 12 Months Ended
Dec. 31, 2021
Auditor Information [Abstract]  
Auditor Name RSM US LLP
Auditor Firm ID 49
Auditor Location New York, New York
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 103,239 $ 84,571
Accounts receivable, net of allowance for doubtful accounts of $928 and $2,092 at December 31, 2021 and 2020, respectively 117,408 98,214
Inventories, net 91,058 70,620
Prepaid expenses 6,116 6,598
Prepaid income taxes 0 3,447
Other current assets 4,411 3,438
Total current assets 322,232 266,888
Property, plant and equipment, net 237,517 228,096
Goodwill 523,949 529,463
Intangible assets with finite lives, net 94,665 121,660
Right of use assets - operating leases 6,929 5,838
Right of use assets - finance lease 2,359 2,572
Other assets 11,674 11,326
Total assets 1,199,325 1,165,843
Current liabilities:    
Trade accounts payable 56,243 23,742
Accrued expenses 43,411 29,655
Accrued compensation and other benefits 19,567 19,753
Dividends payable 20,886 18,941
Income tax payable 1,334 0
Operating lease liabilities - current 2,194 2,178
Finance lease liabilities - current 167 159
Total current liabilities 143,802 94,428
Revolving loan 108,569 163,569
Deferred income taxes 46,455 51,359
Operating lease liabilities - non-current 4,811 3,607
Finance lease liabilities - non-current 2,303 2,472
Derivative liabilities 2,658 11,658
Other long-term obligations 13,712 10,517
Total liabilities 322,310 337,610
Commitments and contingencies (Note 16)
Stockholders’ equity:    
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding 0 0
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,287,150 shares issued and outstanding at December 31, 2021 and 32,372,621 shares issued and outstanding at December 31, 2020, respectively 2,154 2,160
Additional paid-in capital 147,716 165,160
Retained earnings 732,138 656,740
Accumulated other comprehensive (loss)/income (4,993) 4,173
Total stockholders’ equity 877,015 828,233
Total liabilities and stockholders’ equity $ 1,199,325 $ 1,165,843
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Accounts receivable, allowance for doubtful accounts $ 928 $ 2,092
Stockholders’ equity:    
Preferred stock, par value (in dollars per share) $ 25 $ 25
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0667 $ 0.0667
Common stock, shares authorized (in shares) 120,000,000 120,000,000
Common stock, shares issued (in shares) 32,287,150 32,372,621
Common stock, shares outstanding (in shares) 32,287,150 32,372,621
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Earnings - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Net sales $ 799,023 $ 703,644 $ 643,705
Cost of sales 555,849 479,747 432,338
Gross margin 243,174 223,897 211,367
Operating expenses:      
Selling expenses 60,413 58,630 60,932
Research and development expenses 13,524 10,332 11,377
General and administrative expenses 41,735 43,788 36,505
Total operating expenses 115,672 112,750 108,814
Earnings from operations 127,502 111,147 102,553
Other expenses:      
Interest expense, net 2,456 4,439 5,959
Other, net (187) 291 116
Total other expenses 2,269 4,730 6,075
Earnings before income tax expense 125,233 106,417 96,478
Income tax expense 29,129 21,794 16,807
Net earnings $ 96,104 $ 84,623 $ 79,671
Basic net earnings per common share (in dollars per share) $ 2.98 $ 2.63 $ 2.48
Diluted net earnings per common share (in dollars per share) $ 2.94 $ 2.60 $ 2.45
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]      
Net earnings $ 96,104 $ 84,623 $ 79,671
Other comprehensive (loss)/ income, net of tax:      
Net foreign currency translation adjustment (11,255) 12,829 (891)
Unrealized gain/(loss) on cash flow hedge, net of taxes of $654, $809, and $372 at December 31, 2021, 2020, and 2019, respectively 2,053 (2,285) (1,399)
Net change in postretirement benefit plan, net of taxes of $13, $127, and $101 at December 31, 2021, 2020 and 2019, respectively 36 (807) 328
Other comprehensive (loss)/ income, net of tax (9,166) 9,737 (1,962)
Comprehensive income $ 86,938 $ 94,360 $ 77,709
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Other comprehensive (loss)/ income, net of tax:      
Unrealized gain/(loss) on cash flow hedge taxes $ 654 $ 809 $ 372
Net change in postretirement benefit plan taxes $ 13 $ 127 $ 101
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Common Stock
Additional Paid-in Capital
Beginning balance at Dec. 31, 2018 $ 691,618 $ 528,027 $ (3,602) $ 2,151 $ 165,042
Beginning balance (in shares) at Dec. 31, 2018       32,256,209  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net earnings 79,671 79,671     0
Other comprehensive (loss) (1,962)   (1,962)   0
Dividends (16,777) (16,777)     0
Repurchases of common stock (21,321)     $ (16) (21,305)
Repurchases of common stock (in shares)       (240,995)  
Shares and options issued (canceled) under stock plans 12,438     $ 13 12,425
Shares and options issued under stock plans (in shares)       186,703  
Ending balance at Dec. 31, 2019 743,667 590,921 (5,564) $ 2,148 156,162
Ending balance (in shares) at Dec. 31, 2019       32,201,917  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net earnings 84,623 84,623     0
Other comprehensive (loss) 9,737   9,737   0
Dividends (18,804) (18,804)     0
Repurchases of common stock (13,463)     $ (9) (13,454)
Repurchases of common stock (in shares)       (136,629)  
Shares and options issued (canceled) under stock plans 22,473     $ 21 22,452
Shares and options issued under stock plans (in shares)       307,333  
Ending balance at Dec. 31, 2020 828,233 656,740 4,173 $ 2,160 165,160
Ending balance (in shares) at Dec. 31, 2020       32,372,621  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net earnings 96,104 96,104     0
Other comprehensive (loss) (9,166)   (9,166)   0
Dividends (20,706) (20,706)     0
Repurchases of common stock (35,239)     $ (17) (35,222)
Repurchases of common stock (in shares)       (249,848)  
Shares and options issued (canceled) under stock plans 17,789     $ 11 17,778
Shares and options issued under stock plans (in shares)       164,377  
Ending balance at Dec. 31, 2021 $ 877,015 $ 732,138 $ (4,993) $ 2,154 $ 147,716
Ending balance (in shares) at Dec. 31, 2021       32,287,150  
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]      
Dividends (in dollars per share) $ 0.64 $ 0.58 $ 0.52
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net earnings $ 96,104 $ 84,623 $ 79,671
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 48,879 51,281 45,862
Stock compensation expense 10,802 8,303 7,596
Deferred income taxes (5,944) (4,627) (3,563)
Provision for doubtful accounts 180 140 1,776
Unrealized (gain)/loss on foreign currency transactions and deferred compensation (384) 173 72
Asset impairment charge 1,675 1,915 1,140
(Gain)/loss on disposal of assets (1,728) 153 (3,134)
Changes in assets and liabilities, net of acquired balances      
Accounts receivable (20,700) (3,599) 11,623
Inventories (21,023) 13,923 (11,401)
Prepaid expenses and other current assets (881) (2,856) 477
Accounts payable and accrued expenses 47,067 (992) 1,134
Income taxes 4,787 1,859 (5,664)
Other 1,680 198 (1,128)
Net cash provided by operating activities 160,514 150,494 124,461
Cash flows from investing activities:      
Capital expenditures and intangible assets acquired (37,449) (33,828) (28,413)
Cash paid for acquisitions, net of cash acquired 0 0 (141,062)
Proceeds from sale of business and assets 318 87 11,523
Proceeds from insurance 1,831 0 2,727
Purchase of convertible notes 0 (850) (1,000)
Net cash used in investing activities (35,300) (34,591) (156,225)
Cash flows from financing activities:      
Proceeds from revolving loan 5,000 10,000 168,569
Principal payments on revolving loan (60,000) (95,000) (76,000)
Principal payments on finance lease (159) (151) 0
Principal payment on acquired debt 0 0 (17,567)
Proceeds from stock options exercised 6,943 14,155 4,839
Dividends paid (18,723) (16,705) (15,135)
Repurchases of common stock (35,239) (13,463) (21,321)
Net cash (used in) provided by financing activities (102,178) (101,164) 43,385
Effect of exchange rate changes on cash (4,368) 4,160 (217)
Increase in cash and cash equivalents 18,668 18,899 11,404
Cash and cash equivalents beginning of period 84,571 65,672 54,268
Cash and cash equivalents end of period $ 103,239 $ 84,571 $ 65,672
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Description
Balchem Corporation (“Balchem” or the “Company”), including, unless the context otherwise requires, its wholly-owned subsidiaries, incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries.
Principles of Consolidation
The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Revenue Recognition

Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer.

In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.

Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S., Italy, Belgium, Malaysia, Australia, Philippines, and Singapore exceed the Federal Deposit Insurance Corporation (“FDIC”), Fondo Interbancario di Tutela dei Depositi (“FITD”), Financial Services and Markets Authority ("FSMA"), Perbadanan Insurans Deposit Malaysia ("PIDM"), Australian Prudential Regulation Authority ("APRA"), Philippine Deposit Insurance Corporation ("PDIC"), and Singapore Deposit Insurance Corporation ("SDIC") insurance limits, respectively.
Accounts Receivable
Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified,
and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
Inventories
Inventories are valued at the lower of cost (first in, first out or average) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost.
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations
Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2021, 2020 and 2019, no customer accounted for more than 10% of total net sales or accounts receivable.
Post-employment Benefits
We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.
In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets

Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. A goodwill impairment test will now be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. The guidance is effective for
annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020.

As of October 1, 2021 and 2020, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2021. However, during the second quarter of 2020, the Company recorded a goodwill impairment charge of $1,228 related to business formerly included in the Industrial Products segment. The Company may resume performing the qualitative assessment in subsequent periods.
The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
Goodwill at December 31, 2019$523,998 
Goodwill as a result of Zumbro Acquisition432 
Goodwill impairment(1,228)
Impact due to change in foreign exchange rates6,261 
Goodwill at December 31, 2020529,463 
Impact due to change in foreign exchange rates(5,514)
Goodwill at December 31, 2021$523,949 

 December 31, 2021December 31, 2020
HNH$424,044 $424,051 
ANH17,207 17,824 
Specialty Products82,654 87,539 
Other and Unallocated44 49 
Total$523,949 $529,463 
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks & trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents & trade secrets
15 - 17
Other
 2 - 18

Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an
intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2021, there were no triggering events which required intangible asset impairment reviews.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.

We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.

Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates
Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.
In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in either derivative asset or derivative liability, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities.
Cost of Sales
Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Selling, General and Administrative Expenses
Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.
Research and Development
Research and development costs are expensed as incurred.
Net Earnings Per Common Share
Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation
The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets
Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. For the year ended December 31, 2019, we incurred impairment charges of $1,026 in connection with a restructuring in the HNH segment.

Derivative Instruments and Hedging Activities

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes.

On May 28, 2019, the Company entered into a pay-fixed, receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement.
At the same time, the Company also entered into a cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. This derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023.

The derivative instruments are with the above single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet.

On a quarterly basis, we assess the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. As of December 31, 2021, we assessed the hedging relationships and determined them to be highly effective. As such, the net change in fair values of the interest rate swap, that qualifies as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and is subsequently reclassified
into interest expense as interest payments are made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remained in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, "Derivative Instruments and Hedging Activities" for detailed information about our derivative financial instruments.
New Accounting Pronouncements
Recently Adopted Accounting Standards

In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted this new Standard in 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.
In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Standard Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard Update may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new Standard on January 1, 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.
In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance contained in this ASU requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company’s consolidated financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This Update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company's consolidated financial statements and disclosures.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment”, which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new Standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The Update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The
Company adopted the new Standard and related Updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACQUISITIONS AND DIVESTITURES
 12 Months Ended
Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
SIGNIFICANT ACQUISITIONS AND DIVESTITURES SIGNIFICANT ACQUISITIONS AND DIVESTITURES
Acquisitions

On December 13, 2019, the Company completed the acquisition of Zumbro. The Company made payments of $52,403 on the acquisition date, amounting to $47,058 to the former shareholders and $5,345 to Zumbro's lenders to pay Zumbro debt. Considering the cash acquired of $686, net payments made to the former shareholders were $46,372. In May 2020, the Company received an adjustment for working capital acquired of $561.

The goodwill of $18,505 arising from the acquisition consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to Human Nutrition & Health ("HNH") and $4,723 is deductible for income taxes.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$686 
Accounts receivable3,314 
Inventories4,052 
Prepaid & other current assets521 
Property, plant and equipment15,245 
Right of use assets3,181 
Customer relationships8,200 
Developed technology4,400 
Trade name2,300 
Other non-current assets10 
Accounts payable & accrued expenses(1,651)
Lease liabilities(3,181)
Debt(5,345)
Deferred income taxes(3,740)
Goodwill18,505 
Amount paid to shareholders46,497 
Zumbro debt paid on purchase date5,345 
Total amount paid on acquisition date$51,842 
The estimated valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management's estimates and assumptions that are subject to change. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized included cost and market approaches for property, plant and equipment, excess earnings method for customer relationships and the relief from royalty method for other intangible assets.
Customer relationships are amortized over a 15-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name and developed technology are amortized over 10 years and 12 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
The Company is indemnified for tax liabilities related to periods prior to the acquisition date. Indemnified tax liabilities will create an indemnification asset (receivable). An indemnification asset balance has not been established.
On May 27, 2019, the Company acquired 100 percent of the outstanding common shares of Chemogas. The Company made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690).
The goodwill of $59,319 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Specialty Products segment and is not tax deductible for income tax purposes.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$4,412 
Accounts receivable4,176 
Inventories957 
Property, plant and equipment15,972 
Customer relationships39,158 
Developed technology2,461 
Trade name1,119 
Other assets1,491 
Accounts payable(3,261)
Bank debt(12,222)
Other liabilities(1,030)
Pension obligation (net)(594)
Deferred income taxes(12,856)
Goodwill59,319 
Amount paid to shareholders99,102 
Chemogas bank debt paid on purchase date12,222 
Total amount paid on acquisition date$111,324 
The valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized included cost and market approaches for property, plant and equipment, excess earnings method for customer relationships and the relief from royalty method for other intangible assets.
Customer relationships are amortized over a 20-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name and developed technology are amortized over 2 years and 10 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.
The Company is indemnified for tax liabilities related to periods prior to the acquisition date. Indemnified tax liabilities will create an indemnification asset (receivable). An indemnification asset balance has not been established.

In connection with Chemogas and Zumbro acquisitions, the Company incurred transaction and integration costs of $26, $1,480, and $1,947 for the years ended December 31, 2021, 2020 and 2019, respectively.

Total transaction and integration costs related to recent acquisitions, including the Chemogas and Zumbro acquisitions described above, are recorded in general and administrative expenses. These costs amounted to $448, $2,011, and $2,273 for the years ended December 31, 2021, 2020 and 2019, respectively.
Divestiture
On September 6, 2019, the Company sold an insignificant portion of its business. As a result of the transaction, the Company recorded a gain on sale, which was immaterial to the consolidated financial statements and included in general and administrative
expenses. Operating results for the portion of the business sold were insignificant relative to the Company’s consolidated financial results for year ended December 31, 2019.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2021
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
STOCK-BASED COMPENSATION
All share-based payments, including grants of stock options, are recognized in the statements of earnings as operating expenses, based on their fair values.
The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest.
The Company’s results for the years ended December 31, 2021, 2020 and 2019 reflected the following compensation cost and such compensation cost had the following effects on net earnings:
 Increase/(Decrease) for the
Year Ended, December 31
 202120202019
Cost of sales$845 $1,115 $1,147 
Operating expenses9,957 7,188 6,449 
Net earnings(8,370)(6,332)(5,884)
On December 31, 2021, the Company had one share-based compensation plan under which awards may be granted, which is described below.
In June 2017, the Company adopted the Balchem Corporation 2017 Omnibus Incentive Plan (“2017 Plan”) for officers, employees and directors of the Company and its subsidiaries. The 2017 Plan replaced the 1999 Stock Plan and amendments and restatements thereto (collectively to be referred to as the “1999 Plan"), which expired on April 9, 2018. No further awards will be made under the 1999 Plan, and the shares that remained available for grant under the 1999 Plan will only be used to settle outstanding awards granted under the 1999 Plan and will not become available under the 2017 Plan. The 2017 Plan is administered by the Compensation Committee of the Board of Directors of the Company. The 2017 Plan provides as follows: (i) for a termination date of June 13, 2027; (ii) the authorization of 1,600,000 shares for future grants (which represents a reduction from the 6,000,000 shares authorized for grant under the 1999 Plan); (iii) for the making of grants of stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards, as well as for the making of cash performance awards; (iv) except as provided in an employment agreement as in effect on the effective date of the 2017 Plan, no automatic acceleration of outstanding awards upon the occurrence of a change in control of the Company; (v) certain annual limits on the number of shares and amount of cash that may be granted; (vii) for dividends or dividend equivalents otherwise payable on an unvested award to accrue and be paid only at such time as the vesting conditions applicable to the underlying award have been satisfied; (vii) for certain discretionary compensation recovery if the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirements under the securities laws; and (viii) for compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). No option will be exercisable for longer than ten years after the date of grant.
The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2021, the 2017 Plan had 703,707 shares available for future awards.
The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Common Stock have been granted, ranging from 70 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements.
The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents.
The fair value of each option award issued under the Company’s stock plans is estimated on the date of grant using a Black-Scholes based option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
Year Ended December 31,
Weighted Average Assumptions:202120202019
Expected Volatility32.9 %26.9 %24.0 %
Expected Term (in years)4.93.94.0
Risk-Free Interest Rate0.5 %1.3 %2.5 %
Dividend Yield0.5 %0.5 %0.6 %
The value of the restricted shares is based on the fair value of the award at the date of grant.
Performance Share expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the Performance Share vests. The assumptions used in the fair value determination were risk free interest rates of 0.2%, 1.4%, and 2.5%; dividend yields of 0.6%, 0.5%, and 0.5%; volatilities of 33%, 24%, and 24%; and initial TSR’s of 11.7%, 10.9%, and -5.9% in each case for the years ended December 31, 2021, 2020, and 2019, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The Performance Shares will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.
Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three to four years for employee restricted stock awards, three years for employee performance share awards, and three to four years for non-employee director restricted stock awards.
A summary of stock option plan activity for 2021, 2020, and 2019 for all plans is as follows:

202120202019
# of
Shares
(000s)		Weighted Average
Exercise Price		# of
Shares
(000s)		Weighted Average
Exercise Price		# of
Shares
(000s)		Weighted Average
Exercise Price
Outstanding at beginning of year858 $80.58 951 $68.18 887 $61.59 
Granted129 119.12 174 111.75 197 85.13 
Exercised(109)63.42 (256)55.26 (112)43.67 
Forfeited(10)106.93 (11)92.94 (17)80.88 
Cancelled(1)74.57 — — (4)70.90 
Outstanding at end of year867 $88.19 858 $80.58 951 $68.18 
Exercisable at end of year538 $75.51 494 $69.04 581 $59.29 

The aggregate intrinsic value for outstanding stock options was $69,711, $29,735 and $31,814 at December 31, 2021, 2020 and 2019, respectively, with a weighted average remaining contractual term of 6.4 years at December 31, 2021. Exercisable stock options at December 31, 2021 had an aggregate intrinsic value of 50,128 with a weighted average remaining contractual term of 5.3 years.

Other information pertaining to option activity during the years ended December 31, 2021, 2020 and 2019 is as follows:
 Years Ended December 31,
 202120202019
Weighted-average fair value of options granted$33.11 $24.36 $18.51 
Total intrinsic value of stock options exercised ($000s)$7,866 $12,698 $6,135 

Additional information related to stock options outstanding under all plans at December 31, 2021 is as follows:

  Options OutstandingOptions Exercisable
Range of Exercise
Prices		Shares
Outstanding
(000s)		Weighted
Average
Remaining
Contractual
 Term		Weighted
Average
 Exercise
Price		Number
Exercisable
(000s)		Weighted
Average
Exercise
Price
$29.06 - $57.17
26 2.1$47.26 26 $47.26 
$58.52 - $85.40
541 5.575.55 476 74.37 
$91.56 - $120.60
300 8.5114.46 36 109.84 
 867 6.4$88.19 538 $75.51 

Non-vested restricted stock activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:

202120202019
 Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 159 $90.71 138 $80.03 79 $72.75 
Granted42 123.58 46 110.53 73 85.69 
Vested(24)85.83 (21)67.60 (8)58.52 
Forfeited(11)90.49 (4)91.91 (6)84.65 
Non-vested balance at end of year 166 $99.70 159 $90.71 138 $80.03 

Non-vested performance share activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:
202120202019
 Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 71 $91.99 70 $81.26 53 $75.61 
Granted36 108.74 20 126.46 33 81.79 
Vested(24)70.64 (8)104.15 (9)65.54 
Forfeited(14)81.03 (11)82.71 (7)60.85 
Non-vested balance at end of year 69 $110.72 71 $91.99 70 $81.26 

As of December 31, 2021, 2020 and 2019, there was $13,980, $14,154 and $11,643, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2021, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.2 years. We estimate that share-based compensation expense for the year ended December 31, 2022 will be approximately $11,900.
REPURCHASE OF COMMON STOCKThe Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,818,244 shares have been purchased. The Company’s prior presentation of reflecting treasury stock separately within stockholders’ equity has been adjusted to conform to the presentation prescribed by the State of Maryland, where the Company is incorporated. In connection therewith, $7,873 of previously acquired treasury stock has been offset against additional paid-in capital and common stock in the consolidated balance sheet as of December 31, 2020. Corresponding adjustments to balances previously reflected as treasury stock of $7,873 and $18,069 for the years ended December 31, 2020 and 2019 were made to the consolidated statements of stockholders’ equity and prior references to “Treasury shares purchased” were updated to “Repurchases of common stock”, accordingly. There was no impact to total stockholders’ equity in any of the years presented as a result of these updates. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. During 2021, 2020, and 2019, the Company purchased 249,848, 136,629, and 240,995 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $141.04, $98.54, and $88.47 per share, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
INVENTORIES
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories, net of reserves at December 31, 2021 and 2020 consisted of the following:
 20212020
Raw materials$28,639 $24,536 
Work in progress10,563 3,050 
Finished goods51,856 43,034 
Total inventories$91,058 $70,620 
On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are reserved, if necessary. The reserve for inventory was $1,425 and $2,782 at December 31, 2021 and 2020, respectively.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY, PLANT AND EQUIPMENT
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at December 31, 2021 and 2020 are summarized as follows:
 20212020
Land$11,692 $12,215 
Building89,602 86,873 
Equipment253,995 247,884 
Construction in progress52,930 31,240 
 408,219 378,212 
Less: Accumulated depreciation170,702 150,116 
Property, plant and equipment, net$237,517 $228,096 

Geographic Area Data - Long-Lived Assets (excluding intangible assets):
 20212020
United States$197,432 $187,719 
Foreign Countries40,085 40,377 
Total$237,517 $228,096 
Depreciation expense was $23,295, $22,990 and $19,791 for the years ended December 31, 2021, 2020 and 2019, respectively.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS INTANGIBLE ASSETS
The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The decrease in goodwill is due to foreign exchange translation adjustments.

As of December 31, 2021 and 2020, the Company had identifiable intangible assets as follows:
20212020
 Amortization
Period
(In years)		Gross
Carrying
Amount		Accumulated
Amortization		Gross
Carrying
Amount
Accumulated
Amortization
Customer relationships & lists
10-20
$240,059 $173,489 $243,557 $158,051 
Trademarks & trade names
2-17
43,116 28,985 43,208 24,974 
Developed technology
5-12
20,234 14,607 21,674 13,693 
Other
2-18
23,921 15,584 21,624 11,685 
  $327,330 $232,665 $330,063 $208,403 

Amortization of identifiable intangible assets was $25,092, $27,811 and $25,789 for 2021, 2020 and 2019, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $23,641 in 2022, $19,566 in 2023, $10,682 in 2024, $6,413 in 2025, and $5,083 in 2026. At December 31, 2021 and 2020, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2021 and 2020.

The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (the "EPA") because they are considered pesticides. Costs of such registrations are included as other in the table above.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
EQUITY-METHOD INVESTMENT
 12 Months Ended
Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY-METHOD INVESTMENT EQUITY-METHOD INVESTMENTIn 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant.  The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $557, $575, and $388 for the years ended December 31, 2021, 2020, and 2019, respectively, relating to its portion of the joint venture’s expenses in other expense. The carrying value of the joint venture at December 31, 2021 and 2020 was $4,499 and $4,971, respectively, and is recorded in other assets.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
REVOLVING LOAN
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
REVOLVING LOAN REVOLVING LOANOn June 27, 2018, the Company and a bank syndicate entered into the Credit Agreement, which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000.  The Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”).  The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion.  The initial proceeds from the Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. On May 23, 2019, the Company drew down $108,569 to fund the Chemogas acquisition. In connection with these additional borrowings, the Company entered into an interest rate swap to protect against adverse fluctuations in interest rates (see Note 20, "Derivative Instruments and Hedging Activities"). On December 13, 2019, the Company drew down $45,000 to fund the Zumbro acquisition. As of December 31, 2021, the total balance outstanding on the
Credit Agreement amounted to $108,569. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. 

Amounts outstanding under the Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the Credit Agreement plus an applicable rate.  The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the Credit Agreement, and the interest rate was 1.102% at December 31, 2021.  The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the Credit Agreement and ranges from 0.15% to 0.275% (0.15% at December 31, 2021).  The unused portion of the revolving loan amounted to $391,431 at December 31, 2021.  The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.

Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the Credit Agreement.  Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $421 and $703 at December 31, 2021 and 2020, respectively, and are included in other assets on the consolidated balance sheets. Amortization expense pertaining to these costs totaled $282 for each of the years ended December 31, 2021, 2020, and 2019, and is included in interest expense in the accompanying consolidated statements of earnings.

The Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio.  At December 31, 2021, the Company was in compliance with these covenants.  Indebtedness under the Company’s loan agreements is secured by assets of the Company.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
NET EARNINGS PER COMMON SHARE
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
NET EARNINGS PER COMMON SHARE NET EARNINGS PER COMMON SHARE
The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:
Year Ended December 31,
202120202019
Net Earnings - Basic and Diluted$96,104 $84,623 $79,671 
Share (000s)
Weighted Average Common Shares - Basic32,215 32,176 32,136 
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares457 327 369 
Weighted Average Common Shares - Diluted32,672 32,503 32,505 
Net Earnings Per Share - Basic$2.98 $2.63 $2.48 
Net Earnings Per Share - Diluted$2.94 $2.60 $2.45 
The number of anti-dilutive shares were 155,294, 204,672, and 12,250 for 2021, 2020, and 2019. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.
The Company has some share-based payment awards that have non-forfeitable dividend rights. These awards are restricted shares and they participate on a one-for-one basis with holders of Common Stock. These awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company’s effective tax rate for 2021, 2020 and 2019 was 23.3%, 20.5%, and 17.4%, respectively. The increase from 2020 to 2021 is primarily due to a reduction in certain tax credits, lower tax benefits from stock-based compensation, and higher enacted state tax rates.

On March 27, 2020 Congress passed the Coronavirus Aid, Relief, and Economic Security Act, and on December 31, 2020 Congress passed an additional round of COVID relief legislation as part of the Bipartisan-Bicameral Omnibus COVID Relief Deal. The Company has reviewed the change in law and determined that it does not have a significant impact on the Company’s tax provision or financial statements. In addition, Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts
and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the SEC, and/or the Financial Accounting Standards Board ("FASB") regarding this act.

The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and the Company's specific plans for reinvestment of those subsidiary earnings. The Company projects that its foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to its legal entity structure and the complexity of U.S. and local country tax laws. If the Company decides to repatriate the undistributed foreign earnings, it will need to recognize the income tax effects in the period it changes its assertion on indefinite reinvestment.
Income tax expense consists of the following:
 202120202019
Current:   
Federal$25,019 $19,249 $17,757 
Foreign7,553 3,399 1,609 
State3,664 3,590 818 
Deferred:
Federal(3,709)(3,017)(3,707)
Foreign(3,038)167 67 
State(360)(1,594)263 
Total income tax provision$29,129 $21,794 $16,807 
The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2021, 2020, and 2019 to earnings before income tax expense due to the following:
 202120202019
Income tax at Federal statutory rate$26,299 $22,348 $20,260 
State income taxes, net of Federal income taxes2,406 2,288 (244)
Stock Options(924)(1,529)(222)
GILTI — — 2,507 
FDII(1,540)(1,400)(1,922)
Patent Box Decree (related to prior years)— — (1,948)
Foreign Tax Credits— — (1,125)
Other2,888 87 (499)
Total income tax provision$29,129 $21,794 $16,807 
The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 were as follows:
 20212020
Deferred tax assets:  
Inventories$495 $1,470 
Restricted stock and stock options4,082 3,862 
Lease liabilities1,807 1,641 
Currency and interest rate swap649 2,831 
Other3,657 3,308 
Total deferred tax assets10,690 13,112 
Deferred tax liabilities:
Amortization$28,133 $32,872 
Depreciation25,484 27,897 
Prepaid expenses733 915 
Right of use assets1,769 1,926 
Other1,026 731 
Total deferred tax liabilities57,145 64,341 
Valuation allowance— 130 
Net deferred tax liability$46,455 $51,359 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not the Company will not realize the benefits of these deductible differences. The amount of deferred tax asset realizable, however, could change if management’s estimate of future taxable income should change.

As of December 31, 2021, the Company has state income tax net operating loss (NOL) carryforwards of $335. The state NOL carryforwards will expire between 2025 and 2034. The Company believes that the benefit from the state NOL carryforwards will be realized, therefore a valuation allowance is not required to be established on these assets. The Company also acquired an insignificant amount of NOL carryforwards with the acquisition of Chemogas.

The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and specific plans for reinvestment of those subsidiary earnings. The Company projects that foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to the Company's legal entity structure and the complexity of U.S. and local country tax laws. If Balchem decides to repatriate the undistributed foreign earnings, the income tax effects will need to be recognized in the period the Company changes its assertion on indefinite reinvestment.
Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:
 202120202019
Balance at beginning of period$5,335 $4,762 $5,709 
Increases for tax positions of prior years806 267 431 
Decreases for tax positions of prior years(260)(391)(1,978)
Increases for tax positions related to current year— 697 600 
Balance at end of period$5,881 $5,335 $4,762 
All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods.
The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2021, 2020 and 2019, these amounted to approximately $262, $232 and $132, respectively. As of December 31, 2021 and 2020, accrued interest and penalties were $2,106 and $1,845, respectively.
Balchem files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2017 and management does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company currently reports three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Previously, the Company's four reportable segments were: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products. However, effective in the first quarter of 2020, in order to align with the Company's strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, and given the 2019 reduction in portfolio scale of Industrial Products, the Company revised its reporting segment structure to three reportable segments stated above. These reportable segments are strategic businesses that offer products and services to different markets. This realignment has been retrospectively applied. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated" and applied retroactively to 2019. There were no changes to the Consolidated Financial Statements as a result of the change to the reportable segments. The Company expects that the new reportable segment structure will provide investors greater understanding of and alignment with the Company’s strategic focus. In order to ensure appropriate transparency and visibility into the financial performance of the Company, sufficient detail will continue to be provided relative to Other and Unallocated, including material contributions from oil and gas and other industrial market activities.

Human Nutrition & Health
The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. HNH's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. When combined with its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars,
dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.

Animal Nutrition & Health

The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, ANH’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity.

Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a global marketplace.

Specialty Products

Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Specialty Products' 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.

The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging, which are approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment.

The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life.  First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.
The segment information is summarized as follows:

Business Segment Assets
 20212020
Human Nutrition & Health$727,131 $717,232 
Animal Nutrition & Health158,971 157,454 
Specialty Products184,628 190,449 
Other and Unallocated (1)
128,595 100,708 
Total$1,199,325 $1,165,843 

Business Segment Net Sales
 202120202019
Human Nutrition & Health$442,733 $400,330 $347,433 
Animal Nutrition & Health226,776 192,191 177,557 
Specialty Products117,020 103,566 92,257 
Other and Unallocated (2)
12,494 7,557 26,458 
Total$799,023 $703,644 $643,705 

Business Segment Earnings Before Income Taxes

202120202019
Human Nutrition & Health$76,031 $61,397 $48,429 
Animal Nutrition & Health26,179 29,979 25,868 
Specialty Products30,020 26,801 28,513 
Other and Unallocated (2)
(4,728)(7,030)(257)
Interest and other expense(2,269)(4,730)(6,075)
Total$125,233 $106,417 $96,478 


Depreciation/Amortization
 202120202019
Human Nutrition & Health$30,012 $32,117 $30,558 
Animal Nutrition & Health7,414 7,187 6,552 
Specialty Products8,332 9,699 7,401 
Other and Unallocated (2)
3,121 2,278 1,351 
Total$48,879 $51,281 $45,862 

Capital Expenditures
 202120202019
Human Nutrition & Health$23,714 $22,758 $18,159 
Animal Nutrition & Health8,100 6,039 3,921 
Specialty Products3,804 2,860 3,003 
Other and Unallocated (2)
524 423 707 
Total$36,142 $32,080 $25,790 
(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.
(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,264, $2,410 and $3,436 for years ended December 31, 2021, 2020 and 2019, respectively, and (ii) Unallocated amortization expense of $2,792, $1,888, and $833 for years ended December 31, 2021, 2020, and 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
REVENUE
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenue Recognition

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to realize in exchange for those goods.

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.
 202120202019
Product Sales$762,085 $666,193 $609,741 
Co-manufacturing27,994 29,063 24,087 
Bill and Hold— 1,158 3,218 
Consignment4,439 2,939 2,299 
Product Sales Revenue794,518 699,353 639,345 
Royalty Revenue4,505 4,291 4,360 
Total Revenue$799,023 $703,644 $643,705 

The following table presents revenues disaggregated by geography, based on the billing addresses of customers:
 202120202019
United States$584,661 $516,347 $475,033 
Foreign Countries214,362 187,297 168,672 
Total$799,023 $703,644 $643,705 

Product Sales Revenues

The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of four sub-streams: product sales, co-manufacturing, bill and hold, and consignment.

Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials.  The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer.  Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided.

Royalty Revenues

Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.

Contract Liabilities

The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.
The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.

Practical Expedients and Exemptions

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUPPLEMENTAL CASH FLOW INFORMATION
 12 Months Ended
Dec. 31, 2021
Supplemental Cash Flow Information [Abstract]  
SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the year for:
202120202019
Income taxes$25,355 $22,637 $21,771 
Interest$4,547 $4,666 $5,674 
Non-cash financing activities:
 202120202019
Dividends payable$20,886 $18,941 $16,855 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME
 12 Months Ended
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOME
The changes in accumulated other comprehensive income (loss) were as follows:
 Years Ended December 31,
 202120202019
Net foreign currency translation adjustment$(11,255)$12,829 $(891)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized gain/(loss) on cash flow hedge2,707 (3,094)(1,771)
Tax(654)809 372 
Net of tax2,053 (2,285)(1,399)
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service (credit)/cost and (gain)/loss arising during the period(4)(503)199 
Amortization of prior service credit/(cost)74 74 74 
Amortization of gain/(loss)(21)(50)(46)
Total before tax49 (479)227 
Tax(13)127 101 
Adjustment (1)
— (455)— 
Net of tax36 (807)328 
Total other comprehensive (loss)/income$(9,166)$9,737 $(1,962)
(1) One-time adjustment to the postretirement account.
Included in "Net foreign currency translation adjustment" were $4,766 of gain, $4,882 of loss, and $262 of loss, related to a net investment hedge, net of taxes of $1,527, $1,579, and $70, for the years ended December 31, 2021, 2020, and 2019, respectively. See Note 20, "Derivative Instruments and Hedging Activities."

Accumulated other comprehensive (loss)/income at December 31, 2021 consisted of the following:
 Foreign currency
translation
adjustment		Cash flow hedgePostretirement benefit planTotal
Balance December 31, 2020$7,653 $(3,684)$204 4,173 
Other comprehensive (loss)/gain(11,255)2,053 36 (9,166)
Balance December 31, 2021$(3,602)$(1,631)$240 (4,993)
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
Defined Contribution Plans
The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. The Company provided for profit sharing contributions and matching 401(k) savings plan contributions of $1,459 and $4,142 in 2021, $1,022 and $3,751 in 2020, and $592 and $3,451 in 2019, respectively.
Postretirement Medical Plans
The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona, Missouri facility and a plan for those named as executive officers in the Company’s proxy statement. The Company uses a December 31 measurement date for its postretirement medical plans. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:
Change in benefit obligation:
 20212020
Benefit obligation at beginning of year$1,374 $1,076 
Initial adoption of new plan— — 
Service cost with interest to end of year87 68 
Interest cost23 26 
Participant contributions28 23 
Benefits paid(426)(27)
Actuarial gain207 208 
Benefit obligation at end of year$1,293 $1,374 
Change in plan assets:
 20212020
Fair value of plan assets at beginning of year$— $— 
Employer (reimbursement)/contributions398 4 
Participant contributions28 23 
Benefits paid(426)(27)
Fair value of plan assets at end of year$— $— 
Amounts recognized in consolidated balance sheet:
 20212020
Accumulated postretirement benefit obligation$1,293 $1,374 
Fair value of plan assets— — 
Funded status1,293 1,374 
Unrecognized prior service cost74 74 
Unrecognized net gain(50)(46)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$1,293 $1,374 
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Components of net periodic benefit cost:
 202120202019
Service cost with interest to end of year$87 $68 $63 
Interest cost23 26 39 
Amortization of prior service cost74 74 74 
Amortization of gain(24)(50)(46)
Total net periodic benefit cost$160 $118 $130 
Estimated future employer contributions and benefit payments are as follows:
Year 
2022$107 
202391 
2024113 
202591 
202676 
Years 2027-2031479 
Defined Benefit Pension Plans
The Company contributes to one multiemployer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona, Missouri facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company was to stop participating in its multiemployer plan, the Company would be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability.
The Company’s participation in this plan for the annual period ended December 31, 2021 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2021 and 2020 was affected by a 4.0% increase in the 2021 contribution rate. There have been no other significant changes that affect the comparability of 2021 and 2020 contributions. The Company does not represent more than 5% of the contributions to this pension fund.
Pension
Fund		EIN/Pension
Plan
Number		Pension Plan Protection Act Zone StatusFIP/RP Status
Pending/ Implemented		Contributions of Balchem CorporationSurcharge
Imposed		Expiration Date of Collective-
Bargaining
Agreement
20212020202120202019
Central States,
Southeast and
Southwest Areas
Pension Fund		36-6044243Critical & Declining as of 1/1/21Critical & Declining as of 1/1/20Implemented$816$774$677No7/12/2025

On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees.
The actuarial recorded liabilities for such unfunded defined benefit pension plan are as follows:
Change in benefit obligation:
 20212020
Benefit obligation at beginning of year$2,053 $1,738 
Service cost with interest to end of year67 104 
Interest cost14 20 
Participant contributions24 21 
Benefits paid(18)(11)
Actuarial gain(127)18 
Exchange rate changes(154)163 
Benefit obligation at end of year$1,859 $2,053 
Change in plan assets:
 20212020
Fair value of plan assets at beginning of year$1,103 895 
Actual return on plan assets76 57 
Employer (reimbursement)/contributions73 57 
Participant contributions24 21 
Benefits paid(18)(11)
Exchange rate changes(83)84 
Fair value of plan assets at end of year$1,175 $1,103 
Amounts recognized in consolidated balance sheet:
 20212020
Benefit obligation$(1,859)$(2,053)
Fair value of plan assets1,175 1,103 
Funded status(684)(950)
Unrecognized prior service costN/AN/A
Unrecognized net (gain)/lossN/AN/A
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$684 $950 
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Components of net periodic benefit cost:
 202120202019
Service cost with interest to end of year$67 $104 $— 
Interest cost14 20 — 
Expected return on plan assets(34)(14)— 
Amortization of prior service cost— — — 
Amortization of net loss3 — — 
Total net periodic benefit cost$50 $110 $— 
Estimated future benefit payments are as follows:
Year 
2022$1 
2023— 
2024— 
2025— 
2026— 
Years 2027-203122 
Assumptions to determine benefit obligations:
 20212020
Discount rate1.00 %0.75 %
Assumptions to determine net cost:
 202120202019
Discount rate0.75 %1.00 %N/A
Expected return on assets3.25 %1.00 %N/A
Deferred Compensation Plan
On June 1, 2018, the Company established an unfunded, non-qualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of December 31, 2021 and 2020 was $6,270 and $3,581, respectively, and was included in other long-term obligations on the Company's balance sheet. The related rabbi trust assets were $6,267 and $3,582 as of December 31, 2021 and 2020, respectively, and were included in other non-current assets on the Company's consolidated balance sheets.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2021 are as follows:
Year 
2022$2,900 
20232,139 
20241,891 
20251,066 
2026700 
Thereafter2,428 
Total minimum lease payments$11,124 

The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation was conducted by the
prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site. In September 2020, BCP Ingredients, Inc. (“BCP”), the Company subsidiary that operates the site received a General Notice Letter from the EPA regarding BCP’s potential liability for contamination at the site and, in February 2022, received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study at the site with regard to the presence of certain contaminants, including 1,4 dioxane,. The Company has engaged experts to study site conditions and hydrogeology in connection with preparing its response to the notices.

From time to time, the Company is a party to various litigation, claims and assessments.  Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
FAIR VALUE OF FINANCIAL INSTRUMENTS
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2021 and 2020 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio.  The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2021 and 2020 included $933 and $817 in money market funds, respectively.
Non-current assets at December 31, 2021 and 2020 included $6,267 and $3,582, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”
The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in derivative assets or derivative liabilities, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The derivative liability related to the cross-currency swap was $500 and $6,793 at December 31, 2021 and 2020, respectively. The derivative liability related to the interest rate swap was $2,158 and $4,865 at December 31, 2021 and 2020, respectively.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
The Company provides services on a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings.

The services the Company provided amounted to $3,637, $3,396, and $3,883, respectively, for the years ended December 31, 2021, 2020, and 2019. The raw materials purchased and subsequently sold amounted to $27,915, $13,495, and $24,786, respectively, for the years ended December 31, 2021, 2020, and 2019. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $22,043, $12,190, and $18,598, respectively for the years ended December 31, 2021, 2020, and 2019. At December 31, 2021 and 2020, the Company had receivables of $10,504 and $2,809, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold and payables of $7,552 and $2,239, respectively, for finished goods received recorded in accounts payable in 2021 and 2020. In addition, the Company had receivables in the amount of $164 and $72 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of December 31, 2021 and 2020. The
Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of December 31, 2021 and 2020.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
LEASES LEASES
The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the ROU asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2021. In addition, the Company has historically not been exercising purchase options with equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with a new lease. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%.

In connection with the acquisition of Zumbro, the Company assumed a finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023.

Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:

Right of use assets20212020
Operating leases$6,929 $5,838 
Finance leases2,359 2,572 
Total$9,288 $8,410 


Lease liabilities - current20212020
Operating leases$2,194 $2,178 
Finance leases167 159 
Total$2,361 $2,337 

Lease liabilities - non-current20212020
Operating leases$4,811 $3,607 
Finance leases2,303 2,472 
Total$7,114 $6,079 
For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:

Year ended December 31
202120202019
Lease Cost
Operating lease cost$3,143 $3,105 $3,181 
Finance Lease cost
Amortization of ROU asset210 210 — 
Interest on lease liabilities129 137 — 
Total finance lease339 347 — 
Total lease cost$3,482 $3,452 $3,181 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$3,097 $2,864 $3,216 
Operating cash flows from finance leases129 137 — 
Financing cash flows from finance leases159 151 — 
$3,385 $3,152 $3,216 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$3,804 $1,042 $10,173 
ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals$— $2,782 $— 
Weighted-average remaining lease term - operating leases4.21 years4.15 years4.93 years
Weighted-average remaining lease term - finance leases11.41 years12.25 yearsn/a
Weighted-average discount rate - operating leases3.5 %4.5 %4.6 %
Weighted-average discount rate - finance leases5.1 %5.1 %n/a
Rent expense charged to operations under operating lease agreements for 2021, 2020, and 2019 aggregated approximately $3,143, $3,105, and $3,181, respectively.
LEASES LEASES
The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the ROU asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2021. In addition, the Company has historically not been exercising purchase options with equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with a new lease. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%.

In connection with the acquisition of Zumbro, the Company assumed a finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023.

Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:

Right of use assets20212020
Operating leases$6,929 $5,838 
Finance leases2,359 2,572 
Total$9,288 $8,410 


Lease liabilities - current20212020
Operating leases$2,194 $2,178 
Finance leases167 159 
Total$2,361 $2,337 

Lease liabilities - non-current20212020
Operating leases$4,811 $3,607 
Finance leases2,303 2,472 
Total$7,114 $6,079 
For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:

Year ended December 31
202120202019
Lease Cost
Operating lease cost$3,143 $3,105 $3,181 
Finance Lease cost
Amortization of ROU asset210 210 — 
Interest on lease liabilities129 137 — 
Total finance lease339 347 — 
Total lease cost$3,482 $3,452 $3,181 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$3,097 $2,864 $3,216 
Operating cash flows from finance leases129 137 — 
Financing cash flows from finance leases159 151 — 
$3,385 $3,152 $3,216 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$3,804 $1,042 $10,173 
ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals$— $2,782 $— 
Weighted-average remaining lease term - operating leases4.21 years4.15 years4.93 years
Weighted-average remaining lease term - finance leases11.41 years12.25 yearsn/a
Weighted-average discount rate - operating leases3.5 %4.5 %4.6 %
Weighted-average discount rate - finance leases5.1 %5.1 %n/a
Rent expense charged to operations under operating lease agreements for 2021, 2020, and 2019 aggregated approximately $3,143, $3,105, and $3,181, respectively.
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with the Swap Counterparty and a cross-currency swap (net investment hedge) with the Bank Counterparty. The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk.

On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. The net interest expense related to the interest rate swap contract were $2,144 and $1,593 for the year ended December 31, 2021 and 2020. The
net interest income related to the interest rate swap contract was $40 for the year ended December 31, 2019. These amounts were recorded in the consolidated statements of operations under interest expense, net.
At the same time, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $2,257, $2,275, and $1,317 for the years ended December 31, 2021, 2020, and 2019, respectively, which were recorded in the consolidated statements of operations under interest expense, net.

The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheets.
As of December 31, 2021 and 2020, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:

Derivative liabilities20212020
Interest rate swap$2,158 $4,865 
Cross-currency swap500 6,793 
Derivative liabilities$2,658 $11,658 

On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.

In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.
If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting.

As of December 31, 2021, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income.

Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the year ended December 31, 2021, 2020, and 2019:

Location within Statements of Comprehensive IncomeYear ended December 31
202120202019
Cash flow hedge (interest rate swap), net of taxUnrealized gain (loss) on cash flow hedge, net$2,053 $(2,285)$(1,399)
Net investment hedge (cross-currency swap), net of taxNet foreign currency translation adjustment4,766 (4,882)(262)
$6,819 $(7,167)$(1,661)
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
 12 Months Ended
Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]  
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
(In thousands, except per share data)
 20212020
 First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter		First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter
Net sales$185,656 $202,365 $197,869 $213,133 $174,436 $173,355 $175,140 $180,713 
Gross margin58,727 59,447 60,934 64,066 55,331 55,380 56,368 56,818 
Earnings before income taxes29,983 30,019 32,085 33,146 24,490 25,973 27,907 28,047 
Net earnings23,411 22,731 25,013 24,949 19,768 21,125 21,568 22,162 
Basic net earnings per common share$.73 $.71 $.78 $.78 $.62 $.66 $.67 $.69 
Diluted net earnings per common share$.72 $.70 $.77 $.76 $.61 $.65 $.66 $.68 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
VALUATION AND QUALIFYING ACCOUNTS
Allowance
for Doubtful Accounts		Inventory
Reserve
Balance - December 31, 2018$610 $2,575 
Additions charged (credited) to costs and expenses1,776 7,069 
Adjustments/deductions (a)
(306)(5,363)
Balance - December 31, 20192,080 4,281 
Additions charged (credited) to costs and expenses140 5,964 
Adjustments/deductions (a)
(128)(7,463)
Balance - December 31, 20202,092 2,782 
Additions charged (credited) to costs and expenses180 7,312 
Adjustments/deductions (a)
(1,344)(8,669)
Balance - December 31, 2021$928 $1,425 
(a) Represents write-offs and other adjustments
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Principles of Consolidation Principles of ConsolidationThe consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.
Revenue Recognition and Cost of Sales
Revenue Recognition

Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer.

In accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer.
Cost of Sales
Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.
Cash and Cash Equivalents Cash and Cash EquivalentsThe Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S., Italy, Belgium, Malaysia, Australia, Philippines, and Singapore exceed the Federal Deposit Insurance Corporation (“FDIC”), Fondo Interbancario di Tutela dei Depositi (“FITD”), Financial Services and Markets Authority ("FSMA"), Perbadanan Insurans Deposit Malaysia ("PIDM"), Australian Prudential Regulation Authority ("APRA"), Philippine Deposit Insurance Corporation ("PDIC"), and Singapore Deposit Insurance Corporation ("SDIC") insurance limits, respectively.
Accounts Receivable
Accounts Receivable
Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified,
and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
Inventories
Inventories
Inventories are valued at the lower of cost (first in, first out or average) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.
Property, Plant and Equipment and Depreciation
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost.
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.
Business Concentrations
Business Concentrations
Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2021, 2020 and 2019, no customer accounted for more than 10% of total net sales or accounts receivable.
Post-employment Benefits
Post-employment Benefits
We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.
In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Goodwill and Acquired Intangible Assets
Goodwill and Acquired Intangible Assets

Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. A goodwill impairment test will now be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. The guidance is effective for
annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020.

As of October 1, 2021 and 2020, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2021. However, during the second quarter of 2020, the Company recorded a goodwill impairment charge of $1,228 related to business formerly included in the Industrial Products segment. The Company may resume performing the qualitative assessment in subsequent periods.
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks & trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents & trade secrets
15 - 17
Other
 2 - 18

Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an
intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2021, there were no triggering events which required intangible asset impairment reviews.
Income Taxes
Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.

We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.

Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.
Use of Estimates
Use of Estimates
Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.
In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."
The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in either derivative asset or derivative liability, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities.
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses
Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.
Research and Development
Research and Development
Research and development costs are expensed as incurred.
Net Earnings Per Common Share
Net Earnings Per Common Share
Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).
Stock-based Compensation
Stock-based Compensation
The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.
Impairment of Long-lived Assets Impairment of Long-lived AssetsLong-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows.
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes.

On May 28, 2019, the Company entered into a pay-fixed, receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement.
At the same time, the Company also entered into a cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. This derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023.

The derivative instruments are with the above single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet.

On a quarterly basis, we assess the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. As of December 31, 2021, we assessed the hedging relationships and determined them to be highly effective. As such, the net change in fair values of the interest rate swap, that qualifies as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and is subsequently reclassified
into interest expense as interest payments are made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remained in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, "Derivative Instruments and Hedging Activities" for detailed information about our derivative financial instruments.
New Accounting Pronouncements
New Accounting Pronouncements
Recently Adopted Accounting Standards

In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted this new Standard in 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.
In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Standard Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard Update may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new Standard on January 1, 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.
In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance contained in this ASU requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company’s consolidated financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This Update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company's consolidated financial statements and disclosures.

In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment”, which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new Standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The Update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The
Company adopted the new Standard and related Updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Property, Plant and Equipment, Estimated Useful Lives
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Property, plant and equipment at December 31, 2021 and 2020 are summarized as follows:
 20212020
Land$11,692 $12,215 
Building89,602 86,873 
Equipment253,995 247,884 
Construction in progress52,930 31,240 
 408,219 378,212 
Less: Accumulated depreciation170,702 150,116 
Property, plant and equipment, net$237,517 $228,096 
Summary of Goodwill
The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”
Goodwill at December 31, 2019$523,998 
Goodwill as a result of Zumbro Acquisition432 
Goodwill impairment(1,228)
Impact due to change in foreign exchange rates6,261 
Goodwill at December 31, 2020529,463 
Impact due to change in foreign exchange rates(5,514)
Goodwill at December 31, 2021$523,949 

 December 31, 2021December 31, 2020
HNH$424,044 $424,051 
ANH17,207 17,824 
Specialty Products82,654 87,539 
Other and Unallocated44 49 
Total$523,949 $529,463 
Intangible Assets, Estimated Useful Lives
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks & trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents & trade secrets
15 - 17
Other
 2 - 18
As of December 31, 2021 and 2020, the Company had identifiable intangible assets as follows:
20212020
 Amortization
Period
(In years)		Gross
Carrying
Amount		Accumulated
Amortization		Gross
Carrying
Amount
Accumulated
Amortization
Customer relationships & lists
10-20
$240,059 $173,489 $243,557 $158,051 
Trademarks & trade names
2-17
43,116 28,985 43,208 24,974 
Developed technology
5-12
20,234 14,607 21,674 13,693 
Other
2-18
23,921 15,584 21,624 11,685 
  $327,330 $232,665 $330,063 $208,403 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables)
 12 Months Ended
Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Estimated Fair Values of Assets Acquired and Liabilities Assumed
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$686 
Accounts receivable3,314 
Inventories4,052 
Prepaid & other current assets521 
Property, plant and equipment15,245 
Right of use assets3,181 
Customer relationships8,200 
Developed technology4,400 
Trade name2,300 
Other non-current assets10 
Accounts payable & accrued expenses(1,651)
Lease liabilities(3,181)
Debt(5,345)
Deferred income taxes(3,740)
Goodwill18,505 
Amount paid to shareholders46,497 
Zumbro debt paid on purchase date5,345 
Total amount paid on acquisition date$51,842 
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:
Cash and cash equivalents$4,412 
Accounts receivable4,176 
Inventories957 
Property, plant and equipment15,972 
Customer relationships39,158 
Developed technology2,461 
Trade name1,119 
Other assets1,491 
Accounts payable(3,261)
Bank debt(12,222)
Other liabilities(1,030)
Pension obligation (net)(594)
Deferred income taxes(12,856)
Goodwill59,319 
Amount paid to shareholders99,102 
Chemogas bank debt paid on purchase date12,222 
Total amount paid on acquisition date$111,324 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Dec. 31, 2021
Stockholders' Equity Note [Abstract]  
Schedule of Compensation Cost on Net Earnings
The Company’s results for the years ended December 31, 2021, 2020 and 2019 reflected the following compensation cost and such compensation cost had the following effects on net earnings:
 Increase/(Decrease) for the
Year Ended, December 31
 202120202019
Cost of sales$845 $1,115 $1,147 
Operating expenses9,957 7,188 6,449 
Net earnings(8,370)(6,332)(5,884)
Schedule of Assumptions Used in the Valuation of Option Awards Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.
Year Ended December 31,
Weighted Average Assumptions:202120202019
Expected Volatility32.9 %26.9 %24.0 %
Expected Term (in years)4.93.94.0
Risk-Free Interest Rate0.5 %1.3 %2.5 %
Dividend Yield0.5 %0.5 %0.6 %
Summary of Stock Option Activity
A summary of stock option plan activity for 2021, 2020, and 2019 for all plans is as follows:

202120202019
# of
Shares
(000s)		Weighted Average
Exercise Price		# of
Shares
(000s)		Weighted Average
Exercise Price		# of
Shares
(000s)		Weighted Average
Exercise Price
Outstanding at beginning of year858 $80.58 951 $68.18 887 $61.59 
Granted129 119.12 174 111.75 197 85.13 
Exercised(109)63.42 (256)55.26 (112)43.67 
Forfeited(10)106.93 (11)92.94 (17)80.88 
Cancelled(1)74.57 — — (4)70.90 
Outstanding at end of year867 $88.19 858 $80.58 951 $68.18 
Exercisable at end of year538 $75.51 494 $69.04 581 $59.29 
Schedule of Other Information Pertaining to Stock Option Activity Other information pertaining to option activity during the years ended December 31, 2021, 2020 and 2019 is as follows:
 Years Ended December 31,
 202120202019
Weighted-average fair value of options granted$33.11 $24.36 $18.51 
Total intrinsic value of stock options exercised ($000s)$7,866 $12,698 $6,135 
Schedule of Additional Information Relating to Stock Options Outstanding
Additional information related to stock options outstanding under all plans at December 31, 2021 is as follows:

  Options OutstandingOptions Exercisable
Range of Exercise
Prices		Shares
Outstanding
(000s)		Weighted
Average
Remaining
Contractual
 Term		Weighted
Average
 Exercise
Price		Number
Exercisable
(000s)		Weighted
Average
Exercise
Price
$29.06 - $57.17
26 2.1$47.26 26 $47.26 
$58.52 - $85.40
541 5.575.55 476 74.37 
$91.56 - $120.60
300 8.5114.46 36 109.84 
 867 6.4$88.19 538 $75.51 
Schedule of Non-vested Restricted Stock Activity
Non-vested restricted stock activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:

202120202019
 Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 159 $90.71 138 $80.03 79 $72.75 
Granted42 123.58 46 110.53 73 85.69 
Vested(24)85.83 (21)67.60 (8)58.52 
Forfeited(11)90.49 (4)91.91 (6)84.65 
Non-vested balance at end of year 166 $99.70 159 $90.71 138 $80.03 
Schedule of Non-vested Performance Share Activity
Non-vested performance share activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:
202120202019
 Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance at beginning of year 71 $91.99 70 $81.26 53 $75.61 
Granted36 108.74 20 126.46 33 81.79 
Vested(24)70.64 (8)104.15 (9)65.54 
Forfeited(14)81.03 (11)82.71 (7)60.85 
Non-vested balance at end of year 69 $110.72 71 $91.99 70 $81.26 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
INVENTORIES (Tables)
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories, net of reserves at December 31, 2021 and 2020 consisted of the following:
 20212020
Raw materials$28,639 $24,536 
Work in progress10,563 3,050 
Finished goods51,856 43,034 
Total inventories$91,058 $70,620 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY, PLANT AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
Buildings
15-25 years
Equipment
2-28 years
Property, plant and equipment at December 31, 2021 and 2020 are summarized as follows:
 20212020
Land$11,692 $12,215 
Building89,602 86,873 
Equipment253,995 247,884 
Construction in progress52,930 31,240 
 408,219 378,212 
Less: Accumulated depreciation170,702 150,116 
Property, plant and equipment, net$237,517 $228,096 
Schedule of Long-Lived Assets by Geographical Area
Geographic Area Data - Long-Lived Assets (excluding intangible assets):
 20212020
United States$197,432 $187,719 
Foreign Countries40,085 40,377 
Total$237,517 $228,096 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets
The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:
 Amortization Period
(in years)
Customer relationships and lists
10 - 20
Trademarks & trade names
2 - 17
Developed technology
5 - 12
Regulatory registration costs
5 - 10
Patents & trade secrets
15 - 17
Other
 2 - 18
As of December 31, 2021 and 2020, the Company had identifiable intangible assets as follows:
20212020
 Amortization
Period
(In years)		Gross
Carrying
Amount		Accumulated
Amortization		Gross
Carrying
Amount
Accumulated
Amortization
Customer relationships & lists
10-20
$240,059 $173,489 $243,557 $158,051 
Trademarks & trade names
2-17
43,116 28,985 43,208 24,974 
Developed technology
5-12
20,234 14,607 21,674 13,693 
Other
2-18
23,921 15,584 21,624 11,685 
  $327,330 $232,665 $330,063 $208,403 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
NET EARNINGS PER COMMON SHARE (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Reconciliation of the Net Earnings and Shares used in Calculating Basic and Diluted Net Earnings Per Share
The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:
Year Ended December 31,
202120202019
Net Earnings - Basic and Diluted$96,104 $84,623 $79,671 
Share (000s)
Weighted Average Common Shares - Basic32,215 32,176 32,136 
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares457 327 369 
Weighted Average Common Shares - Diluted32,672 32,503 32,505 
Net Earnings Per Share - Basic$2.98 $2.63 $2.48 
Net Earnings Per Share - Diluted$2.94 $2.60 $2.45 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Expense
Income tax expense consists of the following:
 202120202019
Current:   
Federal$25,019 $19,249 $17,757 
Foreign7,553 3,399 1,609 
State3,664 3,590 818 
Deferred:
Federal(3,709)(3,017)(3,707)
Foreign(3,038)167 67 
State(360)(1,594)263 
Total income tax provision$29,129 $21,794 $16,807 
Schedule of Income Tax Reconciliation
The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2021, 2020, and 2019 to earnings before income tax expense due to the following:
 202120202019
Income tax at Federal statutory rate$26,299 $22,348 $20,260 
State income taxes, net of Federal income taxes2,406 2,288 (244)
Stock Options(924)(1,529)(222)
GILTI — — 2,507 
FDII(1,540)(1,400)(1,922)
Patent Box Decree (related to prior years)— — (1,948)
Foreign Tax Credits— — (1,125)
Other2,888 87 (499)
Total income tax provision$29,129 $21,794 $16,807 
Schedule of Deferred Tax Assets and Liabilities
The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 were as follows:
 20212020
Deferred tax assets:  
Inventories$495 $1,470 
Restricted stock and stock options4,082 3,862 
Lease liabilities1,807 1,641 
Currency and interest rate swap649 2,831 
Other3,657 3,308 
Total deferred tax assets10,690 13,112 
Deferred tax liabilities:
Amortization$28,133 $32,872 
Depreciation25,484 27,897 
Prepaid expenses733 915 
Right of use assets1,769 1,926 
Other1,026 731 
Total deferred tax liabilities57,145 64,341 
Valuation allowance— 130 
Net deferred tax liability$46,455 $51,359 
Schedule of Reconciliation of Unrecognized Tax Benefits A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:
 202120202019
Balance at beginning of period$5,335 $4,762 $5,709 
Increases for tax positions of prior years806 267 431 
Decreases for tax positions of prior years(260)(391)(1,978)
Increases for tax positions related to current year— 697 600 
Balance at end of period$5,881 $5,335 $4,762 
All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods.
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The segment information is summarized as follows:

Business Segment Assets
 20212020
Human Nutrition & Health$727,131 $717,232 
Animal Nutrition & Health158,971 157,454 
Specialty Products184,628 190,449 
Other and Unallocated (1)
128,595 100,708 
Total$1,199,325 $1,165,843 

Business Segment Net Sales
 202120202019
Human Nutrition & Health$442,733 $400,330 $347,433 
Animal Nutrition & Health226,776 192,191 177,557 
Specialty Products117,020 103,566 92,257 
Other and Unallocated (2)
12,494 7,557 26,458 
Total$799,023 $703,644 $643,705 

Business Segment Earnings Before Income Taxes

202120202019
Human Nutrition & Health$76,031 $61,397 $48,429 
Animal Nutrition & Health26,179 29,979 25,868 
Specialty Products30,020 26,801 28,513 
Other and Unallocated (2)
(4,728)(7,030)(257)
Interest and other expense(2,269)(4,730)(6,075)
Total$125,233 $106,417 $96,478 


Depreciation/Amortization
 202120202019
Human Nutrition & Health$30,012 $32,117 $30,558 
Animal Nutrition & Health7,414 7,187 6,552 
Specialty Products8,332 9,699 7,401 
Other and Unallocated (2)
3,121 2,278 1,351 
Total$48,879 $51,281 $45,862 

Capital Expenditures
 202120202019
Human Nutrition & Health$23,714 $22,758 $18,159 
Animal Nutrition & Health8,100 6,039 3,921 
Specialty Products3,804 2,860 3,003 
Other and Unallocated (2)
524 423 707 
Total$36,142 $32,080 $25,790 
(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.
(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,264, $2,410 and $3,436 for years ended December 31, 2021, 2020 and 2019, respectively, and (ii) Unallocated amortization expense of $2,792, $1,888, and $833 for years ended December 31, 2021, 2020, and 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings.
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Source and Geography
The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.
 202120202019
Product Sales$762,085 $666,193 $609,741 
Co-manufacturing27,994 29,063 24,087 
Bill and Hold— 1,158 3,218 
Consignment4,439 2,939 2,299 
Product Sales Revenue794,518 699,353 639,345 
Royalty Revenue4,505 4,291 4,360 
Total Revenue$799,023 $703,644 $643,705 

The following table presents revenues disaggregated by geography, based on the billing addresses of customers:
 202120202019
United States$584,661 $516,347 $475,033 
Foreign Countries214,362 187,297 168,672 
Total$799,023 $703,644 $643,705 
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUPPLEMENTAL CASH FLOW INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2021
Supplemental Cash Flow Information [Abstract]  
Supplemental Cash Flow Information
Cash paid during the year for:
202120202019
Income taxes$25,355 $22,637 $21,771 
Interest$4,547 $4,666 $5,674 
Non-cash financing activities:
 202120202019
Dividends payable$20,886 $18,941 $16,855 
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)
 12 Months Ended
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss) were as follows:
 Years Ended December 31,
 202120202019
Net foreign currency translation adjustment$(11,255)$12,829 $(891)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized gain/(loss) on cash flow hedge2,707 (3,094)(1,771)
Tax(654)809 372 
Net of tax2,053 (2,285)(1,399)
Net change in postretirement benefit plan (see Note 15 for further information)
Prior service (credit)/cost and (gain)/loss arising during the period(4)(503)199 
Amortization of prior service credit/(cost)74 74 74 
Amortization of gain/(loss)(21)(50)(46)
Total before tax49 (479)227 
Tax(13)127 101 
Adjustment (1)
— (455)— 
Net of tax36 (807)328 
Total other comprehensive (loss)/income$(9,166)$9,737 $(1,962)
(1) One-time adjustment to the postretirement account.
Components of Accumulated Other Comprehensive Income (Loss)
Accumulated other comprehensive (loss)/income at December 31, 2021 consisted of the following:
 Foreign currency
translation
adjustment		Cash flow hedgePostretirement benefit planTotal
Balance December 31, 2020$7,653 $(3,684)$204 4,173 
Other comprehensive (loss)/gain(11,255)2,053 36 (9,166)
Balance December 31, 2021$(3,602)$(1,631)$240 (4,993)
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS (Tables)
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Schedule of Changes in Benefit Obligation
The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:
Change in benefit obligation:
 20212020
Benefit obligation at beginning of year$1,374 $1,076 
Initial adoption of new plan— — 
Service cost with interest to end of year87 68 
Interest cost23 26 
Participant contributions28 23 
Benefits paid(426)(27)
Actuarial gain207 208 
Benefit obligation at end of year$1,293 $1,374 
Change in benefit obligation:
 20212020
Benefit obligation at beginning of year$2,053 $1,738 
Service cost with interest to end of year67 104 
Interest cost14 20 
Participant contributions24 21 
Benefits paid(18)(11)
Actuarial gain(127)18 
Exchange rate changes(154)163 
Benefit obligation at end of year$1,859 $2,053 
Assumptions to determine benefit obligations:
 20212020
Discount rate1.00 %0.75 %
Schedule of Changes in Plan Assets
Change in plan assets:
 20212020
Fair value of plan assets at beginning of year$— $— 
Employer (reimbursement)/contributions398 4 
Participant contributions28 23 
Benefits paid(426)(27)
Fair value of plan assets at end of year$— $— 
Change in plan assets:
 20212020
Fair value of plan assets at beginning of year$1,103 895 
Actual return on plan assets76 57 
Employer (reimbursement)/contributions73 57 
Participant contributions24 21 
Benefits paid(18)(11)
Exchange rate changes(83)84 
Fair value of plan assets at end of year$1,175 $1,103 
Schedule of Amounts Recognized in Consolidated Balance Sheet
Amounts recognized in consolidated balance sheet:
 20212020
Accumulated postretirement benefit obligation$1,293 $1,374 
Fair value of plan assets— — 
Funded status1,293 1,374 
Unrecognized prior service cost74 74 
Unrecognized net gain(50)(46)
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$1,293 $1,374 
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Amounts recognized in consolidated balance sheet:
 20212020
Benefit obligation$(1,859)$(2,053)
Fair value of plan assets1,175 1,103 
Funded status(684)(950)
Unrecognized prior service costN/AN/A
Unrecognized net (gain)/lossN/AN/A
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)$684 $950 
Accrued postretirement benefit cost (included in other long-term obligations)N/AN/A
Schedule of Components of Net Periodic Benefit Cost
Components of net periodic benefit cost:
 202120202019
Service cost with interest to end of year$87 $68 $63 
Interest cost23 26 39 
Amortization of prior service cost74 74 74 
Amortization of gain(24)(50)(46)
Total net periodic benefit cost$160 $118 $130 
Components of net periodic benefit cost:
 202120202019
Service cost with interest to end of year$67 $104 $— 
Interest cost14 20 — 
Expected return on plan assets(34)(14)— 
Amortization of prior service cost— — — 
Amortization of net loss3 — — 
Total net periodic benefit cost$50 $110 $— 
Assumptions to determine net cost:
 202120202019
Discount rate0.75 %1.00 %N/A
Expected return on assets3.25 %1.00 %N/A
Schedule of Estimated Future Employer Contributions and Benefit Payments
Estimated future employer contributions and benefit payments are as follows:
Year 
2022$107 
202391 
2024113 
202591 
202676 
Years 2027-2031479 
Estimated future benefit payments are as follows:
Year 
2022$1 
2023— 
2024— 
2025— 
2026— 
Years 2027-203122 
Summary of Pension Fund The Company’s participation in this plan for the annual period ended December 31, 2021 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2021 and 2020 was affected by a 4.0% increase in the 2021 contribution rate. There have been no other significant changes that affect the comparability of 2021 and 2020 contributions. The Company does not represent more than 5% of the contributions to this pension fund.
Pension
Fund		EIN/Pension
Plan
Number		Pension Plan Protection Act Zone StatusFIP/RP Status
Pending/ Implemented		Contributions of Balchem CorporationSurcharge
Imposed		Expiration Date of Collective-
Bargaining
Agreement
20212020202120202019
Central States,
Southeast and
Southwest Areas
Pension Fund		36-6044243Critical & Declining as of 1/1/21Critical & Declining as of 1/1/20Implemented$816$774$677No7/12/2025
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases
Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2021 are as follows:
Year 
2022$2,900 
20232,139 
20241,891 
20251,066 
2026700 
Thereafter2,428 
Total minimum lease payments$11,124 
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES (Tables)
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Schedule of Lease Cost
Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:

Right of use assets20212020
Operating leases$6,929 $5,838 
Finance leases2,359 2,572 
Total$9,288 $8,410 


Lease liabilities - current20212020
Operating leases$2,194 $2,178 
Finance leases167 159 
Total$2,361 $2,337 

Lease liabilities - non-current20212020
Operating leases$4,811 $3,607 
Finance leases2,303 2,472 
Total$7,114 $6,079 
For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:

Year ended December 31
202120202019
Lease Cost
Operating lease cost$3,143 $3,105 $3,181 
Finance Lease cost
Amortization of ROU asset210 210 — 
Interest on lease liabilities129 137 — 
Total finance lease339 347 — 
Total lease cost$3,482 $3,452 $3,181 
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$3,097 $2,864 $3,216 
Operating cash flows from finance leases129 137 — 
Financing cash flows from finance leases159 151 — 
$3,385 $3,152 $3,216 
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals$3,804 $1,042 $10,173 
ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals$— $2,782 $— 
Weighted-average remaining lease term - operating leases4.21 years4.15 years4.93 years
Weighted-average remaining lease term - finance leases11.41 years12.25 yearsn/a
Weighted-average discount rate - operating leases3.5 %4.5 %4.6 %
Weighted-average discount rate - finance leases5.1 %5.1 %n/a
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Derivative Instruments
As of December 31, 2021 and 2020, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:

Derivative liabilities20212020
Interest rate swap$2,158 $4,865 
Cross-currency swap500 6,793 
Derivative liabilities$2,658 $11,658 
Schedule of Income (Loss) on Hedging Instruments
Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the year ended December 31, 2021, 2020, and 2019:

Location within Statements of Comprehensive IncomeYear ended December 31
202120202019
Cash flow hedge (interest rate swap), net of taxUnrealized gain (loss) on cash flow hedge, net$2,053 $(2,285)$(1,399)
Net investment hedge (cross-currency swap), net of taxNet foreign currency translation adjustment4,766 (4,882)(262)
$6,819 $(7,167)$(1,661)
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)
 12 Months Ended
Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
(In thousands, except per share data)
 20212020
 First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter		First
Quarter		Second
Quarter		Third
Quarter		Fourth
Quarter
Net sales$185,656 $202,365 $197,869 $213,133 $174,436 $173,355 $175,140 $180,713 
Gross margin58,727 59,447 60,934 64,066 55,331 55,380 56,368 56,818 
Earnings before income taxes29,983 30,019 32,085 33,146 24,490 25,973 27,907 28,047 
Net earnings23,411 22,731 25,013 24,949 19,768 21,125 21,568 22,162 
Basic net earnings per common share$.73 $.71 $.78 $.78 $.62 $.66 $.67 $.69 
Diluted net earnings per common share$.72 $.70 $.77 $.76 $.61 $.65 $.66 $.68 
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2021
May 28, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Goodwill impairment charge $ 1,228 $ 1,228      
Goodwill   529,463 $ 523,998 $ 523,949  
Designated as Hedging Instrument | Interest rate swap          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Notional amount of derivatives         $ 108,569
Designated as Hedging Instrument | Currency swap          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Notional amount of derivatives         $ 108,569
HNH          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Goodwill   $ 424,051   $ 424,044  
Impairment charges     $ 1,026    
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details)
 12 Months Ended
Dec. 31, 2021
Minimum | Buildings  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 15 years
Minimum | Equipment  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 2 years
Maximum | Buildings  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 25 years
Maximum | Equipment  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 28 years
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Goodwill [Roll Forward]      
Goodwill, beginning of period   $ 529,463 $ 523,998
Goodwill as a result of Zumbro Acquisition     432
Goodwill impairment $ (1,228)   (1,228)
Impact due to change in foreign exchange rates   (5,514) 6,261
Goodwill, end of period   523,949 529,463
HNH      
Goodwill [Roll Forward]      
Goodwill, beginning of period   424,051  
Goodwill, end of period   424,044 424,051
ANH      
Goodwill [Roll Forward]      
Goodwill, beginning of period   17,824  
Goodwill, end of period   17,207 17,824
Specialty Products      
Goodwill [Roll Forward]      
Goodwill, beginning of period   87,539  
Goodwill, end of period   82,654 87,539
Other and Unallocated      
Goodwill [Roll Forward]      
Goodwill, beginning of period   49  
Goodwill, end of period   $ 44 $ 49
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details)
 12 Months Ended
Dec. 31, 2021
Minimum | Customer relationships and lists  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 10 years
Minimum | Trademarks & trade names  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 2 years
Minimum | Developed technology  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 5 years
Minimum | Regulatory registration costs  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 5 years
Minimum | Patents & trade secrets  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 15 years
Minimum | Other  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 2 years
Maximum | Customer relationships and lists  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 20 years
Maximum | Trademarks & trade names  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 17 years
Maximum | Developed technology  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 12 years
Maximum | Regulatory registration costs  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 10 years
Maximum | Patents & trade secrets  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 17 years
Maximum | Other  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets 18 years
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details)
€ in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 13, 2019
USD ($)
May 27, 2019
USD ($)
May 27, 2019
EUR (€)
May 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
May 27, 2019
EUR (€)
Business Acquisition [Line Items]                  
Cash paid for acquisitions, net of cash acquired           $ 0 $ 0 $ 141,062  
Goodwill         $ 523,998 523,949 529,463 523,998  
Transaction and integration related costs           448 2,011 2,273  
HNH                  
Business Acquisition [Line Items]                  
Goodwill           424,044 424,051    
Zumbro                  
Business Acquisition [Line Items]                  
Payment made on acquisition date         52,403        
Amount paid to former shareholders         47,058        
Debt paid on purchase date $ 5,345                
Cash and cash equivalents 686                
Cash paid for acquisitions, net of cash acquired         $ 46,372        
Working capital acquired       $ 561          
Goodwill 18,505                
Translated amount on acquisition date 51,842                
Translated amount paid to shareholders $ 46,497                
Zumbro | Customer relationships                  
Business Acquisition [Line Items]                  
Useful life of intangible assets acquired 15 years                
Zumbro | Trade name                  
Business Acquisition [Line Items]                  
Useful life of intangible assets acquired 10 years                
Zumbro | Developed technology                  
Business Acquisition [Line Items]                  
Useful life of intangible assets acquired 12 years                
Zumbro | HNH                  
Business Acquisition [Line Items]                  
Expected deductible amount $ 4,723                
Chemogas                  
Business Acquisition [Line Items]                  
Payment made on acquisition date | €     € 99,503            
Amount paid to former shareholders | €     88,579            
Debt paid on purchase date   $ 12,222             € 10,924
Cash and cash equivalents   4,412             € 3,943
Cash paid for acquisitions, net of cash acquired   94,690 € 84,636            
Goodwill   $ 59,319              
Percentage of outstanding common shares acquired   100.00%             100.00%
Translated amount on acquisition date   $ 111,324              
Translated amount paid to shareholders   $ 99,102              
Chemogas | Customer relationships                  
Business Acquisition [Line Items]                  
Useful life of intangible assets acquired   20 years 20 years            
Chemogas | Trade name                  
Business Acquisition [Line Items]                  
Useful life of intangible assets acquired   2 years 2 years            
Chemogas | Developed technology                  
Business Acquisition [Line Items]                  
Useful life of intangible assets acquired   10 years 10 years            
Chemogas and Zumbro                  
Business Acquisition [Line Items]                  
Transaction and integration related costs           $ 26 $ 1,480 $ 1,947  
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Fair Value of Assets Acquired and Liabilities Assumed (Details)
€ in Thousands, $ in Thousands
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 13, 2019
USD ($)
May 27, 2019
USD ($)
May 27, 2019
EUR (€)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Goodwill $ 523,949 $ 529,463 $ 523,998      
Zumbro            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Cash and cash equivalents       $ 686    
Accounts receivable       3,314    
Inventories       4,052    
Prepaid & other current assets       521    
Property, plant and equipment       15,245    
Right of use assets       3,181    
Other non-current assets       10    
Accounts payable & accrued expenses       (1,651)    
Lease liabilities       (3,181)    
Debt       (5,345)    
Deferred income taxes       (3,740)    
Goodwill       18,505    
Amount paid to shareholders       46,497    
Debt paid on purchase date       5,345    
Total amount paid on acquisition date       51,842    
Zumbro | Customer relationships            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Intangible assets       8,200    
Zumbro | Developed technology            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Intangible assets       4,400    
Zumbro | Trade name            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Intangible assets       $ 2,300    
Chemogas            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Cash and cash equivalents         $ 4,412 € 3,943
Accounts receivable         4,176  
Inventories         957  
Property, plant and equipment         15,972  
Other non-current assets         1,491  
Accounts payable & accrued expenses         (3,261)  
Debt         (12,222)  
Other liabilities         (1,030)  
Pension obligation (net)         (594)  
Deferred income taxes         (12,856)  
Goodwill         59,319  
Amount paid to shareholders         99,102  
Debt paid on purchase date         12,222 € 10,924
Total amount paid on acquisition date         111,324  
Chemogas | Customer relationships            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Intangible assets         39,158  
Chemogas | Developed technology            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Intangible assets         2,461  
Chemogas | Trade name            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]            
Intangible assets         $ 1,119  
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Net earnings $ (8,370) $ (6,332) $ (5,884)
Cost of sales      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation cost 845 1,115 1,147
Operating expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation cost $ 9,957 $ 7,188 $ 6,449
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Stock-based Compensation (Details)
 12 Months Ended
Dec. 31, 2021
plan
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of share-based compensation plans | plan 1
Stock Options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 3 years
Performance Shares | Employee  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 3 years
2017 Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares authorized for grants (in shares) 1,600,000
Expiration period of options granted 10 years
2017 Plan | Non-employee Director  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares purchased under restricted stock purchase agreements, minimum (in shares) 70
Shares purchased under restricted stock purchase agreements, maximum (in shares) 54,000
2017 Plan | Stock Options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares available for future awards (in shares) 703,707
1999 Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares authorized for grants (in shares) 6,000,000
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Stock Options      
Weighted Average Assumptions [Abstract]      
Expected Volatility 32.90% 26.90% 24.00%
Expected Term (in years) 4 years 10 months 24 days 3 years 10 months 24 days 4 years
Risk-Free Interest Rate 0.50% 1.30% 2.50%
Dividend Yield 0.50% 0.50% 0.60%
Vesting period 3 years    
Performance Shares | Employee      
Weighted Average Assumptions [Abstract]      
Expected Volatility 33.00% 24.00% 24.00%
Risk-Free Interest Rate 0.20% 1.40% 2.50%
Dividend Yield 0.60% 0.50% 0.50%
Initial total shareholder return percentage 11.70% 10.90% (5.90%)
Cliff vesting percentage 100.00%    
Vesting period 3 years    
Restricted Stock | Employee | Minimum      
Weighted Average Assumptions [Abstract]      
Vesting period 3 years    
Restricted Stock | Employee | Maximum      
Weighted Average Assumptions [Abstract]      
Vesting period 4 years    
Restricted Stock | Non-employee Director | Minimum      
Weighted Average Assumptions [Abstract]      
Vesting period 3 years    
Restricted Stock | Non-employee Director | Maximum      
Weighted Average Assumptions [Abstract]      
Vesting period 4 years    
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding at beginning of year (in shares) 858 951 887
Granted (in shares) 129 174 197
Exercised (in shares) (109) (256) (112)
Forfeited (in shares) (10) (11) (17)
Cancelled (in shares) (1) 0 (4)
Outstanding at end of year (in shares) 867 858 951
Exercisable at end of year (in shares) 538 494 581
Weighted Average Exercise Price [Abstract]      
Outstanding at beginning of year (in dollars per share) $ 80.58 $ 68.18 $ 61.59
Granted (in dollars per share) 119.12 111.75 85.13
Exercised (in dollars per share) 63.42 55.26 43.67
Forfeited (in dollars per share) 106.93 92.94 80.88
Cancelled (in dollars per share) 74.57 0 70.90
Outstanding at end of year (in dollars per share) 88.19 80.58 68.18
Exercisable at end of period (in dollars per share) $ 75.51 $ 69.04 $ 59.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Aggregate intrinsic value for outstanding stock options $ 69,711 $ 29,735 $ 31,814
Weighted average remaining contractual term for outstanding stock options 6 years 4 months 24 days    
Aggregate intrinsic value for exercisable stock options outstanding $ 50,128    
Weighted average remaining contractual term for exercisable stock options outstanding 5 years 3 months 18 days    
Weighted-average fair value of options granted (in dollars per share) $ 33.11 $ 24.36 $ 18.51
Total intrinsic value of stock options exercised $ 7,866 $ 12,698 $ 6,135
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Shares Outstanding (in shares) | shares 867
Weighted Average Remaining Contractual  Term 6 years 4 months 24 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 88.19
Number of Options Exercisable (in shares) | shares 538
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 75.51
$29.06 - $57.17  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of exercise prices, minimum (in dollars per share) 29.06
Range of exercise prices, maximum (in dollars per share) $ 57.17
Shares Outstanding (in shares) | shares 26
Weighted Average Remaining Contractual  Term 2 years 1 month 6 days
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 47.26
Number of Options Exercisable (in shares) | shares 26
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 47.26
$58.52 - $85.40  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of exercise prices, minimum (in dollars per share) 58.52
Range of exercise prices, maximum (in dollars per share) $ 85.40
Shares Outstanding (in shares) | shares 541
Weighted Average Remaining Contractual  Term 5 years 6 months
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 75.55
Number of Options Exercisable (in shares) | shares 476
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 74.37
$91.56 - $120.60  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of exercise prices, minimum (in dollars per share) 91.56
Range of exercise prices, maximum (in dollars per share) $ 120.60
Shares Outstanding (in shares) | shares 300
Weighted Average Remaining Contractual  Term 8 years 6 months
Weighted Average Exercise Price of Options Outstanding (in dollars per share) $ 114.46
Number of Options Exercisable (in shares) | shares 36
Weighted Average Exercise Price of Options Exercisable (in dollars per share) $ 109.84
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Unrecognized compensation cost related to non-vested shares $ 13,980 $ 14,154 $ 11,643
Weighted-average period of recognition for unrecognized compensation cost 1 year 2 months 12 days    
Estimated share-based compensation expense for current fiscal year $ 11,900    
Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Non-vested balance as of beginning of year (in shares) 159 138 79
Granted (in shares) 42 46 73
Vested (in shares) (24) (21) (8)
Forfeited (in shares) (11) (4) (6)
Non-vested balance as of end of year (in shares) 166 159 138
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Non-vested balance as of beginning of year (in dollars per share) $ 90.71 $ 80.03 $ 72.75
Granted (in dollars per share) 123.58 110.53 85.69
Vested (in dollars per share) 85.83 67.60 58.52
Forfeited (in dollars per share) 90.49 91.91 84.65
Non-vested balance as of end of year (in dollars per share) $ 99.70 $ 90.71 $ 80.03
Performance Shares      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Non-vested balance as of beginning of year (in shares) 71 70 53
Granted (in shares) 36 20 33
Vested (in shares) (24) (8) (9)
Forfeited (in shares) (14) (11) (7)
Non-vested balance as of end of year (in shares) 69 71 70
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Non-vested balance as of beginning of year (in dollars per share) $ 91.99 $ 81.26 $ 75.61
Granted (in dollars per share) 108.74 126.46 81.79
Vested (in dollars per share) 70.64 104.15 65.54
Forfeited (in dollars per share) 81.03 82.71 60.85
Non-vested balance as of end of year (in dollars per share) $ 110.72 $ 91.99 $ 81.26
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Stockholders' Equity Note [Abstract]      
Number of shares authorized to be repurchased (in shares) 3,763,038    
Aggregate number of shares repurchased since inception (in shares) 2,818,244    
Previously acquired treasury stock offset   $ 7,873 $ 18,069
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares) 249,848 136,629 240,995
Shares repurchased, average cost (in dollars per share) $ 141.04 $ 98.54 $ 88.47
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
INVENTORIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 28,639 $ 24,536
Work in progress 10,563 3,050
Finished goods 51,856 43,034
Total inventories 91,058 70,620
Reserve for inventory $ 1,425 $ 2,782
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 408,219 $ 378,212
Less: Accumulated depreciation 170,702 150,116
Property, plant and equipment, net 237,517 228,096
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 11,692 12,215
Building    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 89,602 86,873
Equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 253,995 247,884
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 52,930 $ 31,240
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets, excluding intangible assets $ 237,517 $ 228,096
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets, excluding intangible assets 197,432 187,719
Foreign Countries    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets, excluding intangible assets $ 40,085 $ 40,377
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 23,295 $ 22,990 $ 19,791
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill $ 523,949,000 $ 529,463,000 $ 523,998,000
Identifiable intangible assets [Abstract]      
Gross Carrying Amount 327,330,000 330,063,000  
Accumulated Amortization 232,665,000 208,403,000  
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]      
Amortization of identifiable intangible assets 25,092,000 27,811,000 $ 25,789,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]      
2022 23,641,000    
2023 19,566,000    
2024 10,682,000    
2025 6,413,000    
2026 5,083,000    
Identifiable intangible assets 0 0  
Customer relationships and lists      
Identifiable intangible assets [Abstract]      
Gross Carrying Amount 240,059,000 243,557,000  
Accumulated Amortization $ 173,489,000 158,051,000  
Customer relationships and lists | Minimum      
Identifiable intangible assets [Abstract]      
Amortization Period 10 years    
Customer relationships and lists | Maximum      
Identifiable intangible assets [Abstract]      
Amortization Period 20 years    
Trademarks & trade names      
Identifiable intangible assets [Abstract]      
Gross Carrying Amount $ 43,116,000 43,208,000  
Accumulated Amortization $ 28,985,000 24,974,000  
Trademarks & trade names | Minimum      
Identifiable intangible assets [Abstract]      
Amortization Period 2 years    
Trademarks & trade names | Maximum      
Identifiable intangible assets [Abstract]      
Amortization Period 17 years    
Developed technology      
Identifiable intangible assets [Abstract]      
Gross Carrying Amount $ 20,234,000 21,674,000  
Accumulated Amortization $ 14,607,000 13,693,000  
Developed technology | Minimum      
Identifiable intangible assets [Abstract]      
Amortization Period 5 years    
Developed technology | Maximum      
Identifiable intangible assets [Abstract]      
Amortization Period 12 years    
Other      
Identifiable intangible assets [Abstract]      
Gross Carrying Amount $ 23,921,000 21,624,000  
Accumulated Amortization $ 15,584,000 $ 11,685,000  
Other | Minimum      
Identifiable intangible assets [Abstract]      
Amortization Period 2 years    
Other | Maximum      
Identifiable intangible assets [Abstract]      
Amortization Period 18 years    
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
EQUITY-METHOD INVESTMENT (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
vote
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]        
Number of votes | vote 2      
Percentage of operating expenses to be absorbed 66.66%      
Percentage of production offtake 66.66%      
St. Gabriel CC Company, LLC        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage in joint venture       66.66%
Loss relating to joint venture's expenses $ 557 $ 575 $ 388  
Carrying value of joint venture $ 4,499 $ 4,971    
St. Gabriel CC Company, LLC | Eastman Chemical Company        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage in joint venture       33.34%
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
REVOLVING LOAN (Details) - USD ($)
 12 Months Ended
Dec. 13, 2019
May 23, 2019
Jun. 27, 2018
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Debt Instrument [Line Items]            
Maximum borrowing capacity     $ 500,000,000      
Outstanding balance       $ 108,569,000 $ 163,569,000  
Capitalized costs net of accumulated amortization       421,000 703,000  
Amortization expense pertaining to capitalized costs       $ 282,000 $ 282,000 $ 282,000
Credit Agreement            
Debt Instrument [Line Items]            
Interest rate       1.102%    
Commitment fee percentage       0.15%    
Unused portion of revolving loan       $ 391,431,000    
Credit Agreement | Minimum            
Debt Instrument [Line Items]            
Commitment fee percentage       0.15%    
Credit Agreement | Maximum            
Debt Instrument [Line Items]            
Commitment fee percentage       0.275%    
Term A Loan            
Debt Instrument [Line Items]            
Maximum borrowing capacity     350,000,000      
Payments for outstanding balance     210,750,000      
Proceeds from revolving loan $ 45,000,000 $ 108,569,000        
Revolving loan            
Debt Instrument [Line Items]            
Maximum borrowing capacity     $ 100,000,000      
Installment payments required       $ 0    
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
NET EARNINGS PER COMMON SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Earnings (Numerator) [Abstract]                      
Net Earnings - Basic and Diluted $ 24,949 $ 25,013 $ 22,731 $ 23,411 $ 22,162 $ 21,568 $ 21,125 $ 19,768 $ 96,104 $ 84,623 $ 79,671
Number of Shares (Denominator) [Abstract]                      
Weighted average common shares - basic (in shares)                 32,215,000 32,176,000 32,136,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)                 457,000 327,000 369,000
Weighted average common shares - diluted (in shares)                 32,672,000 32,503,000 32,505,000
Per Share Amount [Abstract]                      
Net earnings per share - basic (in dollars per share) $ 0.78 $ 0.78 $ 0.71 $ 0.73 $ 0.69 $ 0.67 $ 0.66 $ 0.62 $ 2.98 $ 2.63 $ 2.48
Net earnings per share - diluted (in dollars per share) $ 0.76 $ 0.77 $ 0.70 $ 0.72 $ 0.68 $ 0.66 $ 0.65 $ 0.61 2.94 $ 2.60 $ 2.45
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                      
Award participation per share of common stock                 $ 1    
Stock Options                      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                      
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)                 155,294 204,672 12,250
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Loss Carryforwards [Line Items]      
Effective tax rate 23.30% 20.50% 17.40%
Interest and penalties $ 262 $ 232 $ 132
Accrued interest and penalties 2,106 $ 1,845  
State      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards $ 335    
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES - Components of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Current:      
Federal $ 25,019 $ 19,249 $ 17,757
Foreign 7,553 3,399 1,609
State 3,664 3,590 818
Deferred:      
Federal (3,709) (3,017) (3,707)
Foreign (3,038) 167 67
State (360) (1,594) 263
Total income tax provision $ 29,129 $ 21,794 $ 16,807
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES - Effective Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Reconciliation [Abstract]      
Income tax at Federal statutory rate $ 26,299 $ 22,348 $ 20,260
State income taxes, net of Federal income taxes 2,406 2,288 (244)
Stock Options (924) (1,529) (222)
GILTI 0 0 2,507
FDII (1,540) (1,400) (1,922)
Patent Box Decree (related to prior years) 0 0 (1,948)
Foreign Tax Credits 0 0 (1,125)
Other 2,888 87 (499)
Total income tax provision $ 29,129 $ 21,794 $ 16,807
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Inventories $ 495 $ 1,470
Restricted stock and stock options 4,082 3,862
Lease liabilities 1,807 1,641
Currency and interest rate swap 649 2,831
Other 3,657 3,308
Total deferred tax assets 10,690 13,112
Deferred tax liabilities:    
Amortization 28,133 32,872
Depreciation 25,484 27,897
Prepaid expenses 733 915
Right of use assets 1,769 1,926
Other 1,026 731
Total deferred tax liabilities 57,145 64,341
Valuation allowance 0 130
Net deferred tax liability $ 46,455 $ 51,359
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
INCOME TAXES - Income Tax Uncertainties (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Balance at beginning of period $ 5,335 $ 4,762 $ 5,709
Increases for tax positions of prior years 806 267 431
Decreases for tax positions of prior years (260) (391) (1,978)
Increases for tax positions related to current year 0 697 600
Balance at end of period $ 5,881 $ 5,335 $ 4,762
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION - Narrative (Details)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
segment
Dec. 31, 2021
facility
segment
Dec. 31, 2019
segment
Segment Reporting [Abstract]      
Number of reportable segments | segment 3 3 4
Number of filing facilities | facility   5  
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Assets $ 1,199,325 $ 1,165,843  
Net sales 799,023 703,644 $ 643,705
Operating Segments | Human Nutrition & Health      
Segment Reporting Information [Line Items]      
Assets 727,131 717,232  
Net sales 442,733 400,330 347,433
Operating Segments | Animal Nutrition & Health      
Segment Reporting Information [Line Items]      
Assets 158,971 157,454  
Net sales 226,776 192,191 177,557
Operating Segments | Specialty Products      
Segment Reporting Information [Line Items]      
Assets 184,628 190,449  
Net sales 117,020 103,566 92,257
Other and Unallocated      
Segment Reporting Information [Line Items]      
Assets 128,595 100,708  
Net sales $ 12,494 $ 7,557 $ 26,458
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]                      
Earnings from operations                 $ 127,502 $ 111,147 $ 102,553
Interest and other expense                 (2,269) (4,730) (6,075)
Earnings before income tax expense $ 33,146 $ 32,085 $ 30,019 $ 29,983 $ 28,047 $ 27,907 $ 25,973 $ 24,490 125,233 106,417 96,478
Other and Unallocated                      
Segment Reporting Information [Line Items]                      
Earnings from operations                 (4,728) (7,030) (257)
Interest and other expense                      
Segment Reporting Information [Line Items]                      
Interest and other expense                 (2,269) (4,730) (6,075)
Human Nutrition & Health | Operating Segments                      
Segment Reporting Information [Line Items]                      
Earnings from operations                 76,031 61,397 48,429
Animal Nutrition & Health | Operating Segments                      
Segment Reporting Information [Line Items]                      
Earnings from operations                 26,179 29,979 25,868
Specialty Products | Operating Segments                      
Segment Reporting Information [Line Items]                      
Earnings from operations                 $ 30,020 $ 26,801 $ 28,513
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION - Depreciation/Amortization (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Depreciation and amortization $ 48,879 $ 51,281 $ 45,862
Other and Unallocated      
Segment Reporting Information [Line Items]      
Depreciation and amortization 3,121 2,278 1,351
Human Nutrition & Health | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization 30,012 32,117 30,558
Animal Nutrition & Health | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization 7,414 7,187 6,552
Specialty Products | Operating Segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization $ 8,332 $ 9,699 $ 7,401
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Capital expenditures $ 36,142 $ 32,080 $ 25,790
Transaction and integration related costs 448 2,011 2,273
Amortization of identifiable intangible assets 25,092 27,811 25,789
Other and Unallocated      
Segment Reporting Information [Line Items]      
Capital expenditures 524 423 707
Transaction and integration related costs 1,264 2,410 3,436
Amortization of identifiable intangible assets 2,792 1,888 833
Human Nutrition & Health | Operating Segments      
Segment Reporting Information [Line Items]      
Capital expenditures 23,714 22,758 18,159
Animal Nutrition & Health | Operating Segments      
Segment Reporting Information [Line Items]      
Capital expenditures 8,100 6,039 3,921
Specialty Products | Operating Segments      
Segment Reporting Information [Line Items]      
Capital expenditures $ 3,804 $ 2,860 $ 3,003
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
REVENUE (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
revenue_substream
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Disaggregation of Revenue [Line Items]                      
Net sales $ 213,133 $ 197,869 $ 202,365 $ 185,656 $ 180,713 $ 175,140 $ 173,355 $ 174,436 $ 799,023 $ 703,644 $ 643,705
Number of sub-streams of revenue | revenue_substream                 4    
United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 584,661 516,347 475,033
Foreign Countries                      
Disaggregation of Revenue [Line Items]                      
Net sales                 214,362 187,297 168,672
Product Sales                      
Disaggregation of Revenue [Line Items]                      
Net sales                 762,085 666,193 609,741
Co-manufacturing                      
Disaggregation of Revenue [Line Items]                      
Net sales                 27,994 29,063 24,087
Bill and Hold                      
Disaggregation of Revenue [Line Items]                      
Net sales                 0 1,158 3,218
Consignment                      
Disaggregation of Revenue [Line Items]                      
Net sales                 4,439 2,939 2,299
Product Sales Revenue                      
Disaggregation of Revenue [Line Items]                      
Net sales                 794,518 699,353 639,345
Royalty Revenue                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 4,505 $ 4,291 $ 4,360
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash Paid for Income Taxes and Interest [Abstract]      
Income taxes $ 25,355 $ 22,637 $ 21,771
Interest 4,547 4,666 5,674
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]      
Dividends payable $ 20,886 $ 18,941 $ 16,855
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Other Comprehensive Income (Loss), Net of Tax [Abstract]      
Net foreign currency translation adjustment $ (11,255) $ 12,829 $ (891)
Unrealized gain/(loss) on cash flow hedge 2,707 (3,094) (1,771)
Tax (654) 809 372
Net of tax 2,053 (2,285) (1,399)
Net change in postretirement benefit plan (see Note 15 for further information)      
Prior service (credit)/cost and (gain)/loss arising during the period (4) (503) 199
Amortization of prior service credit/(cost) 74 74 74
Amortization of gain/(loss) (21) (50) (46)
Total before tax 49 (479) 227
Tax (13) 127 101
Adjustment 0 (455) 0
Net of tax 36 (807) 328
Total other comprehensive (loss)/income (9,166) 9,737 (1,962)
Net investment hedge      
Net change in postretirement benefit plan (see Note 15 for further information)      
Net foreign currency translation adjustment tax 1,527 1,579 70
Net investment hedge | Currency swap      
Other Comprehensive Income (Loss), Net of Tax [Abstract]      
Net foreign currency translation adjustment $ 4,766 $ (4,882) $ (262)
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance $ 828,233 $ 743,667 $ 691,618
Other comprehensive (loss)/gain (9,166) 9,737 (1,962)
Ending balance 877,015 828,233 743,667
Total      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 4,173 (5,564) (3,602)
Ending balance (4,993) 4,173 $ (5,564)
Foreign currency translation adjustment      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 7,653    
Other comprehensive (loss)/gain (11,255)    
Ending balance (3,602) 7,653  
Cash flow hedge      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (3,684)    
Other comprehensive (loss)/gain 2,053    
Ending balance (1,631) (3,684)  
Postretirement benefit plan      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 204    
Other comprehensive (loss)/gain 36    
Ending balance $ 240 $ 204  
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Narrative (Details)
$ in Thousands
 12 Months Ended
Jan. 01, 2021
plan
Dec. 31, 2021
USD ($)
plan
Dec. 31, 2020
USD ($)
plan
Dec. 31, 2019
USD ($)
Retirement Benefits [Abstract]        
Number of savings plan | plan 1   2  
Profit Sharing contributions   $ 1,459 $ 1,022 $ 592
401(k) contributions   $ 4,142 $ 3,751 $ 3,451
Number of unfunded plans | plan   2    
Number of multiemployer benefit pension plans | plan   1    
Contribution rate increase   4.00% 4.00%  
Deferred compensation liability   $ 6,270 $ 3,581  
Related rabbi trust assets   $ 6,267 $ 3,582  
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Postretirement Medical Plans      
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation at beginning of year $ 1,374 $ 1,076  
Initial adoption of new plan 0 0  
Service cost with interest to end of year 87 68 $ 63
Interest cost 23 26 39
Participant contributions 28 23  
Benefits paid (426) (27)  
Actuarial gain 207 208  
Benefit obligation at end of year 1,293 1,374 1,076
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 0 0  
Employer (reimbursement)/contributions 398 4  
Participant contributions 28 23  
Benefits paid (426) (27)  
Fair value of plan assets at end of year 0 0 0
Pension Plan | Chemogas Defined Pension Plan      
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation at beginning of year 2,053 1,738  
Service cost with interest to end of year 67 104 0
Interest cost 14 20 0
Participant contributions 24 21  
Benefits paid (18) (11)  
Actuarial gain (127) 18  
Exchange rate changes (154) 163  
Benefit obligation at end of year 1,859 2,053 1,738
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 1,103 895  
Actual return on plan assets 76 57  
Employer (reimbursement)/contributions 73 57  
Participant contributions 24 21  
Benefits paid (18) (11)  
Exchange rate changes (83) 84  
Fair value of plan assets at end of year $ 1,175 $ 1,103 $ 895
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]      
Unrecognized prior service cost $ 74 $ 74  
Unrecognized net gain (50) (46)  
Postretirement Medical Plans      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated postretirement benefit obligation 1,293 1,374  
Fair value of plan assets 0 0 $ 0
Funded status 1,293 1,374  
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) 1,293 1,374  
Pension Plan | Chemogas Defined Pension Plan      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated postretirement benefit obligation 1,859 2,053  
Fair value of plan assets 1,175 1,103 $ 895
Funded status 684 950  
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) $ 684 $ 950  
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Postretirement Medical Plans      
Defined Benefit Plan Disclosure [Line Items]      
Service cost with interest to end of year $ 87 $ 68 $ 63
Interest cost 23 26 39
Amortization of prior service cost 74 74 74
Amortization of gain (24) (50) (46)
Total net periodic benefit cost 160 118 130
Pension Plan | Chemogas Defined Pension Plan      
Defined Benefit Plan Disclosure [Line Items]      
Service cost with interest to end of year 67 104 0
Interest cost 14 20 0
Expected return on plan assets (34) (14) 0
Amortization of prior service cost 0 0 0
Amortization of gain 3 0 0
Total net periodic benefit cost $ 50 $ 110 $ 0
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Postretirement Medical Plans  
Defined Benefit Plan Disclosure [Line Items]  
2022 $ 107
2023 91
2024 113
2025 91
2026 76
Years 2027-2031 479
Pension Plan | Chemogas Defined Pension Plan  
Defined Benefit Plan Disclosure [Line Items]  
2022 1
2023 0
2024 0
2025 0
2026 0
Years 2027-2031 $ 22
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Central States, Southeast and Southwest Areas Pension Fund      
Multiemployer Plans [Line Items]      
Contributions of Balchem Corporation $ 816 $ 774 $ 677
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.22.0.1
EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details) - Pension Plan - Chemogas Defined Pension Plan
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Benefit Obligatoins    
Discount rate 1.00% 0.75%
Net Cost    
Discount rate 0.75% 1.00%
Expected return on assets 3.25% 1.00%
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]  
2022 $ 2,900
2023 2,139
2024 1,891
2025 1,066
2026 700
Thereafter 2,428
Total minimum lease payments $ 11,124
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.22.0.1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Related rabbi trust assets $ 6,267 $ 3,582
Derivative liabilities    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative liabilities 2,658 11,658
Derivative liabilities | Cross-currency swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative liabilities 500 6,793
Derivative liabilities | Interest rate swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Derivative liabilities 2,158 4,865
Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Related rabbi trust assets 6,267 3,582
Money Market Funds    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cash and cash equivalents $ 933 $ 817
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.22.0.1
RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Related Party Transaction [Line Items]      
Finished goods received from related party recorded in cost of goods sold $ 22,043 $ 12,190 $ 18,598
Receivable from related party 10,504 2,809  
Payable to related party 7,552 2,239  
Other receivable from related party 164 72  
Accounts payable 296 296  
Services Provided      
Related Party Transaction [Line Items]      
Revenues from related party 3,637 3,396 3,883
Raw Materials Sold      
Related Party Transaction [Line Items]      
Revenues from related party $ 27,915 $ 13,495 $ 24,786
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES - Narrative (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
tranche
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Lessee, Lease, Description [Line Items]      
Number of tranches | tranche 4    
Operating lease cost | $ $ 3,143 $ 3,105 $ 3,181
Years 1 and 2      
Lessee, Lease, Description [Line Items]      
Discount rate 1.45%    
Years 1 and 2 | Minimum      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 1 year    
Years 1 and 2 | Maximum      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 2 years    
Years 3 and 4      
Lessee, Lease, Description [Line Items]      
Discount rate 2.04%    
Years 3 and 4 | Minimum      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 3 years    
Years 3 and 4 | Maximum      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 4 years    
Years 5 through 9      
Lessee, Lease, Description [Line Items]      
Discount rate 2.38%    
Years 5 through 9 | Minimum      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 5 years    
Years 5 through 9 | Maximum      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 9 years    
More than 10 years      
Lessee, Lease, Description [Line Items]      
Term of contract for operating leases 10 years    
Discount rate 3.10%    
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Assets and Liabilities, Lessee [Abstract]    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease - ROU Operating Lease - ROU
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Right of use assets - finance lease Right of use assets - finance lease
Operating Lease - ROU $ 6,929 $ 5,838
Finance Leases - ROU 2,359 2,572
Total right-of-use assets $ 9,288 $ 8,410
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating leases liabilities - current Operating leases liabilities - current
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance lease liabilities - current Finance lease liabilities - current
Operating leases liabilities - current $ 2,194 $ 2,178
Finance lease liabilities - current 167 159
Total lease liabilities, current $ 2,361 $ 2,337
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating lease liabilities - non-current Finance lease liabilities - non-current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance lease liabilities - non-current Operating lease liabilities - non-current
Operating lease liabilities - non-current $ 4,811 $ 3,607
Finance lease liabilities - non-current 2,303 2,472
Total lease liabilities, non-current $ 7,114 $ 6,079
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES - Schedule of Lease Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Lease Cost      
Operating lease cost $ 3,143 $ 3,105 $ 3,181
Amortization of ROU asset 210 210 0
Interest on lease liabilities 129 137 0
Total finance lease 339 347 0
Total lease cost 3,482 3,452 3,181
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from operating leases 3,097 2,864 3,216
Operating cash flows from finance leases 129 137 0
Principal payments on finance lease 159 151 0
Cash flows from operating and finance leases 3,385 3,152 3,216
ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals 3,804 1,042 10,173
ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals $ 0 $ 2,782 $ 0
Weighted-average remaining lease term - operating leases 4 years 2 months 15 days 4 years 1 month 24 days 4 years 11 months 4 days
Weighted-average remaining lease term - finance leases 11 years 4 months 28 days 12 years 3 months  
Weighted-average discount rate - operating leases 3.50% 4.50% 4.60%
Weighted-average discount rate - finance leases 5.10% 5.10%  
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.22.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
May 28, 2019
Interest rate swap | Interest Expense        
Derivative [Line Items]        
Net interest income (expense) $ (2,144) $ (1,593) $ 40  
Designated as Hedging Instrument | Interest rate swap        
Derivative [Line Items]        
Notional amount of derivatives       $ 108,569
Designated as Hedging Instrument | Interest rate swap | Pay-Fixed Interest Rate        
Derivative [Line Items]        
Fixed interest rate       2.05%
Designated as Hedging Instrument | Cross-currency swap        
Derivative [Line Items]        
Notional amount of derivatives       $ 108,569
Designated as Hedging Instrument | Cross-currency swap | Pay-Fixed Interest Rate        
Derivative [Line Items]        
Fixed interest rate       0.00%
Designated as Hedging Instrument | Cross-currency swap | Receive-Fixed Interest Rate        
Derivative [Line Items]        
Fixed interest rate       2.05%
Designated as Hedging Instrument | Cross-currency swap | Interest Expense        
Derivative [Line Items]        
Net interest income (expense) $ 2,257 $ 2,275 $ 1,317  
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.22.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) - Derivative liabilities - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Derivative liabilities    
Derivative liabilities $ 2,658 $ 11,658
Interest rate swap    
Derivative liabilities    
Derivative liabilities 2,158 4,865
Cross-currency swap    
Derivative liabilities    
Derivative liabilities $ 500 $ 6,793
XML 115 R101.htm IDEA: XBRL DOCUMENT v3.22.0.1
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedge (interest rate swap), net of tax $ 2,053 $ (2,285) $ (1,399)
Net foreign currency translation adjustment (11,255) 12,829 (891)
Losses and gains recognized in accumulated other comprehensive income (loss) 6,819 (7,167) (1,661)
Interest rate swap      
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedge (interest rate swap), net of tax 2,053 (2,285) (1,399)
Cross-currency swap | Net investment hedge      
Derivative Instruments, Gain (Loss) [Line Items]      
Net foreign currency translation adjustment $ 4,766 $ (4,882) $ (262)
XML 116 R102.htm IDEA: XBRL DOCUMENT v3.22.0.1
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]                      
Net sales $ 213,133 $ 197,869 $ 202,365 $ 185,656 $ 180,713 $ 175,140 $ 173,355 $ 174,436 $ 799,023 $ 703,644 $ 643,705
Gross margin 64,066 60,934 59,447 58,727 56,818 56,368 55,380 55,331 243,174 223,897 211,367
Earnings before income tax expense 33,146 32,085 30,019 29,983 28,047 27,907 25,973 24,490 125,233 106,417 96,478
Net earnings $ 24,949 $ 25,013 $ 22,731 $ 23,411 $ 22,162 $ 21,568 $ 21,125 $ 19,768 $ 96,104 $ 84,623 $ 79,671
Basic net earnings per common share (in dollars per share) $ 0.78 $ 0.78 $ 0.71 $ 0.73 $ 0.69 $ 0.67 $ 0.66 $ 0.62 $ 2.98 $ 2.63 $ 2.48
Diluted net earnings per common share (in dollars per share) $ 0.76 $ 0.77 $ 0.70 $ 0.72 $ 0.68 $ 0.66 $ 0.65 $ 0.61 $ 2.94 $ 2.60 $ 2.45
XML 117 R103.htm IDEA: XBRL DOCUMENT v3.22.0.1
VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Allowance for Doubtful Accounts      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning balance $ 2,092 $ 2,080 $ 610
Additions charged (credited) to costs and expenses 180 140 1,776
Adjustments/deductions (1,344) (128) (306)
Ending balance 928 2,092 2,080
Inventory Reserve      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning balance 2,782 4,281 2,575
Additions charged (credited) to costs and expenses 7,312 5,964 7,069
Adjustments/deductions (8,669) (7,463) (5,363)
Ending balance $ 1,425 $ 2,782 $ 4,281
XML 118 bcpc-20211231_htm.xml IDEA: XBRL DOCUMENT 0000009326 2021-01-01 2021-12-31 0000009326 2021-06-30 0000009326 2022-02-10 0000009326 2021-12-31 0000009326 2020-12-31 0000009326 2020-01-01 2020-12-31 0000009326 2019-01-01 2019-12-31 0000009326 2018-12-31 0000009326 us-gaap:RetainedEarningsMember 2018-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000009326 us-gaap:CommonStockMember 2018-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000009326 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000009326 2019-12-31 0000009326 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000009326 us-gaap:RetainedEarningsMember 2019-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000009326 us-gaap:CommonStockMember 2019-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000009326 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000009326 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000009326 us-gaap:RetainedEarningsMember 2020-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000009326 us-gaap:CommonStockMember 2020-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000009326 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000009326 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000009326 us-gaap:RetainedEarningsMember 2021-12-31 0000009326 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000009326 us-gaap:CommonStockMember 2021-12-31 0000009326 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000009326 srt:MinimumMember us-gaap:BuildingMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember us-gaap:BuildingMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0000009326 2020-04-01 2020-06-30 0000009326 bcpc:HumanNutritionAndHealthMember 2021-12-31 0000009326 bcpc:HumanNutritionAndHealthMember 2020-12-31 0000009326 bcpc:AnimalNutritionAndHealthMember 2021-12-31 0000009326 bcpc:AnimalNutritionAndHealthMember 2020-12-31 0000009326 bcpc:SpecialtyProductsMember 2021-12-31 0000009326 bcpc:SpecialtyProductsMember 2020-12-31 0000009326 bcpc:IndustrialProductsMember 2021-12-31 0000009326 bcpc:IndustrialProductsMember 2020-12-31 0000009326 srt:MinimumMember us-gaap:CustomerListsMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember us-gaap:CustomerListsMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember us-gaap:TrademarksAndTradeNamesMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember us-gaap:TrademarksAndTradeNamesMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember bcpc:RegulatoryRegistrationCostsMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember bcpc:RegulatoryRegistrationCostsMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember bcpc:PatentsTradeSecretsMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember bcpc:PatentsTradeSecretsMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember bcpc:OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember bcpc:OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMember 2021-01-01 2021-12-31 0000009326 bcpc:HumanNutritionAndHealthMember 2019-01-01 2019-12-31 0000009326 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-28 0000009326 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-28 0000009326 bcpc:ZumbroRiverBrandIncMember 2019-12-13 2019-12-31 0000009326 bcpc:ZumbroRiverBrandIncMember 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember 2020-05-01 2020-05-31 0000009326 bcpc:ZumbroRiverBrandIncMember bcpc:HumanNutritionAndHealthMember 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember us-gaap:CustomerRelationshipsMember 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember us-gaap:DevelopedTechnologyRightsMember 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember us-gaap:TradeNamesMember 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember us-gaap:CustomerRelationshipsMember 2019-12-13 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember us-gaap:TradeNamesMember 2019-12-13 2019-12-13 0000009326 bcpc:ZumbroRiverBrandIncMember us-gaap:DevelopedTechnologyRightsMember 2019-12-13 2019-12-13 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember 2019-05-27 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember us-gaap:TradeNamesMember 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2019-05-27 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember us-gaap:TradeNamesMember 2019-05-27 2019-05-27 0000009326 bcpc:ChemogasHoldingNVAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2019-05-27 2019-05-27 0000009326 bcpc:ChemogasAndZumbroRiverBrandIncMember 2021-01-01 2021-12-31 0000009326 bcpc:ChemogasAndZumbroRiverBrandIncMember 2020-01-01 2020-12-31 0000009326 bcpc:ChemogasAndZumbroRiverBrandIncMember 2019-01-01 2019-12-31 0000009326 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000009326 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000009326 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000009326 us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0000009326 us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0000009326 us-gaap:OperatingExpenseMember 2019-01-01 2019-12-31 0000009326 bcpc:OmnibusIncentivePlan2017Member 2021-12-31 0000009326 bcpc:StockPlan1999Member 2021-12-31 0000009326 bcpc:OmnibusIncentivePlan2017Member 2021-01-01 2021-12-31 0000009326 us-gaap:EmployeeStockOptionMember bcpc:OmnibusIncentivePlan2017Member 2021-12-31 0000009326 srt:DirectorMember bcpc:OmnibusIncentivePlan2017Member 2021-01-01 2021-12-31 0000009326 bcpc:EmployeeMember us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000009326 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000009326 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000009326 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000009326 bcpc:EmployeeMember us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000009326 bcpc:EmployeeMember us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000009326 srt:MinimumMember bcpc:EmployeeMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember bcpc:EmployeeMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000009326 srt:MinimumMember srt:DirectorMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember srt:DirectorMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000009326 bcpc:ExercisePriceRange1Member 2021-01-01 2021-12-31 0000009326 bcpc:ExercisePriceRange1Member 2021-12-31 0000009326 bcpc:ExercisePriceRange2Member 2021-01-01 2021-12-31 0000009326 bcpc:ExercisePriceRange2Member 2021-12-31 0000009326 bcpc:ExercisePriceRange3Member 2021-01-01 2021-12-31 0000009326 bcpc:ExercisePriceRange3Member 2021-12-31 0000009326 us-gaap:RestrictedStockMember 2020-12-31 0000009326 us-gaap:RestrictedStockMember 2019-12-31 0000009326 us-gaap:RestrictedStockMember 2018-12-31 0000009326 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000009326 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000009326 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000009326 us-gaap:RestrictedStockMember 2021-12-31 0000009326 us-gaap:PerformanceSharesMember 2020-12-31 0000009326 us-gaap:PerformanceSharesMember 2019-12-31 0000009326 us-gaap:PerformanceSharesMember 2018-12-31 0000009326 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000009326 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000009326 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000009326 us-gaap:PerformanceSharesMember 2021-12-31 0000009326 us-gaap:LandMember 2021-12-31 0000009326 us-gaap:LandMember 2020-12-31 0000009326 us-gaap:BuildingMember 2021-12-31 0000009326 us-gaap:BuildingMember 2020-12-31 0000009326 us-gaap:EquipmentMember 2021-12-31 0000009326 us-gaap:EquipmentMember 2020-12-31 0000009326 us-gaap:ConstructionInProgressMember 2021-12-31 0000009326 us-gaap:ConstructionInProgressMember 2020-12-31 0000009326 srt:NorthAmericaMember 2021-12-31 0000009326 srt:NorthAmericaMember 2020-12-31 0000009326 srt:EuropeMember 2021-12-31 0000009326 srt:EuropeMember 2020-12-31 0000009326 us-gaap:CustomerListsMember 2021-12-31 0000009326 us-gaap:CustomerListsMember 2020-12-31 0000009326 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0000009326 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0000009326 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000009326 us-gaap:DevelopedTechnologyRightsMember 2020-12-31 0000009326 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-12-31 0000009326 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0000009326 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0000009326 bcpc:StGabrielCCCompanyLLCMember 2013-12-31 0000009326 bcpc:EastmanChemicalCompanyMember bcpc:StGabrielCCCompanyLLCMember 2013-12-31 0000009326 bcpc:StGabrielCCCompanyLLCMember 2021-01-01 2021-12-31 0000009326 bcpc:StGabrielCCCompanyLLCMember 2020-01-01 2020-12-31 0000009326 bcpc:StGabrielCCCompanyLLCMember 2019-01-01 2019-12-31 0000009326 bcpc:StGabrielCCCompanyLLCMember 2021-12-31 0000009326 bcpc:StGabrielCCCompanyLLCMember 2020-12-31 0000009326 us-gaap:SecuredDebtMember 2018-06-27 0000009326 us-gaap:RevolvingCreditFacilityMember 2018-06-27 0000009326 2018-06-27 0000009326 us-gaap:SecuredDebtMember 2018-06-27 2018-06-27 0000009326 us-gaap:SecuredDebtMember 2019-05-23 2019-05-23 0000009326 us-gaap:SecuredDebtMember 2019-12-13 2019-12-13 0000009326 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-12-31 0000009326 bcpc:RevolvingCreditAgreementMember 2021-12-31 0000009326 srt:MinimumMember bcpc:RevolvingCreditAgreementMember 2021-01-01 2021-12-31 0000009326 srt:MaximumMember bcpc:RevolvingCreditAgreementMember 2021-01-01 2021-12-31 0000009326 bcpc:RevolvingCreditAgreementMember 2021-01-01 2021-12-31 0000009326 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000009326 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000009326 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000009326 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000009326 2020-01-01 2020-03-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:HumanNutritionAndHealthMember 2021-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:HumanNutritionAndHealthMember 2020-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:AnimalNutritionAndHealthMember 2021-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:AnimalNutritionAndHealthMember 2020-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:SpecialtyProductsMember 2021-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:SpecialtyProductsMember 2020-12-31 0000009326 us-gaap:CorporateNonSegmentMember 2021-12-31 0000009326 us-gaap:CorporateNonSegmentMember 2020-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:HumanNutritionAndHealthMember 2021-01-01 2021-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:HumanNutritionAndHealthMember 2020-01-01 2020-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:HumanNutritionAndHealthMember 2019-01-01 2019-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:AnimalNutritionAndHealthMember 2021-01-01 2021-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:AnimalNutritionAndHealthMember 2020-01-01 2020-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:AnimalNutritionAndHealthMember 2019-01-01 2019-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:SpecialtyProductsMember 2021-01-01 2021-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:SpecialtyProductsMember 2020-01-01 2020-12-31 0000009326 us-gaap:OperatingSegmentsMember bcpc:SpecialtyProductsMember 2019-01-01 2019-12-31 0000009326 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000009326 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000009326 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0000009326 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0000009326 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-12-31 0000009326 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0000009326 bcpc:ProductSalesMember 2021-01-01 2021-12-31 0000009326 bcpc:ProductSalesMember 2020-01-01 2020-12-31 0000009326 bcpc:ProductSalesMember 2019-01-01 2019-12-31 0000009326 bcpc:CoManufacturingMember 2021-01-01 2021-12-31 0000009326 bcpc:CoManufacturingMember 2020-01-01 2020-12-31 0000009326 bcpc:CoManufacturingMember 2019-01-01 2019-12-31 0000009326 bcpc:BillAndHoldMember 2021-01-01 2021-12-31 0000009326 bcpc:BillAndHoldMember 2020-01-01 2020-12-31 0000009326 bcpc:BillAndHoldMember 2019-01-01 2019-12-31 0000009326 bcpc:ConsignmentMember 2021-01-01 2021-12-31 0000009326 bcpc:ConsignmentMember 2020-01-01 2020-12-31 0000009326 bcpc:ConsignmentMember 2019-01-01 2019-12-31 0000009326 us-gaap:ProductMember 2021-01-01 2021-12-31 0000009326 us-gaap:ProductMember 2020-01-01 2020-12-31 0000009326 us-gaap:ProductMember 2019-01-01 2019-12-31 0000009326 us-gaap:RoyaltyMember 2021-01-01 2021-12-31 0000009326 us-gaap:RoyaltyMember 2020-01-01 2020-12-31 0000009326 us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0000009326 country:US 2021-01-01 2021-12-31 0000009326 country:US 2020-01-01 2020-12-31 0000009326 country:US 2019-01-01 2019-12-31 0000009326 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000009326 us-gaap:NonUsMember 2020-01-01 2020-12-31 0000009326 us-gaap:NonUsMember 2019-01-01 2019-12-31 0000009326 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-12-31 0000009326 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-12-31 0000009326 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0000009326 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-12-31 0000009326 us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-12-31 0000009326 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0000009326 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000009326 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000009326 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000009326 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000009326 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-12-31 0000009326 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0000009326 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000009326 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000009326 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000009326 2021-01-01 2021-01-01 0000009326 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-12-31 0000009326 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-12-31 0000009326 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2021-01-01 2021-12-31 0000009326 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-01-01 2020-12-31 0000009326 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2021-12-31 0000009326 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2019-01-01 2019-12-31 0000009326 bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember 2021-01-01 2021-12-31 0000009326 bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember 2020-01-01 2020-12-31 0000009326 bcpc:CentralStatesSoutheastAndSouthwestAreasPensionFundMember 2019-01-01 2019-12-31 0000009326 bcpc:ChemogasDefinedPensionPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000009326 bcpc:ChemogasDefinedPensionPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000009326 bcpc:ChemogasDefinedPensionPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000009326 bcpc:ChemogasDefinedPensionPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000009326 bcpc:ChemogasDefinedPensionPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000009326 bcpc:ChemogasDefinedPensionPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000009326 us-gaap:MoneyMarketFundsMember 2021-12-31 0000009326 us-gaap:MoneyMarketFundsMember 2020-12-31 0000009326 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000009326 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000009326 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:CurrencySwapMember 2021-12-31 0000009326 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:CurrencySwapMember 2020-12-31 0000009326 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:InterestRateSwapMember 2021-12-31 0000009326 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:InterestRateSwapMember 2020-12-31 0000009326 bcpc:ServicesProvidedMember us-gaap:CorporateJointVentureMember 2021-01-01 2021-12-31 0000009326 bcpc:ServicesProvidedMember us-gaap:CorporateJointVentureMember 2020-01-01 2020-12-31 0000009326 bcpc:ServicesProvidedMember us-gaap:CorporateJointVentureMember 2019-01-01 2019-12-31 0000009326 bcpc:RawMaterialsSoldMember us-gaap:CorporateJointVentureMember 2021-01-01 2021-12-31 0000009326 bcpc:RawMaterialsSoldMember us-gaap:CorporateJointVentureMember 2020-01-01 2020-12-31 0000009326 bcpc:RawMaterialsSoldMember us-gaap:CorporateJointVentureMember 2019-01-01 2019-12-31 0000009326 us-gaap:CorporateJointVentureMember 2021-01-01 2021-12-31 0000009326 us-gaap:CorporateJointVentureMember 2020-01-01 2020-12-31 0000009326 us-gaap:CorporateJointVentureMember 2019-01-01 2019-12-31 0000009326 us-gaap:CorporateJointVentureMember 2021-12-31 0000009326 us-gaap:CorporateJointVentureMember 2020-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheOneMember srt:MinimumMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheOneMember srt:MaximumMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheOneMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheTwoMember srt:MinimumMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheTwoMember srt:MaximumMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheTwoMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheThreeMember srt:MinimumMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheThreeMember srt:MaximumMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheThreeMember 2021-12-31 0000009326 bcpc:LesseeOperatingLeaseTrancheFourMember 2021-12-31 0000009326 bcpc:PayFixedInterestRateMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-28 0000009326 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000009326 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000009326 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000009326 bcpc:PayFixedInterestRateMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-28 0000009326 bcpc:ReceiveFixedInterestRateMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-05-28 0000009326 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000009326 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000009326 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000009326 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-12-31 0000009326 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2020-12-31 0000009326 us-gaap:InterestRateSwapMember 2021-01-01 2021-12-31 0000009326 us-gaap:InterestRateSwapMember 2020-01-01 2020-12-31 0000009326 us-gaap:InterestRateSwapMember 2019-01-01 2019-12-31 0000009326 2021-01-01 2021-03-31 0000009326 2021-04-01 2021-06-30 0000009326 2021-07-01 2021-09-30 0000009326 2021-10-01 2021-12-31 0000009326 2020-07-01 2020-09-30 0000009326 2020-10-01 2020-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2018-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2019-01-01 2019-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2019-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2020-01-01 2020-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2020-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2020-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2021-01-01 2021-12-31 0000009326 us-gaap:AllowanceForCreditLossMember 2021-12-31 0000009326 us-gaap:InventoryValuationReserveMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure iso4217:EUR bcpc:plan bcpc:vote bcpc:segment bcpc:facility bcpc:revenue_substream bcpc:tranche 2021 FY false 0000009326 P3Y P3Y 0.6666 0.6666 http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset http://fasb.org/us-gaap/2021-01-31#FinanceLeaseRightOfUseAsset http://fasb.org/us-gaap/2021-01-31#FinanceLeaseRightOfUseAsset http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2021-01-31#FinanceLeaseLiabilityNoncurrent 10-K true 2021-12-31 --12-31 false 1-13648 Balchem Corporation MD 13-2578432 52 Sunrise Park Road New Hampton NY 10958 845 326-5600 Common Stock, par value $.06-2/3 per share BCPC NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 4224000000 32187345 Selected portions of the Registrant’s proxy statement for its 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end of December 31, 2021 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated therein. 49 RSM US LLP New York, New York 103239000 84571000 928000 2092000 117408000 98214000 91058000 70620000 6116000 6598000 0 3447000 4411000 3438000 322232000 266888000 237517000 228096000 523949000 529463000 94665000 121660000 6929000 5838000 2359000 2572000 11674000 11326000 1199325000 1165843000 56243000 23742000 43411000 29655000 19567000 19753000 20886000 18941000 1334000 0 2194000 2178000 167000 159000 143802000 94428000 108569000 163569000 46455000 51359000 4811000 3607000 2303000 2472000 2658000 11658000 13712000 10517000 322310000 337610000 25 25 2000000 2000000 0 0 0 0 0 0 0.0667 0.0667 120000000 120000000 32287150 32287150 32372621 32372621 2154000 2160000 147716000 165160000 732138000 656740000 -4993000 4173000 877015000 828233000 1199325000 1165843000 799023000 703644000 643705000 555849000 479747000 432338000 243174000 223897000 211367000 60413000 58630000 60932000 13524000 10332000 11377000 41735000 43788000 36505000 115672000 112750000 108814000 127502000 111147000 102553000 -2456000 -4439000 -5959000 187000 -291000 -116000 -2269000 -4730000 -6075000 125233000 106417000 96478000 29129000 21794000 16807000 96104000 84623000 79671000 2.98 2.63 2.48 2.94 2.60 2.45 96104000 84623000 79671000 -11255000 12829000 -891000 -654000 -809000 -372000 2053000 -2285000 -1399000 -13000 -127000 -101000 36000 -807000 328000 -9166000 9737000 -1962000 86938000 94360000 77709000 691618000 528027000 -3602000 32256209 2151000 165042000 79671000 79671000 0 -1962000 -1962000 0 0.52 16777000 16777000 0 21321000 240995 16000 21305000 12438000 186703 13000 12425000 743667000 590921000 -5564000 32201917 2148000 156162000 84623000 84623000 0 9737000 9737000 0 0.58 18804000 18804000 0 13463000 136629 9000 13454000 22473000 307333 21000 22452000 828233000 656740000 4173000 32372621 2160000 165160000 96104000 96104000 0 -9166000 -9166000 0 0.64 20706000 20706000 0 35239000 249848 17000 35222000 17789000 164377 11000 17778000 877015000 732138000 -4993000 32287150 2154000 147716000 96104000 84623000 79671000 48879000 51281000 45862000 10802000 8303000 7596000 -5944000 -4627000 -3563000 180000 140000 1776000 -384000 173000 72000 1675000 1915000 1140000 1728000 -153000 3134000 20700000 3599000 -11623000 21023000 -13923000 11401000 881000 2856000 -477000 47067000 -992000 1134000 4787000 1859000 -5664000 1680000 198000 -1128000 160514000 150494000 124461000 37449000 33828000 28413000 0 0 141062000 318000 87000 11523000 1831000 0 2727000 0 850000 1000000 -35300000 -34591000 -156225000 5000000 10000000 168569000 60000000 95000000 76000000 159000 151000 0 0 0 17567000 6943000 14155000 4839000 18723000 16705000 15135000 35239000 13463000 21321000 -102178000 -101164000 43385000 -4368000 4160000 -217000 18668000 18899000 11404000 84571000 65672000 54268000 103239000 84571000 65672000 BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Description</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balchem Corporation (“Balchem” or the “Company”), including, unless the context otherwise requires, its wholly-owned subsidiaries, incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Principles of Consolidation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S., Italy, Belgium, Malaysia, Australia, Philippines, and Singapore exceed the Federal Deposit Insurance Corporation (“FDIC”), Fondo Interbancario di Tutela dei Depositi (“FITD”), Financial Services and Markets Authority ("FSMA"), Perbadanan Insurans Deposit Malaysia ("PIDM"), Australian Prudential Regulation Authority ("APRA"), Philippine Deposit Insurance Corporation ("PDIC"), and Singapore Deposit Insurance Corporation ("SDIC") insurance limits, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounts Receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (first in, first out or average) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment and Depreciation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-25 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-28 years</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Concentrations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2021, 2020 and 2019, no customer accounted for more than 10% of total net sales or accounts receivable.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Post-employment Benefits</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill and Acquired Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. A goodwill impairment test will now be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. The guidance is effective for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 1, 2021 and 2020, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2021. However, during the second quarter of 2020, the Company recorded a goodwill impairment charge of $1,228 related to business formerly included in the Industrial Products segment. The Company may resume performing the qualitative assessment in subsequent periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of Zumbro Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact due to change in foreign exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact due to change in foreign exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:69.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HNH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,463 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks &amp; trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 17</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory registration costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents &amp; trade secrets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 17</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2 - 18</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2021, there were no triggering events which required intangible asset impairment reviews. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in either derivative asset or derivative liability, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Earnings Per Common Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of Long-lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. For the year ended December 31, 2019, we incurred impairment charges of $1,026 in connection with a restructuring in the HNH segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Instruments and Hedging Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, the Company entered into a pay-fixed, receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, the Company also entered into a cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. This derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments are with the above single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we assess the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. As of December 31, 2021, we assessed the hedging relationships and determined them to be highly effective. As such, the net change in fair values of the interest rate swap, that qualifies as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and is subsequently reclassified </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into interest expense as interest payments are made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remained in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, "Derivative Instruments and Hedging Activities" for detailed information about our derivative financial instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted this new Standard in 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Standard Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard Update may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new Standard on January 1, 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance contained in this ASU requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company’s consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This Update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company's consolidated financial statements and disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment”, which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new Standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The Update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The </span></div>Company adopted the new Standard and related Updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements. Principles of ConsolidationThe consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for each of the Company’s business segments is recognized when control of the promised goods is transferred to our customers, in an amount that reflects the consideration we expect to realize in exchange for those goods. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is recognized when control is transferred to the customer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue-generating contracts are assessed to identify distinct performance obligations, allocating transaction prices to those performance obligations, and criteria for satisfaction of a performance obligation. The standard allows for recognition of revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. The Company assesses collectability based primarily on the customer’s payment history and on the creditworthiness of the customer. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense.</span></div> Cash and Cash EquivalentsThe Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has funds in its cash accounts that are with third party financial institutions, primarily in certificates of deposit and money market funds. The Company's balances of cash and cash equivalents in the U.S., Italy, Belgium, Malaysia, Australia, Philippines, and Singapore exceed the Federal Deposit Insurance Corporation (“FDIC”), Fondo Interbancario di Tutela dei Depositi (“FITD”), Financial Services and Markets Authority ("FSMA"), Perbadanan Insurans Deposit Malaysia ("PIDM"), Australian Prudential Regulation Authority ("APRA"), Philippine Deposit Insurance Corporation ("PDIC"), and Singapore Deposit Insurance Corporation ("SDIC") insurance limits, respectively. <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounts Receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit terms are granted in the normal course of business to the Company’s customers and on-going credit evaluations are performed on the Company’s customers. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. Based on this ASU, customers' credit limits are adjusted based upon their reasonably expected credit worthiness which is determined through review of their payment history, their current credit information, and any foreseeable future events. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make required payments are maintained. Estimated losses are based on historical experience, any specific customer collection issues identified, </span></div>and any reasonably expected future adverse events. If the financial condition of our customers were to deteriorate resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required. <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (first in, first out or average) or net realizable value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment and Depreciation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-25 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-28 years</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings from operations.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-25 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-28 years</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment at December 31, 2021 and 2020 are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P15Y P25Y P2Y P28Y <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Concentrations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. In 2021, 2020 and 2019, no customer accounted for more than 10% of total net sales or accounts receivable.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Post-employment Benefits</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide life insurance, health care benefits, and defined benefit pension plan payments for certain eligible retirees and health care benefits for certain retirees’ eligible survivors. The costs and obligations related to these benefits reflect our assumptions as to health care cost trends and key economic conditions including discount rates, expected rate of return on plan assets, and expected salary increases. The cost of providing plan benefits also depends on demographic assumptions including retirements, mortality, turnover, and plan participation. If actual experience differs from these assumptions, the cost of providing these benefits could increase or decrease.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 715, “Compensation-Retirement Benefits,” we are required to recognize the overfunded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in our statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill and Acquired Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performed its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. A goodwill impairment test will now be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. The guidance is effective for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 1, 2021 and 2020, the Company opted to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. The Company assessed the fair values of its reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for its conclusions. The Company's estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. The Company's assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units was not considered impaired as of October 1, 2021. However, during the second quarter of 2020, the Company recorded a goodwill impairment charge of $1,228 related to business formerly included in the Industrial Products segment. The Company may resume performing the qualitative assessment in subsequent periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks &amp; trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 17</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory registration costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents &amp; trade secrets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 17</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2 - 18</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. The useful life of an intangible asset is based on our assumptions regarding expected use of the asset; the relationship of the intangible asset to another asset or group of assets; any legal, regulatory or contractual provisions that may limit the useful life of the asset or that enable renewal or extension of the asset’s legal or contractual life without substantial cost; the effects of obsolescence, demand, competition and other economic factors; and the level of maintenance expenditures required to obtain the expected future cash flows from the asset and their related impact on the asset’s useful life. If events or circumstances indicate that the life of an </span></div>intangible asset has changed, it could result in higher future amortization charges or recognition of an impairment loss. For the year ended December 31, 2021, there were no triggering events which required intangible asset impairment reviews. 1228000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.”</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of Zumbro Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact due to change in foreign exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact due to change in foreign exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:69.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HNH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,463 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 523949000 529463000 523998000 432000 1228000 6261000 529463000 -5514000 523949000 424044000 424051000 17207000 17824000 82654000 87539000 44000 49000 523949000 529463000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:74.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Period<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks &amp; trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 17</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 12</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory registration costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents &amp; trade secrets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 17</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2 - 18</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had identifiable intangible assets as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:34.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Period<br/>(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships &amp; lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-20</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks &amp; trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-17</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,116 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,208 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,974 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-18</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,921 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,624 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,330 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,403 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P10Y P20Y P2Y P17Y P5Y P12Y P5Y P10Y P15Y P17Y P2Y P18Y <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In evaluating our ability to recover our deferred tax assets, in full or in part, we consider all available positive and negative evidence, including our past operating results, our forecast of future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies. The assumptions utilized in determining future taxable income require judgment and are consistent with the plans and estimates we are using to manage the underlying businesses.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize uncertain income tax positions taken on income tax returns at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty percent likelihood of being sustained.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of financial instruments, none of which are held for trading purposes. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, non-current assets includes rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, "Fair Value Measurement."</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in either derivative asset or derivative liability, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Earnings Per Common Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method).</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results.</span></div> Impairment of Long-lived AssetsLong-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. 1026000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Instruments and Hedging Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. The Company does not enter into derivative financial instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, the Company entered into a pay-fixed, receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, the Company also entered into a cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. This derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments are with the above single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheet. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we assess the effectiveness of the hedging relationships for the interest rate swap and cross-currency swap by reviewing the critical terms indicated in the applicable agreement. As of December 31, 2021, we assessed the hedging relationships and determined them to be highly effective. As such, the net change in fair values of the interest rate swap, that qualifies as a cash flow hedge, was recorded in accumulated other comprehensive income/(loss) and is subsequently reclassified </span></div>into interest expense as interest payments are made on our debt. For the cross-currency swap, the amounts that have not yet been recognized in earnings remained in the cumulative translation adjustment section of accumulated other comprehensive income until the hedged net investment is sold or liquidated in accordance with paragraphs 815-35-35-5A, "Derivatives and Hedging - Net Investment Hedges", and 830-30-40-1 through 40-1A, "Foreign Currency Matters - Derecognition". Refer to Note 20, "Derivative Instruments and Hedging Activities" for detailed information about our derivative financial instruments. 108569000 108569000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted this new Standard in 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Standard Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard Update may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new Standard on January 1, 2021. The Standard did not have a significant impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance contained in this ASU requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company’s consolidated financial statements and disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This Update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new Standard on January 1, 2020. The Standard Update did not have a significant impact on the Company's consolidated financial statements and disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment”, which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new Standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The Update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The </span></div>Company adopted the new Standard and related Updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements. SIGNIFICANT ACQUISITIONS AND DIVESTITURES<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2019, the Company completed the acquisition of Zumbro. The Company made payments of $52,403 on the acquisition date, amounting to $47,058 to the former shareholders and $5,345 to Zumbro's lenders to pay Zumbro debt. Considering the cash acquired of $686, net payments made to the former shareholders were $46,372. In May 2020, the Company received an adjustment for working capital acquired of $561.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill of $18,505 arising from the acquisition consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to Human Nutrition &amp; Health ("HNH") and $4,723 is deductible for income taxes. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:77.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid &amp; other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable &amp; accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zumbro debt paid on purchase date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount paid on acquisition date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management's estimates and assumptions that are subject to change. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized included cost and market approaches for property, plant and equipment, excess earnings method for customer relationships and the relief from royalty method for other intangible assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships are amortized over a 15-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name and developed technology are amortized over 10 years and 12 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is indemnified for tax liabilities related to periods prior to the acquisition date. Indemnified tax liabilities will create an indemnification asset (receivable). An indemnification asset balance has not been established.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2019, the Company acquired 100 percent of the outstanding common shares of Chemogas. The Company made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill of $59,319 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Specialty Products segment and is not tax deductible for income tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:77.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension obligation (net)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemogas bank debt paid on purchase date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount paid on acquisition date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,324 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. In preparing our fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized included cost and market approaches for property, plant and equipment, excess earnings method for customer relationships and the relief from royalty method for other intangible assets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships are amortized over a 20-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name and developed technology are amortized over 2 years and 10 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is indemnified for tax liabilities related to periods prior to the acquisition date. Indemnified tax liabilities will create an indemnification asset (receivable). An indemnification asset balance has not been established. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Chemogas and Zumbro acquisitions, the Company incurred transaction and integration costs of $26, $1,480, and $1,947 for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction and integration costs related to recent acquisitions, including the Chemogas and Zumbro acquisitions described above, are recorded in general and administrative expenses. These costs amounted to $448, $2,011, and $2,273 for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2019, the Company sold an insignificant portion of its business. As a result of the transaction, the Company recorded a gain on sale, which was immaterial to the consolidated financial statements and included in general and administrative </span></div>expenses. Operating results for the portion of the business sold were insignificant relative to the Company’s consolidated financial results for year ended December 31, 2019. 52403000 47058000 5345000 686000 46372000 561000 18505000 4723000 <div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:77.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid &amp; other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable &amp; accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zumbro debt paid on purchase date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount paid on acquisition date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:77.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension obligation (net)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemogas bank debt paid on purchase date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount paid on acquisition date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,324 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 686000 3314000 4052000 521000 15245000 3181000 8200000 4400000 2300000 10000 1651000 3181000 5345000 3740000 18505000 46497000 5345000 51842000 P15Y P10Y P12Y 1 99503000 111324000 88579000 99102000 10924000 12222000 3943000 4412000 84636000 94690000 59319000 4412000 4176000 957000 15972000 39158000 2461000 1119000 1491000 3261000 12222000 1030000 594000 12856000 59319000 99102000 12222000 111324000 P20Y P2Y P10Y 26000 1480000 1947000 448000 2011000 2273000 STOCKHOLDERS’ EQUITY<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK-BASED COMPENSATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock options, are recognized in the statements of earnings as operating expenses, based on their fair values.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s results for the years ended December 31, 2021, 2020 and 2019 reflected the following compensation cost and such compensation cost had the following effects on net earnings:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease) for the<br/>Year Ended, December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company had one share-based compensation plan under which awards may be granted, which is described below.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company adopted the Balchem Corporation 2017 Omnibus Incentive Plan (“2017 Plan”) for officers, employees and directors of the Company and its subsidiaries. The 2017 Plan replaced the 1999 Stock Plan and amendments and restatements thereto (collectively to be referred to as the “1999 Plan"), which expired on April 9, 2018. No further awards will be made under the 1999 Plan, and the shares that remained available for grant under the 1999 Plan will only be used to settle outstanding awards granted under the 1999 Plan and will not become available under the 2017 Plan. The 2017 Plan is administered by the Compensation Committee of the Board of Directors of the Company. The 2017 Plan provides as follows: (i) for a termination date of June 13, 2027; (ii) the authorization of 1,600,000 shares for future grants (which represents a reduction from the 6,000,000 shares authorized for grant under the 1999 Plan); (iii) for the making of grants of stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards, as well as for the making of cash performance awards; (iv) except as provided in an employment agreement as in effect on the effective date of the 2017 Plan, no automatic acceleration of outstanding awards upon the occurrence of a change in control of the Company; (v) certain annual limits on the number of shares and amount of cash that may be granted; (vii) for dividends or dividend equivalents otherwise payable on an unvested award to accrue and be paid only at such time as the vesting conditions applicable to the underlying award have been satisfied; (vii) for certain discretionary compensation recovery if the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirements under the securities laws; and (viii) for compliance with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). No option will be exercisable for longer than ten years after the date of grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2021, the 2017 Plan had 703,707 shares available for future awards.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Common Stock have been granted, ranging from 70 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award issued under the Company’s stock plans is estimated on the date of grant using a Black-Scholes based option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:55.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Assumptions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of the restricted shares is based on the fair value of the award at the date of grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Share expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the Performance Share vests. The assumptions used in the fair value determination were risk free interest rates of 0.2%, 1.4%, and 2.5%; dividend yields of 0.6%, 0.5%, and 0.5%; volatilities of 33%, 24%, and 24%; and initial TSR’s of 11.7%, 10.9%, and -5.9% in each case for the years ended December 31, 2021, 2020, and 2019, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The Performance Shares will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV85NC9mcmFnOmVmMGE3NzFkMWQxOTQ4MWZiZjY1ZDU4NDQ1ZmUyMjljL3RleHRyZWdpb246ZWYwYTc3MWQxZDE5NDgxZmJmNjVkNTg0NDVmZTIyOWNfNTk1NA_0ceb84a5-220d-4a7d-b56f-de3e4016d155">three</span> to four years for employee restricted stock awards, three years for employee performance share awards, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV85NC9mcmFnOmVmMGE3NzFkMWQxOTQ4MWZiZjY1ZDU4NDQ1ZmUyMjljL3RleHRyZWdpb246ZWYwYTc3MWQxZDE5NDgxZmJmNjVkNTg0NDVmZTIyOWNfNjA0Nw_2f2aaacd-efba-49df-8cae-1363bf24895f">three</span> to four years for non-employee director restricted stock awards.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option plan activity for 2021, 2020, and 2019 for all plans is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:26.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of<br/>Shares<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of<br/>Shares<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of<br/>Shares<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value for outstanding stock options was $69,711, $29,735 and $31,814 at December 31, 2021, 2020 and 2019, respectively, with a weighted average remaining contractual term of 6.4 years at December 31, 2021. Exercisable stock options at December 31, 2021 had an aggregate intrinsic value of 50,128 with a weighted average remaining contractual term of 5.3 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information pertaining to option activity during the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised ($000s)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information related to stock options outstanding under all plans at December 31, 2021 is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of Exercise<br/>Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares<br/>Outstanding<br/>(000s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/> Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/> Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>Exercisable<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.06 - $57.17</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$58.52 - $85.40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$91.56 - $120.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested restricted stock activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at beginning of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at end of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested performance share activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at beginning of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at end of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019, there was $13,980, $14,154 and $11,643, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2021, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.2 years. We estimate that share-based compensation expense for the year ended December 31, 2022 will be approximately $11,900.</span></div>REPURCHASE OF COMMON STOCKThe Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,818,244 shares have been purchased. The Company’s prior presentation of reflecting treasury stock separately within stockholders’ equity has been adjusted to conform to the presentation prescribed by the State of Maryland, where the Company is incorporated. In connection therewith, $7,873 of previously acquired treasury stock has been offset against additional paid-in capital and common stock in the consolidated balance sheet as of December 31, 2020. Corresponding adjustments to balances previously reflected as treasury stock of $7,873 and $18,069 for the years ended December 31, 2020 and 2019 were made to the consolidated statements of stockholders’ equity and prior references to “Treasury shares purchased” were updated to “Repurchases of common stock”, accordingly. There was no impact to total stockholders’ equity in any of the years presented as a result of these updates. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. During 2021, 2020, and 2019, the Company purchased 249,848, 136,629, and 240,995 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $141.04, $98.54, and $88.47 per share, respectively. <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s results for the years ended December 31, 2021, 2020 and 2019 reflected the following compensation cost and such compensation cost had the following effects on net earnings:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease) for the<br/>Year Ended, December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 845000 1115000 1147000 9957000 7188000 6449000 8370000 6332000 5884000 1 1600000 6000000 P10Y 703707 70 54000 P3Y Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:55.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Assumptions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.329 0.269 0.240 P4Y10M24D P3Y10M24D P4Y 0.005 0.013 0.025 0.005 0.005 0.006 0.002 0.014 0.025 0.006 0.005 0.005 0.33 0.24 0.24 0.117 0.109 -0.059 1 P3Y P4Y P3Y P4Y <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option plan activity for 2021, 2020, and 2019 for all plans is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:26.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of<br/>Shares<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of<br/>Shares<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of<br/>Shares<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 858000 80.58 951000 68.18 887000 61.59 129000 119.12 174000 111.75 197000 85.13 109000 63.42 256000 55.26 112000 43.67 10000 106.93 11000 92.94 17000 80.88 1000 74.57 0 0 4000 70.90 867000 88.19 858000 80.58 951000 68.18 538000 75.51 494000 69.04 581000 59.29 69711000 29735000 31814000 P6Y4M24D 50128000 P5Y3M18D Other information pertaining to option activity during the years ended December 31, 2021, 2020 and 2019 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised ($000s)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 33.11 24.36 18.51 7866000 12698000 6135000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information related to stock options outstanding under all plans at December 31, 2021 is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of Exercise<br/>Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares<br/>Outstanding<br/>(000s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/> Term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/> Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>Exercisable<br/>(000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.06 - $57.17</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$58.52 - $85.40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$91.56 - $120.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 29.06 57.17 26000 P2Y1M6D 47.26 26000 47.26 58.52 85.40 541000 P5Y6M 75.55 476000 74.37 91.56 120.60 300000 P8Y6M 114.46 36000 109.84 867000 P6Y4M24D 88.19 538000 75.51 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested restricted stock activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at beginning of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at end of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 159000 90.71 138000 80.03 79000 72.75 42000 123.58 46000 110.53 73000 85.69 24000 85.83 21000 67.60 8000 58.52 11000 90.49 4000 91.91 6000 84.65 166000 99.70 159000 90.71 138000 80.03 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested performance share activity for the years ended December 31, 2021, 2020 and 2019 is summarized below:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares (000s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at beginning of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested balance at end of year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 71000 91.99 70000 81.26 53000 75.61 36000 108.74 20000 126.46 33000 81.79 24000 70.64 8000 104.15 9000 65.54 14000 81.03 11000 82.71 7000 60.85 69000 110.72 71000 91.99 70000 81.26 13980000 14154000 11643000 P1Y2M12D 11900000 3763038 2818244 7873000 7873000 18069000 249848 136629 240995 141.04 98.54 88.47 INVENTORIES<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of reserves at December 31, 2021 and 2020 consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,620 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, the Company evaluates its inventory balances for excess quantities and obsolescence by analyzing demand, inventory on hand, sales levels and other information. Based on these evaluations, inventory balances are reserved, if necessary. The reserve for inventory was $1,425 and $2,782 at December 31, 2021 and 2020, respectively.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of reserves at December 31, 2021 and 2020 consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,620 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 28639000 24536000 10563000 3050000 51856000 43034000 91058000 70620000 1425000 2782000 PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment at December 31, 2021 and 2020 are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geographic Area Data - Long-Lived Assets (excluding intangible assets):</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,085 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $23,295, $22,990 and $19,791 for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div> 11692000 12215000 89602000 86873000 253995000 247884000 52930000 31240000 408219000 378212000 170702000 150116000 237517000 228096000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geographic Area Data - Long-Lived Assets (excluding intangible assets):</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,085 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 197432000 187719000 40085000 40377000 237517000 228096000 23295000 22990000 19791000 INTANGIBLE ASSETS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had goodwill in the amount of $523,949 and $529,463 as of December 31, 2021 and 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The decrease in goodwill is due to foreign exchange translation adjustments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had identifiable intangible assets as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:34.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization<br/>Period<br/>(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships &amp; lists</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-20</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks &amp; trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-17</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,116 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,208 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,974 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-18</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,921 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,624 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,330 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,403 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of identifiable intangible assets was $25,092, $27,811 and $25,789 for 2021, 2020 and 2019, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $23,641 in 2022, $19,566 in 2023, $10,682 in 2024, $6,413 in 2025, and $5,083 in 2026. At December 31, 2021 and 2020, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2021 and 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (the "EPA") because they are considered pesticides. Costs of such registrations are included as other in the table above.</span></div> 523949000 529463000 P10Y P20Y 240059000 173489000 243557000 158051000 P2Y P17Y 43116000 28985000 43208000 24974000 P5Y P12Y 20234000 14607000 21674000 13693000 P2Y P18Y 23921000 15584000 21624000 11685000 327330000 232665000 330063000 208403000 25092000 27811000 25789000 23641000 19566000 10682000 6413000 5083000 0 0 EQUITY-METHOD INVESTMENTIn 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant.  The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $557, $575, and $388 for the years ended December 31, 2021, 2020, and 2019, respectively, relating to its portion of the joint venture’s expenses in other expense. The carrying value of the joint venture at December 31, 2021 and 2020 was $4,499 and $4,971, respectively, and is recorded in other assets. 0.6666 0.3334 2 -557000 -575000 -388000 4499000 4971000 REVOLVING LOANOn June 27, 2018, the Company and a bank syndicate entered into the Credit Agreement, which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000.  The Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”).  The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion.  The initial proceeds from the Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. On May 23, 2019, the Company drew down $108,569 to fund the Chemogas acquisition. In connection with these additional borrowings, the Company entered into an interest rate swap to protect against adverse fluctuations in interest rates (see Note 20, "Derivative Instruments and Hedging Activities"). On December 13, 2019, the Company drew down $45,000 to fund the Zumbro acquisition. As of December 31, 2021, the total balance outstanding on the <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit Agreement amounted to $108,569. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the Credit Agreement plus an applicable rate.  The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the Credit Agreement, and the interest rate was 1.102% at December 31, 2021.  The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the Credit Agreement and ranges from 0.15% to 0.275% (0.15% at December 31, 2021).  The unused portion of the revolving loan amounted to $391,431 at December 31, 2021.  The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the Credit Agreement.  Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $421 and $703 at December 31, 2021 and 2020, respectively, and are included in other assets on the consolidated balance sheets. Amortization expense pertaining to these costs totaled $282 for each of the years ended December 31, 2021, 2020, and 2019, and is included in interest expense in the accompanying consolidated statements of earnings. </span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio.  At December 31, 2021, the Company was in compliance with these covenants.  Indebtedness under the Company’s loan agreements is secured by assets of the Company.</span></div> 350000000 100000000 500000000 210750000 108569000 45000000 108569000 0 0.01102 0.0015 0.00275 0.0015 391431000 421000 703000 282000 282000 282000 NET EARNINGS PER COMMON SHARE<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:55.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings - Basic and Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Share (000s)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Common Shares - Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Common Shares - Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,505 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings Per Share - Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings Per Share - Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares were 155,294, 204,672, and 12,250 for 2021, 2020, and 2019. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has some share-based payment awards that have non-forfeitable dividend rights. These awards are restricted shares and they participate on a one-for-one basis with holders of Common Stock. These awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:55.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings - Basic and Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Share (000s)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Common Shares - Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Common Shares - Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,505 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings Per Share - Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings Per Share - Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 96104000 84623000 79671000 32215000 32176000 32136000 457000 327000 369000 32672000 32503000 32505000 2.98 2.63 2.48 2.94 2.60 2.45 155294 204672 12250 1 INCOME TAXES<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s effective tax rate for 2021, 2020 and 2019 was 23.3%, 20.5%, and 17.4%, respectively. The increase from 2020 to 2021 is primarily due to a reduction in certain tax credits, lower tax benefits from stock-based compensation, and higher enacted state tax rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020 Congress passed the Coronavirus Aid, Relief, and Economic Security Act, and on December 31, 2020 Congress passed an additional round of COVID relief legislation as part of the Bipartisan-Bicameral Omnibus COVID Relief Deal. The Company has reviewed the change in law and determined that it does not have a significant impact on the Company’s tax provision or financial statements. In addition, Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the SEC, and/or the Financial Accounting Standards Board ("FASB") regarding this act. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and the Company's specific plans for reinvestment of those subsidiary earnings. The Company projects that its foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to its legal entity structure and the complexity of U.S. and local country tax laws. If the Company decides to repatriate the undistributed foreign earnings, it will need to recognize the income tax effects in the period it changes its assertion on indefinite reinvestment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax expense consists of the following:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,129 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,794 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,807 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2021, 2020, and 2019 to earnings before income tax expense due to the following:</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent Box Decree (related to prior years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Tax Credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,129 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,794 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,807 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock and stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,082 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency and interest rate swap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,690 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,112 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,872 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not the Company will not realize the benefits of these deductible differences. The amount of deferred tax asset realizable, however, could change if management’s estimate of future taxable income should change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company has state income tax net operating loss (NOL) carryforwards of $335. The state NOL carryforwards will expire between 2025 and 2034. The Company believes that the benefit from the state NOL carryforwards will be realized, therefore a valuation allowance is not required to be established on these assets. The Company also acquired an insignificant amount of NOL carryforwards with the acquisition of Chemogas. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers the undistributed earnings of certain non-U.S. subsidiaries to be indefinitely reinvested outside of the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and specific plans for reinvestment of those subsidiary earnings. The Company projects that foreign earnings will be utilized offshore for working capital and future foreign growth. The determination of the unrecognized deferred tax liability on those undistributed earnings is not practicable due to the Company's legal entity structure and the complexity of U.S. and local country tax laws. If Balchem decides to repatriate the undistributed foreign earnings, the income tax effects will need to be recognized in the period the Company changes its assertion on indefinite reinvestment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions of prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions related to current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2021, 2020 and 2019, these amounted to approximate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly $262, $232 and $132, respectively. As of December 31, 2021 and 2020, accrued interest and penalties were $2,106 and $1,845, respectivel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balchem files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2017 and management does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months.</span></div> 0.233 0.205 0.174 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax expense consists of the following:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,038)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,129 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,794 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,807 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25019000 19249000 17757000 7553000 3399000 1609000 3664000 3590000 818000 -3709000 -3017000 -3707000 -3038000 167000 67000 -360000 -1594000 263000 29129000 21794000 16807000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 21% for 2021, 2020, and 2019 to earnings before income tax expense due to the following:</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent Box Decree (related to prior years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Tax Credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,129 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,794 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,807 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 26299000 22348000 20260000 2406000 2288000 -244000 -924000 -1529000 -222000 0 0 2507000 1540000 1400000 1922000 0 0 1948000 0 0 1125000 2888000 87000 -499000 29129000 21794000 16807000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock and stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,082 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency and interest rate swap</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,690 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,112 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,872 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 495000 1470000 4082000 3862000 1807000 1641000 649000 2831000 3657000 3308000 10690000 13112000 28133000 32872000 25484000 27897000 733000 915000 1769000 1926000 1026000 731000 57145000 64341000 0 130000 46455000 51359000 335000 A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions of prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions related to current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>All of Balchem's unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate in such future periods. 5335000 4762000 5709000 806000 267000 431000 260000 391000 1978000 0 697000 600000 5881000 5335000 4762000 262000 232000 132000 2106000 1845000 SEGMENT INFORMATION<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently reports three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Previously, the Company's four reportable segments were: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products. However, effective in the first quarter of 2020, in order to align with the Company's strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, and given the 2019 reduction in portfolio scale of Industrial Products, the Company revised its reporting segment structure to three reportable segments stated above. These reportable segments are strategic businesses that offer products and services to different markets. This realignment has been retrospectively applied. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated" and applied retroactively to 2019. There were no changes to the Consolidated Financial Statements as a result of the change to the reportable segments. The Company expects that the new reportable segment structure will provide investors greater understanding of and alignment with the Company’s strategic focus. In order to ensure appropriate transparency and visibility into the financial performance of the Company, sufficient detail will continue to be provided relative to Other and Unallocated, including material contributions from oil and gas and other industrial market activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Nutrition &amp; Health</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Human Nutrition &amp; Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. HNH's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. When combined with its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Animal Nutrition &amp; Health</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Animal Nutrition &amp; Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, ANH’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a global marketplace.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Specialty Products</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Specialty Products' 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging, which are approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life.  First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment information is summarized as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,454 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,708 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,325 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment Net Sales</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,776 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,191 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,458 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,705 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment Earnings Before Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,233 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,417 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,478 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation/Amortization</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,039 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,080 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,790 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,264, $2,410 and $3,436 for years ended December 31, 2021, 2020 and 2019, respectively, and (ii) Unallocated amortization expense of $2,792, $1,888, and $833 for years ended December 31, 2021, 2020, and 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings. </span></div></td></tr></table> 3 4 3 5 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment information is summarized as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,454 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,708 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,325 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment Net Sales</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,776 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,191 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,458 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,705 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment Earnings Before Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,233 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,417 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,478 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation/Amortization</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Nutrition &amp; Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Nutrition &amp; Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,039 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and Unallocated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,080 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,790 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,264, $2,410 and $3,436 for years ended December 31, 2021, 2020 and 2019, respectively, and (ii) Unallocated amortization expense of $2,792, $1,888, and $833 for years ended December 31, 2021, 2020, and 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings. </span></div></td></tr></table> 727131000 717232000 158971000 157454000 184628000 190449000 128595000 100708000 1199325000 1165843000 442733000 400330000 347433000 226776000 192191000 177557000 117020000 103566000 92257000 12494000 7557000 26458000 799023000 703644000 643705000 76031000 61397000 48429000 26179000 29979000 25868000 30020000 26801000 28513000 -4728000 -7030000 -257000 -2269000 -4730000 -6075000 125233000 106417000 96478000 30012000 32117000 30558000 7414000 7187000 6552000 8332000 9699000 7401000 3121000 2278000 1351000 48879000 51281000 45862000 23714000 22758000 18159000 8100000 6039000 3921000 3804000 2860000 3003000 524000 423000 707000 36142000 32080000 25790000 1264000 2410000 3436000 2792000 1888000 833000 REVENUE<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to realize in exchange for those goods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,085 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bill and Hold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consignment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Sales Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,705 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by geography, based on the billing addresses of customers:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,033 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,705 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Revenues</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of four sub-streams: product sales, co-manufacturing, bill and hold, and consignment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials.  The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer.  Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenues</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,085 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bill and Hold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consignment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Sales Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,705 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by geography, based on the billing addresses of customers:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,033 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,705 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 762085000 666193000 609741000 27994000 29063000 24087000 0 1158000 3218000 4439000 2939000 2299000 794518000 699353000 639345000 4505000 4291000 4360000 799023000 703644000 643705000 584661000 516347000 475033000 214362000 187297000 168672000 799023000 703644000 643705000 4 SUPPLEMENTAL CASH FLOW INFORMATION<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the year for:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,547 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,666 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash financing activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the year for:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,547 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,666 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash financing activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25355000 22637000 21771000 4547000 4666000 5674000 20886000 18941000 16855000 ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss) were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change of cash flow hedge (see Note 20 for further information) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain/(loss) on cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in postretirement benefit plan (see Note 15 for further information)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service (credit)/cost and (gain)/loss arising during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit/(cost)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of gain/(loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss)/income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,166)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,962)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> One-time adjustment to the postretirement account.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in "Net foreign currency translation adjustment" were $4,766 of gain, $4,882 of loss, and $262 of loss, related to a net investment hedge, net of taxes of $1,527, $1,579, and $70, for the years ended December 31, 2021, 2020, and 2019, respectively. See Note 20, "Derivative Instruments and Hedging Activities."</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive (loss)/income at December 31, 2021 consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement benefit plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,653 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,684)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss)/gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,602)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,631)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,993)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss) were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change of cash flow hedge (see Note 20 for further information) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain/(loss) on cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in postretirement benefit plan (see Note 15 for further information)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service (credit)/cost and (gain)/loss arising during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit/(cost)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of gain/(loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss)/income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,166)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,962)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> One-time adjustment to the postretirement account.</span></div> -11255000 12829000 -891000 2707000 -3094000 -1771000 654000 -809000 -372000 2053000 -2285000 -1399000 4000 503000 -199000 -74000 -74000 -74000 -21000 -50000 -46000 49000 -479000 227000 13000 -127000 -101000 0 -455000 0 36000 -807000 328000 -9166000 9737000 -1962000 4766000 -4882000 -262000 -1527000 -1579000 -70000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive (loss)/income at December 31, 2021 consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement benefit plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,653 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,684)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss)/gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,602)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,631)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,993)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7653000 -3684000 204000 4173000 -11255000 2053000 36000 -9166000 -3602000 -1631000 240000 -4993000 EMPLOYEE BENEFIT PLANS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. The Company provided for profit sharing contributions and matching 401(k) savings plan contributions of $1,459 and $4,142 in 2021, $1,022 and $3,751 in 2020, and $592 and $3,451 in 2019, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Postretirement Medical Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona, Missouri facility and a plan for those named as executive officers in the Company’s proxy statement. The Company uses a December 31 measurement date for its postretirement medical plans. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in benefit obligation:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial adoption of new plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer (reimbursement)/contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in consolidated balance sheet:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated postretirement benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued postretirement benefit cost (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future employer contributions and benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years 2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contributes to one multiemployer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona, Missouri facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company was to stop participating in its multiemployer plan, the Company would be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s participation in this plan for the annual period ended December 31, 2021 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2021 and 2020 was affected by a 4.0% increase in the 2021 contribution rate. There have been no other significant changes that affect the comparability of 2021 and 2020 contributions. The Company does not represent more than 5% of the contributions to this pension fund.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension<br/>Fund</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EIN/Pension<br/>Plan<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plan Protection Act Zone Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FIP/RP Status<br/>Pending/ Implemented</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions of Balchem Corporation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surcharge<br/>Imposed</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration Date of Collective-<br/>Bargaining<br/>Agreement</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central States,<br/>Southeast and<br/>Southwest Areas<br/>Pension Fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36-6044243</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical &amp; Declining as of 1/1/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical &amp; Declining as of 1/1/20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implemented</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$816</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$774</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$677</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/12/2025</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial recorded liabilities for such unfunded defined benefit pension plan are as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in benefit obligation:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer (reimbursement)/contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in consolidated balance sheet:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net (gain)/loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued postretirement benefit cost (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years 2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions to determine benefit obligations:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions to determine net cost:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company established an unfunded, non-qualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of December 31, 2021 and 2020 was $6,270 and $3,581, respectively, and was included in other long-term obligations on the Company's balance sheet. The related rabbi trust assets were $6,267 and $3,582 as of December 31, 2021 and 2020, respectively, and were included in other non-current assets on the Company's consolidated balance sheets.</span></div> 2 1 1459000 4142000 1022000 3751000 592000 3451000 2 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial recorded liabilities for such unfunded postretirement benefits are as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in benefit obligation:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial adoption of new plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in benefit obligation:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions to determine benefit obligations:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 1374000 1076000 0 0 87000 68000 23000 26000 28000 23000 426000 27000 -207000 -208000 1293000 1374000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer (reimbursement)/contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in plan assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer (reimbursement)/contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 398000 4000 28000 23000 426000 27000 0 0 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in consolidated balance sheet:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated postretirement benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued postretirement benefit cost (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in consolidated balance sheet:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net (gain)/loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued postretirement benefit cost (included in other long-term obligations)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div> 1293000 1374000 0 0 -1293000 -1374000 74000 74000 50000 46000 1293000 1374000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost with interest to end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions to determine net cost:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div> 87000 68000 63000 23000 26000 39000 -74000 -74000 -74000 24000 50000 46000 160000 118000 130000 <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future employer contributions and benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years 2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future benefit payments are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years 2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 107000 91000 113000 91000 76000 479000 1 The Company’s participation in this plan for the annual period ended December 31, 2021 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone or critical and declining zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2021 and 2020 was affected by a 4.0% increase in the 2021 contribution rate. There have been no other significant changes that affect the comparability of 2021 and 2020 contributions. The Company does not represent more than 5% of the contributions to this pension fund.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension<br/>Fund</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EIN/Pension<br/>Plan<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plan Protection Act Zone Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FIP/RP Status<br/>Pending/ Implemented</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions of Balchem Corporation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surcharge<br/>Imposed</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration Date of Collective-<br/>Bargaining<br/>Agreement</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central States,<br/>Southeast and<br/>Southwest Areas<br/>Pension Fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36-6044243</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical &amp; Declining as of 1/1/21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical &amp; Declining as of 1/1/20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implemented</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$816</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$774</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$677</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/12/2025</span></td></tr></table> 0.040 0.040 816000 774000 677000 2053000 1738000 67000 104000 14000 20000 24000 21000 18000 11000 127000 -18000 -154000 163000 1859000 2053000 1103000 895000 76000 57000 73000 57000 24000 21000 18000 11000 -83000 84000 1175000 1103000 1859000 2053000 1175000 1103000 -684000 -950000 684000 950000 67000 104000 0 14000 20000 0 34000 14000 0 0 0 0 -3000 0 0 50000 110000 0 1000 0 0 0 0 22000 0.0100 0.0075 0.0075 0.0100 0.0325 0.0100 6270000 3581000 6267000 3582000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2021 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.999%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation was conducted by the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site. In September 2020, BCP Ingredients, Inc. (“BCP”), the Company subsidiary that operates the site received a General Notice Letter from the EPA regarding BCP’s potential liability for contamination at the site and, in February 2022, received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study at the site with regard to the presence of certain contaminants, including 1,4 dioxane,. The Company has engaged experts to study site conditions and hydrogeology in connection with preparing its response to the notices. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various litigation, claims and assessments.  Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate future minimum rental payments required under non-cancelable operating and finance leases at December 31, 2021 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.999%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 2900000 2139000 1891000 1066000 700000 2428000 11124000 FAIR VALUE OF FINANCIAL INSTRUMENTS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2021 and 2020 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio.  The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2021 and 2020 included $933 and $817 in money market funds, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets at December 31, 2021 and 2020 included $6,267 and $3,582, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in derivative assets or derivative liabilities, in the consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The derivative liability related to the cross-currency swap was $500 and $6,793 at December 31, 2021 and 2020, respectively. The derivative liability related to the interest rate swap was $2,158 and $4,865 at December 31, 2021 and 2020, respectively.</span></div> 933000 817000 6267000 3582000 500000 6793000 2158000 4865000 RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides services on a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The services the Company provided amounted to $3,637, $3,396, and $3,883, respectively, for the years ended December 31, 2021, 2020, and 2019. The raw materials purchased and subsequently sold amounted to $27,915, $13,495, and $24,786, respectively, for the years ended December 31, 2021, 2020, and 2019. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $22,043, $12,190, and $18,598, respectively for the years ended December 31, 2021, 2020, and 2019. At December 31, 2021 and 2020, the Company had receivables of $10,504 and $2,809, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold and payables of $7,552 and $2,239, respectively, for finished goods received recorded in accounts payable in 2021 and 2020. In addition, the Company had receivables in the amount of $164 and $72 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of December 31, 2021 and 2020. The </span></div>Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of December 31, 2021 and 2020. 3637000 3396000 3883000 27915000 13495000 24786000 22043000 12190000 18598000 10504000 2809000 7552000 2239000 164000 72000 296000 296000 LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the ROU asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2021. In addition, the Company has historically not been exercising purchase options with equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with a new lease. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Zumbro, the Company assumed a finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_1b9d908f-2944-424c-9f67-890f3088f321"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_5f7a5c94-b14e-464e-b8f7-6c1271aea442"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_aece5c3b-1b50-48a3-8304-c996365b0124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_ca4ea1ce-0155-48c1-a679-0d2dca684c56">Right of use assets</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_5446c1ae-16b9-4c90-ba59-01e61ca8caf1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_c4028ca6-9c3b-489f-af89-61d08b36ee6c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_de4b2810-e20f-4d42-bd8f-d22e19c69a3c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_ea319ab9-7d50-4d84-bd52-ff1e68e5b791">Lease liabilities - current</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_a3e36b3d-1a47-4ed2-aaec-338da92c239a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_aad47175-80e8-4eb1-b060-4dc3a7a80512"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_e2cf108f-908f-400c-930b-64c864e461cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_ff76a161-4de5-4de1-a40b-478c9dfe1121">Lease liabilities - non-current</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.41 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div>Rent expense charged to operations under operating lease agreements for 2021, 2020, and 2019 aggregated approximately $3,143, $3,105, and $3,181, respectively. LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the ROU asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from December 31, 2021. In addition, the Company has historically not been exercising purchase options with equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with a new lease. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Zumbro, the Company assumed a finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_1b9d908f-2944-424c-9f67-890f3088f321"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_5f7a5c94-b14e-464e-b8f7-6c1271aea442"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_aece5c3b-1b50-48a3-8304-c996365b0124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_ca4ea1ce-0155-48c1-a679-0d2dca684c56">Right of use assets</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_5446c1ae-16b9-4c90-ba59-01e61ca8caf1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_c4028ca6-9c3b-489f-af89-61d08b36ee6c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_de4b2810-e20f-4d42-bd8f-d22e19c69a3c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_ea319ab9-7d50-4d84-bd52-ff1e68e5b791">Lease liabilities - current</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_a3e36b3d-1a47-4ed2-aaec-338da92c239a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_aad47175-80e8-4eb1-b060-4dc3a7a80512"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_e2cf108f-908f-400c-930b-64c864e461cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_ff76a161-4de5-4de1-a40b-478c9dfe1121">Lease liabilities - non-current</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.41 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div>Rent expense charged to operations under operating lease agreements for 2021, 2020, and 2019 aggregated approximately $3,143, $3,105, and $3,181, respectively. 4 P1Y P2Y 0.0145 P3Y P4Y 0.0204 P5Y P9Y 0.0238 P10Y 0.0310 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets and lease liabilities at December 31, 2021 and 2020 are summarized as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_1b9d908f-2944-424c-9f67-890f3088f321"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_5f7a5c94-b14e-464e-b8f7-6c1271aea442"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_aece5c3b-1b50-48a3-8304-c996365b0124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpiODdhNDA0NWRmZDE0ODZiOGZhYzM3ZGI2MjJmMGYwNy90YWJsZXJhbmdlOmI4N2E0MDQ1ZGZkMTQ4NmI4ZmFjMzdkYjYyMmYwZjA3XzAtMC0xLTEtMjExODc_ca4ea1ce-0155-48c1-a679-0d2dca684c56">Right of use assets</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_5446c1ae-16b9-4c90-ba59-01e61ca8caf1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_c4028ca6-9c3b-489f-af89-61d08b36ee6c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_de4b2810-e20f-4d42-bd8f-d22e19c69a3c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZTpkY2ZmZGQzZDMzY2Q0MjM0ODA4YTYxYjA2YThjMDU4ZC90YWJsZXJhbmdlOmRjZmZkZDNkMzNjZDQyMzQ4MDhhNjFiMDZhOGMwNThkXzAtMC0xLTEtMjExOTA_ea319ab9-7d50-4d84-bd52-ff1e68e5b791">Lease liabilities - current</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_a3e36b3d-1a47-4ed2-aaec-338da92c239a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_aad47175-80e8-4eb1-b060-4dc3a7a80512"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_e2cf108f-908f-400c-930b-64c864e461cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJjNGJmZmM4MjNlZjRmNjA4YTM2ZDRhYzg4YjI4NWUxL3NlYzoyYzRiZmZjODIzZWY0ZjYwOGEzNmQ0YWM4OGIyODVlMV8xNDIvZnJhZzo5NjE3ZTcyOWJjZTA0MzM3OWM1YzY0NmI0Y2Y4YTFhOS90YWJsZToyOTAzMjUxYzMyM2Y0ZTg5YjZkZWY1OGQ3NTAzNDNmMi90YWJsZXJhbmdlOjI5MDMyNTFjMzIzZjRlODliNmRlZjU4ZDc1MDM0M2YyXzAtMC0xLTEtMjExOTM_ff76a161-4de5-4de1-a40b-478c9dfe1121">Lease liabilities - non-current</span></span></span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.41 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div> 6929000 5838000 2359000 2572000 9288000 8410000 2194000 2178000 167000 159000 2361000 2337000 4811000 3607000 2303000 2472000 7114000 6079000 3143000 3105000 3181000 210000 210000 0 129000 137000 0 339000 347000 0 3482000 3452000 3181000 3097000 2864000 3216000 129000 137000 0 159000 151000 0 3385000 3152000 3216000 3804000 1042000 10173000 0 2782000 0 P4Y2M15D P4Y1M24D P4Y11M4D P11Y4M28D P12Y3M 0.035 0.045 0.046 0.051 0.051 3143000 3105000 3181000 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with the Swap Counterparty and a cross-currency swap (net investment hedge) with the Bank Counterparty. The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. The net interest expense related to the interest rate swap contract were $2,144 and $1,593 for the year ended December 31, 2021 and 2020. The </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net interest income related to the interest rate swap contract was $40 for the year ended December 31, 2019. These amounts were recorded in the consolidated statements of operations under interest expense, net. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $2,257, $2,275, and $1,317 for the years ended December 31, 2021, 2020, and 2019, respectively, which were recorded in the consolidated statements of operations under interest expense, net. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,658 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the year ended December 31, 2021, 2020, and 2019:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location within Statements of Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge (interest rate swap), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on cash flow hedge, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge (cross-currency swap), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,819 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,167)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0205 108569000 -2144000 -1593000 40000 0.0000 0.0205 108569000 2257000 2275000 1317000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the fair value of the derivative instruments is presented as follows in the Company's consolidated balance sheets:</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,658 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2158000 4865000 500000 6793000 2658000 11658000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the year ended December 31, 2021, 2020, and 2019:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.278%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location within Statements of Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge (interest rate swap), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on cash flow hedge, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge (cross-currency swap), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,819 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,167)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2053000 -2285000 -1399000 4766000 -4882000 -262000 6819000 -7167000 -1661000 QUARTERLY FINANCIAL INFORMATION (UNAUDITED)<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:26.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:26.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 185656000 202365000 197869000 213133000 174436000 173355000 175140000 180713000 58727000 59447000 60934000 64066000 55331000 55380000 56368000 56818000 29983000 30019000 32085000 33146000 24490000 25973000 27907000 28047000 23411000 22731000 25013000 24949000 19768000 21125000 21568000 22162000 0.73 0.71 0.78 0.78 0.62 0.66 0.67 0.69 0.72 0.70 0.77 0.76 0.61 0.65 0.66 0.68 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance <br/>for Doubtful Accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory <br/>Reserve</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions charged (credited) to costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments/deductions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,080</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions charged (credited) to costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments/deductions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions charged (credited) to costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments/deductions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents write-offs and other adjustments</span></div></td></tr></table> 610000 2575000 1776000 7069000 306000 5363000 2080000 4281000 140000 5964000 128000 7463000 2092000 2782000 180000 7312000 1344000 8669000 928000 1425000 EXCEL 119 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

UCJ;Q.8ZW(U]N1@;+ MR!]4'66(V?2PV;6L]7[1PVSDV6$7;^-XE:^R-N4_ZX4LR53E>E\N MF@WS*,F[(E:Y)"?O556=(N[GA]UK9[G>,VWY$.OP&\$E2=KLN2@C5U&:G.DB M3Z-E.JC56$_T;K9A-]O0.G%01+GG MN)VOO2*Q79'8_RS2B9Z$:A&5LCH]IF#SC7_>BXL!>!R< (_,W47FMI;,$IE> MF)H>E0Y(A]!>G3:;$-VH_URK+".Z^ZZC,OGWP-KQ=H-[!\ORA\:I0J'*HS^P=BOY7)5Q@N]<%O" MQ)M.65DZY:4_#!,H V.US/UA1Z'<2 5WY7AX/L$NG^![\^DW#:Q'!$A KA,$ MEHBHTP'=.1C333LFT5 F:MF0I")I5:TTZT[BIIME,CDEJT(WBVV@2]WD<'X[ M@Q@IN,SH^_.M;*\-,Z/\N"NP)=O[]4*_,]E!AM^:D.U(>R'Z7#C,$F/'7'H8 MNO,B.4#< *T\#-NDRS@W]S&B\P(G,'?(#-&=>1YWS9G$J.OZYEP.G5&/4V[! M+NVX2P^#URC4 >IB19M3%+M:3(4ELHZ[]"> EW;DI4]#+QWRTG"D8 MPY"@ *XPIP"&,#9I$.*N/$O_A@[&\&(PAB&,F2,8L\ 8>@?@)\ 8'+3R0][Y MX ,SVRNBXQX7KF/T+43GTN%$8BSFCCF5"(NYU]?MUZEC,3P3B]&:S0%C,1/ M>XMQ/[*.Q? 36 P=B^%I+(8A/0-.!]W_.%F(R&Q3V[$8GI/%@!QS \JYN:B/ MDH6(S)9/1V-X HT!H2PXPN'F?!RG"Q&=+8&.QO"L- :$H,P#%I@=!#L7FS^/ M+,[ !H,.Q_##< SHV3CP>R>1_3_V.ARSE\(Q0PZT0OCF'##D;&SB&'LZ3FV>+O47F? MZA62R3MMZKP6.K=R\[AN>^;9"MT"SM&%;6 /^;%;:1G10*7@-TG EB89R'CQ$]\O$ MX3W@%X?6G,R)ZV2CU,X%3\4\"%U!("!'I\#L<( %".&$;!DOO68PI'3$T_E1 M_9OOW?:R80862OSF!5;S8!:0 DJV%_BLVN_0]S-Q>KD2QG])VV>X#D>X.J M[LFV@IK+;F2OO0\GA&A\@1#WA/A:0M(3DFL)XYXP]LYTK7@?E@Q9EFK5$NW0 M5LU-O)F>;=OGTAW[&K7=Y9:'V4))HP0O&$)!UF@'>Z9HB"IMI/)=I40!VGPD M7U_V'-_(S8II"Z@ ><[$+?E,/A!*3&5734K15N1T:=YG?^RRQQ>R+R$?D23Z M1.(PCL[0%]?3PS/TY=7TZ,M[.K4V#E[&@Y>QUTLNZ WV773OS\/&H+9W_>]_ MTB5#NL2G&U\JGQ]X ;(PY(9+4B@AF#:D =T=Q^VYX^@49U[1O0B'+!S=C5-Z M.#7]'&@R>P]:G@7% ZCKB)Y<3/>*_&!ZRZ4A DI+"T?324!T]V=V :K&W]6- M0GOS_;2RCQEH![#[I5)X#-SU'Y['[!]02P,$% @ .4]85)];5UHL" MO2( !D !X;"]W;W)K&ULE5I=<^,H%OTK*M<\ M=%=-V@+TV96D*AW/[/;#S*8ZV[O/LH1CMF7A 9RDY]?O!2F6#5=*\I)8\@%Q M+I=[#EB73U+]T%O.3?2\:SM]M=@:L_^\7.IZRW>5_B3WO(-O-E+M*@.7ZF&I M]XI7C6NT:Y^#TWW_=W"JZ6QUX:L>.=%K*+%-]<+6[(YU42VP8.\1_! MG_3)Y\A264OYPUY\;:X6L1T1;WEM;!<5_'ODM[QM;4\PCK^&3A?'9]J&IY]? M>O_=D0[4H%E'#-]6A-=_DTS_Y0"BU_=6RU>YO]#1@XT54 M'[21NZ$QC& GNOY_]3P$XJ0!R28:T*$!]1LD$PW8T("]M4$R-$A<9'HJ+@ZK MRE37ETH^1EO7PO"_] M\^C$\PB-_I"=V>KHMZ[AS7D'2QC\D0%]8?"%SO:XXO6GB)%?(QI3@@SH]NW- M8Z3YZLW-23G#AAWG@[G^V-1\V*!O7- W2NXB6."J,J)[Z%>(,(+KSS//28[/ M2=QSDHGG_ DEA5>J@Y[16>Q;IZZUK1V/UV5&XN1R^7@:VA!5)!EEYZA5B,K+ M+"='U!F!]$@@G0W43?,_6!U]LAH)):B672U:'G4GS.PW]KJV4=TK^2@@YZ+U MSW>'-3N.*IL-ZXI#]:U%U=>TKHFJG51&_.UN8''NN\M.8I,415YZ<0Y1*:$% M\>*,])46&<7CG!\9Y;.,[HVL?T2UW('2Z)X7?[:?.48G#X9 XB*F'IT05;#8 MSYH0E*=EAI,ICF2*5Z9GPY6"%! =,.*1J9XYFOY%\/"+M$S\]$=0D/ZY1P1! ML31C.)/RR*2<97)GD]F)+VA_U,C#VFP.+61S+0^P)#!.93@W1>PQ0C")AUDA MF#R?F!@2CSH4SQ+ZWH%M:<7?,#D?'L"O?%RV4H,..8*@WAVH(4Q=5_^,C*H@ M%9UOT&Z1-2_3>IJFJ#;%R%P4_K0B*)+[Z8F \HFE1D[$F,P&X49KJ%9BMZ^$ MLJ4MJK>5>D!7VM#3V2"S//6I(*B2I#X7!'4Z[^=LZ,B&SK+Y\(^S>6R$WDM= MM=9;5)8H;A]H.$4DIX5/+(21-)@CI"]&6#)!;-1H\HI(;ZON@6MKA7HB+@M; M4:U%ZZ3D5ZO&^&56Y5CXO':MWB*9*$ M]&F"D>6I^S(+'O,FX1 M'&%E8$:P[FRR3]@1,BH_F9?^.\5AV38OZMCGA#1;KH;*9>:R/M3NB\(7^%L, M18LT\RDB1B#/)_B-/H#,&X%CTNVKGS;C>GM3U^K 1](HMU#)DSS.?0&9-P9?7_$#)!3Q)"\""B&*%&FPCC!SD653'$9'0.8MP;]L MKJQ0["Z0?0Y6%/_80!*OGI#J?;^%&]:?SZO_G6TTZQH\B>IW%*?%U'<.E M<5)ZN!6&HTF2390(.LH[)>_:W FH?/H=NQ Z2B^=E][;:B\,2*U;EXTP!S44 M)-$9T"[AUN\@78-$H9'%!#1/$G]_@N)8X:OV"L/1(B$3&D)'1:;L%;XV=VSY MM7;84=+"&<2C%+OTFB7+@L'Y:^1UR J!7)"$Q%/[,#JJ/IU7?;#\->?-D#M@ MI+BEM3YHP.E^=J<%AH;BS8AOJA"07^-6"(:0=,H%T-$%T'D7<,Y.=/J@K&%" MN2!*7S!?+!%4,%DI7_$@>%( MFE&:3E <'0 MWE6;-Z*#_'M';1YUFKZZ=3_)=,4?9?MHG]/*"MVTTE!STSB, M("+?<0!;8; ,+&2)QX^-"L[F%?Q."0C7'C0'_.%PAMR]@1U#MN19./!;#%>& M<5AAN#R;7 -L%&\VOS?'"?9IPJ.65_B)& OWUI"QOH#B*#_[$=04K=$IL'FG M$-"*W*\QP[:UX6N#L@J%/)BP5R$K! )[_32;J,#LY!!]W@YX4NF.,.6^/S#B MSUS50N,>@(7JG96)O]5$4"#QJ7^L@L"2@DVMM-$'L'D?L!+6(7>-=H8'98%L MZ$F1!UMF%)?E<4 $PZ6$311=-HH^FQ?];WP_:*7NQ7*W@^QS\X7R0O;N#+Q' ML)JP/3Y+,O\L ,-1PNB$T6>C V#S#N"HEQ\&P?QXMK'!M 7EB\HY);EOW' @ M(9F_M4& "1CUJ8D<#0*;-PB_;3:\=C:;/]?N="R"K1N/ZN&D#&;5Q@,EB4AZ MPK* (G** +L\GQ_2&<1K@MYH#MBKQP/*%GAK??I]!)AM]X%#H7P$*SYQYLZP M$X$L)(?!BN $#H.1))XX.6"C(V'SCN1VBE*TY@^BLS^EV:F%[;B0>,$)7461 MI+EOR1%8!M7>/^-!8&E"LXE#AF2T*,F\19FFR>U1W1S!H>?3WS!)S,+*@^"0 M0*P0V'D@>H;+D]_U=UP]N/O_ U!+ P04 " Y3UA418!+K4(E #Y

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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 121 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 122 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 313 572 1 false 84 0 false 11 false false R1.htm 0001001 - Document - Cover Sheet http://balchem.com/role/Cover Cover Cover 1 false false R2.htm 0002002 - Document - Audit Information Sheet http://balchem.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 1001003 - Statement - Consolidated Balance Sheets Sheet http://balchem.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Uncategorized 3 false false R4.htm 1002004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Cover 4 false false R5.htm 1003005 - Statement - Consolidated Statements of Earnings Sheet http://balchem.com/role/ConsolidatedStatementsofEarnings Consolidated Statements of Earnings Statements 5 false false R6.htm 1004006 - Statement - Consolidated Statements of Comprehensive Income Sheet http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 6 false false R7.htm 1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical Consolidated Statements of Comprehensive Income (Parenthetical) Statements 7 false false R8.htm 1006008 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 8 false false R9.htm 1007009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://balchem.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 9 false false R10.htm 1008010 - Statement - Consolidated Statements of Cash Flows Sheet http://balchem.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 10 false false R11.htm 2101101 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 11 false false R12.htm 2108102 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES Sheet http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURES SIGNIFICANT ACQUISITIONS AND DIVESTITURES Notes 12 false false R13.htm 2112103 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://balchem.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 2121104 - Disclosure - INVENTORIES Sheet http://balchem.com/role/INVENTORIES INVENTORIES Notes 14 false false R15.htm 2124105 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://balchem.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 15 false false R16.htm 2129106 - Disclosure - INTANGIBLE ASSETS Sheet http://balchem.com/role/INTANGIBLEASSETS INTANGIBLE ASSETS Notes 16 false false R17.htm 2132107 - Disclosure - EQUITY-METHOD INVESTMENT Sheet http://balchem.com/role/EQUITYMETHODINVESTMENT EQUITY-METHOD INVESTMENT Notes 17 false false R18.htm 2134108 - Disclosure - REVOLVING LOAN Sheet http://balchem.com/role/REVOLVINGLOAN REVOLVING LOAN Notes 18 false false R19.htm 2136109 - Disclosure - NET EARNINGS PER COMMON SHARE Sheet http://balchem.com/role/NETEARNINGSPERCOMMONSHARE NET EARNINGS PER COMMON SHARE Notes 19 false false R20.htm 2139110 - Disclosure - INCOME TAXES Sheet http://balchem.com/role/INCOMETAXES INCOME TAXES Notes 20 false false R21.htm 2146111 - Disclosure - SEGMENT INFORMATION Sheet http://balchem.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 21 false false R22.htm 2153112 - Disclosure - REVENUE Sheet http://balchem.com/role/REVENUE REVENUE Notes 22 false false R23.htm 2156113 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Sheet http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATION SUPPLEMENTAL CASH FLOW INFORMATION Notes 23 false false R24.htm 2159114 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME Sheet http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME ACCUMULATED OTHER COMPREHENSIVE INCOME Notes 24 false false R25.htm 2163115 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 25 false false R26.htm 2172116 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://balchem.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 26 false false R27.htm 2175117 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 27 false false R28.htm 2177118 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://balchem.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 28 false false R29.htm 2179119 - Disclosure - LEASES Sheet http://balchem.com/role/LEASES LEASES Notes 29 false false R30.htm 2184120 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Sheet http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Notes 30 false false R31.htm 2189121 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) Sheet http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) Notes 31 false false R32.htm 2192122 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS Sheet http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTS VALUATION AND QUALIFYING ACCOUNTS Notes 32 false false R33.htm 2202201 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 33 false false R34.htm 2303301 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 34 false false R35.htm 2309302 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables) Sheet http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESTables SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables) Tables http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURES 35 false false R36.htm 2313303 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://balchem.com/role/STOCKHOLDERSEQUITY 36 false false R37.htm 2322304 - Disclosure - INVENTORIES (Tables) Sheet http://balchem.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://balchem.com/role/INVENTORIES 37 false false R38.htm 2325305 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://balchem.com/role/PROPERTYPLANTANDEQUIPMENT 38 false false R39.htm 2330306 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://balchem.com/role/INTANGIBLEASSETSTables INTANGIBLE ASSETS (Tables) Tables http://balchem.com/role/INTANGIBLEASSETS 39 false false R40.htm 2337307 - Disclosure - NET EARNINGS PER COMMON SHARE (Tables) Sheet http://balchem.com/role/NETEARNINGSPERCOMMONSHARETables NET EARNINGS PER COMMON SHARE (Tables) Tables http://balchem.com/role/NETEARNINGSPERCOMMONSHARE 40 false false R41.htm 2340308 - Disclosure - INCOME TAXES (Tables) Sheet http://balchem.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://balchem.com/role/INCOMETAXES 41 false false R42.htm 2347309 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://balchem.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://balchem.com/role/SEGMENTINFORMATION 42 false false R43.htm 2354310 - Disclosure - REVENUE (Tables) Sheet http://balchem.com/role/REVENUETables REVENUE (Tables) Tables http://balchem.com/role/REVENUE 43 false false R44.htm 2357311 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Sheet http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Tables http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATION 44 false false R45.htm 2360312 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Sheet http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Tables http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME 45 false false R46.htm 2364313 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSTables EMPLOYEE BENEFIT PLANS (Tables) Tables http://balchem.com/role/EMPLOYEEBENEFITPLANS 46 false false R47.htm 2373314 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://balchem.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://balchem.com/role/COMMITMENTSANDCONTINGENCIES 47 false false R48.htm 2380315 - Disclosure - LEASES (Tables) Sheet http://balchem.com/role/LEASESTables LEASES (Tables) Tables http://balchem.com/role/LEASES 48 false false R49.htm 2385316 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) Sheet http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) Tables http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES 49 false false R50.htm 2390317 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables) Sheet http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDTables QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables) Tables http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITED 50 false false R51.htm 2404401 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 51 false false R52.htm 2405402 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details) Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details) Details 52 false false R53.htm 2406403 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details) Details http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 53 false false R54.htm 2407404 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details) Sheet http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details) Details 54 false false R55.htm 2410405 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details) Sheet http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details) Details 55 false false R56.htm 2411406 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 56 false false R57.htm 2414407 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details) Details 57 false false R58.htm 2415408 - Disclosure - STOCKHOLDERS' EQUITY - Stock-based Compensation (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails STOCKHOLDERS' EQUITY - Stock-based Compensation (Details) Details 58 false false R59.htm 2416409 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details) Details 59 false false R60.htm 2417410 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Details 60 false false R61.htm 2418411 - Disclosure - STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details) Details 61 false false R62.htm 2419412 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details) Details 62 false false R63.htm 2420413 - Disclosure - STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) Sheet http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) Details 63 false false R64.htm 2423414 - Disclosure - INVENTORIES (Details) Sheet http://balchem.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://balchem.com/role/INVENTORIESTables 64 false false R65.htm 2426415 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) Sheet http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) Details 65 false false R66.htm 2427416 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) Sheet http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details) Details 66 false false R67.htm 2428417 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Sheet http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Details 67 false false R68.htm 2431418 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://balchem.com/role/INTANGIBLEASSETSDetails INTANGIBLE ASSETS (Details) Details http://balchem.com/role/INTANGIBLEASSETSTables 68 false false R69.htm 2433419 - Disclosure - EQUITY-METHOD INVESTMENT (Details) Sheet http://balchem.com/role/EQUITYMETHODINVESTMENTDetails EQUITY-METHOD INVESTMENT (Details) Details http://balchem.com/role/EQUITYMETHODINVESTMENT 69 false false R70.htm 2435420 - Disclosure - REVOLVING LOAN (Details) Sheet http://balchem.com/role/REVOLVINGLOANDetails REVOLVING LOAN (Details) Details http://balchem.com/role/REVOLVINGLOAN 70 false false R71.htm 2438421 - Disclosure - NET EARNINGS PER COMMON SHARE (Details) Sheet http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails NET EARNINGS PER COMMON SHARE (Details) Details http://balchem.com/role/NETEARNINGSPERCOMMONSHARETables 71 false false R72.htm 2441422 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://balchem.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 72 false false R73.htm 2442423 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Details) Sheet http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails INCOME TAXES - Components of Income Tax Expense (Details) Details 73 false false R74.htm 2443424 - Disclosure - INCOME TAXES - Effective Income Tax Reconciliation (Details) Sheet http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails INCOME TAXES - Effective Income Tax Reconciliation (Details) Details 74 false false R75.htm 2444425 - Disclosure - INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) Sheet http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details) Details 75 false false R76.htm 2445426 - Disclosure - INCOME TAXES - Income Tax Uncertainties (Details) Sheet http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails INCOME TAXES - Income Tax Uncertainties (Details) Details 76 false false R77.htm 2448427 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://balchem.com/role/SEGMENTINFORMATIONNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 77 false false R78.htm 2449428 - Disclosure - SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details) Sheet http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details) Details 78 false false R79.htm 2450429 - Disclosure - SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details) Sheet http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details) Details 79 false false R80.htm 2451430 - Disclosure - SEGMENT INFORMATION - Depreciation/Amortization (Details) Sheet http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails SEGMENT INFORMATION - Depreciation/Amortization (Details) Details 80 false false R81.htm 2452431 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details) Sheet http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails SEGMENT INFORMATION - Capital Expenditures (Details) Details 81 false false R82.htm 2455432 - Disclosure - REVENUE (Details) Sheet http://balchem.com/role/REVENUEDetails REVENUE (Details) Details http://balchem.com/role/REVENUETables 82 false false R83.htm 2458433 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details) Sheet http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails SUPPLEMENTAL CASH FLOW INFORMATION (Details) Details http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables 83 false false R84.htm 2461434 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details) Details 84 false false R85.htm 2462435 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive Income (Loss) (Details) Details 85 false false R86.htm 2465436 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails EMPLOYEE BENEFIT PLANS - Narrative (Details) Details 86 false false R87.htm 2466437 - Disclosure - EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details) Details 87 false false R88.htm 2467438 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details) Details 88 false false R89.htm 2468439 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) Details 89 false false R90.htm 2469440 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details) Details 90 false false R91.htm 2470441 - Disclosure - EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details) Details 91 false false R92.htm 2471442 - Disclosure - EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details) Sheet http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details) Details 92 false false R93.htm 2474443 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments (Details) Sheet http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments (Details) Details 93 false false R94.htm 2476444 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS 94 false false R95.htm 2478445 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://balchem.com/role/RELATEDPARTYTRANSACTIONS 95 false false R96.htm 2481446 - Disclosure - LEASES - Narrative (Details) Sheet http://balchem.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 96 false false R97.htm 2482447 - Disclosure - LEASES - Right-of-Use Assets and Lease Liabilities (Details) Sheet http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails LEASES - Right-of-Use Assets and Lease Liabilities (Details) Details 97 false false R98.htm 2483448 - Disclosure - LEASES - Schedule of Lease Costs (Details) Sheet http://balchem.com/role/LEASESScheduleofLeaseCostsDetails LEASES - Schedule of Lease Costs (Details) Details 98 false false R99.htm 2486449 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) Sheet http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) Details 99 false false R100.htm 2487450 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) Sheet http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) Details 100 false false R101.htm 2488451 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) Sheet http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) Details 101 false false R102.htm 2491452 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) Sheet http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) Details http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDTables 102 false false R103.htm 2493453 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details) Sheet http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails VALUATION AND QUALIFYING ACCOUNTS (Details) Details http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTS 103 false false All Reports Book All Reports bcpc-20211231.htm bcpc-20211231.xsd bcpc-20211231_cal.xml bcpc-20211231_def.xml bcpc-20211231_lab.xml bcpc-20211231_pre.xml bcpc-20211231x10xkexhibit41.htm bcpc202110k-ex21.htm bcpc202110k-ex231.htm bcpc202110k-ex311.htm bcpc202110k-ex312.htm bcpc202110k-ex321.htm bcpc202110k-ex322.htm bcpc-20211231_g1.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 125 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bcpc-20211231.htm": { "axisCustom": 2, "axisStandard": 30, "contextCount": 313, "dts": { "calculationLink": { "local": [ "bcpc-20211231_cal.xml" ] }, "definitionLink": { "local": [ "bcpc-20211231_def.xml" ] }, "inline": { "local": [ "bcpc-20211231.htm" ] }, "labelLink": { "local": [ "bcpc-20211231_lab.xml" ] }, "presentationLink": { "local": [ "bcpc-20211231_pre.xml" ] }, "schema": { "local": [ "bcpc-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 765, "entityCount": 1, "hidden": { "http://balchem.com/20211231": 2, "http://fasb.org/us-gaap/2021-01-31": 14, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 20 }, "keyCustom": 42, "keyStandard": 530, "memberCustom": 33, "memberStandard": 50, "nsprefix": "bcpc", "nsuri": "http://balchem.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://balchem.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008010 - Statement - Consolidated Statements of Cash Flows", "role": "http://balchem.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i3a79394ffdd943668a1b342c764444f7_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2487450 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details)", "role": "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2488451 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details)", "role": "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ib1875797d2144bfb98433f99321be028_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2491452 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details)", "role": "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails", "shortName": "QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ib1875797d2144bfb98433f99321be028_D20211001-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ifda3f7be98804cd3b35da190e5c13b3f_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2493453 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Details)", "role": "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails", "shortName": "VALUATION AND QUALIFYING ACCOUNTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i03e6e43522f74c71be9499198076f0f8_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108102 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES", "role": "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURES", "shortName": "SIGNIFICANT ACQUISITIONS AND DIVESTITURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112103 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://balchem.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121104 - Disclosure - INVENTORIES", "role": "http://balchem.com/role/INVENTORIES", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124105 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "role": "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129106 - Disclosure - INTANGIBLE ASSETS", "role": "http://balchem.com/role/INTANGIBLEASSETS", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132107 - Disclosure - EQUITY-METHOD INVESTMENT", "role": "http://balchem.com/role/EQUITYMETHODINVESTMENT", "shortName": "EQUITY-METHOD INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134108 - Disclosure - REVOLVING LOAN", "role": "http://balchem.com/role/REVOLVINGLOAN", "shortName": "REVOLVING LOAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136109 - Disclosure - NET EARNINGS PER COMMON SHARE", "role": "http://balchem.com/role/NETEARNINGSPERCOMMONSHARE", "shortName": "NET EARNINGS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0002002 - Document - Audit Information", "role": "http://balchem.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139110 - Disclosure - INCOME TAXES", "role": "http://balchem.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146111 - Disclosure - SEGMENT INFORMATION", "role": "http://balchem.com/role/SEGMENTINFORMATION", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153112 - Disclosure - REVENUE", "role": "http://balchem.com/role/REVENUE", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156113 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION", "role": "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATION", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159114 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME", "role": "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2163115 - Disclosure - EMPLOYEE BENEFIT PLANS", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2172116 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://balchem.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2175117 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "role": "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2177118 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://balchem.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2179119 - Disclosure - LEASES", "role": "http://balchem.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001003 - Statement - Consolidated Balance Sheets", "role": "http://balchem.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2184120 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "role": "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2189121 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED)", "role": "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITED", "shortName": "QUARTERLY FINANCIAL INFORMATION (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2192122 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS", "role": "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTS", "shortName": "VALUATION AND QUALIFYING ACCOUNTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables)", "role": "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESTables", "shortName": "SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322304 - Disclosure - INVENTORIES (Tables)", "role": "http://balchem.com/role/INVENTORIESTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "role": "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330306 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://balchem.com/role/INTANGIBLEASSETSTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - NET EARNINGS PER COMMON SHARE (Tables)", "role": "http://balchem.com/role/NETEARNINGSPERCOMMONSHARETables", "shortName": "NET EARNINGS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - INCOME TAXES (Tables)", "role": "http://balchem.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347309 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://balchem.com/role/SEGMENTINFORMATIONTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354310 - Disclosure - REVENUE (Tables)", "role": "http://balchem.com/role/REVENUETables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357311 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "role": "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2360312 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "role": "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2364313 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables", "shortName": "EMPLOYEE BENEFIT PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2373314 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2380315 - Disclosure - LEASES (Tables)", "role": "http://balchem.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2385316 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)", "role": "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003005 - Statement - Consolidated Statements of Earnings", "role": "http://balchem.com/role/ConsolidatedStatementsofEarnings", "shortName": "Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2390317 - Disclosure - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)", "role": "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDTables", "shortName": "QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5e58f0c8533d4dd08311fa2344017f6f_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i757c3262661541fba251658b0eb71f76_D20190101-20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i33b12cfa0bfd4c69a148e65c448f6fe3_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details)", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i33b12cfa0bfd4c69a148e65c448f6fe3_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "idd57f882bc0542c9847574e07f0c4150_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i8cd84629bf784c4e949855ee8b16ea60_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i3661a893e1fb4c008ae3779f0efd1563_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details)", "role": "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "shortName": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ifee87f637c264f40aa9018722fb1f7bf_D20210101-20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "role": "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails", "shortName": "SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5d5cc1a61b9944ed834b122fdab1cda6_D20191213-20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "role": "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i442a54c164604496bcf4ad69515bc435_I20191213", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Compensation Cost on Net Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:NumberOfShareBasedCompensationPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - STOCKHOLDERS' EQUITY - Stock-based Compensation (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:NumberOfShareBasedCompensationPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic564b84179354217909b66997770e09d_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "shortName": "STOCKHOLDERS' EQUITY - Assumptions Used in Fair Value Determination (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic564b84179354217909b66997770e09d_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "idd57f882bc0542c9847574e07f0c4150_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417410 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ibf1927b97348483ba61cef3f0f9fc5d8_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418411 - Disclosure - STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails", "shortName": "STOCKHOLDERS' EQUITY - Information Related to Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419412 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420413 - Disclosure - STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details)", "role": "http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - INVENTORIES (Details)", "role": "http://balchem.com/role/INVENTORIESDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details)", "role": "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details)", "role": "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Long-Lived Assets by Geographical Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "role": "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431418 - Disclosure - INTANGIBLE ASSETS (Details)", "role": "http://balchem.com/role/INTANGIBLEASSETSDetails", "shortName": "INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:EquityMethodInvestmentNumberOfVotes", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - EQUITY-METHOD INVESTMENT (Details)", "role": "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails", "shortName": "EQUITY-METHOD INVESTMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:EquityMethodInvestmentNumberOfVotes", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical", "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i2b92beea560643649b7716b9e109c4b3_I20180627", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435420 - Disclosure - REVOLVING LOAN (Details)", "role": "http://balchem.com/role/REVOLVINGLOANDetails", "shortName": "REVOLVING LOAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i2b92beea560643649b7716b9e109c4b3_I20180627", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ib1875797d2144bfb98433f99321be028_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - NET EARNINGS PER COMMON SHARE (Details)", "role": "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails", "shortName": "NET EARNINGS PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - INCOME TAXES - Narrative (Details)", "role": "http://balchem.com/role/INCOMETAXESNarrativeDetails", "shortName": "INCOME TAXES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Details)", "role": "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails", "shortName": "INCOME TAXES - Components of Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443424 - Disclosure - INCOME TAXES - Effective Income Tax Reconciliation (Details)", "role": "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails", "shortName": "INCOME TAXES - Effective Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details)", "role": "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails", "shortName": "INCOME TAXES - Significant Portions of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "idd57f882bc0542c9847574e07f0c4150_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - INCOME TAXES - Income Tax Uncertainties (Details)", "role": "http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails", "shortName": "INCOME TAXES - Income Tax Uncertainties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ibf1927b97348483ba61cef3f0f9fc5d8_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5eee93c7287f4420a645b48d1df240f1_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "role": "http://balchem.com/role/SEGMENTINFORMATIONNarrativeDetails", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5eee93c7287f4420a645b48d1df240f1_D20200101-20200331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details)", "role": "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "shortName": "SEGMENT INFORMATION - Business Segment Assets and Net Sales (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450429 - Disclosure - SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details)", "role": "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "shortName": "SEGMENT INFORMATION - Business Segment Earnings Before Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i683d382e0df246feb796b6666d6bfb75_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ibf1927b97348483ba61cef3f0f9fc5d8_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006008 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i9966a229e7734b88be8ba3e422219bdd_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451430 - Disclosure - SEGMENT INFORMATION - Depreciation/Amortization (Details)", "role": "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails", "shortName": "SEGMENT INFORMATION - Depreciation/Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i683d382e0df246feb796b6666d6bfb75_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452431 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details)", "role": "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "shortName": "SEGMENT INFORMATION - Capital Expenditures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ib1875797d2144bfb98433f99321be028_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455432 - Disclosure - REVENUE (Details)", "role": "http://balchem.com/role/REVENUEDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "bcpc:NumberOfSubStreamsOfRevenue", "reportCount": 1, "unique": true, "unitRef": "revenue_substream", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458433 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details)", "role": "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461434 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME - Changes in Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "idd57f882bc0542c9847574e07f0c4150_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462435 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME - Components of Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ifd28446843264335a55058236f0ef6da_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "icd36b750f6fb44f2a69d9adceeb2be40_D20210101-20210101", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:NumberOfSavingsPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465436 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "icd36b750f6fb44f2a69d9adceeb2be40_D20210101-20210101", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:NumberOfSavingsPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ibab08a912fb04f9ba2437d12e251277a_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466437 - Disclosure - EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Changes in Benefit Obligations and Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i71b2f6f100b44adc8048f42ca5a75660_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPlanAmendments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467438 - Disclosure - EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Amounts Recognized in Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i71b2f6f100b44adc8048f42ca5a75660_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468439 - Disclosure - EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i71b2f6f100b44adc8048f42ca5a75660_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ib62be48b89cb4466a6890d18ac83b212_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469440 - Disclosure - EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Estimated Future Employer Contributions and Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ib62be48b89cb4466a6890d18ac83b212_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ie72bf625217f427a9399a2b903bf2aee_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MultiemployerPlanEmployerContributionCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470441 - Disclosure - EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Defined Benefit Pension Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ie72bf625217f427a9399a2b903bf2aee_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MultiemployerPlanEmployerContributionCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "id5e0b6473a054361a57512db160a896f_I20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471442 - Disclosure - EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details)", "role": "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "shortName": "EMPLOYEE BENEFIT PLANS - Assumptions Used in Calculations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "id5e0b6473a054361a57512db160a896f_I20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474443 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments (Details)", "role": "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2476444 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "role": "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ie3510d8382aa4c97a748370510c2f30e_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic2598b84f4fd45858cfef16384c24df5_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478445 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic2598b84f4fd45858cfef16384c24df5_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:LesseeOperatingLeaseNumberOfTranches", "reportCount": 1, "unique": true, "unitRef": "tranche", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481446 - Disclosure - LEASES - Narrative (Details)", "role": "http://balchem.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bcpc:LesseeOperatingLeaseNumberOfTranches", "reportCount": 1, "unique": true, "unitRef": "tranche", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2482447 - Disclosure - LEASES - Right-of-Use Assets and Lease Liabilities (Details)", "role": "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails", "shortName": "LEASES - Right-of-Use Assets and Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "ic36b7143f43b42bb8fe47cffb818f34e_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483448 - Disclosure - LEASES - Schedule of Lease Costs (Details)", "role": "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails", "shortName": "LEASES - Schedule of Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i5c1c5c5691674ef789f4416fca51b4b8_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i802adec444a34449b1aa498aa3a5894b_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2486449 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details)", "role": "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bcpc-20211231.htm", "contextRef": "i802adec444a34449b1aa498aa3a5894b_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 84, "tag": { "bcpc_AnimalNutritionAndHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A reportable segment of the company that provides the animal, nutrition and health markets with products derived from its micro capsulation, chelation and basic choline chloride technologies.", "label": "Animal Nutrition and Health [Member]", "terseLabel": "ANH", "verboseLabel": "Animal Nutrition & Health" } } }, "localname": "AnimalNutritionAndHealthMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "domainItemType" }, "bcpc_AuditorInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Auditor Information", "label": "Auditor Information [Abstract]" } } }, "localname": "AuditorInformationAbstract", "nsuri": "http://balchem.com/20211231", "xbrltype": "stringItemType" }, "bcpc_BillAndHoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues generated from bill and hold in which seller of a good bills a customer for products but does not ship the product until a later date.", "label": "Bill And Hold [Member]", "terseLabel": "Bill and Hold" } } }, "localname": "BillAndHoldMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "bcpc_BusinessCombinationCostOfAcquiredEntityDebtPaid": { "auth_ref": [], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of debt of acquired entity paid by the acquirer in a business combination.", "label": "Business Combination, Cost of Acquired Entity Debt Paid", "terseLabel": "Debt paid on purchase date" } } }, "localname": "BusinessCombinationCostOfAcquiredEntityDebtPaid", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapitalAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Acquired", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Acquired", "terseLabel": "Working capital acquired" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapitalAcquired", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "auth_ref": [], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "terseLabel": "Translated amount paid to shareholders", "totalLabel": "Amount paid to shareholders" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesBankDebt": { "auth_ref": [], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Bank Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Bank Debt", "negatedLabel": "Debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesBankDebt", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesPensionObligations": { "auth_ref": [], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 11.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Pension Obligations", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Pension Obligations", "negatedLabel": "Pension obligation (net)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesPensionObligations", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiresAndLiabilitiesAssumedRightOfUseAssets": { "auth_ref": [], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 15.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquires and Liabilities Assumed, Right-of-Use Assets", "label": "Business Combination, Recognized Identifiable Assets Acquires and Liabilities Assumed, Right-of-Use Assets", "terseLabel": "Right of use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiresAndLiabilitiesAssumedRightOfUseAssets", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_BusinessCombinationTransactionAndIntegrationRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs could include legal, accounting and other professional fees. This element also includes costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs and systems integration and conversion costs.", "label": "Business Combination, Transaction and Integration Related Costs", "terseLabel": "Transaction and integration related costs" } } }, "localname": "BusinessCombinationTransactionAndIntegrationRelatedCosts", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_CashPaidForIncomeTaxesAndInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Paid for Income Taxes and Interest [Abstract]", "verboseLabel": "Cash Paid for Income Taxes and Interest [Abstract]" } } }, "localname": "CashPaidForIncomeTaxesAndInterestAbstract", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "bcpc_CashPaymentsForOperatingAndFinanceLeases": { "auth_ref": [], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Payments for Operating and Finance Leases", "label": "Cash Payments for Operating and Finance Leases", "totalLabel": "Cash flows from operating and finance leases" } } }, "localname": "CashPaymentsForOperatingAndFinanceLeases", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_CentralStatesSoutheastAndSouthwestAreasPensionFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A multiemployer defined benefit plan, in which the Company participates under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona facility.", "label": "Central States, Southeast and Southwest Areas Pension Fund [Member]", "terseLabel": "Central States, Southeast and Southwest Areas Pension Fund" } } }, "localname": "CentralStatesSoutheastAndSouthwestAreasPensionFundMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails" ], "xbrltype": "domainItemType" }, "bcpc_ChemogasAndZumbroRiverBrandIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chemogas And Zumbro River Brand, Inc.", "label": "Chemogas And Zumbro River Brand, Inc. [Member]", "terseLabel": "Chemogas and Zumbro" } } }, "localname": "ChemogasAndZumbroRiverBrandIncMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_ChemogasDefinedPensionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chemogas Defined Pension Plan", "label": "Chemogas Defined Pension Plan [Member]", "terseLabel": "Chemogas Defined Pension Plan" } } }, "localname": "ChemogasDefinedPensionPlanMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "domainItemType" }, "bcpc_ChemogasHoldingNVAndSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chemogas Holding NV and Subsidiaries", "label": "Chemogas Holding NV and Subsidiaries [Member]", "terseLabel": "Chemogas" } } }, "localname": "ChemogasHoldingNVAndSubsidiariesMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_CoManufacturingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues generated from co-manufacturing.", "label": "Co-manufacturing [Member]", "terseLabel": "Co-manufacturing" } } }, "localname": "CoManufacturingMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "bcpc_ConsignmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues generated from consignment sales.", "label": "Consignment [Member]", "terseLabel": "Consignment" } } }, "localname": "ConsignmentMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "bcpc_DeferredTaxAssetsOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Liability", "label": "Deferred Tax Assets, Operating Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiability", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Assets", "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Assets", "terseLabel": "Right of use assets" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_DeferredTaxLiabilityCustomerListAndGoodwillAmortization": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of customer lists and goodwill and the basis of customer lists and goodwill computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.", "label": "Deferred Tax Liability, Customer list and goodwill amortization", "terseLabel": "Amortization" } } }, "localname": "DeferredTaxLiabilityCustomerListAndGoodwillAmortization", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_DefinedBenefitPlanNumberOfBenefitPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Number of Benefit Plans", "label": "Defined Benefit Plan, Number of Benefit Plans", "terseLabel": "Number of unfunded plans" } } }, "localname": "DefinedBenefitPlanNumberOfBenefitPlans", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bcpc_DerivativeInterestRateTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Interest Rate, Type", "label": "Derivative Interest Rate, Type [Axis]", "terseLabel": "Derivative Interest Rate, Type [Axis]" } } }, "localname": "DerivativeInterestRateTypeAxis", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bcpc_DerivativeInterestRateTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Interest Rate, Type", "label": "Derivative Interest Rate, Type [Domain]", "terseLabel": "Derivative Interest Rate, Type [Domain]" } } }, "localname": "DerivativeInterestRateTypeDomain", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_EastmanChemicalCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the entity with which the joint venture is formed.", "label": "Eastman Chemical Company [Member]", "terseLabel": "Eastman Chemical Company" } } }, "localname": "EastmanChemicalCompanyMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "bcpc_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Foreign-Derived Intangible Income", "label": "Effective Income Tax Rate Reconciliation, Foreign-Derived Intangible Income", "negatedTerseLabel": "FDII" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxIncomeAndForeignDerivedIntangibleIncome": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low-Tax Income And Foreign-Derived Intangible Income", "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low-Tax Income And Foreign-Derived Intangible Income", "terseLabel": "GILTI" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxIncomeAndForeignDerivedIntangibleIncome", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_EffectiveIncomeTaxRateReconciliationPatentBoxDecree": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Patent Box Decree", "label": "Effective Income Tax Rate Reconciliation, Patent Box Decree", "negatedLabel": "Patent Box Decree (related to prior years)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPatentBoxDecree", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An individual that is currently employed by the entity.", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bcpc_EquityMethodInvestmentNumberOfVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Number Of Votes", "label": "Equity Method Investment, Number Of Votes", "terseLabel": "Number of votes" } } }, "localname": "EquityMethodInvestmentNumberOfVotes", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "integerItemType" }, "bcpc_EstimatedShareBasedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated share-based compensation expense for current fiscal year.", "label": "Estimated Share Based Compensation Expense", "verboseLabel": "Estimated share-based compensation expense for current fiscal year" } } }, "localname": "EstimatedShareBasedCompensationExpense", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range for stock options outstanding.", "label": "Exercise Price Range 1 [Member]", "verboseLabel": "$29.06 - $57.17" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "bcpc_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range for stock options outstanding.", "label": "Exercise Price Range 2 [Member]", "verboseLabel": "$58.52 - $85.40" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "bcpc_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range for stock options outstanding.", "label": "Exercise Price Range 3 [Member]", "verboseLabel": "$91.56 - $120.60" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "bcpc_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "totalLabel": "Total finance lease" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_HumanNutritionAndHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A reportable segment of the company that provides the human, nutrition and health markets with products derived from its micro capsulation, chelation and basic choline chloride technologies.", "label": "Human Nutrition and Health [Member]", "terseLabel": "HNH", "verboseLabel": "Human Nutrition & Health" } } }, "localname": "HumanNutritionAndHealthMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_IndustrialProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A reportable segment of the company that provides certain derivatives of industrial applications predominately as a component for hydraulic fracturing of shale natural gas wells.", "label": "Industrial Products [Member]", "terseLabel": "Other and Unallocated" } } }, "localname": "IndustrialProductsMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails" ], "xbrltype": "domainItemType" }, "bcpc_InitialTotalShareholderReturnPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The initial percentage of total shareholder return.", "label": "Initial TSR", "terseLabel": "Initial total shareholder return percentage" } } }, "localname": "InitialTotalShareholderReturnPercentage", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "percentItemType" }, "bcpc_LesseeOperatingLeaseNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Tranches", "label": "Lessee, Operating Lease, Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "LesseeOperatingLeaseNumberOfTranches", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "integerItemType" }, "bcpc_LesseeOperatingLeaseTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tranche Four [Member]", "label": "Lessee, Operating Lease, Tranche Four [Member]", "terseLabel": "More than 10 years" } } }, "localname": "LesseeOperatingLeaseTrancheFourMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_LesseeOperatingLeaseTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tranche One [Member]", "label": "Lessee, Operating Lease, Tranche One [Member]", "terseLabel": "Years 1 and 2" } } }, "localname": "LesseeOperatingLeaseTrancheOneMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_LesseeOperatingLeaseTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tranche Three [Member]", "label": "Lessee, Operating Lease, Tranche Three [Member]", "terseLabel": "Years 5 through 9" } } }, "localname": "LesseeOperatingLeaseTrancheThreeMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_LesseeOperatingLeaseTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tranche Two [Member]", "label": "Lessee, Operating Lease, Tranche Two [Member]", "terseLabel": "Years 3 and 4" } } }, "localname": "LesseeOperatingLeaseTrancheTwoMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_LesseeOperatingLeaseTranchesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tranches [Axis]", "label": "Lessee, Operating Lease, Tranches [Axis]", "terseLabel": "Lessee, Operating Lease, Tranches [Axis]" } } }, "localname": "LesseeOperatingLeaseTranchesAxis", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bcpc_LesseeOperatingLeaseTranchesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Lessee, Operating Lease, Tranches [Axis]", "label": "Lessee, Operating Lease, Tranches [Domain]", "terseLabel": "Lessee, Operating Lease, Tranches [Domain]" } } }, "localname": "LesseeOperatingLeaseTranchesDomain", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_MultiemployerPlanPensionNumberOfPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multiemployer Plan, Pension, Number Of Plans", "label": "Multiemployer Plan, Pension, Number Of Plans", "terseLabel": "Number of multiemployer benefit pension plans" } } }, "localname": "MultiemployerPlanPensionNumberOfPlans", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bcpc_NumberOfFillingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Filling Facilities", "label": "Number of Filling Facilities", "terseLabel": "Number of filing facilities" } } }, "localname": "NumberOfFillingFacilities", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "bcpc_NumberOfSavingsPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Savings Plans", "label": "Number of Savings Plans", "terseLabel": "Number of savings plan" } } }, "localname": "NumberOfSavingsPlans", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bcpc_NumberOfShareBasedCompensationPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Share Based Compensation Plans", "label": "Number of Share Based Compensation Plans", "terseLabel": "Number of share-based compensation plans" } } }, "localname": "NumberOfShareBasedCompensationPlans", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "integerItemType" }, "bcpc_NumberOfSubStreamsOfRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of sub-streams of revenue associated with revenue from contract with customers.", "label": "Number of Sub-streams of Revenue", "terseLabel": "Number of sub-streams of revenue" } } }, "localname": "NumberOfSubStreamsOfRevenue", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "integerItemType" }, "bcpc_OmnibusIncentivePlan2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A share-based compensation plan under which awards may be granted for officers, employees and directors of the Company and its subsidiaries.", "label": "Omnibus Incentive Plan 2017 [Member]", "terseLabel": "2017 Plan" } } }, "localname": "OmnibusIncentivePlan2017Member", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bcpc_OperatingAndFinanceLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease, Liability, Current", "label": "Operating and Finance Lease, Liability, Current", "totalLabel": "Total lease liabilities, current" } } }, "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_OperatingAndFinanceLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease, Liability, Noncurrent", "label": "Operating and Finance Lease, Liability, Noncurrent", "totalLabel": "Total lease liabilities, non-current" } } }, "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_OperatingAndFinanceLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating and Finance Lease, Right-of-Use Asset", "label": "Operating and Finance Lease, Right-of-Use Asset", "totalLabel": "Total right-of-use assets" } } }, "localname": "OperatingAndFinanceLeaseRightOfUseAsset", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_OtherComprehensiveIncomeLossDefinedBenefitPlanOneTimeAdjustmentAfterTax": { "auth_ref": [], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive (Income) Loss, Defined Benefit Plan, One Time Adjustment, after Tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, One Time Adjustment, after Tax", "terseLabel": "Adjustment" } } }, "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanOneTimeAdjustmentAfterTax", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other excluding regulatory registration costs and patents & trade secrets.", "label": "Other Intangible Assets Excluding Regulatory registration Costs and Patents & Trade Secrets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsExcludingRegulatoryRegistrationCostsAndPatentsTradeSecretsMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "bcpc_ParticipatingAwardsCommonStockParticipation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Participating Awards, Common Stock Participation", "label": "Participating Awards, Common Stock Participation", "terseLabel": "Award participation per share of common stock" } } }, "localname": "ParticipatingAwardsCommonStockParticipation", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "perShareItemType" }, "bcpc_PatentsTradeSecretsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, and information generally known to only a limited number of the entity's employees, such as a formula, pattern, machine, technology, and production process that may give an entity a competitive advantage.", "label": "Patents & Trade Secrets [Member]", "terseLabel": "Patents & trade secrets" } } }, "localname": "PatentsTradeSecretsMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "bcpc_PayFixedInterestRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pay-Fixed Interest Rate", "label": "Pay-Fixed Interest Rate [Member]", "terseLabel": "Pay-Fixed Interest Rate" } } }, "localname": "PayFixedInterestRateMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_PaymentsToAcquireBusinessesAmountPaidToFormerShareholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for payment to former shareholders associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Amount Paid to Former Shareholders", "terseLabel": "Amount paid to former shareholders" } } }, "localname": "PaymentsToAcquireBusinessesAmountPaidToFormerShareholders", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_PercentageOfOperatingExpensesToBeAbsorbed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the percentage of operating expenses to be absorbed.", "label": "Percentage of Operating Expenses to be Absorbed", "terseLabel": "Percentage of operating expenses to be absorbed" } } }, "localname": "PercentageOfOperatingExpensesToBeAbsorbed", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "percentItemType" }, "bcpc_PercentageOfProductionOfftake": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the percentage of production offtake.", "label": "Percentage of Production Offtake", "terseLabel": "Percentage of production offtake" } } }, "localname": "PercentageOfProductionOfftake", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "percentItemType" }, "bcpc_ProductSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues generated from product sales.", "label": "Product Sales [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductSalesMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "bcpc_ProfitSharingPlanCostRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the cost recognized during the period for profit sharing plans.", "label": "Profit Sharing Plan Cost Recognized", "terseLabel": "Profit Sharing contributions" } } }, "localname": "ProfitSharingPlanCostRecognized", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_RawMaterialsSoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Raw materials sold to the customers.", "label": "Raw Materials Sold [Member]", "terseLabel": "Raw Materials Sold" } } }, "localname": "RawMaterialsSoldMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "bcpc_ReceiveFixedInterestRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receive-Fixed Interest Rate", "label": "Receive-Fixed Interest Rate [Member]", "terseLabel": "Receive-Fixed Interest Rate" } } }, "localname": "ReceiveFixedInterestRateMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bcpc_RegulatoryRegistrationCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs associated with the required registration, with the U.S. Environmental Protection Agency, of certain products considered pesticides under the Federal Insecticide, Fungicide and Rodenticide Act.", "label": "Regulatory registration Costs [Member]", "terseLabel": "Regulatory registration costs" } } }, "localname": "RegulatoryRegistrationCostsMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "bcpc_RevolvingCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Agreement", "label": "Revolving Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "RevolvingCreditAgreementMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "domainItemType" }, "bcpc_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiabilityNetOfRightOfUseAssetsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-use Asset Obtained in exchange for Finance Lease Liability, net of Right-of-Use Assets Sold", "label": "Right-of-use Asset Obtained in exchange for Finance Lease Liability, net of Right-of-Use Assets Sold", "terseLabel": "ROU assets obtained in exchange for new finance lease liabilities, net of ROU asset disposals" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiabilityNetOfRightOfUseAssetsSold", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfRightOfUseAssetsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net Of Right-Of Use Assets Sold", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Net Of Right-Of Use Assets Sold", "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities, net of ROU asset disposals" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfRightOfUseAssetsSold", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "bcpc_ServicesProvidedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services provided to the customers.", "label": "Services Provided [Member]", "terseLabel": "Services Provided" } } }, "localname": "ServicesProvidedMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "bcpc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndGrantDateIntrinsicValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value and intrinsic value of equity options granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value and Grant Date Intrinsic Value [Table Text Block]", "verboseLabel": "Schedule of Other Information Pertaining to Stock Option Activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndGrantDateIntrinsicValueTableTextBlock", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "bcpc_SharesPurchasedUnderRestrictedStockPurchaseAgreementsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares purchased under restricted stock purchase agreements.", "label": "Shares purchased under restricted stock purchase agreements, maximum", "verboseLabel": "Shares purchased under restricted stock purchase agreements, maximum (in shares)" } } }, "localname": "SharesPurchasedUnderRestrictedStockPurchaseAgreementsMaximum", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "bcpc_SharesPurchasedUnderRestrictedStockPurchaseAgreementsMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum number of shares purchased under restricted stock purchase agreements.", "label": "Shares purchased under restricted stock purchase agreements, minimum", "verboseLabel": "Shares purchased under restricted stock purchase agreements, minimum (in shares)" } } }, "localname": "SharesPurchasedUnderRestrictedStockPurchaseAgreementsMinimum", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "bcpc_SpecialtyProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A reportable segment of the company that provides specialty-packaged chemicals for use in healthcare and other industries.", "label": "Specialty Products [Member]", "terseLabel": "Specialty Products" } } }, "localname": "SpecialtyProductsMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "domainItemType" }, "bcpc_StGabrielCCCompanyLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A joint venture formed in 2013 by the Company and Eastman Chemical Company (formerly Taminco Corporation) to design, develop, and construct an expansion of the Company's St. Gabriel aqueous choline chloride plant.", "label": "St. Gabriel CC Company, LLC [Member]", "terseLabel": "St. Gabriel CC Company, LLC" } } }, "localname": "StGabrielCCCompanyLLCMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "bcpc_StockPlan1999Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock plan for officers, directors, directors emeritus and employees of and consultants of the company.", "label": "Stock Plan 1999 [Member]", "terseLabel": "1999 Plan" } } }, "localname": "StockPlan1999Member", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bcpc_StockRepurchaseProgramAggregateNumberOfSharesRepurchasedSinceInception": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative number of shares repurchased under the repurchase program since the inception of the program as of balance sheet date.", "label": "Stock Repurchase Program, Aggregate Number of Shares Repurchased Since Inception", "terseLabel": "Aggregate number of shares repurchased since inception (in shares)" } } }, "localname": "StockRepurchaseProgramAggregateNumberOfSharesRepurchasedSinceInception", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "bcpc_TreasuryStockSharesAcquiredAndReissued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and reissued during the period.", "label": "Treasury Stock Shares Acquired And Reissued", "terseLabel": "Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares)" } } }, "localname": "TreasuryStockSharesAcquiredAndReissued", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "bcpc_UnrealizedLossGainOnForeignCurrencyTransactionsAndDeferredCompensation": { "auth_ref": [], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrealized Loss (Gain) on Foreign Currency Transactions and Deferred Compensation", "label": "Unrealized Loss (Gain) on Foreign Currency Transactions and Deferred Compensation", "terseLabel": "Unrealized (gain)/loss on foreign currency transactions and deferred compensation" } } }, "localname": "UnrealizedLossGainOnForeignCurrencyTransactionsAndDeferredCompensation", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bcpc_ZumbroRiverBrandIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zumbro River Brand, Inc.", "label": "Zumbro River Brand, Inc. [Member]", "terseLabel": "Zumbro" } } }, "localname": "ZumbroRiverBrandIncMember", "nsuri": "http://balchem.com/20211231", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r844" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r845" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Small Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r869" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r837" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://balchem.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r148", "r211", "r224", "r225", "r226", "r227", "r229", "r231", "r235", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r332", "r334", "r335", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r148", "r211", "r224", "r225", "r226", "r227", "r229", "r231", "r235", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r332", "r334", "r335", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r66", "r68", "r145", "r146", "r341", "r363", "r868" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Non-employee Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Foreign Countries" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r340", "r362", "r501", "r512", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r803", "r806", "r834", "r835" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/LEASESNarrativeDetails", "http://balchem.com/role/REVOLVINGLOANDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r340", "r362", "r501", "r512", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r803", "r806", "r834", "r835" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/LEASESNarrativeDetails", "http://balchem.com/role/REVOLVINGLOANDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of North America.", "label": "North America [Member]", "terseLabel": "United States" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r238", "r401", "r403", "r747", "r802", "r804" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r238", "r401", "r403", "r747", "r802", "r804" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r340", "r362", "r438", "r501", "r512", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r803", "r806", "r834", "r835" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/LEASESNarrativeDetails", "http://balchem.com/role/REVOLVINGLOANDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r340", "r362", "r438", "r501", "r512", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r803", "r806", "r834", "r835" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/LEASESNarrativeDetails", "http://balchem.com/role/REVOLVINGLOANDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r67", "r68", "r145", "r146", "r341", "r363" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r155", "r856" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "verboseLabel": "VALUATION AND QUALIFYING ACCOUNTS" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTS" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r239", "r240", "r401", "r404", "r805", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r846", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails", "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r239", "r240", "r401", "r404", "r805", "r820", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r846", "r847" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails", "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r245", "r728" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154", "r856" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r50", "r144", "r727", "r729" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r144", "r726", "r771", "r794" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Payable to related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r16", "r50" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r30", "r246", "r247" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $928 and $2,092 at December\u00a031, 2021 and 2020, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r29", "r144", "r726", "r729", "r791" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Receivable from related party" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r59", "r144", "r726", "r729" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "verboseLabel": "Other receivable from related party" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r73", "r79", "r89", "r90", "r91", "r630" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Postretirement benefit plan" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r48", "r303" ], "calculation": { "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r79", "r89", "r90", "r91", "r92", "r629" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash flow hedge" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r76", "r78", "r79", "r788", "r814", "r818" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss)/income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r89", "r90", "r691", "r692", "r693", "r694", "r695", "r697" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r75", "r79", "r89", "r90", "r91", "r157", "r158", "r159", "r630", "r809", "r810", "r874" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r70", "r79", "r89", "r90", "r91", "r630", "r692", "r693", "r694", "r695", "r697" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Useful life of intangible assets acquired" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r31", "r561", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r157", "r158", "r159", "r558", "r559", "r560", "r669" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r516", "r550", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation cost" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "negatedTerseLabel": "Net earnings" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "Allowance for Doubtful Accounts" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r37", "r252", "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r101", "r126", "r353", "r700" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization expense pertaining to capitalized costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r126", "r287", "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of identifiable intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r126", "r300" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment charge" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r140", "r219", "r226", "r233", "r261", "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r626", "r631", "r681", "r732", "r734", "r766", "r787" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Assets and Liabilities, Lessee [Abstract]" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r13", "r15", "r63", "r140", "r261", "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r626", "r631", "r681", "r732", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r137" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Related rabbi trust assets" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r517", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r643", "r647" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building", "verboseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r494", "r507" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r494", "r507", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of outstanding common shares acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Expected deductible amount" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 14.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "negatedTerseLabel": "Lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "verboseLabel": "Prepaid & other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable & accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 12.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred income taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r614", "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r614", "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 10.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other non-current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r614", "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r615" ], "calculation": { "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Translated amount on acquisition date", "totalLabel": "Total amount paid on acquisition date" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r44", "r128" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r18", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r120", "r128", "r132" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r120", "r690" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "verboseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r316", "r772", "r793" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r313", "r314", "r315", "r317", "r821" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r157", "r158", "r669" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r28", "r375" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r28", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,287,150 shares issued and outstanding at December\u00a031, 2021 and 32,372,621 shares issued and outstanding at December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "verboseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "verboseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r84", "r86", "r87", "r98", "r777", "r799" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r84", "r86", "r97", "r624", "r633", "r776", "r798" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Other comprehensive (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r96", "r108", "r775", "r797" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r199", "r784" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Business Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r134", "r628" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.", "label": "Corporate Joint Venture [Member]", "verboseLabel": "St. Gabriel CC Company, LLC" } } }, "localname": "CorporateJointVentureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r224", "r225", "r226", "r227", "r229", "r235", "r237" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other and Unallocated" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r104", "r140", "r261", "r322", "r323", "r324", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r681" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency swap", "verboseLabel": "Cross-currency swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r141", "r594", "r603" ], "calculation": { "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r141", "r594" ], "calculation": { "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r141", "r594", "r603" ], "calculation": { "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerListsMember": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information.", "label": "Customer Lists [Member]", "terseLabel": "Customer relationships and lists" } } }, "localname": "CustomerListsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r139", "r148", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r701", "r767", "r769", "r786" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r56", "r139", "r148", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r701" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r56", "r139", "r148", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r376", "r377", "r378", "r379", "r698", "r699", "r701", "r702", "r783" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r141", "r595", "r603" ], "calculation": { "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r49", "r344", "r700" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Capitalized costs net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r141", "r595", "r603" ], "calculation": { "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r126", "r141", "r595", "r603", "r604", "r605" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r25", "r26", "r584", "r768", "r785" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r570", "r571" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r141", "r595", "r603" ], "calculation": { "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r585" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsHedgingTransactions": { "auth_ref": [ "r592", "r593" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from hedging transactions.", "label": "Deferred Tax Assets, Hedging Transactions", "terseLabel": "Currency and interest rate swap" } } }, "localname": "DeferredTaxAssetsHedgingTransactions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r592", "r593" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "verboseLabel": "Inventories" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r592", "r593" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r592", "r593" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "verboseLabel": "Restricted stock and stock options" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r586" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r571", "r587" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "totalLabel": "Net deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r592", "r593" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "verboseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r592", "r593" ], "calculation": { "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "verboseLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESSignificantPortionsofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "auth_ref": [ "r24", "r414", "r415", "r437" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "terseLabel": "Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations)" } } }, "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r447" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "verboseLabel": "Accumulated postretirement benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r79", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedTerseLabel": "Unrecognized net gain" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r79", "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Unrecognized prior service cost" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r429", "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedLabel": "Actuarial gain" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r416", "r454", "r481", "r487", "r488" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of gain" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r416", "r455", "r482", "r487", "r488" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "negatedLabel": "Amortization of prior service cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r462", "r486" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Expected return on assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation at end of year", "periodStartLabel": "Benefit obligation at beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r424", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r421" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Participant contributions" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "verboseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "verboseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r431", "r439", "r441", "r485", "r487", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "verboseLabel": "Employer (reimbursement)/contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "verboseLabel": "Years 2027-2031" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "verboseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "verboseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "verboseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "verboseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "verboseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r416", "r453", "r480", "r487", "r488" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r428", "r439", "r441", "r442", "r487" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets at end of year", "periodStartLabel": "Fair value of plan assets at beginning of year", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Exchange rate changes" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r414", "r437", "r487" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "negatedTotalLabel": "Funded status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r416", "r420", "r452", "r479", "r487", "r488" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r450", "r477", "r487", "r488" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Total net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Initial adoption of new plan" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r433", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Participant contributions" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Exchange rate changes" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r418", "r451", "r478", "r487", "r488" ], "calculation": { "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost with interest to end of year" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Benefit Obligatoins" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Net Cost" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Postretirement Health Coverage [Member]", "terseLabel": "Postretirement Medical Plans" } } }, "localname": "DefinedBenefitPostretirementHealthCoverageMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "401(k) contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r126", "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r126", "r214" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r645" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Losses and gains recognized in accumulated other comprehensive income (loss)" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r68", "r644", "r646", "r650", "r653" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r660", "r672" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r641", "r644", "r650" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r641", "r644", "r650", "r653", "r654", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r64", "r65", "r68", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability [Abstract]", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r636", "r637", "r639" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Notional amount of derivatives" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r635", "r638", "r639", "r641", "r642", "r648", "r650", "r655", "r657", "r659", "r660" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r147", "r635", "r638", "r641", "r642", "r656" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue by Source and Geography" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r380", "r782" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedLabel": "Dividends" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Dividends (in dollars per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r16", "r54" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable", "verboseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r99", "r166", "r167", "r168", "r169", "r170", "r176", "r178", "r183", "r184", "r185", "r189", "r190", "r670", "r671", "r778", "r800" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net earnings per share - basic (in dollars per share)", "verboseLabel": "Basic net earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails", "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "verboseLabel": "Per Share Amount [Abstract]" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r99", "r166", "r167", "r168", "r169", "r170", "r178", "r183", "r184", "r185", "r189", "r190", "r670", "r671", "r778", "r800" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net earnings per common share (in dollars per share)", "verboseLabel": "Net earnings per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails", "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Earnings Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r186", "r187", "r188", "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "NET EARNINGS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r690" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "verboseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and other benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to non-vested shares" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period of recognition for unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r89", "r90", "r91", "r157", "r158", "r159", "r162", "r171", "r173", "r196", "r266", "r375", "r380", "r558", "r559", "r560", "r599", "r600", "r669", "r691", "r692", "r693", "r694", "r695", "r697", "r809", "r810", "r811", "r874" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage in joint venture" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r45", "r220", "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Carrying value of joint venture" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "EQUITY-METHOD INVESTMENT" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r673", "r679", "r680" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r346", "r355", "r356", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r487", "r674", "r735", "r736", "r737" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r346", "r439", "r441", "r446", "r487", "r674", "r735" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r346", "r355", "r356", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r487", "r735", "r736", "r737" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r643", "r648", "r658" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r706", "r713", "r720" ], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r708", "r715" ], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": 2.0, "parentTag": "bcpc_CashPaymentsForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r704" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "bcpc_OperatingAndFinanceLeaseLiabilityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities - current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r704" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "bcpc_OperatingAndFinanceLeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities - non-current" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r707", "r715" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 }, "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": 1.0, "parentTag": "bcpc_CashPaymentsForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Principal payments on finance lease", "terseLabel": "Principal payments on finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows", "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r703" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Right of use assets - finance lease" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r706", "r713", "r720" ], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of ROU asset" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r703" ], "calculation": { "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "bcpc_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Finance Leases - ROU" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r717", "r720" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r716", "r720" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life of intangible assets", "verboseLabel": "Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r288", "r290", "r293", "r297", "r748", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r293", "r752" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r288", "r292" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r293", "r748" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets with finite lives, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "verboseLabel": "Identifiable intangible assets [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r126" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "(Gain)/loss on disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r105" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r278", "r280", "r734", "r765" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 13.0, "parentTag": "bcpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, end of period", "periodStartLabel": "Goodwill, beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/INTANGIBLEASSETSDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill as a result of Zumbro Acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r284", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Acquired Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Impact due to change in foreign exchange rates" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r126", "r279", "r282", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Goodwill impairment", "terseLabel": "Goodwill impairment charge" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r103", "r140", "r219", "r225", "r229", "r232", "r235", "r261", "r322", "r323", "r324", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r681" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r641", "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r126", "r300", "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment charges" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r299", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r219", "r225", "r229", "r232", "r235" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r94", "r126", "r216", "r258", "r773", "r795" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss relating to joint venture's expenses" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r306", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r142", "r574", "r582", "r589", "r601", "r606", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r143", "r172", "r173", "r217", "r572", "r602", "r607", "r801" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "totalLabel": "Total income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/INCOMETAXESComponentsofIncomeTaxExpenseDetails", "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]", "verboseLabel": "Income Tax Reconciliation [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r88", "r568", "r569", "r582", "r583", "r588", "r596" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r573" ], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax at Federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r573" ], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Stock Options" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r573" ], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "verboseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r573" ], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income taxes, net of Federal income taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r573" ], "calculation": { "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "negatedTerseLabel": "Foreign Tax Credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r122", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r125" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r125" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r125" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r125" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities, net of acquired balances" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r125" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r179", "r180", "r181", "r185" ], "calculation": { "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "verboseLabel": "Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Identifiable intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r779" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r118", "r121", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofFairValueofDerivativeInstrumentsDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails", "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INVENTORIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r38", "r274" ], "calculation": { "http://balchem.com/role/INVENTORIESDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r60", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://balchem.com/role/INVENTORIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r17", "r61", "r135", "r192", "r271", "r272", "r275", "r745" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r40", "r274" ], "calculation": { "http://balchem.com/role/INVENTORIESDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserveMember": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Reserve to reduce inventory to lower of cost or net realizable value.", "label": "SEC Schedule, 12-09, Reserve, Inventory [Member]", "terseLabel": "Inventory Reserve" } } }, "localname": "InventoryValuationReserveMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r60", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Reserve for inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r39", "r274" ], "calculation": { "http://balchem.com/role/INVENTORIESDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r718", "r720" ], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r711" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r719" ], "calculation": { "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract for operating leases" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r53", "r140", "r227", "r261", "r322", "r323", "r324", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r627", "r631", "r632", "r681", "r732", "r733" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r140", "r261", "r681", "r734", "r770", "r790" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r55", "r140", "r261", "r322", "r323", "r324", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r627", "r631", "r632", "r681", "r732", "r733", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Interest rate" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityPeriodicPayment": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments of both interest and principal.", "label": "Line of Credit Facility, Periodic Payment", "terseLabel": "Installment payments required" } } }, "localname": "LineOfCreditFacilityPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Unused portion of revolving loan" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Long-Lived Assets by Geographical Area" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "REVOLVING LOAN" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r56", "r318", "r319" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "terseLabel": "Revolving loan", "verboseLabel": "Outstanding balance" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r56", "r320" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Interest and other expense" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r7", "r623" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "SIGNIFICANT ACQUISITIONS AND DIVESTITURES" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURES" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MultiemployerPlanContributionRateIncreaseDecrease": { "auth_ref": [ "r495", "r508" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in employer's contractual contribution rate to multiemployer plan.", "label": "Multiemployer Plan, Contribution Rate Increase (Decrease)", "terseLabel": "Contribution rate increase" } } }, "localname": "MultiemployerPlanContributionRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MultiemployerPlanEmployerContributionCost": { "auth_ref": [ "r493", "r497", "r511", "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for employer contribution to multiemployer plan. Multiemployer plan includes, but is not limited to, pension plan determined to be individually significant and insignificant and other postretirement benefit plan.", "label": "Multiemployer Plan, Employer Contribution, Cost", "verboseLabel": "Contributions of Balchem Corporation" } } }, "localname": "MultiemployerPlanEmployerContributionCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MultiemployerPlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Multiemployer Plan [Line Items]", "terseLabel": "Multiemployer Plans [Line Items]" } } }, "localname": "MultiemployerPlansLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r120", "r123", "r127" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r82", "r85", "r91", "r95", "r127", "r140", "r161", "r166", "r167", "r168", "r169", "r172", "r173", "r182", "r219", "r225", "r229", "r232", "r235", "r261", "r322", "r323", "r324", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r671", "r681", "r774", "r796" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings", "totalLabel": "Net earnings", "verboseLabel": "Net Earnings - Basic and Diluted" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows", "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity", "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails", "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "verboseLabel": "Earnings (Numerator) [Abstract]" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net investment hedge" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r160", "r161", "r162", "r163", "r164", "r165", "r168", "r174", "r189", "r256", "r257", "r263", "r264", "r265", "r266", "r267", "r268", "r321", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r597", "r598", "r599", "r600", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r722", "r749", "r750", "r751", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Foreign Countries" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets, excluding intangible assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses", "terseLabel": "Interest and other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expenses:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r219", "r225", "r229", "r232", "r235" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Earnings from operations", "totalLabel": "Earnings from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r714", "r720" ], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESNarrativeDetails", "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r704" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "bcpc_OperatingAndFinanceLeaseLiabilityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities - current", "verboseLabel": "Operating leases liabilities - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r704" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "bcpc_OperatingAndFinanceLeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities - non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r709", "r715" ], "calculation": { "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails": { "order": 3.0, "parentTag": "bcpc_CashPaymentsForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r703" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "bcpc_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets - operating leases", "verboseLabel": "Operating Lease - ROU" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESRightofUseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r717", "r720" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r716", "r720" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/LEASESScheduleofLeaseCostsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r590" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r224", "r225", "r226", "r227", "r229", "r235" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r156", "r175", "r205", "r634" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r62", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]", "terseLabel": "Net change in postretirement benefit plan (see Note 15 for further information)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r72", "r76", "r458" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "terseLabel": "Net change in postretirement benefit plan, net of taxes of $13, $127, and $101 at December\u00a031, 2021, 2020 and 2019, respectively" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r624", "r625", "r629" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Net foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "auth_ref": [ "r624", "r625", "r629" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "negatedTerseLabel": "Net foreign currency translation adjustment tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r76", "r80", "r81", "r458" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "negatedLabel": "Amortization of prior service credit/(cost)" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r71", "r76" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Cash flow hedge (interest rate swap), net of tax", "totalLabel": "Net of tax", "verboseLabel": "Unrealized gain/(loss) on cash flow hedge, net of taxes of $654, $809, and $372 at December\u00a031, 2021, 2020, and 2019, respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESScheduleofGainsLossesonHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": { "auth_ref": [ "r71", "r76" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "terseLabel": "Unrealized gain/(loss) on cash flow hedge" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r77" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "negatedTerseLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r76", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Net change in postretirement benefit plan taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r76", "r80", "r649" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Net interest income (expense)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "negatedLabel": "Unrealized gain/(loss) on cash flow hedge taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r83", "r86", "r624", "r625", "r629" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Total other comprehensive (loss)/income", "totalLabel": "Other comprehensive (loss)/ income, net of tax", "verboseLabel": "Other comprehensive (loss)/gain" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss)/ income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://balchem.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r74", "r76", "r458", "r487" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "totalLabel": "Total before tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r74", "r76" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "totalLabel": "Net of tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r72", "r76", "r458" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "negatedTerseLabel": "Prior service (credit)/cost and (gain)/loss\u00a0arising during the period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r74", "r77", "r624" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "negatedLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r76", "r80", "r81", "r458" ], "calculation": { "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amortization of gain/(loss)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-term Debt, Noncurrent", "terseLabel": "Other long-term obligations" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r107" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "verboseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r11", "r14", "r277" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForHedgeInvestingActivities": { "auth_ref": [ "r113", "r124" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for Hedge, Investing Activities", "negatedLabel": "Purchase of convertible notes" } } }, "localname": "PaymentsForHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r116" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r116" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r111", "r621" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payment made on acquisition date" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r111" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired", "terseLabel": "Cash paid for acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r112" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Capital expenditures and intangible assets acquired" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "terseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r438", "r440", "r446", "r464", "r466", "r467", "r468", "r469", "r470", "r487", "r489", "r490", "r492", "r513" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r411", "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r468", "r472", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r493", "r507", "r508", "r509", "r511" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r517", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitPlansPolicy": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.", "label": "Postemployment Benefit Plans, Policy [Policy Text Block]", "terseLabel": "Post-employment Benefits" } } }, "localname": "PostemploymentBenefitPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r27", "r360" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r27", "r360" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r27", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r12", "r14", "r276", "r277" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "auth_ref": [ "r110", "r119" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.", "label": "Proceeds from Insurance Settlement, Investing Activities", "terseLabel": "Proceeds from insurance" } } }, "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r115", "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving loan" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r115" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from revolving loan" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r109" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of business and assets" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r114", "r553" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales Revenue" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r48", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r309", "r822", "r823", "r824" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r47", "r302" ], "calculation": { "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r304", "r734", "r781", "r792" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r46", "r304", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property, Plant and Equipment and Depreciation" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment", "verboseLabel": "Property, Plant and Equipment, Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r302" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r100", "r270" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]", "terseLabel": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "verboseLabel": "QUARTERLY FINANCIAL INFORMATION (UNAUDITED)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITED" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "verboseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r465", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Finished goods received from related party recorded in cost of goods sold" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r465", "r725", "r729", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r723", "r724", "r726", "r730", "r731" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfAssumedDebt": { "auth_ref": [ "r117" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayments of a long-term debt originally issued by another party but is assumed by the entity.", "label": "Repayments of Assumed Debt", "negatedLabel": "Principal payment on acquired debt" } } }, "localname": "RepaymentsOfAssumedDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r117", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Payments for outstanding balance" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r117" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedLabel": "Principal payments on revolving loan" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r566", "r746", "r836" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r380", "r561", "r734", "r789", "r813", "r818" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r157", "r158", "r159", "r162", "r171", "r173", "r266", "r558", "r559", "r560", "r599", "r600", "r669", "r809", "r811" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r512" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r411", "r412", "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r468", "r472", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r493", "r494", "r495", "r496", "r497", "r507", "r508", "r509", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r411", "r412", "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r468", "r472", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r492", "r493", "r494", "r495", "r496", "r497", "r507", "r508", "r509", "r511" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r210", "r211", "r224", "r230", "r231", "r238", "r239", "r243", "r400", "r401", "r747" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings", "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDDetails", "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r136", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r410" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition and Cost of Sales" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r402", "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r102", "r325", "r327", "r328", "r334", "r335", "r336", "r819" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenues from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r93", "r140", "r210", "r211", "r224", "r230", "r231", "r238", "r239", "r243", "r261", "r322", "r323", "r324", "r327", "r328", "r329", "r331", "r333", "r335", "r336", "r681", "r780" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving loan" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty Revenue" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r79", "r696", "r697" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Schedule of Amounts Recognized in Consolidated Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Changes in Plan Assets" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.", "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of Changes in Benefit Obligation" } } }, "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Income Tax Expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r471", "r472", "r475", "r476", "r487" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSAmountsRecognizedinBalanceSheetDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSAssumptionsUsedinCalculationsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSChangesinBenefitObligationsandPlanAssetsDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails", "http://balchem.com/role/EMPLOYEEBENEFITPLANSEstimatedFutureEmployerContributionsandBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r644", "r650", "r654" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Income (Loss) on Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Fair Value of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGACTIVITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of the Net Earnings and Shares used in Calculating Basic and Diluted Net Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Schedule of Income Tax Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r516", "r549", "r563" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "verboseLabel": "Schedule of Compensation Cost on Net Earnings" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r6", "r140", "r260", "r261", "r681" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EQUITYMETHODINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Estimated Future Employer Contributions and Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r288", "r292", "r748" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r288", "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Identifiable Intangible Assets", "verboseLabel": "Intangible Assets, Estimated Useful Lives" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "http://balchem.com/role/INTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r17", "r41", "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INVENTORIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMultiemployerPlansTable": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about multiemployer plan.", "label": "Multiemployer Plan [Table]", "terseLabel": "Schedule of Multiemployer Plans [Table]" } } }, "localname": "ScheduleOfMultiemployerPlansTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSDefinedBenefitPensionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMultiemployerPlansTableTextBlock": { "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about multiemployer plan.", "label": "Multiemployer Plan [Table Text Block]", "verboseLabel": "Summary of Pension Fund" } } }, "localname": "ScheduleOfMultiemployerPlansTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "verboseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Non-vested Performance Share Activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r48", "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentUsefulLivesDetails", "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/QUARTERLYFINANCIALINFORMATIONUNAUDITEDTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Estimated Fair Values of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r727", "r729" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r93", "r242" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/PROPERTYPLANTANDEQUIPMENTLongLivedAssetsbyGeographicalAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r219", "r222", "r228", "r284" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r219", "r222", "r228", "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r517", "r552" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "verboseLabel": "Schedule of Additional Information Relating to Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r523", "r537", "r540" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used in the Valuation of Option Awards" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Non-vested Restricted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Term A Loan" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/REVOLVINGLOANDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r206", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r235", "r243", "r311", "r312", "r802" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r206", "r208", "r209", "r219", "r223", "r229", "r233", "r234", "r235", "r236", "r238", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingExpense": { "auth_ref": [ "r105" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.", "label": "Selling Expense", "terseLabel": "Selling expenses" } } }, "localname": "SellingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r125" ], "calculation": { "http://balchem.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Non-vested balance as of end of year (in shares)", "periodStartLabel": "Non-vested balance as of beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Non-vested balance as of end of year (in dollars per share)", "periodStartLabel": "Non-vested balance as of beginning of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "verboseLabel": "Weighted Average Assumptions [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYScheduleofCompensationCostonNetEarningsDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of shares authorized for grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Shares and options issued under stock plans (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value for outstanding stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r525", "r552" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of year (in shares)", "periodStartLabel": "Outstanding at beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of year (in dollars per share)", "periodStartLabel": "Outstanding at beginning of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r515", "r521" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYRestrictedStockandPerformanceShareActivityDetails", "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r517", "r522" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "verboseLabel": "Range of exercise prices, minimum (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "verboseLabel": "Number of Options Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "verboseLabel": "Shares Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "verboseLabel": "Range of exercise prices, maximum (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Cliff vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "verboseLabel": "Expiration period of options granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockbasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r544", "r562" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYAssumptionsUsedinFairValueDeterminationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value for exercisable stock options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term for exercisable stock options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average remaining contractual term for outstanding stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price of Options Exercisable (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price of Options Outstanding (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual \u00a0Term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYInformationRelatedtoStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r206", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r235", "r243", "r284", "r307", "r311", "r312", "r802" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESGoodwillDetails", "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentAssetsandNetSalesDetails", "http://balchem.com/role/SEGMENTINFORMATIONBusinessSegmentEarningsBeforeIncomeTaxDetails", "http://balchem.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails", "http://balchem.com/role/SEGMENTINFORMATIONDepreciationAmortizationDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r58", "r89", "r90", "r91", "r157", "r158", "r159", "r162", "r171", "r173", "r196", "r266", "r375", "r380", "r558", "r559", "r560", "r599", "r600", "r669", "r691", "r692", "r693", "r694", "r695", "r697", "r809", "r810", "r811", "r874" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r157", "r158", "r159", "r196", "r747" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r514", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Shares and options issued (canceled) under stock plans" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r27", "r28", "r375", "r380", "r528" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares authorized to be repurchased (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r28", "r34", "r35", "r140", "r254", "r261", "r681", "r734" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEComponentsofAccumulatedOtherComprehensiveIncomeLossDetails", "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets", "http://balchem.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r138", "r361", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r380", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r576", "r581", "r583" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "verboseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://balchem.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income tax payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r248", "r249", "r250", "r251", "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "verboseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://balchem.com/role/SIGNIFICANTACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks & trade names" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsUsefulLivesDetails", "http://balchem.com/role/INTANGIBLEASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Shares repurchased, average cost (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockRetiredParValueMethodAmount": { "auth_ref": [ "r28", "r375", "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.", "label": "Treasury Stock, Retired, Par Value Method, Amount", "terseLabel": "Previously acquired treasury stock offset" } } }, "localname": "TreasuryStockRetiredParValueMethodAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/STOCKHOLDERSEQUITYRepurchaseofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesRetired": { "auth_ref": [ "r28", "r375", "r380" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock retired from treasury during the period.", "label": "Treasury Stock, Shares, Retired", "negatedLabel": "Repurchases of common stock (in shares)" } } }, "localname": "TreasuryStockSharesRetired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredParValueMethod": { "auth_ref": [ "r375", "r380", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.", "label": "Treasury Stock, Value, Acquired, Par Value Method", "negatedLabel": "Repurchases of common stock" } } }, "localname": "TreasuryStockValueAcquiredParValueMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r567", "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Decreases for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r575" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r580" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases for tax positions related to current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r579" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/INCOMETAXESIncomeTaxUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/BUSINESSDESCRIPTIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r149", "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additions charged (credited) to costs and expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Adjustments/deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r149", "r150", "r151", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/VALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r177", "r185" ], "calculation": { "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average common shares - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r176", "r185" ], "calculation": { "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "verboseLabel": "Number of Shares (Denominator) [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://balchem.com/role/NETEARNINGSPERCOMMONSHAREDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080549-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3581-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r513": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r623": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r634": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r672": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e526-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r721": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r731": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r837": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r838": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r839": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r840": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r841": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r842": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r843": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r844": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r845": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r846": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r847": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r848": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r849": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r850": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r851": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r852": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r853": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r854": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r855": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r856": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r857": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r858": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02" }, "r859": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r860": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01" }, "r861": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01" }, "r862": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02" }, "r863": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01" }, "r864": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02" }, "r865": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02" }, "r866": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r867": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r868": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r869": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 126 0001628280-22-003669-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-003669-xbrl.zip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�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�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�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end